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1. Introduction 
Parts of this chapter have been published in: P1) C. Englert, J. C. Brendel, T. Majdanski, T. 
Yildirim, S. Schubert, M. Gottschaldt, N. Windhab, U. S. Schubert, “Pharmapolymers in the 21st 
century: Synthetic polymers in drug delivery applications”, submitted. 
Polymeric nanoparticles have attracted tremendous interest, in particular for controlled drug 
delivery applications. According to the National Nanotechnology Initiative, the term 
‘nanoparticle’ refers to materials with dimensions between 1 and 100 nm. However, several 
materials are considered as nanoparticles in literature although they have larger dimensions (up to 
several hundred nanometers).[1] Nanoparticles in literature usually refer to liposomes, micelles, 
polymersomes, nanogels and polymer drug conjugates. Within this thesis, the focus will be on 
stable solid dispersions (prepared by nanoprecipitation of statistical copolymers), polymeric 
micelles and polymersomes (polymeric vesicles). In the last few decades, numerous polymeric 
nanoparticle based drug delivery systems have been used in various stages of clinical trials for the 
treatment of different diseases. These systems improve the therapeutic efficiency of the 
physically encapsulated or chemically conjugated drugs mainly by (i) improving the solubility of 
poorly water-soluble drugs, (ii) prolonging the circulation time, (iii) helping preferential 
accumulation at the tumor sites by the enhanced permeability and retention (EPR) effect[2] as well 
as by (iv) reducing systemic side effects.[3] Nevertheless, poor cellular internalization and 
premature drug release still limit the therapeutic efficacy. To circumvent these limitations, 
stimuli-responsive polymeric nanoparticles became the focus of considerable interest as a result 
of their on demand drug release ability as well as their tunable physicochemical properties.[4] In 
order to ensure the reliability and the reproducibility of the stimuli-responsive polymeric 
nanoparticle systems, synthesis of polymers with well-defined chemical composition, molar 
mass, high end group fidelity and low dispersity are crucial.[5] The development of reversible 
deactivation radical polymerization (RDRP) techniques during the last decades including 
nitroxide mediated polymerization (NMP),[6] atom transfer radical polymerization (ATRP)[7] and 
reversible addition fragmentation chain transfer (RAFT) polymerization[8] has tremendously 
simplified the synthesis of well-defined polymers. Among these polymerization methods, the 
RAFT polymerization process is probably the most commonly used one as a result of its 
tolerance of a wide variety of polymerization conditions and different functionalities in the 
monomers.[9] However, successful synthesis of the polymers is only the first step in reaching the 
goal; the polymers also need to be formulated into nanoparticles in a controlled and reproducible 
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way. Being facile, time-saving and cheap, nanoprecipitation represents a straightforward 
technique to fabricate nanoparticles.[10] The nanoprecipitation method usually relies on (i) 
dissolution of the polymer in a good solvent (an organic solvent that is miscible with water), (ii) 
self-assembly of the well-dissolved polymers into nanoparticles by exposure of polymer to water 
(non-solvent), and (iii) removing of organic solvents by evaporation (for low boiling point 
solvents) or by dialysis (for high boiling point organic solvents). Nanoprecipitation also allows 
efficient encapsulation of active ingredients into nanoparticles during the self-assembly 
process.[11] 
 
Figure 1.1 Schematic representation of the vinylic monomers polymerized via RAFT 
polymerization together with the corresponding investigated responses: methyl methacrylate 
(MMA), 2-(dimethylamino)ethyl methacrylate (DMAEMA), 2-aminoethyl methacrylate 
hydrochloride (AEMA·HCl), 2-(tert-butylamino)ethyl methacrylate (tBAEMA), pyridyldisulfide 
ethyl methacrylate (PDSM), 2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl methacrylate (THP-HEMA), 
2-((tert-butoxycarbonyl)(2-((tert-butoxycarbonyl)amino)ethyl)amino)-ethyl methacrylate 
(BocAEAEMA); chain transfer agents (CTA): 4-cyano-4-(phenylcarbonothioylthio) pentanoic 
acid (CPADB), 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanol (CDP); initiators: 
2,2′-azobis(2-methylpropionitrile) (AIBN), 4,4′-azobis(4-cyanovaleric acid) (ACVA). 
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The aim of this thesis is to design and synthesize novel stimuli-responsive polymeric nanoparticle 
systems for controlled drug delivery applications. To this end, this thesis investigates (i) the 
synthesis of several novel amphiphilic stimuli-responsive statistical or block copolymers via 
RAFT copolymerization of various functional monomers (Figure 1.1), (ii) the self-assembly 
behavior of the polymers by nanoprecipitation, (iii) studies the stimuli-responsive behavior of the 
nanoparticles, and (iv) evaluates these nanoparticles for possible drug delivery applications. 
Stimuli-responsive nanoparticles, also known as “smart nanoparticles”, can recognize the 
environmental stimuli and respond to it by changing their physical or chemical properties. The 
stimuli can be broadly classified into two main categories: (i) endogenous (biological) stimuli 
including pH value, glutathione (GSH) concentration,[12-13] enzyme activity[14] and receptor,[15-16] 
and (ii) exogenous stimuli (physical) such as temperature,[17-18] magnetic field,[19-20] light,[21] and 
ultrasound.[22-23] Among the endogenous stimuli, pH-responsiveness is maybe the most studied 
one due to the presence of physiological pH gradients within the body.[24] For instance, the 
extracellular pH value of inflammatory and tumor tissues is slightly more acidic (pH ∼ 6.5−7.2) 
than normal tissues.[25] Following endocytosis, the pH value even drops to 5.0 in endosomes and 
4.5 in the lysosomes. These physiological pH gradients are the reasons to formulate pH-
responsive nanoparticles aiming (i) to release drugs at the target site of action and (ii) to tune the 
physical properties (e.g, size, surface charge and morphology) of the nanoparticles within the 
different parts of the physiological environment leading to enhanced safety and cellular uptake of 
the nanoparticles. There are two common routes to prepare pH-responsive polymeric 
nanoparticles: (i) By incorporating ionizable pendant groups into the polymers, (ii) by using pH-
labile bonds within the backbone or the side chain of the corresponding polymers. Therefore, the 
pH-responsiveness of nanoparticles obtained from both routes relies mainly on the change of the 
hydrophobic-to-hydrophilic ratio of the polymers as a result of cleavage of the acid labile bonds 
or the ionization of the pendant groups. The hydrophobic-to-hydrophilic ratio of the nanoparticles 
is the key parameter, which determines the size, surface charge, morphology and solubility of the 
nanoparticles. Weakly basic amino groups represent interesting ionizable moieties to formulate 
biologically relevant pH-responsive nanoparticles due to their pH value dependent 
protonation/deprotonation abilities. Below their pKa values, amino groups are protonated and 
become hydrophilic. In contrast, above their pKa values amino groups become hydrophobic as a 
consequence of the deprotonation. The pH responsive behavior of the nanoparticles is affected by 
the amount and the chemical structure of the amino groups incorporated in the corresponding 
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copolymers. Chapter 2 discusses the effect of various amino structures (primary, secondary and 
tertiary) on the pH responsive behavior of poly(methyl methacrylate) (PMMA) based 
nanoparticles. Most of the nanoparticle based drug delivery systems rely on the physical 
encapsulation of active molecules into nanoparticles during the formulation of the corresponding 
polymers. However, these systems usually exhibit some drawbacks including premature release 
of the cargo as well as insufficient loading.[26] Conjugation of polymers with bioactive molecules 
can overcome these limitations.[27] Primary amino groups enable the chemical conjugation of the 
bioactive molecules including proteins and peptides to the polymers.[28] In the second part of 
Chapter 2, chemical conjugation of the retinoic acid (RA) and a fluorescent dye (DY590) to a 
primary amino functional PMMA based copolymer is demonstrated. Moreover, formulation of 
the cationic nanoparticles and an application for label free Raman imaging as well as possible 
selectivity of RA for hepatic stellate cells (HSC) via intravital microscopy is discussed.  
Apart from the pH value gradients within the physiological environment, the reductive 
environment of the cytosol compared to extracellular environments (100 to 1000 times higher 
glutathione (GSH) concentration than the extracellular GSH) also provides a rationale for the 
intracellular delivery of therapeutic agents.[29-30] Such GSH responsive nanoparticles are 
generally constructed by incorporating disulphide functionality at the side chain,[31] in the 
backbone (main chain),[32] or in the cross-linker.[33] The disulphide functionality can react with 
intracellular GSH via thiol–disulfide exchange reaction and can result in disruption of the 
nanoparticles leading to a cargo release. Pyridyldisulfide ethylmethacrylate (PDSM) is a well-
known monomer that is commonly used to produce polymers with disulfide pendants.[34-36] 
Chapter 3 describes the synthesis of the statistical copolymer library of PDSM with different 
compositions of 2-((tert-butoxycarbonyl)(2-((tert-butoxycarbonyl)amino)ethyl)amino)-ethyl 
methacrylate (BocAEAEMA) that contains primary and secondary amino groups in the side 
chain (after deprotection of the Boc-group).[37] Moreover, both glutathione and pH-
responsiveness of respective nanoparticles and their potential application for the controlled 
delivery of doxorubicin (DOX) is demonstrated.  
The surface charge of nanoparticles plays a crucial role on the cellular internalization, blood 
circulation, and the safety of the nanoparticles. For instance, it is well-known that positively 
charged nanoparticles are internalized faster by the cells than negatively charged and neutral 
nanoparticles as a result of their high interaction with the negatively charged cell membranes.[38] 
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However, the positively charged nanoparticles can interact with proteins in the bloodstream 
causing severe aggregation and rapid clearance from circulation. Moreover, positive charge can 
cause perturbation of the plasma membrane inducing cytotoxicity and immune response.[39] In 
contrast, neutral and negatively charged nanoparticles have less interaction with proteins and 
longer circulation times.[40] As a consequence, the construction of charge-conversional 
nanoparticles that are neutral or have negative surface charge values in the blood but become 
positively charged under a slightly acidic environment have become appealing for intravenous 
drug delivery systems. Drug delivery systems with these features are expected to combine the 
advantages of positively and negatively charged nanoparticles to improve the targeting 
efficiency.[41-42] Chapter 4 demonstrates that random incorporation of the 2-
(dimethylamino)ethyl methacrylate (DMAEMA) moieties into a 2-((tetrahydro-2H-pyran-2-
yl)oxy)ethyl methacrylate (THP-HEMA) based hydrophobic polymer allows obtaining 
nanoparticles with pH-dependent surface charge conversion properties. Furthermore, it is shown 
that the disassembly pH value and the isoelectric point (IEP) of the nanoparticles can be 
systematically tuned by varying the amino content of the polymers. The majority of the reported 
stimuli responsive nanoparticle systems depend on the endogenous (biological) stimuli like 
endosomal pH value or GSH concentration. However, biological stimuli are complicated and can 
limit the control over the drug release. In contrast, exogenous stimuli are independent of the 
complex conditions of the biological environment, and they can be applied in a remotely and 
spatiotemporally controlled manner.[43] This can provide a precise control over the release of the 
encapsulated payloads. Among the exogenous stimuli, ultrasound has recently attracted a great 
deal of attention because of its noninvasiveness, lack of ionizing radiations, deeper penetration 
into the interior of the body as well as tunable frequency and time of treatment, which prevents 
damage to healthy tissue.[4, 44-45] Chapter 4 shows that THP-HEMA based nanoparticles are 
responsive to ultrasound as a result of their relatively low glass transition temperatures (Tg) and 
lack of any crystallization temperatures (Tc). It is believed that nanoparticles that possess 
hydrophobic segments that have a low Tg value can respond to a stimuli by changing their 
morphologies.[46-48] In the second part of the Chapter 4, it is shown that polymersomes 
constructed by using a diblock copolymer of THP-HEMA with DMAEMA exhibit a morphology 
transition from vesicles at neutral pH values to micelles upon decreasing the pH value. 
Furthermore, the ability of this system for the controlled delivery of a hydrophilic anti-cancer 
drug doxorubicin hydrochloride (DOX·HCl) is demonstrated.  
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2. PMMA based cationic nanoparticles 
Parts of this chapter have been published: P2) T. Yildirim, A. C. Rinkenauer, C. Weber, A. 
Traeger, S. Schubert, U. S. Schubert, J. Polym. Sci., Part A: Polym. Chem. 2015, 53, 2711-2721; 
P3) T. Yildirim,# C. Matthäus,# A. T. Press, S. Schubert, M. Bauer, J. Popp, U. S. Schubert, 
Macromol. Biosci. 2017, DOI: 10.1002/mabi.201700064. #Authors contributed equally. 
Incorporation of amino groups into hydrophobic polymer chains enables to obtain pH responsive 
polymers and the corresponding cationic nanoparticles. In order to investigate the influence of the 
amino structure and the amount of the amino content on the pH responsive behavior of the 
nanoparticles, a series of statistical copolymers of PMMA with three different commercially 
available amino methacrylates including tertiary (DMAEMA), secondary (tBAEMA) and 
protonated primary amino functionalities (AEMA·HCI) were synthesized using the reversible 
addition-fragmentation chain transfer (RAFT) polymerization process (Scheme 2.1). 4-Cyano-4-
(phenylcarbonothioylthio) pentanoic acid (CPADB) was chosen as chain transfer agent (CTA), 
because it has previously effectively mediated the RAFT polymerization of various amino 
methacrylates.[37, 49] In order to vary the amino content, two different feed ratios were used 
aiming to obtain 10% as well as 20% amino content for each monomer. Considering the possible 
cytotoxic effects of the amino groups and the required hydrophobicity of the copolymers for the 
capability to form nanoparticles via nanoprecipitation, the amino content in the copolymers was 
kept low (in between 9 and 21%). It is known that the deprotonated primary amino functional 
monomer AEMA can rearrange to its thermodynamically more stable isomer 2-hydroxyethyl 
methacrylamide.[49-50] Moreover, free primary amino groups in the polymerization mixture can 
decompose the dithiobenzoate moiety of the CTA.[51] To avoid these unwanted reactions, AEMA 
in its hydrochloride salt form was used for the polymerizations. For DMAEMA and tBAEMA 
copolymerizations (P1 to P4) ethanol was used as solvent. However, methanol under reflux was 
used as solvent for the AEMA·HCl copolymerizations (P5 and P6) as a result of the poor 
solubility of AEMA·HCl in ethanol. All copolymerizations were performed utilizing 2,2′-
azobis(2-methylpropionitrile) (AIBN) as source of radicals. Purified copolymers were 
characterized by SEC measurements and 1H NMR spectroscopy (Table 2.1). The calculated Mn 
values estimated by 1H NMR are in good agreement with the theoretical values that are estimated 
using the [monomer] to [CTA] ratio and the monomer conversions. 
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Scheme 2.1 Schematic representation of the RAFT copolymerization of MMA with amino-
functionalized methacrylates. 
Table 2.1 Selected characterization data of the MMA (M1) copolymers with corresponding 
amino methacrylates (M2). 
Entry M2 
f(M1/
M2)a 
F(M1/
M2)b,d 
Conv. (%) 
M1   M2 
Mn, theo.
e 
[g mol-1] 
DPd 
M1   M2 
Mn
d 
[g mol-1] 
Mn
f 
[g mol-1] 
Đ f 
 
P1 DMAEMA 9 7.4 39c   45c 4,500 41     5.5 5,200 6,100 1.16 
P2 DMAEMA 4 4 42c   50c 5,200 40     10 5,900 7,600 1.17 
P3 tBAEMA 19 9.5 29c    70c 3,700 35    3.7 4,500 5,200 1.19 
P4 tBAEMA 5.7 3.8 36c   72c 5,300 35    9.2 5,500 7,900 1.15 
P5 AEMA·HCI 9 9.1 45d   44d 5,000 42    4.6 5,200 5,100 1.13 
P6 AEMA·HCI 4 3.7 48d   52d 5,900 30    8.2 4,600 4,500 1.19 
P7g AEMA  9   45       5 5,200 5,300 1.18 
P8h AEMA  3.6   35    9.8 5,000 4,800 1.18 
a
Initial monomer feed ratio. 
b
Monomer ratio in the isolated copolymer. 
c
Determined by GC. 
d
Determined by 
1
H NMR spectroscopy. 
e
Determined by the formula Mn,theo. = [([M]M1/[CTA] × 
Conv. × MM1) + ([M]M2/[CTA] × Conv. × MM2) + (MCTA)]. 
f
Determined by SEC in CHCl3 
analysis (RI detection, PMMA calibration). 
g
Deprotonated form of P5. 
h
Deprotonated form of 
P6. 
SEC measurements in chloroform revealed monomodal molar mass distributions for all polymers 
with low dispersities (Đ < 1.2). Before nanoparticle formulation, the copolymers of AEMA·HCl 
(P5 and P6) were treated with Amberlyst® A21, which is a weak base, to obtain the desired 
primary amino-functionalized copolymers (P7 and P8). After treatment with Amberlyst® A21, 
P6, which is soluble in water, became hydrophobic and water non-soluble (P8) as a result of 
deprotonation of the amino groups. Nanoparticles were formulated by nanoprecipitation of the 
synthesized tertiary (P1 and P2), secondary (P3 and P4) and primary (P7 and P8) amino-
functionalized PMMA based copolymers without using any stabilizers/surfactants. For 
nanoprecipitation, acetone was used as solvent and water was used as non-solvent. In order to 
vary the dimensions of the obtained nanoparticles, different formulation conditions were utilized 
such as two different dropping methods (dropping acetone polymer solution to water (AW) and 
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dropping water to acetone polymer solution (WA)) and two different initial acetone polymer 
solution concentrations. As commonly observed for the nanoprecipitation technique, 
nanoparticles with smaller diameters were obtained with the AW method compared to the WA 
process (Table 2.2).[52] Well-defined nanoparticles with positive zeta potential values could be 
obtained with all polymers by using initial acetone-polymer solution concentrations of 1 mg mL-
1. The positive zeta potentials of the nanoparticles are ascribed to the amino moieties into the 
polymers. SEM investigations revealed spherical shapes for all nanoparticles. Although 
nanoparticles with monomodal size distributions and low PDI values could be produced using 
DMAEMA (P1 and P2) and AEMA (P7 and P8) copolymers with an initial acetone-polymer 
solution concentration of 10 mg mL-1, tBAEMA (P3 and P4) copolymers yielded nanoparticles 
and undefined aggregates. This can be attributed to the lower pKa values of tBAEMA 
copolymers compared to the DMAEMA and AEMA copolymers preventing the nanoparticles to 
have an appreciable surface charge at neutral pH values. In agreement with this assumption, 
nanoparticles without any aggregation could be obtained using an acetate buffer with a pH value 
of 5.0 instead of using pure water (Table 2.2).  
Table 2.2 Characterization results of the prepared nanoparticles. 
Polymer Methoda 
Z-averageb 
[d, nm] 
PDIb 
Zeta potentialc 
[mV] 
c = 1 g L-1 c = 10 g L-1 c = 1 g L-1 c = 10 g L-1 c = 1 g L-1 c = 10 g L-1 
P1 
AW 152 ± 2 123 ± 1 0.16 ± 0.02 0.12 ± 0.01 +35 ± 4.4 +37 ± 0.3 
WA 340 ± 3 720 ± 18 0.11 ± 0.03 0.07 ± 0.05 +25 ± 4.3 +48 ± 1.1 
P2 
AW 184 ± 2 131 ± 2 0.16 ± 0.01 0.11 ± 0.04 +52 ± 0.4 +31 ± 0.7 
WA 473 ± 3 636 ± 4 0.18 ± 0.04 0.07 ± 0.05 +47 ± 0.4 +51 ± 0.7 
P3 
AW 126 ± 1 200 ± 1d 0.12 ± 0.02 0.19 ± 0.03d +44 ± 3.3 + 56 ± 9d 
WA 314 ± 3 1079 ± 28d 0.14 ± 0.04 0.26 ± 0.12d +29 ± 0.4 + 40 ± 3d 
P4 
AW 169 ± 2 158 ± 1d 0.15 ± 0.01 0.15 ± 0.03d +36 ± 6.4 + 41 ± 3d 
WA 331 ± 3 610 ± 12d 0.09 ± 0.05 0.14 ± 0.01d +20 ± 2.1 + 26 ± 2d 
P7 
AW 121 ± 1 110 ± 1 0.17 ± 0.01 0.14 ± 0.02 +56 ± 3.2 +59 ± 0.6 
WA 306 ± 2 339 ± 2 0.11 ± 0.02 0.10 ± 0.03 +61 ± 0.5 +64 ± 1.0 
P8 
AW 133 ± 1 182 ± 1 0.14 ± 0.02 0.08 ± 0.04 +54 ± 2.1 +59 ± 0.8 
WA 254 ± 3 582 ± 13 0.07 ± 0.05 0.17 ± 0.02 +53 ± 3.7 +61 ± 0.6 
aAW, dropping acetone to water; WA, dropping water to acetone. bAverage values of three DLS 
measurements. cAverage values of three zeta potential measurements. dNanoprecipitation with 
acetate buffer (pH = 5) as non-solvent. 
In order to understand the pH responsive behavior of the nanoparticles, the suspensions were 
stored for 24 h at 37 °C at various pH values. Subsequently, changes in size and surface charge 
values were investigated by DLS and zeta potential measurements. The DLS measurements 
revealed that P1 nanoparticles that contain 10% DMAEMA functionality are stable at slightly 
acidic pH values (3.4 to 6) but they aggregate at pH values 7 and 8 (Figure 2.3, A). The 
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aggregation of the nanoparticles is due to the decrease in the zeta potential values of the 
nanoparticles as a result of deprotonation of the DMAEMA moieties (Figure 2.3, B). It is known 
that van der Waals attractions become stronger than electrostatic repulsions causing aggregation 
when the absolute zeta potential values of the nanoparticles are lower than 20 mV.[53] In 
agreement with this, P1 nanoparticles are stable at a pH value of 9 due to having zeta potential 
values beyond ˗20 mV. The negative zeta potential value of the P1 nanoparticles at pH 9 can be 
attributed to a complete deprotonation of the DMAEMA groups and the carboxylic acid 
functionality of the utilized CTA into the polymer. Unlike P1, P2 nanoparticles are stable at a pH 
value of 7. This is due to the higher DMAEMA content (20%) of P2 leading to a sufficient 
character of the nanoparticles for stabilizing of the nanoparticles. Between the pH values 3.4 to 5 
P2 nanoparticles exhibited a significant increase in the PDI value and a tremendous decrease in 
the count rate, which is proportional to the size and the number of the nanoparticles. These 
observations are attributed to the dissolution of the nanoparticles at acidic pH values caused by 
the complete protonation of the DMAEMA groups. Furthermore, a control experiment with 
nanoparticles prepared using Eudragit® E100, which is a well-known coating polymer that 
exhibits dissolution at acidic media,[54] revealed similar results like P2 nanoparticles. 
Nanoparticles deriving from P3 and P4 are stable at acidic pH values but they revealed a reduced 
stability around neutral pH values compared to DMAEMA nanoparticles. This could be due to 
bulky tert-butoxy group the tBAEMA that inhibits the protonation of the amino groups, resulting 
in low zeta potential values and accordingly causing aggregation of the nanoparticles. In contrast, 
AEMA containing nanoparticles (P7 and P8) revealed improved stabilities around neutral pH 
values compared to DMAEMA nanoparticles. This is ascribed to the primary amino structure of 
the AEMA rendering nanoparticles to protonate easily under neutral conditions. P7 nanoparticles 
are stable at acidic pH values. However, P8 nanoparticles that contain 20% AEMA functionality 
revealed nanoparticle disassembly between pH values 3.4 to 5 as a result of the polymer 
dissolution. It is known that PMMA is nontoxic, whereas amino functional polymers usually 
induce toxic effects to the cells as a result of their undesired destructive interactions with the 
negatively charged cell membranes.[55] Therefore, cytotoxicity of the nanoparticles and the water 
soluble polymer P6 on L929 cells was investigated (Figure 2.2). 
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Figure 2.1 (A) Z-Average diameter (represented up to 1000 nm) and PDI values of nanoparticles 
as a function of the pH value. (B) Zeta potentials of the nanoparticles as a function of the pH 
value. 
P6 revealed severe toxic effects on L929 cells after 24 h incubation. However, the nanoparticles 
prepared from P8, which is the deprotonated form of P6, did not show any cytotoxic effect under 
the same conditions. This is attributed to the decrease of the cationic character of the polymer 
after deprotonation.  
 
Figure 2.2 Cytotoxicity test of nanoparticles (NPs) that are prepared from P1 to P4, P7, P8 and 
water soluble polymer P6 in L929 cells. Untreated cells on the same well plate were used as 
positive controls.  
The majority of the nanoparticle based drug delivery systems count on the physical entrapment of 
therapeutic agents into nanoparticles during the self-assembly of the polymers in aqueous 
solution. However, these systems mainly suffer from a premature release of the cargo and an 
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insufficient loading. As a result, chemical conjugation of the active molecules to the polymers 
have become a common strategy to overcome these limitations.[27] Primary amino groups offer a 
number of postpolymerization modification approaches including Michael addition, formation of 
amides and imines, ring-opening of epoxy moieties and so on.[56] As a consequence, they are one 
of the most common functional groups that are amenable to conjugate bioactive molecules to the 
polymers. Raman microscopic imaging of cells and tissues have become an attractive tool due to 
its non-destructive and label-free approach. Raman imaging enables to image individual cellular 
components including endoplasmic reticulum, Golgi apparatus, vesicles and mitochondria.[57-59] 
Moreover, the intracellular uptake of molecules and particles can also be monitored by Raman 
imaging when their spectral contrast with respect to the cellular environment is sufficient. 
Molecules that have extended -conjugated systems represent a very high Raman sensitivity as a 
result of their high Raman scattering cross sections. For instance, cellular uptake of the beta-
carotene loaded PLGA nanoparticles could be investigated by Raman microscopy.[60] Raman 
spectroscopy has also been used to quantify vitamin A in hepatic stellate cells (HSCs) of the 
liver.[61] Retinoic acid (RA), that is a biosynthetic analogues (precursors) of vitamin A, has also 
desired features for direct observation by Raman spectroscopy.[62] Moreover, it is known that 
HSC take up vitamin A independent of their needs through cell-type specific receptors and store 
it in large vesicles located near their nuclei.[63-64] As a consequence, RA was covalently attached 
to a before synthesized primary amino functional PMMA based copolymer (P5, Table 2.1) to 
study the suitability of the RA conjugated polymeric nanoparticles for Raman imaging 
investigations. Furthermore, in order to investigate the possible selectivity of the RA bearing 
nanoparticles for HSCs the copolymer is additionally functionalized with a fluorescent dye. In 
order to prove the covalent coupling of RA to the polymer by SEC (UV detector) and UV-vis 
spectroscopy, the ω RAFT end-group of the polymer, which exhibits a strong UV absorption in a 
similar region like RA, was cleaved by following a procedure reported in literature before 
yielding a hydroxyl-terminated polymer (P9) (Scheme 3.1).[65] Before the coupling reactions, P9 
was treated with Amberlyst® A21 to deprotonate the polymer that contains HCl salt. 
Subsequently, DCC coupling was utilized to chemically attach RA to the pendant primary amino 
groups of the P9, resulting in a RA conjugated polymer (P10). Furthermore, amino groups of the 
P10 and P9 were functionalized with NHS ester functional fluorescent dye DY590, yielding P11 
and P12, respectively. Successful coupling of RA and DY590 to the polymers was confirmed by 
1H NMR spectroscopy, SEC and UV-vis spectroscopy. RA and/or DY590 bearing nanoparticles 
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were prepared by the nanoprecipitation of the modified polymers (P10, P11 and P12). Cationic 
nanoparticles were obtained with diameters between 70 to 85 nm with monomodal size 
distributions and relatively low PDI values. 
 
Scheme 2.2 Schematic representation of the (i) RAFT end group cleavage; (ii) deprotonation of 
P9; (iii) coupling of the retinoic acid (RA) to deprotonated form of P19; (iv and v) coupling of 
DY590 to P10 and the deprotonated form of P9. 
Figure 2.3 displays the Raman images of two LX2 cells incubated with RA conjugated (P10) 
nanoparticles for 1 and 3 h at a concentration of 50 mg mL-1 along with the corresponding 
spectral information. The cytosol is plotted in cyan, whereas the distribution of the nanoparticles 
is plotted in red. After 1 h, the endocytotic cellular uptake of the particles was clearly visible. 
Small vesicle-like inclusions in dimensions of 0.5 to 1 µm that are distributed throughout the 
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cytosol could be observed. The typical RA Raman band at 1596 cm-1 was distinctly visible in the 
corresponding endmember spectrum (in red). The cyan endmember spectrum corresponding to 
the cytosol has the appearance of typical Raman spectra of cells and reveals all of the typical 
protein bands. After 3 h, the cellular uptake of the particles was increased. Large inclusions of the 
particles were observed throughout the whole cell. Moreover, the typical RA Raman band at 
1596 cm-1, which is three times as intense compared to the 1 h incubation time, became the 
dominated band in the corresponding endmember spectrum. There was no change observed in the 
corresponding endmember spectrum of the cytosol. 
 
Figure 2.3 Raman images of LX2 cells incubated with PRA nanoparticles for 1 hour (A) and 
3 hours (C) along with the corresponding spectral information plotted in (B) and (D) respectively. 
The distribution of the nanoparticles is shown in red. Distinctly pronounced in the Raman spectra 
is the RA marker band at 1596 cm-1. Scale bars represent 10 µm. 
In order to track modified nanoparticles, in vivo intravital microscopy was used. Cationic 
nanoparticles prepared from DY590 conjugated polymers (P11 and P12) entered to the cells 
located in the sinusoids (Figure 2.4). Greater occurring accumulations, in particular in the curves 
of the sinusoids, could be assigned to Kupffer cells and HSC. Smaller accumulations scattered 
along the sinusoids could be contributed to liver sinusoidal endothelia cells (LSECs). Kupffer 
cells, also known as stellate macrophages, are macrophages located in the liver and represent 
together with LSECs the immunological line of defense in the liver. It is known that cationic 
nanoparticles can be recognized and eliminated rapidly by immune cells in particular in the liver. 
Interestingly, the attachment of the RA did not alter the pharmacokinetics of the nanoparticles. 
These results indicate that surface charge of the nanoparticles should be carefully engineered to 
employ targeting moieties.  
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Figure 2.4 Hepatic uptake of DY590 conjugated polymeric nanoparticles without (P12) and with 
(P11) retinoic acid after 40 min. 
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3. Glutathione and pH-responsive nanoparticles for the controlled delivery of 
doxorubicin 
Parts of this chapter have been published: P4) T. Yildirim, A. Traeger, E. Preussger, S. Stumpf, 
C. Fritzsche, S. Hoeppener, S. Schubert, U. S. Schubert, Macromolecules 2016, 49, 3856-3868. 
In order to obtain a new glutathione and pH-responsive nanoparticle system, a library of well-
defined statistical copolymers of pyridyldisulfide ethyl methacrylate (PDSM) with different 
compositions of 2-((tert-butoxycarbonyl)(2-((tert-butoxycarbonyl)amino)ethyl)amino) 
ethylmethacrylate (BocAEAEMA) were synthesized using the RAFT polymerization process 
(Scheme 3.1). PDSM is used as glutathione (GSH) responsive moiety since it contains a 
pyridyldisulfide functionality, which is reactive to free thiol moieties under ambient 
conditions.[66] AEAEMA that contains primary and secondary amino groups in the side chain is 
used as pH-responsive moiety.[37] It is known that block copolymer nanoparticles hide the 
hydrophobic segments of the polymers in the core of the micelles or in the bilayer of the 
vesicles.[67-68] In contrast, statistical copolymer assemblies can provide surface exposed 
hydrophobic moieties. We envisioned that surface exposed hydrophobic PDSM functionality can 
accelerate the GSH responsive behavior of the corresponding nanoparticles. As a consequence, a 
number of statistical copolymers with similar molar mass values but varying monomer 
compositions were synthesized. 
 
Scheme 3.1 Schematic representation of the RAFT copolymerization of PDSM with 
BocAEAEMA. 
The isolated (co)polymers were characterized by 1H NMR spectroscopy (Figure 3.1) and SEC 
measurements (Table 3.1). The DP values for each monomer and the according number average 
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molar mass (Mn) values were calculated by 
1H NMR end group analysis. SEC in DMAc revealed 
monomodal traces and low dispersities (Đ < 1.2) for all polymers. 
Table 3.1 Selected characterization data of the PDSM (M1) copolymers with BocAEAEMA 
(M2). 
Entry 
Monomer/CTA/ 
ACPA 
f(M1/
M2)
a
 
F(M1/
M2)
b
 
Conv. 
[%]
c
 
M1/M2 
Mn,theo.
d
 
[g mol
-1
] 
DP
c
 
M1/M2 
Mn
c
 
[g mol
-1
] 
Mn,SEC
f
 
[g mol
-1
] 
Đf 
P13
g
 38.07/1/0.25   76/0 7,700 24/0 6,400 7,300 1.18 
P14 37.19/1/0.25 19.0 19.1 78/60 7,700 23/1.2 6,600 7,000 1.13 
P15 36.40/1/0.25 9.0 11.1 73/62 7,200 21/1.9 6,300 7,400 1.15 
P16 35.62/1/0.25 5.7 7.5 87/67 8,300 24/3.2 7,600 8,300 1.14 
P17 34.86/1/0.25 4.0 5.5 75/60 7,200 21/3.8 7,000 8,000 1.14 
P18 33.42/1/0.25 2.3 3.5 78/70 7,600 19/5.5 7,200 9,200 1.13 
P19 32.17/1/0.25 1.5 2.5 78/68 7,400 17/6.8 7,200 10,000 1.09 
P20 29.86/1/0.25 0.7 1.0 83/74 7,700 11/11 7,200 9,700 1.12 
P21
h
 25.92/1/0.25   0/69 6,900 0/18.3 7,100 7,600 1.08 
a
Initial monomer feed ratio. 
b
Monomer ratio in the isolated copolymer. 
c
Determined by 
1
H NMR 
spectroscopy. 
d
Determined by the formula Mn,theo. = [([M]M1/[CTA] × Conv. × MM1) + 
([M]M2/[CTA] × Conv. × MM2) + (MCTA)]. 
f
Determined by SEC in DMAc analysis (RI detection, 
PS calibration). 
g
Homopolymer of the PDSM. 
h
Homopolymer of the BocAEAEMA. 
 
Figure 3.1 1H NMR spectra (300 MHz, CDCl3) of P1, P6, and P9 and the assignment of the 
peaks used to calculate the degree of polymerization (DP). 
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Prior to the nanoparticle formulation, the Boc-groups of the polymers were cleaved by treating 
with trifluoroacetic acid. The quantitative cleavage of the Boc-groups was proven by 1H NMR 
spectroscopy by the disappearance of the tert-butoxy carbonyl proton signals at 1.41 ppm. 
Polymeric nanoparticles could be obtained by nanoprecipitation of the deprotected copolymers of 
P14, P15, and P16 containing 5, 8, and 12 mol% AEAEMA functionality, respectively. 
However, with polymers that contain higher mol% AEAEMA, no well-defined nanoparticles 
could be obtained as a result of their insufficient hydrophobicity. Variations of the initial 
formulation conditions (initial acetone-polymer solution concentration, dropping methods) 
enabled to obtain cationic nanoparticles with diameters ranging from 50 to 460 nm (Table 3.2). 
SEM measurements revealed homogenous spherical shapes (Figure 3.2). An increase of the 
mol% of the AEAEMA content of the polymers caused a decrease of the nanoparticles size for 
both initial polymer concentrations. The decrease in the size of the nanoparticles with increasing 
AEMA content is attributed to the increase of the amount of charged groups in the polymer 
chains.[69] 
Table 3.2 Selected characterization results of the prepared nanoparticles. 
Entry Z-average [d, nm]a PDIa ζ-potential [mV]b 
c = 5 g L-1 c = 5 g L-1 c = 5 g L-1 c = 5 g L-1 c = 5 g L-1 c = 5 g L-1 
P14 466 ± 4c 74 ± 1d 0.07 ± 0.02c 0.20 ± 0.01d 72 ± 5c 69 ± 3d 
P15 274 ± 1c 51 ± 1d 0.11 ± 0.02c 0.26 ± 0.01d 62 ± 2c 72 ± 5d 
P16 180 ± 1c ---e 0.05 ± 0.01c ---e 59 ± 3c ---e 
a
Average values of three DLS measurements. 
b
Average values of three zeta potential 
measurements. 
c
WA, dropping water to acetone. 
d
AW, dropping acetone to water. 
e
No well 
defined nanoparticles. 
 
Figure 3.2 SEM images of nanoparticles that were prepared from P14, P15, and P16 (5 mg mL-1) 
by dropping water to acetone-polymer solution (WA). Upper scale bars represent 200 nm, lower 
scale bars represent 1000 nm. 
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In order to test the pH-responsive behavior of the nanoparticles, suspensions were titrated in the 
pH value range from 3.5 to 9, and the changes in size and zeta potential values were recorded 
simultaneously. The nanoparticles revealed stable size and PDI values at acidic pH values. 
However, a gradual increase in the size as well as in the PDI values of the nanoparticles was 
observed as the pH value increases. The nanoparticles were aggregated over a certain pH value. 
This is attributed to the deprotonation of the AEAEMA moieties of the polymers. In accordance 
with this, the zeta potential of the nanoparticles is inversely proportional to the pH value (Figure 
3.3). The GSH responsive behavior of the nanoparticles was studied by monitoring the changes in 
particle size and the derived count rate over time in respond to 10 µM and 10 mM GSH 
concentration at 37 °C (Figure 3.4). These conditions mimic the GSH concentration in the blood 
and the cytosol, respectively. At a 10 µM GSH concentration, there was no change either in the 
nanoparticle size or in the derived count rate of the nanoparticles indicating the stability of the 
nanoparticles in the plasma. However, at a 10 mM GSH concentration, all nanoparticles exhibited 
an increase in size as well as a decrease in the derived count rate indicating a disassembly of the 
nanoparticles. The disassembly of the nanoparticles was attributed to the attachment of the GSH 
to the polymers via thiol-disulfide exchange reaction converting the amphiphilic copolymers into 
more hydrophilic polymers. 
 
Figure 3.3 (A) Z-Average diameter and PDI values of the nanoparticles as a function of the pH 
value. (B) Zeta potentials of the nanoparticles as a function of the pH value. 
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Figure 3.4 (A) Z-Average diameter and PDI values of the nanoparticles as a function of 10 µM 
and 10 mM GSH. (B) Derived count rate of the nanoparticles as a function of 10 µM and 10 mM 
GSH. 
DOX was encapsulated into P15 nanoparticles utilizing the nanoprecipitation method. DLS and 
zeta potential measurements revealed that DOX-loaded nanoparticles have a Z-average diameter 
of 130 nm, a PDI value of 0.1 and a zeta potential of +30 mV. The drug loading efficiency 
(19.2%) and drug loading content (1.9%) were calculated using a fluorescence intensity 
calibration function of DOX in pure water. The release experiments revealed that the DOX 
release was significantly enhanced with the trigger of 10 mM GSH compared to the physiological 
conditions. The cytotoxicity studies revealed that the nanoparticles and the deprotonated water 
soluble P21 represented no cytotoxic effect on L929 cells after 48 h of incubation at 
concentrations up to 0.75 and 0.5 mg mL-1, respectively (Figure 3.5 A). Above the indicated 
concentrations, nanoparticles and P21 exhibited moderate toxic effects to the cells, which could 
be attributed to the amino functionality of the polymers.[15] DOX-loaded nanoparticles resulted in 
a cell death in a concentration and time dependent manner comparable with free DOX (Figure 3.5 
B). The efficient cell death was attributed to the release of DOX from the nanoparticles in the 
intracellular environment inhibiting the proliferation of the cells. The intracellular trafficking of 
DOX-loaded nanoparticles in comparison with free DOX was followed in HEK cells using 
confocal laser scanning microscopy (CLSM) (Figure 3.6). DOX fluorescence was clearly 
observed in the cytosol and in the nuclei for cells treated with DOX-loaded nanoparticles after 
incubation for 6 h. This indicates that the DOX-loaded nanoparticles efficiently entered the cells, 
and the DOX was released from the nanoparticles by the intracellular triggers. A longer 
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incubation time (24 h) resulted in stronger DOX fluorescence inside the cell nuclei. Similar 
results were obtained with free DOX.  
 
Figure 3.5 (A) Cytotoxicity test of nanoparticles (NPs) that were prepared from P14, P15, P16, 
and AEAEMA homopolymer P21 in L929 cells. (B) Cytotoxicity test of DOX-loaded 
nanoparticles and free DOX. The relative viability is expressed as percentage to control cells not 
treated with NPs. Untreated cells on the same well plate were used as positive controls. 
 
Figure 3.6 Live cell CLSM images of HEK cells incubated with DOX-loaded nanoparticles and 
free DOX at 1 μg/mL pure and encapsulated DOX. For each panel, the images from left to right 
show DOX fluorescence in cells (red), cell nuclei stained by Hoechst (blue), and overlays of the 
two images and a brightfield image. The scale bars correspond to 20 μm in all the images. (A) 
DOX-loaded nanoparticles, 6 h incubation; (B) free DOX, 6 h incubation; (C) DOX-loaded 
nanoparticles, 24 h incubation; (D) free DOX, 24 h incubation. 
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These results indicate that the prepared polymeric nanoparticles are promising vehicles for the 
controlled release of loaded pharmaceutical agents in the cytosol. 
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4. Effect of glass transition temperature on the stimuli responsive behavior of 
the nanoparticles 
Parts of this chapter have been published: P5) T. Yildirim, I. Yildirim, R. Yanez-Macias, S. 
Stumpf, C. Fritzsche, S. Hoeppener, C. Guerrero-Sanchez, S. Schubert, U. S. Schubert, Polym. 
Chem. 2017, 8, 1328-1340; P6) T. Yildirim, A. Traeger, P. Sungur, S. Hoeppener, C. Fritzsche, I. 
Yildirim, D. Pretzel, S. Schubert, U. S. Schubert, submitted. 
It is known that nanoparticles derived from THP functional polymers can be disrupted by 
ultrasound exposure.[70-71] Moreover, the THP group can be cleaved under acidic conditions.[32] 
As a consequence, a library of well-defined statistical copolymers of 2-((tetrahydro-2H-pyran-2-
yl)oxy)ethyl methacrylate (THP-HEMA) with different compositions of 2-(dimethylamino) ethyl 
methacrylate (DMAEMA) were synthesized using the RAFT polymerization process to develop a 
novel ultrasound- and pH value responsive nanoparticle system with surface charge conversion 
from negative to positive at slightly acidic conditions (Scheme 4.1). In order to investigate 
comprehensively the effect of the DMAEMA content on the stimuli response of the 
corresponding nanoparticles, one homopolymer of THP-HEMA (P22) and four copolymers of 
THP-HEMA and DMAEMA (P23 to P26) with 5 mol% of DMAEMA content increment (5 to 
20 mol% DMAEMA) with similar molar mass values were synthesized utilizing a Chemspeed 
Swing-SLT automated parallel synthesizer.[72-73] Moreover, it is known that the ionizable 
carboxylic acid end-group of the CPADB could potentially affect the pH-responsive behavior of 
the corresponding nanoparticles.[74-75] To investigate the effect of functional CTA end groups on 
pH-responsive behavior of the nanoparticles, analogues of P22 and P26 (P22OH and P26OH) 
were synthesized by utilizing a non-ionizable hydroxyl functional chain transfer agent 4-cyano-4-
((dodecylsulfanylthiocarbonyl)sulfanyl)pentanol (CDP). 
 
Scheme 4.1 Schematic representation of the RAFT copolymerization of THP-HEMA with 
DMAEMA. 
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Table 4.1 Selected characterization data of the THP-HEMA (M1) (co)polymers with DMAEMA 
(M2). 
Entry 
Monomer/ 
CTA/ACPA 
f(M1/ 
M2) a 
F(M1/ 
M2)b 
Conv. 
[%]c 
M1/M2 
Mn,theo.
d 
[g mol-1] 
DPc 
M1/M2 
Mn
c 
[g mol-1] 
Mn,SEC
e 
[g mol-1] 
Đe Tg [°C]
 f 
P22 45.37/1/0.25   85/0 8,500 40/0 8,800 6,300 1.13 29.4 
P22OH 45.37/1/0.25   90/0 9,000   6,800 1.24 - 
P23 45.98/1/0.25 19 15.7 85/84 8,500 36/2.3 8,300 5,700 1.18 30.6 
P24 46.61/1/0.25 9 8.2 80/90 8,100 33/4 7,800 5,600 1.18 28.0 
P25 47.26/1/0.25 5.7 5.6 76/84 7,800 31/5.5 7,800 6,200 1.17 29.9 
P6 47.92/1/0.25 4 4 84/87 8,500 29/7.3 7,600 6,300 1.18 29.1 
P26OH 47.92/1/0.25 4 4 82/90 8,600   6,400 1.27 - 
aInitial monomer feed ratio. bMonomer ratio in the isolated copolymer. cDetermined by 1H NMR 
spectroscopy. dDetermined by the formula Mn,theo. = [([M]M1/[CTA] × Conv. × MM1) + 
([M]M2/[CTA] × Conv. × MM2) + (MCTA)]. 
eDetermined by SEC in CHCl3 analysis (RI detection, 
PMMA calibration). fDetermined by DSC analysis. 
Differential scanning calorimetry (DSC) studies under nitrogen atmosphere revealed that 
polymers exhibit single Tg temperatures ranging from 29.1 to 30.6 °C. The pendant tertiary amino 
moieties of the polymers were quaternized by treating with an excess of methyl iodide in order to 
study the pH response of the nanoparticles prepared from permanently positively charged 
polymers (P23q to P26q). The nanoparticles were obtained from the synthesized (co)polymers 
(P22 to P26, P22OH, P26OH, P22q to P26q) using the nanoprecipitation method. Quaternized 
polymers (P23q to P26q) resulted in smaller nanoparticles compared to unquaternized ones (P23 
to P26) for both dropping methods as a result of permanently charged groups in quaternized 
polymers (P23q to P26q).[69] 
Table 4.2 Selected characterization results of the prepared nanoparticles. 
Entry Z-average [d, nm]a PDIa ζ-potential [mV]b 
AWc WAd AWc WAd AWc WAd 
P22 108 ± 1 242 ± 3 0.14 ± 0.01 0.01 ± 0.01 - 31 ± 1  - 26 ± 1 
P22OH 119 ± 1 223 ± 3 0.08 ± 0.02 0.08 ± 0.02 - 33 ± 1 - 25 ± 1 
P23q   57 ± 1 182 ± 1 0.23 ± 0.01 0.06 ± 0.01 + 29 ± 1 + 37 ± 2 
P24   98 ± 1 216 ± 3 0.13 ± 0.02 0.03 ± 0.01 + 42 ± 1 + 46 ± 6 
P24q   42 ± 1 172 ± 2 0.26 ± 0.01 0.07 ± 0.02 + 54 ± 3 + 57 ± 1 
P25 130 ± 1 233 ± 1 0.13 ± 0.01 0.01 ± 0.01 + 48 ± 1 + 30 ± 1 
P25q   38 ± 1 120 ± 1 0.28 ± 0.01 0.11 ± 0.01 + 65 ± 3 + 48 ± 1 
P26 120 ± 1 247 ± 2 0.11 ± 0.01 0.02 ± 0.01 + 45 ± 1 + 47 ± 1 
P26OH 89 ± 1 229 ± 3 0.15 ± 0.11 0.05 ± 0.03 + 42 ± 1 + 51 ± 1 
P26q  51 ± 1 138 ± 2 0.28 ± 0.01 0.01 ± 0.01 + 48 ± 5 + 63 ± 2 
PMMA - 187 ± 1 - 0.03 ± 0.03 - - 18 ± 1 
aAverage values of three DLS measurements. bAverage values of three ζ-potential measurements 
in pure water. cDropping acetone to water. dDropping water to acetone. 
In order to investigate the effect of the pH value on the size and the surface charge of the 
nanoparticles, variations in the diameter and zeta potential values of the nanoparticles were 
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studied at different pH values after 1 h of incubation at 37 °C. P22 nanoparticles possessed stable 
size and PDI values at neutral and basic pH values (pH = 7.4, 8, and 9) (Figure 4.1). Upon 
lowering the pH value below 7.4, a gradual increase in the size was observed. This is due to the 
decrease in the ζ-potential values from ˗66 mV at a pH value of 9 to ˗19 mV at a pH value of 6.3. 
In accordance with this, P22 nanoparticles were precipitated around a pH value of 6.3. Below its 
isoelectric point (IEP) (the pH value at which the surface charge of the nanoparticles is zero), P22 
nanoparticles became positively charged. Lovett et al. reported that a carboxylic acid based CTA 
can be ionized in neutral media and protonated at acidic pH values leading to a nanoparticle ζ-
potential conversion.[75] As a consequence, the observed IEP of the P22 nanoparticles was first 
attributed to the protonation of the carboxyl end-group of the polymers. However, similar results 
were observed with P22OH nanoparticles that contain a hydroxyl functional CTA instead of a 
carboxyl functionality. Therefore, exhibition of IEPs for both polymers was attributed to the 
existence of THP-HEMA groups. In contrast to P22 and P22OH, the P24 nanoparticles were 
stable in the pH range from 4 to 6 with ζ-potential values higher than +58 mV as a result of 
protonated DMAEMA groups. At a pH value of 3.1, P24 nanoparticles exhibited a significant 
decrease in size from 200 to 80 nm. This was ascribed to the protonation of the DMAEMA as 
well as the THP-HEMA groups. The protonation of the THP-HEMA moieties was expected to 
result in a cleavage of the cyclic acetal functionality of the THP-HEMA pendants. However, 1H 
NMR studies revealed that even with an incubation in 0.1 acetic acid (pH = 3.1) at 37 °C for 24 h 
a negligible acetal group cleavage was observed indicating the slow cleavage of the THP-HEMA 
moieties. Between the pH values from 6.3 to 7.4, P24 nanoparticles were aggregated due to the 
insufficient ζ-potential values (lower than ±20 mV) as a result of the deprotonated DMAEMA 
moieties. However, at a pH value of 8 and above, they became stable due to having ζ-potential 
values beyond ˗37 mV. In contrast to P24, the size of the P25 decreased from 200 nm to 33 nm at 
pH 4. Moreover, prolonging the incubation time to 6 h resulted in dissolution of the polymers in 
acidic media as a result of the protonation of the DMAEMA groups. In agreement with this, P26 
nanoparticles that contain a higher DMAEMA content than P25 revealed dissolution even at a pH 
value of 5. Moreover, it was observed that the IEP of the nanoparticles shifted to the higher pH 
values as the DMAEMA content of the polymers increases.  
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Figure 4.1 (A) Intensity-weighted size and PDI values of the nanoparticles as a function of the 
pH value. (B) ζ-Potential values of the nanoparticles as a function of the pH value. 
Ultrasound responsiveness of the nanoparticles was investigated by exposing the nanoparticles to 
ultrasound with a power of 20 W and a frequency of 26 kHz. The variations in particle size, PDI 
value and derived count rate were recorded by DLS at intervals of 5 minutes of the ultrasound 
treatment. DLS measurements revealed a gradual increase in size and PDI values but a 
continuous decrease in the derived count rate upon prolonged ultrasound exposure for all 
nanoparticles due to the disassembly of the nanoparticles upon ultrasound treatment. In 
agreement with this, SEM measurements revealed that uniform spherical shapes of the 
nanoparticles distorted to irregular larger aggregates and some smaller structures. In a control 
experiment, PMMA nanoparticles did not show any response to the applied ultrasound. After 
ultrasound treatment no change in the 1H NMR spectrum of the nanoparticles was observed. As a 
consequence, the ultrasound responsiveness of the nanoparticles was attributed to the elastic 
nature (low Tg values) of the corresponding THP-HEMA based polymers. In agreement with this 
assumption, a control experiment with poly(methyl acrylate) (PMA) (Tg = 16 °C) nanoparticles 
revealed similar responsive behavior to ultrasound. As a consequence, ultrasound behavior of the 
THP-HEMA based nanoparticles ascribed to their high motion abilities as a result of having low 
Tg values. Nile Red was used as a model compound to study the ability of the nanoparticles to 
encapsulate hydrophobic guest molecules. It is known that the fluorescence of Nile Red is 
sensitive to its environment.[76] Nanoparticles prepared from unquaternized polymers exhibited 
similar emission intensities as well as comparable emission wavelength maxima (Figure 4.2 A) 
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indicating that the cores of the nanoparticles have similar hydrophobicities. However, quaternized 
nanoparticles exhibited a gradual decrease in the emission intensity of Nile Red upon increasing 
the ratio of the quaternized DMAEMA content. Moreover, a continuous red shift in the emission 
wavelength maximum of Nile Red was observed as the quaternized DMAEMA content increased 
in the polymers (Figure 4.2 B). This indicates that simply by variation of the amount of the 
charged groups in the polymers the hydrophilicity of the core of the nanoparticles can be tuned. 
Additionally, dye release experiments demonstrated that release of Nile Red was significantly 
accelerated in acidic media or upon ultrasound exposure. 
 
Figure 4.2 Fluorescence emission spectra of Nile Red encapsulated into nanoparticles (0.5 mg 
mL−1) formed by P22, P24 to P26 (A) as well as P22, P23q to P26q (B). 
Polymersomes, also known as polymeric vesicles, are hollow structures enclosed by a polymeric 
bimembrane composed from amphiphilic copolymers.[77-79] Polymersomes contain an aqueous 
interior and a hydrophobic membrane. As a consequence, they are capable to encapsulate both 
hydrophobic and hydrophilic molecules.[80] Stimuli responsive polymersomes usually release the 
encapsulated drugs in response to a certain stimuli by swelling, dissolution, precipitation or 
collapsing.[81] However, polymersomes can also undergo morphology transition in response to 
stimuli when their membranes have enough chain motilities.[46, 82] In particular, vesicle-to-micelle 
transitions are of particular interest for the controlled delivery of hydrophilic molecules as a 
result of offering a loss of aqueous cavities within the vesicles.[83-85] It is known that 
polymersomes can undergo shape transformations in response to stimuli when their membrane 
has a sufficient chain mobility. As a consequence, three well-defined diblock copolymers of 
poly((THP-HEMA)-b-DMAEMA) were synthesized by reversible addition-fragmentation chain 
transfer (RAFT) polymerization using a macro chain transfer approach (Scheme 4.2) in order to 
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obtain a polymersome system with pH value dependent morphology transition abilities. The 
macro chain transfer agent (P27) was synthesized by RAFT polymerization of THP-HEMA using 
CPADB as CTA. The mean DP of the P27 was estimated to be 35 using 1H NMR end group 
analysis. For the synthesis of diblock copolymers, P27 was utilized as RAFT CTA and ACVA as 
initiator (Scheme 4.2).  
 
Scheme 4.2 (A) Schematic representation of the synthesis of P27 via RAFT polymerization of 
THP-HEMA and (B) its subsequent chain extension with DMAEMA. 
To identify the optimal monomer composition for a polymersome formation, the length of the 
p(THP-HEMA) block was kept constant and the DP of p(DMAEMA) block was systematically 
varied from 21 to 50 by variation of the [P27] to [DMAEMA] ratio or the polymerization time. 
The mean DPs of the DMAEMA block of the copolymers were calculated via 1H NMR 
spectroscopy by comparing the integral values of the characteristic signals of DMAEMA with 
THP-HEMA. SEC analysis demonstrated a narrow molar mass distribution (Đ < 1.1) for all 
polymers indicating the effectiveness of P27 for the controlled RAFT polymerization of 
DMAEMA (Table 4.3). Differential scanning calorimetry (DSC) analysis revealed that all 
copolymers have single Tg temperatures in the range of 21 to 25 °C suggesting that THP-HEMA 
and DMAEMA block segments are thermodynamically miscible. Self-assembly behavior of the 
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amphiphilic diblock copolymers in water was investigated utilizing the nanoprecipitation method 
using dropping water into acetone polymer solutions with an initial polymer concentration of 5 
mg mL-1. 
Table 4.3 Selected characterization data of the block copolymers (P28 to P30). 
Entry 
DMAEMA/ 
mCTAa 
mCTA/ 
ACVAb 
Polym. 
time [h] 
Conv. 
[%]c 
DPtheo.
d 
Mn,theo.
e 
[g mol-1] 
DPf 
 
Mn
g 
[g mol-1] 
Mn,SEC
i 
[g mol-1] 
Đ
i Tg
j 
P28 49.62/1 15/1 4 36 18 10,600 21 11,100 8,300 1.09 24.9 
P29 49.62/1 15/1 8 58 29 12,400 30 12,500 9,300 1.08 23.4 
P30 102.54/1 15/1 7 49 50 15,700 50 15,700 11,200 1.10 20.7 
a
Monomer to mCTA ratio. 
b
mCTA to ACVA ratio. 
c
Determined by 
1
H NMR spectroscopy. 
d
Determined by the formula DPtheo. = [([M]/[mCTA] × Conv.]. 
e
Determined by the formula 
Mn,theo. = [([M]/[mCTA] × Conv. × MmCTA) + (MmCTA)]. 
f
Determined by 
1
H NMR spectroscopy of 
isolated polymers. 
g
Determined by the formula Mn,theo. = [(DP × MDMAEMA) + MmCTA]. 
i
Determined by SEC in DMAc analysis (RI detection, PS calibration). 
j
Determined by DSC 
analysis. 
A monomodal number distribution with an average hydrodynamic diameter (Dav) of 30 nm was 
observed by DLS for the P28 suspensions. However, some small number of medium sized 
aggregates (Dav ~300 nm) could also be observed in the volume distribution. In accordance with 
this, cryo-TEM analysis exhibited predominantly polydisperse vesicles ranging from 20 to 90 nm 
diameters and some larger spherical aggregates (~200 nm). The bilayer thickness of the 
polymersomes was found to be around 8 ± 2 nm. DLS measurements revealed a monomodal 
number distribution (Dav = 15 nm) for the P29 suspensions. Some larger structures were also 
observed in the DLS volume distribution with a Dav of 120 nm. Cryo-TEM measurements 
revealed a coexistence of spherical micelles with diameters around 12 nm and polydisperse 
vesicles which have diameters ranging from 30 to 180 nm. For the P30 suspensions, DLS 
measurements showed a monomodal number distribution (Dav = 10 nm). In agreement with this, 
cryo-TEM analysis exhibited homogeneous spherical micelles that have diameters around 10 nm. 
These results indicate that the morphology of the suspensions changes from vesicles to spherical 
micelles as the block length of the DMAEMA increases as a result of the increased 
hydrophilicity, which correlates with before reported literature.[79] The hydrophilicity of the 
synthesized block copolymers can also be varied by the variation of the pH value of the 
environment as a result of the pH responsiveness of the DMAEMA block. As a consequence, the 
pH responsive behavior of the polymersomes was investigated by examining the variations in 
diameters and zeta potentials at different pH values after 3 h of incubation at 37 °C. The P28 
suspensions exhibited a stable size distribution at neutral pH values (pH = 7.0 and 7.4). However, 
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an increase in the diameter of the polymersomes was observed at a pH value of 8.0. This is due to 
the decrease of the ζ-potential of the polymersomes from +33 mV at pH 7.4 to +20 mV at pH 8.0 
due to the partial deprotonation of the DMAEMA moieties. In accordance with this, the 
polymersomes were precipitated at pH value of 9.0 as a result of a further decrease of the ζ-
potential from +20 mV to ˗11 mV. In contrast, a decrease of the pH value from neutral to acidic 
pH values resulted in a continuous decrease in the diameter and an increase in the ζ-potential 
values. Moreover, the turbid solution became transparent at acidic pH values.  
 
Figure 4.3 DLS plots and cryo-TEM images of the suspensions obtained from P28, P29, and P30 
in water (c = 2.5 mg mL-1). 
Cryo-TEM measurements revealed exclusively vesicular aggregates with clearly visible 
membranes at pH 7.4. On the contrary, only homogeneous spherical micelles were observed at a 
pH value of 5.0. As a consequence, the decrease in the diameter upon decreasing the pH to acidic 
values was correlated to the morphology transition from vesicles to micelles as a result of an 
increase of the polymer hydrophilicity. The critical aggregation concentration (CAC) of the 
polymersomes was calculated as 0.084 mg mL-1 using Nile Red as a fluorescent probe. The 
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calculated CAC of the polymersomes is slightly lower than the before reported values for p(THP-
HEMA) copolymer based micelles.[32] The ability of polymersomes to encapsulate hydrophilic 
molecules was investigated using the water soluble anticancer drug doxorubicin hydrochloride 
(DOX). DOX was loaded in P28 polymersomes utilizing nanoprecipitation. DLS measurements 
exhibited a number average diameter of 30 nm and a ζ-potential of +30 mV for the DOX-loaded 
polymersomes. Cryo-TEM investigations showed relatively uniform vesicular structures. The 
drug loading efficiency and drug loading content were calculated by fluorescence measurements 
as 30.7% and 1.5%, respectively. The DOX experiments revealed that DOX was released from 
the polymersomes faster at a pH value of 5.0 compared to 7.4. This was attributed to the 
morphology change of the polymersomes at acidic pH values to micelles that cause a loss of 
hydrophilic aqueous cavities. 
 
Figure 4.4 (A) Cryo-TEM image of the P28 suspension at pH 7.4. (B) Photograph of vial 
containing the P28 suspension at pH 7.4. (C) Cryo-TEM image of the P28 suspension at pH 5.0. 
(D) Photograph of vial containing the P28 suspension at pH 5.0. (E) Schematic illustration of the 
pH value change induced vesicle-to-micelle morphology transition as a result of an increase of 
the volume of hydrophilic blocks at acidic media. 
The cytotoxicity studies of copolymer aqueous nanoparticle suspensions revealed that P28 is not 
toxic to L929 cells after 48 h incubation up to a concentration of 250 µg mL-1. However, the P28 
suspensions exhibited toxic effects to the cells starting from 300 mg mL-1 became more 
pronounced Figure 4.5 A). The cytotoxicity of P28 suspensions was ascribed to the 
p(DMAEMA) block, which can induce toxic effects to cells as a result of its cationic character.[86-
87] The P29 suspensions revealed similar cell viabilities compared to P28 at the tested 
concentrations. However, the P30 suspensions that contains the longest p(DMAEMA) block 
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exhibited the highest toxic effects to the cells. Moreover, the cytotoxicity of the DOX-loaded 
polymersomes was also evaluated in comparison with free DOX (Figure 4.5 B). The results 
exhibited that DOX-loaded polymersomes had similar cell killing efficiencies as the free DOX.   
 
Figure 4.5 (A) Cytotoxicity test of P28, P29, and P30 aqueous suspensions in L929 cells after 
48 h incubation. (B) Cytotoxicity test of DOX·HCl encapsulated P28 suspensions and free 
DOX·HCl in L929 cells. The relative viability is expressed as percentage to control cells not 
treated with NPs. Untreated cells on the same well plate were used as positive controls. 
Confocal laser scanning microscopy (CLSM) was used to monitor the cellular uptake of the DOX 
loaded polymersomes and the free DOX. The red fluorescence of DOX was clearly observed in 
the nucleus of L929 cells after incubation for only 2 h indicating the efficient cellular uptake of 
DOX loaded polymersomes and the fast release of the DOX in the endo/lysosomes as a result of 
the morphology change. A longer incubation time of DOX loaded polymersomes to 24 h yielded 
a stronger DOX fluorescence. Similar results were obtained with free DOX. The cellular uptake 
of the DOX-loaded polymersomes and the free DOX were further quantified through flow 
cytometry. Flow cytometry results indicated that fluorescence intensity of the DOX-loaded 
polymersomes is higher than that of the free DOX after 2 h and this becomes even more 
pronounced for longer incubation times. This indicated that DOX-loaded polymersomes entered 
the cells faster than the free DOX. It is known that cationic nanoparticle systems can be uptaken 
by the cells even faster than small molecules including the free DOX.[88-90] Therefore, the faster 
uptake of the DOX-loaded polymersomes was attributed to their positive surface charges. 
These results show that the glass transition temperature of the polymers represents an important 
parameter for the stimuli-responsive behavior of the nanoparticles.  
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5. Summary 
Stimuli-responsive polymeric nanoparticles have recently gained tremendous attention, in 
particular in the field of controlled drug delivery as a result of offering prolonged circulation 
times and on demand delivery. The tailor-made design of stimuli-responsive nanoparticles mostly 
relies on the incorporation of desired stimuli-responsive motifs into the polymers. However, the 
challenge is to synthesize the corresponding polymers in a well-defined and reproducible way. In 
the context of the synthesis of stimuli-responsive polymers, the reversible addition fragmentation 
chain transfer (RAFT) polymerization process is advantageous compared to other techniques due 
to its high tolerance to various functional groups and polymerization conditions. After the 
synthesis of the stimuli responsive polymers, it is also crucial to formulate the resulting stimuli-
responsive nanoparticles in a controlled way. Nanoprecipitation represents a facile and reliable 
way to produce polymeric nanoparticles. As a result, the RAFT polymerization process and the 
nanoprecipitation technique were selected as the methods of choice within this thesis for the 
synthesis of (multi)functional polymers and the formation of the corresponding nanoparticles. 
The presented thesis represents an overview of (i) the synthesis of various new stimuli-responsive 
polymers with tailor-made functionalities and polymer structures, (ii) the formulation of stimuli-
responsive nanoparticles via nanoprecipitation, (iii) the investigation of stimuli-responsive 
behavior of the nanoparticles, as well as (iv) the evaluation of synthesized nanoparticles for drug 
delivery applications (Figure 5.1).   
It is shown that methyl methacrylate (MMA) could be copolymerized with various amino 
methacrylates including primary amino functional 2-aminoethyl methacrylate hydrochloride 
(AEMA·HCl), secondary amino functional 2-(tert-butylamino)ethyl methacrylate (tBAEAMA) 
and tertiary amino functional 2-(dimethylamino)ethyl methacrylate (DMAEMA) using the RAFT 
polymerization process. Furthermore, it is demonstrated that nanoprecipitation of these polymers 
yielded pH responsive PMMA based nanoparticles. The resulting nanoparticles exhibited a pH 
responsive behavior in a way that strongly depends on the amount and the chemical structure of 
the amino groups of the polymers. Additionally, it was proven that these nanoparticles can host 
hydrophobic compounds at neutral pH values and release them at acidic pH values as a result of 
their dissolution abilities.  
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Figure 5.1 Schematic representation of the workflow of the represented studies in this thesis.  
The primary amino groups enable the covalent conjugation of bioactive molecules to the 
polymers using various reactions. In this context it was demonstrated that retinoic acid and a 
fluorescent dye could be successfully coupled to the AEMA·HCl functionalized PMMA based 
copolymer. The utilization of the nanoprecipitation method for the modified polymers resulted in 
cationic nanoparticles. Raman imaging studies demonstrated that retinoic acid (RA) 
functionalized nanoparticles can be detectable in cells without any need of additional labels. 
Moreover, the conjugation of the dye allowed monitoring nanoparticles via intravital microscopy. 
The incorporation of disulphide bridges into copolymer pendants enables the possibility to obtain 
glutathione responsive nanoparticles. To this end, the RAFT polymerization process was used for 
the preparation of a statistical copolymer library of pyridyldisulfide ethylmethacrylate (PDSM) 
with 2-((tert-butoxycarbonyl)(2-((tert-butoxycarbonyl)amino)ethyl)amino)-ethyl methacrylate 
(Boc-AEAEMA). The nanoprecipitation method was utilized to formulate nanoparticles. It was 
observed that an increase of the AEAEMA content leads to a decrease of the nanoparticles size. 
The resulting nanoparticles were found to be responsive both to the glutathione concentration as 
well as the pH value. It could be shown that these nanoparticles can encapsulate the antitumor 
drug doxorubicin hydrochloride, carry it into the cells and release it in a response to intracellular 
glutathione concentration and pH value change.  
Exogenous stimuli responsive nanoparticles have also gained increased interest for drug delivery 
applications. Particular interest in this regards focused on the ultrasound responsiveness. The 
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RAFT polymerization process was used to synthesize a well-defined statistical copolymer library 
of 2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl methacrylate (THP-HEMA) with DMAEMA with 
different monomer compositions. The nanoparticle suspensions of these polymers were prepared 
by nanoprecipitation method. The pH-responsive behavior of the nanoparticles showed that 
incorporation of DMAEMA units into THP-HEMA based nanoparticles can provide effective 
pH-dependent surface charge conversion features. Moreover, it was shown that the disassembly 
pH value and the isoelectric point (IEP) of the nanoparticles could be systematically tuned by 
varying the DMAEMA content of the polymers. The ultrasound responsiveness tests revealed 
that THP-HEMA nanoparticles are responsive to ultrasound as a result of their high chain 
mobility. Moreover, cytotoxicity studies demonstrated that positively charged nanoparticles at the 
pH value of the cell media exhibited toxic effects to the cells, whereas the negatively charged 
nanoparticles were biocompatible and not cytotoxic. 
Besides sustaining ultrasound responsiveness, the high chain mobility of THP-HEMA based 
polymers can possibly allow to obtain nanoparticles that also exhibit morphology transition in a 
response to a stimulus. In this context, three different block copolymers of THP-HEMA and 
DMAEMA were synthesized via RAFT polymerization by utilization of p(THP-HEMA) as a 
macro chain transfer agent. The length of the p(THP-HEMA) block was kept constant, whereas 
the length of the p(DMAEMA) block was systematically varied. Self-assembly studies 
demonstrated that the block copolymer with the shortest p(DMAEMA) block favors 
polymersome formation in water, whereas an increase of the DP of the p(DMAEMA) resulted in 
micellar structures. It was demonstrated that polymersomes undergo a morphology transition 
from vesicles to micelles in response to a decrease of the pH value from neutral to acidic values. 
Furthermore, it was verified that the polymersomes are capable of encapsulating DOX and 
transporting it into cells.  
In summary, this thesis presents the synthesis of new stimuli-responsive polymers and the 
formulation of their corresponding nanoparticles. The nanoparticle systems show promising 
properties for potential drug delivery applications.  
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6. Zusammenfassung 
Polymere Nanopartikel, welche auf einen bestimmten Reiz reagiesen, haben vor kurzem eine 
enorme Aufmerksamkeit erlangt, insbesondere im Bereich der kontrollierten Arzneimittelabgabe, 
da sie längere Verweilzeiten haben und nach Bedarf liefern. Die maßgeschneiderte Gestaltung 
von solchen reaktionsfähigen Nanopartikeln beruht meist auf dem Einbau von gewünschten 
reaktiven Motiven in die Polymere, sogenannte stimuli-responsive Polymere. Die 
Herausforderung besteht jedoch darin, die entsprechenden Polymere in einer klar definierten und 
reproduzierbaren Weise zu synthetisieren. Im Rahmen der Synthese von stimuli-responsiven 
Polymeren ist die reversible Additions-Fragmentierungs-Kettentransfer (RAFT) Polymerisation 
im Vergleich zu anderen Techniken aufgrund ihrer hohen Toleranz gegenüber verschiedenen 
funktionellen Gruppen und Polymerisationsbedingungen vorteilhaft. Nach der Synthese der auf 
Stimuli reagierenden Polymere ist es auch entscheidend, die resultierenden stimuli-responsiven 
Nanopartikel kontrolliert zu formulieren. Die Nanofällung stellt eine einfache und zuverlässige 
Methode zur Herstellung von Polymer-Nanopartikeln dar. Somit wurden in dieser Arbeit RAFT-
Polymerisationsverfahren und die Nanofällung als Methoden der Wahl für die Synthese von 
(multi) funktionellen Polymeren und die Formulierung zu entsprechenden Nanopartikeln 
ausgewählt. 
Die vorliegende Arbeit stellt einen Überblick über (i) die Synthese verschiedener neuer stimuli-
reaktionsfähiger Polymere mit maßgeschneiderten Funktionalitäten und Polymerstrukturen dar, 
(ii) die Formulierung von stimuli-reaktionsfähigen Nanopartikeln durch Nanofällung, (iii) die 
Untersuchung des stimuli-responsiven Verhaltens der Nanopartikel sowie (iv) die Auswertung 
von synthetisierten Nanopartikeln für Arzneimittelabgabeanwendungen (Abbildung 6.1). 
Es konnte gezeigt werden, dass Methylmethacrylat (MMA) mit verschiedenen 
Aminomethacrylaten einschließlich primären Aminofunktionen 2-Aminoethylmethacrylat-
hydrochlorid (AEMA·HCl), sekundären Aminofunktionen 2-(Tert-Butylamino) ethylmethacrylat 
(tBAEAMA) und tertiären Aminofunktionen 2-(Dimethylamino) ethylmethacrylat (DMAEMA) 
unter Verwendung von RAFT-Polymerisationsverfahren copolymerisiert werden könnte. 
Weiterhin wird gezeigt, dass die Nanofällung dieser Polymere PMMA-basierte Nanopartikel 
ergab, welche auf pH-Wertveränderungen reagieren. Dieses Verhalten hängt stark von der Menge 
und der chemischen Struktur der Aminogruppen der Polymere ab. Darüber hinaus wurde 
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bewiesen, dass diese Nanopartikel hydrophobe Verbindungen bei neutralen pH-Werten 
einschließen und sie bei niedrigen pH-Werten infolge ihrer Löslichkeit freisetzen können. 
 
Abbildung 6.1 Schematische Darstellung des Arbeitsablaufs der dargestellten Studien in dieser 
Arbeit. 
Die primären Aminogruppen erlauben die kovalente Anbindung von bioaktiven Molekülen an die 
Polymere mittels verschiedener Reaktionen. In diesem Zusammenhang wurde gezeigt, dass 
Retinolsäure (RA) und ein Fluoreszenzfarbstoff erfolgreich an das AEMA·HCl-funktionalisierte 
Copolymer auf PMMA-Basis gekoppelt werden konnten. Die Verwendung der Nanofällung für 
die modifizierten Polymere führte zu kationischen Nanopartikeln. Raman-Imaging-Studien 
zeigten, dass RA-funktionelle Nanopartikel in Zellen nachweisbar sind, ohne dass zusätzliche 
Marker benötigt werden. Darüber hinaus erlaubte die Konjugation des Farbstoffs die 
Überwachung von Nanopartikeln mit Hilfe der intravitalen Mikroskopie. 
Der Einbau von Disulfidbrücken in Copolymer-Seitenketten ermöglicht die Herstellung von, 
redoxaktiven Nanopartikeln. Zu diesem Zweck wurde ein RAFT-Polymerisationsverfahren für 
die Herstellung einer statistischen Copolymerbibliothek von Pyridyldisulfid ethylmethacrylat 
(PDSM) mit  2-((Tert-Butoxycarbonyl)(2-((tert-butoxycarbonyl) amino) ethyl) amino) 
ethylmethacrylat (Boc-AEAEMA) verwendet. Die Nanofällung wurde erneut zur Formulierung 
von Nanopartikeln verwendet. Es wurde beobachtet, dass eine Erhöhung des AEAEMA-Gehalts 
zu einer Abnahme der Nanopartikelgröße führt. Es konnte weiterhin festgestellt werden, dass die 
resultierenden Nanopartikel sowohl auf die Glutathionkonzentration als auch auf den pH-Wert 
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ansprechen. Das Antitumor-Medikament Doxorubicin-Hydrochlorid wurde in die Nanopartikel 
eingekapselt, in die Zellen transportiert und entsprechend der intrazellulären Glutathion-
Konzentration und der pH-Wert-Änderung freigesetzt. 
Exogene stimuli-responsive Nanopartikel haben ebenfalls an Interesse für Anwendungen in der 
Arzneimittelabgabe gewonnen. Besonderes Interesse in dieser Hinsicht konzentriert sich auf 
Partikel, die auf Ultaschall reagieren. Das RAFT-Polymerisationsverfahren wurde verwendet, um 
eine definierte, statistische Copolymerbibliothek von THP-HEMA mit DMAEMA mit 
verschiedenen Monomerzusammensetzungen zu synthetisieren. Die Nanopartikel-Suspensionen 
dieser Polymere wurden nach dem Nanofällungsverfahren hergestellt. Das Verhalten der 
Nanopartikel zeigt, dass der Einbau von DMAEMA-Einheiten in THP-HEMA-basierte 
Nanopartikel zu einer Umwaldung der Oberflächenladung in Abhängigkeit der pH-Wertes führen 
kann. Darüber hinaus wurde gezeigt, dass der kritische-pH-Wert und der Isoelektrische Punket 
(IEP) der Nanopartikel systematisch durch Variation des DMAEMA-Gehaltes der Polymere 
abgestimmt werden konnten. Die Ultraschall empfindlich zeigt, dass THP-HEMA-Nanopartikel 
aufgrund ihrer hohen Kettenmobilität auf Ultraschall reagieren. Darüber hinaus zeigten 
Zytotoxizitätsstudien, dass positiv geladene Nanopartikel bei dem pH-Wert im Zellmedien 
toxisch für Zellen sind, während die negativ geladenen Nanopartikel biokompatibel und nicht 
zytotoxisch sind. 
Neben der Sensibilität auf Ultraschall kann die hohe Kettenbeweglichkeit von THP-HEMA-
basierten Polymeren möglicherweise zu, Nanopartikeln führen, die einen Morphologiewechsel 
als Reaktion auf einen Stimulus aufweisen. In diesem Zusammenhang wurden drei verschiedene 
Blockcopolymere von THP-HEMA und DMAEMA mittels RAFT-Polymerisation unter 
Verwendung von p(THP-HEMA) als Makro-Kettenübertragungsmittel synthetisiert. Die Länge 
des p(THP-HEMA)-Blocks wurde konstant gehalten, während die Länge des p(DMAEMA)-
Blocks systematisch variiert wurde. Versuche zur Selbstorganisation zeigten, dass das 
Blockcopolymer mit dem kürzesten p(DMAEMA)-Block die Bildung von Vesikeln in Wasser 
begünstigt, während eine Erhöhung des DP des p(DMAEMA) zu mizellaren Strukturen führte. Es 
wurde gezeigt, dass Polymere einen Morphologieübergang von Vesikeln zu Micellen in Reaktion 
auf eine Abnahme des pH-Wertes von neutral zu sauer erfahren. Weiterhin wurde bestätigt, dass 
die Polymere in der Lage sind, DOX zu verkapseln und in Zellen zu transportieren. 
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Zusammenfassend stellt diese Arbeit die Synthese von neuartigen stimuli-responsiven Polymeren 
und die Formulierung ihrer entsprechenden Nanopartikel dar. Die Nanopartikel-Systeme weisen 
potentiell interessante Eigenschaften für mögliche Anwendungen als Medikamententransporter 
auf. 
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List of abbreviations 
ACVA 4,4′-Azobis(4-cyanovaleric acid) 
AEMA 2-Aminoethyl methacrylate  
AEMA·HCI 2-Aminoethyl methacrylate hydrochloride 
AIBN 2,2′-Azobis(2-methylpropionitrile) 
ATRP Atom transfer radical polymerization 
BocAEAEMA 2-((tert-Butoxycarbonyl)(2-((tert-butoxycarbonyl)amino)ethyl)amino)-ethyl 
methacrylate 
CAC Critical aggregation concentration 
CDP 4-Cyano-4-((dodecylsulfanylthiocarbonyl)sulfanyl)pentanol 
CLSM Confocal laser scanning microscopy 
CPADB 4-Cyano-4-(phenylcarbonothioylthio) pentanoic acid 
cryo-TEM Cryo-transmission electron microscopy 
CTA Chain transfer agent 
Đ Dispersity 
DCC N,N’-Dicyclohexylcarbodiimide 
DLS Dynamic light scattering 
DMAc N,N-Dimethylacetamide 
DMAEMA 2-(Dimethylamino)ethyl methacrylate 
DMF Dimethylformamide 
DOX Doxorubicin hydrochloride 
DP Degree of polymerization 
DSC Differential scanning calorimetry 
GSH Glutathione 
HSC Hepatic stellate cells 
IEP Isoelectric point 
LSECs Liver sinusoidal endothelia cells 
MMA Methyl methacrylate 
Mn Number average molar mass 
NHS N-Hydroxysuccinimide 
NMP Nitroxide mediated polymerization 
NMR Nuclear magnetic resonance 
NP Nanoparticle 
PDI Polydispersity index 
PDSM Pyridyldisulfide ethylmethacrylate 
PLGA Poly(lactide-co-glycolide) 
PMA Poly(methyl acrylate) 
PMMA Poly(methyl methacrylate) 
RA Retinoic acid 
RAFT Reversible addition fragmentation chain transfer 
RDRP Reversible deactivation radical polymerization 
SEC Size exclusion chromatography 
SEM Scanning electron microscopy 
tBAEMA 2-(tert-Butylamino)ethyl methacrylate 
Tc Crystallization temperature 
Tg Glass transition temperature 
THP-HEMA 2-((Tetrahydro-2H-pyran-2-yl)oxy)ethyl methacrylate 
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Abstract 21 
The administration of drugs, as a main challenge of pharmaceutical and medicinal applications, has certainly 22 
benefited from the application of synthetic polymers. However, despite an enormous effort to develop new 23 
materials for drug delivery applications, only few of them have entered the market due to the hurdles of 24 
regulation, production, cost efficiency and both industrial’s and patients’ acceptance. In this review, we summarize 25 
all these classes of synthetic polymers, which are on the market as well as the latest developments in clinical trials, 26 
and describe their application in polymer-drug conjugates, as excipients, in nano-/microscopic and macroscopic 27 
drug carriers, as polymeric coatings, or as polymeric drugs. Our intention is to create a link between the underlying 28 
chemical structures, the properties of the polymers, and their area of application, where they are often just known 29 
by their trade names or abbreviations. In addition selected types of synthetic polymers are highlighted that feature 30 
interesting properties and have the potential to make it to the market in future. 31 
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1. Introduction 59 
 60 
The administration of drugs is one of the main tasks within the area of pharmaceutical and medicinal applications. 61 
Drugs are defined as "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of 62 
disease" and "articles (other than food) intended to affect the structure or any function of the body of man or 63 
other animals” by the Federal Food, Drug, and Cosmetic Act (FD&C Act). Starting in the early 1960s, controlled drug 64 
delivery research has broadened and has developed from macroscopic devices and implants (1970s and 1980s) to 65 
microscopic (1980s and 1990s) as well as nanoscopic systems.[1] Besides liposomes, nanocrystals, bio-compatible 66 
metal-organic frameworks and others, polymeric materials represent a useful option to fulfill the challenges of drug 67 
storage and delivery. They can be subdivided into natural, pseudo-synthetic and synthetic macromolecules. 68 
The latter offer several advantages compared to natural polymers like an easier synthesis of large quantities, 69 
nonsignificant batch-to-batch variations and countless possibilities for modifications to achieve the desired 70 
properties. These factors turn polymers into very promising candidates to solve numerous problems in drug 71 
administration. 72 
In this review, we introduce the term ‘Pharmapolymers’, which describes synthetic polymers used during the 73 
administration of drugs. They are based on an artificially made polymeric backbone, excluding chemically modified 74 
natural polymer species plus dendrimers, which do not reveal a distribution in the number of repeating units per 75 
molecule (molar mass distribution). The first part comprises an overview of potential polymer classes, which are 76 
discussed concerning their suitability (structure, properties etc.) as potential drug delivery systems. This represents 77 
the basis for the following parts of the work. To be considered as drug delivery system, the polymer structure has 78 
to fulfill at least parts of the following requirements: Biocompatibility, biodegradability or complete chemical 79 
inertness as well as sufficient control over its synthetic structure. In 1999, Uhrich et al. already reviewed polymeric 80 
systems for controlled drug delivery.[2] Almost two decades later, this work misses completeness and the modern 81 
developments of the polymer classes applied nowadays. The second part summarizes all pharmapolymers which 82 
are currently or have previously been on the market subdivided according to their form of appearance. In addition, 83 
we included materials which are currently undergoing clinical trials. The main routes of drug administration 84 
discussed here are oral, topical and by injection (intravenous, intramuscular, subcutaneous). The third section 85 
highlights recent progress in research and exemplarily describes a few chosen in vivo studies to emphasize future 86 
prospects of pharmapolymers in drug delivery applications. On average, only one out of 5,000 compounds that 87 
enters pre-clinical studies (and only one out of 10 that enters clinical studies) becomes an approved drug after 88 
10 years from the starting idea to the market approval.[2] The clinical phases necessary for market approval and a 89 
short description are listed in Table 1.  90 
The present study is the most comprehensive summary of established synthetic polymers in drug administration 91 
so far, comprising far more than 100 polymeric products on the market and 70 under clinical investigations. 92 
Our intent is to provide a link between chemical structures as well as properties of the polymers and their area of 93 
application, where they are often just known by their trade names or abbreviations. Even so, the authors apologize 94 
in advance for all omissions since it is nearly impossible to keep track of the whole wealth of materials applied in 95 
drug delivery. 96 
 97 
 98 
 99 
 100 
 101 
 102 
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Table 1. Overview of clinical trial phases. 103 
Phase Primary goal Secondary goal Participants Duration Special Features 
Preclinical 
Checking for preliminary safety, efficacy and pharmacokinetic 
information (in vitro & in vivo) 
- 
Several 
years 
 
Phase 0 
Pharmacokinetics  
(i.e. oral bioavailability and half-life of the drug) 
10  
Often skipped for 
phase I, subtherapeutic, 
doses too low to cause 
any therapeutic effect 
Phase I Checking for safety 
Establish the max. tolerated 
dose, determine side effects, 
determine the metabolism and 
pharmacologic actions of drugs 
20 to 100 
Several  
months 
Often first time tested in 
humans, subtherapeutic 
with ascending doses 
Phase II Checking for efficacy 
Determine the common short-
term side effects and risks 
Several hundred 
Up to 2 
years 
Therapeutic doses, 
“Proof of concept” 
Phase III 
Confirm findings in large 
patient population 
Evaluate the overall risk-
benefit ratio 
300 to 3,000 1 to 4 years 
Usually randomized 
controlled trials, pivotal 
studies for drug licensing 
Phase IV 
Testing long-term safety in 
diverse patient population 
Identify additional, unusual 
side effects 
“Real-life patients”,  
several thousands 
Ongoing  
 104 
 105 
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2. Polymer classes 106 
The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human 107 
Services, which is responsible for the monitoring of trading and safety standards in the food and drug industries in 108 
the United States. A large number of different polymer types are used in pharmaceutical research and applications 109 
nowadays, whether in an early scientific stage or already in FDA approved formulations. To fulfill specific 110 
requirements, often different polymer classes have to be combined to create smart solutions for specific problems. 111 
The following chapter discusses the most important polymer classes including individual representatives of 112 
pharmapolymers. All structures of homopolymer systems mentioned later in the application Chapter 3 or the 113 
future prospects Chapter 4 are marked in bold and can be found in Table 2. 114 
 115 
2.1 Polyethers 116 
The term polyether generally describes polymers that contain the ether functional group in their main chain. 117 
Although there are several FDA approved polyethers, they all reveal one major drawback: They lack 118 
biodegradability (referring to the degradation of the polymer backbone, independent of the molar mass of the 119 
respective polymer species).  120 
Among them, poly(ethylene glycol) (PEG) (also poly(ethylene oxide) (PEO) for Mn >20,000 g mol
-1) represents 121 
probably the most well-known polyether in pharmaceutical applications. The oldest[3] and most frequently used 122 
method to synthesize PEG in laboratory and industrial scale is via anionic ring-opening polymerization of ethylene 123 
oxide[4] resulting in polymers with a wide range of possible molar masses and very low dispersities.[5] Cationic 124 
polymerization is also feasible, with the drawback of broad molar mass distribution due to backbiting reactions.[6] 125 
A variety of functionalized PEGs are offered from commercial sources, with different α and/or ω functionalities, 126 
e.g. methoxy groups, amines, or thiols. Furthermore, side group functionalized PEG derivatives are known in 127 
literature, e.g. functionalized with furfuryl.[7] PEG has several interesting advantages for pharmaceutical 128 
applications. It is water soluble, even at higher molar masses,[8] non-ionic, non-toxic and biocompatible. 129 
Furthermore, it was already approved by the FDA for different applications in foods, cosmetics and 130 
pharmaceuticals.[9] The success of PEG in the biomedical area started with the covalent decoration of bio(active) 131 
molecules,[10] often named PEGylation,[11] which will be described in detail in Chapter 3.1.1. One outstanding 132 
property of PEG is the so-called “stealth-effect”, discovered in 1990 for modified liposomes.[12] It describes the 133 
ability to protect molecules or nanoscopic objects against unspecific interactions with blood components 134 
(e.g. opsonization), by attaching specific proteins to the surface.[13] Until now, PEG is still regarded as the gold 135 
standard for stealth behavior. Furthermore, renal filtration was found to be decreased by the attachment of PEG 136 
which comes along with an increase of the molar masses. These two points lead to significantly elongated in vivo 137 
blood circulation times of formulations associated with PEG.[13-14] Besides all the advantages of PEG a few 138 
drawbacks have to be addressed as well.[15] With increasing molar mass of the polymers, PEG tends to accumulate 139 
within certain organs, which has to be avoided.[16] If, however, the applied product contains oligomers 140 
below 400 g mol-1 or becomes fragmented, toxic species can be produced by oxidation in vivo.[17] A second issue 141 
concerns the possibility of an immune response due to compliment C activation, which can lead to hypersensitive 142 
reactions and, consequently, to an anaphylactic shock.[18] Furthermore – despite the established large scale 143 
production – the anionic polymerization technique requires still an high effort, in particular considering the highly 144 
toxic and explosive monomer and the purification of the polymer for pharmaceutical applications (formaldehyde 145 
and 1,4-dioxane can occur as side products, which need to be excluded from pharmacological grade PEG). 146 
Nevertheless, PEG remains the most commonly used polymer in drug administration and can be considered as the 147 
standard. 148 
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Poly(propylene glycol) (PPG) (also named poly(propylene oxide): PPO) represents another polyether which is 149 
applied for drug delivery. The common way to synthesize PPG is anionic ring-opening polymerization with an 150 
alcoholate as initiator and a base as catalyst resulting in the atactic product. The change of the catalyst enables the 151 
synthesis of the isotactic product. However, like most mono-substituted epoxides, the monomer tends to induce 152 
chain transfer reactions during the polymerization limiting the maximum molar mass (Mn) of the resulting polymer 153 
to approximately 6,000 g mol-1.[4-5] The water solubility of the polymer is, compared to PEG, reduced considerably, 154 
which causes an lower critical solution temperature (LCST) between 15 and 42 °C depending on the molar mass[19] 155 
(LCSTPEG ≈ 100 °C),
[20] whereas the biocompatibility is even more distinct as for PEG.[21] The polymer appears mostly 156 
as a central, non-ionic, hydrophobic, non-toxic segment in PEG-b-PPG-b-PEG block copolymers named 157 
poloxameres, which are also known by their trade names Pluronic®, Synperonic® and Kolliphor® (a subgroup are 158 
poloxamines consisting of an ethylene diamine core). The commercial products are available in various 159 
compositions. The polymerization of the block copolymer is similar to the PPG homopolymer synthesis. After the 160 
homopolymer is formed, ethylene oxide is added to the reaction, which then grows from both sides of the PPG 161 
homopolymer. The resulting products often contain admixtures, e.g homopolymer, di- and triblock polymers, which 162 
can be removed by chromatographic fractionation. Poloxameres are increasing the rate of wound and burn healing, 163 
which is the reason why they can be found in skin healing creams and skin substitutes. Furthermore, they form 164 
micelles in aqueous solution, making them attractive for drug delivery applications. 165 
 166 
Poly(glycerol) (PG) represents an alternative for PEG and PPG in terms of solubility- and biological behavior. PG’s 167 
are produced by anionic[22] or cationic[23] ring-opening polymerization of glycidol leading to branched polymer 168 
architectures. Using anionic ring-opening polymerization, high molar mass polymers comprising a relatively narrow 169 
distribution (up to 700,000 g mol-1 at dispersities of below 1.4) can be synthesized.[24] The main advantage of PG 170 
compared to PEG is the presence of hydroxyl groups at the main chain, which can be utilized to introduce 171 
additional functionalities to the polymer backbone.[25] If the alcohol group on the monomer is protected, a linear 172 
polymerization with molar masses (Mn) up to 30,000 g mol
-1 can be accomplished.[26] Both, linear and 173 
hyperbranched PGs are fully biocompatible,[27] revealing even better profiles compared to PEG.[28] Similar to PEG, 174 
modifications with PG lead to an elongated circulation time.[29] A rather well-known example is poly(glycerol) 175 
polyricinoleate (PGPR) as food additive being considered by the FDA as general recognized as safe (GRAS) for 176 
human consumption (Code of Federal Regulations: 21 CFR 172.854). Several other poly(glycerol) esters are known 177 
for their application as emulsifier in food, cosmetics and pharmaceutical preparations. 178 
 179 
2.2 Poly(ethylene imine)s 180 
Poly(ethylene imine)s (PEI) are characterized by the presence of amine group functionalities within the polymer 181 
backbone, which determine their chemical and physical behavior. PEI reveals one of the highest cationic-charge-182 
densities of all organic macromolecules.[30] Every third atom is an amine group of which every sixth nitrogen atom is 183 
protonated under physiological conditions.[30] This high charge density enables the interaction with the phosphate 184 
groups of genetic material leading to the formation of toroidal complexes that are readily endocytosed by cells.[31] 185 
This feature makes PEI a highly efficient vector for delivering oligonucleotides in vitro and in vivo.[32] It occurs in two 186 
different forms: Linear and branched PEI. 187 
Branched poly(ethylene imine) (BPEI) can be synthesized by the ring-opening polymerization of unsubstituted 188 
aziridine as described in 1944 by Jones et al. leading to uncontrolled branching and chains with primary, secondary, 189 
and tertiary amine groups.[33] Increasing molar masses result in higher degrees of branching and, to this end, cross-190 
linking becomes more likely. The handling of explosive and toxic aziridine requires safety precautions, which are 191 
often not applicable in most chemistry laboratories. The molar masses of commercially available BPEI cover the 192 
8 
 
complete range up to 750,000 g mol-1 (Mw), however, no dispersities are reported. The exact determination of the 193 
number average molar mass Mn of PEI is extremely complex and has been in the focus of several literature 194 
reports.[31a, 34] The synthesis of linear poly(ethylene imine) (LPEI) via hydrolysis of poly(2-alkyl-2-oxazoline)s was 195 
first described in the 1960s.[35] Therefore, linear 2-methyl or 2-ethyl substituted poly(2-oxazoline)s (POx) are mainly 196 
used as precursors. The hydrolysis can be performed under acidic[35b, 36] or basic conditions[35b, 37] and results in 197 
products hydrolyzed up to 97%. The molar mass of LPEI and its distribution is limited by the respective POx 198 
precursor. However, the living character of the cationic polymerization of POx (see Chapter 2.7) produces 199 
well-defined polymers with controlled molar masses and low dispersities, which comply with the biological 200 
demands for LPEI (Mn up to 25,000 g mol
-1, Ð < 1.2).[38] LPEI can be purchased in the range from 400 to 201 
250,000 g mol-1 (Mw). The robust polymerization protocols tolerate a variety of comonomers, initiators, and 202 
quenchers, including allyl and aryl groups enabling the selective introduction of various functionalities to the LPEI 203 
backbone.[39] An alternative is the controlled partial hydrolysis of the amide bonds which has been studied in the 204 
last decades.[40] A further approach to LPEIs is the controlled polymerization of N-substituted aziridines followed by 205 
the deprotection of the amines.[37a] However, this route comes along with unwanted side reactions due to the 206 
harsh conditions or incomplete cleavage.[41] None of the products based on PEI have been approved by the FDA so 207 
far, which is mainly related to its cytotoxicity. 208 
 209 
2.3 Polyesters 210 
Polyester describe a class of polymers containing the ester functional group in their main chain which renders most 211 
of these polymers biodegradable.  212 
One of the earliest polymers was poly(caprolactone) (PCL) synthesized by the Carothers team in the 1930’s. PCL is 213 
a non-toxic, biodegradable, semi-crystalline aliphatic polyester, which is approved by the FDA for several 214 
applications, e.g. drug delivery systems, sutures, long-term implants and adhesion barriers as well as new tissue 215 
scaffold host systems. It is hydrophobic, but soluble in several solvents, can be blended with a variety of other 216 
materials and degrades very slowly under physiological conditions (from months to years) compared to other 217 
polyesters.[42] The main reason for the extended degradation time is the lack of enzymes suitable to hydrolyze the 218 
ester in the human body.[43] Furthermore, the hydrolysis time of PCL depends on the physical and chemical 219 
properties of the polymer, in particular the crystallinity and the molar mass. However, this degradation profile 220 
makes PCL very attractive for long term drug delivery devices or implants.[44] PCL degrades into 6-hydroxyhexanoic 221 
acid, which is less acidic than degradation products from other polyesters reducing the effect of autocatalysis 222 
occurring with the hydrolysis of polyesters. Besides the degradability, PCL exhibits a high permeability for most 223 
drug molecules. Furthermore, functional groups can be introduced for example by copolymerization, which enables 224 
an adjustment of several properties, including hydrophilicity, adhesivity and biocompatibility.[45] PCL can be 225 
synthesized in several ways, such as by anionic, cationic, coordination or free radical ring-opening polymerization 226 
(ROP) processes first described by Carothers for PLA. The most common synthesis routes comprise the ring-opening 227 
polymerization using metal catalysts which have to be removed afterwards and the often used polycondensation. 228 
A well-known catalyst for ROP is stannous octoate due to its high efficiency and its approval by the FDA as food 229 
additive.[46] The reported molar masses (Mn) range from 530 to 630,000 g mol
-1.[47] Numerous strategies to improve 230 
the degradation and mechanical properties of PCL, such as copolymerization and blending with different polymers, 231 
are described in literature.[42a, 44e, 48] The exceptional compatibility of PCL in blends is utilized to improve the 232 
material properties by mixing PCL with polysaccharides, PLA, chitosan and many more.[48-49] 233 
Poly(lactic acid) (PLA) and poly(glycolic acid) (PGA) are aliphatic polyesters approved by the FDA for a wide range 234 
of applications. These materials are well-established in pharmaceutical industry as drug carriers and traditionally 235 
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applied as suture material.[50] Major advantages are their biocompatibility, biodegradability and their mechanical 236 
strength.[51] The degradation products are further non-toxic and can be cleared or consumed within bioprocesses 237 
occurring in the body, which makes them a powerful tool for in vivo delivery. Similar to PCL, the material properties 238 
such as degradation rate and mechanical strength depend on the structural features of the polymer including 239 
crystallinity and chain length.[52] High molar mass species are obtained by ROP[53] using stannous octoate as 240 
catalyst.[50b, 51a] Additional metal-free methods including enzymatic techniques are under investigation for the 241 
polycondensation of PLA.[52b, 54] PLA represents a stiff and hard polymer revealing versatile properties depending on 242 
the tacticity and molar mass. Compared to PGA it comprises an extra methyl group, and, therefore, a stereocenter, 243 
which results in three possible products: Poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA) and the mixture of 244 
both, poly(D-lactic acid-co-L-lactic acid) (PDLLA). PLLA and PDLA are semi-crystalline, while PDLLA is amorphous and, 245 
consequently, reveals the fastest degradation rate.[50c, 52b] Nevertheless, the hydrophobic methyl side group 246 
increases the steric hindrance and shields the ester bond from hydrolysis by water which results in a decreased 247 
degradation time compared to PGA. In consequence, PLA is a promising material for long term applications.[55] 248 
PGA has been known since 1954 as potential low cost fiber forming, highly crystalline polymer.[50b] However, the 249 
high sensitivity towards hydrolysis and the poor solubility in organic solvents limits its use for pharmaceutical 250 
applications.[47, 51b] The respective copolymer poly(lactic-co-glycolic acid) (PLGA) is probably the best established 251 
and studied polymer for pharmaceutical applications and tissue engineering. 252 
Poly(oxalate)s (PO) represent another subgroup of polyesters, which is prepared by the ester interchange reaction 253 
of diols with the diester of the oxalic acid. In 1980, Shalaby et al. filed a patent for the preparation of polyalkylene 254 
oxalates from different aliphatic diols.[56] Since that time, POs and copoly(oxalate)s have been reported only a few 255 
times in literature. They represent a family of biocompatible and biodegradable polymers, which degrade 256 
hydrolytically (and comparatively rapid) into non-toxic products that can easily be removed from the body.[57] 257 
Oxalate-based polymers allow a facile control over their biodegradability, crystallinity and mechanical strength. 258 
Their hydrolytic stability and their mechanical properties are mainly influenced by the composition and 259 
hydrophobicity of the incorporated diol. Compared to the commercial biodegradable polymers PCL or PLGA, they 260 
exhibit faster degradation kinetics. This turns POs into useful materials for medical grade plastics and devices 261 
(e.g. syringes and scrub brushes).[58] Garcia and Miller established the oxalate metathesis polymerization using diols 262 
from renewable sources and without the need of any solvents. They obtained POs with molar masses (Mn) ranging 263 
from 40,000 to 70,000 g mol-1.[58] Despite its biocompatibility and degradability none of the polymers in this class is 264 
yet approved by the FDA. 265 
Poly(butylene terephthalate) (PBT) is obtained by the ester interchange reaction of 1,4-butanediol and 266 
terephthalic acid and subsequent polycondensation. Its resistance to solvents, heat and mechanical strongness 267 
turns PBT into a basic module in many electronic devices and home appliances. Considering biomedical application 268 
PBT has not gained much attention, yet. 269 
 270 
2.4 Polycarbonates 271 
Polycarbonates (PC) are a group of thermoplastic polymers containing carbonate links in their backbone, firstly 272 
discovered in 1898 by Alfred Einhorn.[59] After 50 years without commercialization, Schnell (Bayer AG, Germany) 273 
patented the synthesis of linear PCs in 1953.[60] In the same year, Fox (General Electric Company, USA) synthesized 274 
independently a branched PC.[61] Since the late 50’s, PCs became frequently used in commercial applications. 275 
The excellent biocompatibility, non-toxic degradation products and the absence of autocatalytic degradation 276 
processes render aliphatic PCs interesting polymeric materials.[62] The polymers are commonly synthesized by 277 
polycondensation methods (step growth), as performed by the phosgenation of hydroxyl compounds or the 278 
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transesterification of diols with lower dialkyl carbonates.[63] Another approach is the utilization of CO2 and oxiranes 279 
to produce “green” PCs (up to 100,000 g mol-1, Ð < 1.2) via an addition polymerization,[64] whereas the low 280 
reactivity of CO2 requires very efficient catalysts.
[65] However, these polymerization techniques suffer from 281 
drawbacks such as the poor control over molecular parameters and broad molar mass distributions.[66] A suitable 282 
preparation method to obtain well-defined PC is the ring-opening polymerization (ROP) of cyclic carbonates (chain 283 
growth, “living”), which can be performed by both cationic and anionic polymerization. The ROP allows the control 284 
of molar masses (Mn) with low dispersities (30,000 g mol
-1, Ð < 1.1[67]) at fast polymerization rates and facilitates 285 
the formation of more complex architectures like block polymers[68] and star shaped polymers.[69] Furthermore, in 286 
contrast to polycondensation, no by-products are obtained from the polymerization. Compared to aliphatic 287 
polyesters (i.e. PCL or the copolymer PLGA), polycarbonates are degraded in vivo by surface erosion.[70] 288 
Their degradation does not cause an acidic environment, which may occur during polyester degradation and might 289 
be hazardous for loaded drugs or healthy tissues. PC resins are solely FDA approved for use as articles or 290 
components of articles intended for use in producing, manufacturing, packing, processing, preparing, treating, 291 
packaging, transporting, or holding food in accordance with defined conditions (21 CFR 177.1580). Nowadays, the 292 
design of functional cyclic carbonate monomers has gained increasing interest, comprising hydroxyl,[71] carboxyl,[72] 293 
amine,[73] alkene[74]/alkyne,[75] halogen,[76] azido[77] and sugar[78] pendant groups. 294 
 295 
2.5 Poly(amino acid)s 296 
Synthetic polypeptides are based on the same peptide bonds present in natural proteins and, therefore, exhibit a 297 
good biodegradability and excellent biocompatibility. Nevertheless, they are prepared by purely synthetic reaction 298 
processes and therefore included in this review.[79] As almost all types of amino acids can be applied for the 299 
polymerization, a large variety of different functionalities such as ionic or stimuli responsive side groups are 300 
accessible and complex superstructures including micelles and gels can be formed.[80] In 1906, Hermann Leuchs first 301 
reported the synthesis and polymerization of α-amino acid N-carboxyanhydrides (NCAs).[81] Since this time, NCAs 302 
have gained increasing interest for the synthesis of homo- and copolymers as well as cyclic polypeptides. A large 303 
number of reviews can be found dealing with the immense variety of synthetic procedures.[82] Nowadays, the most 304 
established way to obtain synthetic polypeptides is the ring-opening polymerization (ROP) of NCAs using amine-305 
based initiators. Remarkable reactions have been developed to synthesize polypeptides and polypeptide-based 306 
copolymers with controlled molar masses and dispersities as well as complex architectures. Deming and co-workers 307 
reached macromolecules with Mn up to 500,000 g mol
-1 (Ð < 1.2) by applying different transition-metal-based 308 
initiators in a living ROP.[83] Conventional amines as initiators allow the synthesis of polypeptides with 309 
100,000 g mol-1 and comparable dispersities.[84] Side reactions can further be suppressed using ammonium chloride 310 
functionalized macro-initiators[85] or an organosilicon.[86] The functionalization of polypeptides has gained 311 
increasing attention in recent years. The introduction of various functional groups or stimuli-sensitive moieties to 312 
the side chains of the polypeptides render them particularly appealing for the design and development of multi-313 
functional active biomaterials. The functionalization is mainly achieved by two approaches: I) The one-step ROP of 314 
NCA monomers, already containing the desired functional moieties or II) the post-polymerization modification of 315 
polypeptides. Reported modifications comprise click chemistry, in particular alkyne-azide cycloadditions and thiol-316 
ene reactions, controlled free-radical polymerizations, aminolysis and transesterifications, which have extensively 317 
been reviewed.[82c, 87] The modularity of using unnatural amino acid derivatives as monomers leads to a versatility 318 
of polymer structures with molecular and physical properties far from those of proteins. Trifunctional amino acids, 319 
such as glutamic acid, lysine and aspartic acid, are often used to achieve structural viability within the respective 320 
polymer, in particular poly(glutamic acid) (PGluA),[88] poly(lysine)[89] or poly(aspartic acid).[90] The FDA classifies 321 
chosen poly(amino acid)s under the GRAS status for different food applications. 322 
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2.6 Poly(peptoid)s 323 
In 1982, Farmer and Ariens introduced the term “peptoid” as a peptidomimetic/pseudopeptide that is able to 324 
mimic the biological action of peptides while not resembling them structurally.[91] One decade later, Bartlett and 325 
co-workers defined them more specifically as oligomers of N-substituted glycine (poly(α-peptoids)).[92] 326 
Nowadays, most reports of peptoids, e.g. those indexed in PubMed, refer to the mentioned N-substituted glycines 327 
or respective poly(β-/γ-peptoids). In both cases, side chains are attached to the amide nitrogen and make the 328 
polymer resistant to protease degradation.[93] Poly(peptoid)s (PoP) are particularly interesting due to their 329 
convenient synthesis, chemical diversity and biological relevance. They can be synthesized in a sequence defined 330 
(stepwise) or statistical (chain growth) manner.[94] They are routinely obtained in a stepwise procedure, particularly 331 
the submonomer solid phase synthesis developed by Zuckermann et al.,[95] and have been reviewed 332 
continuously.[96] This two-step sequence method does not require the protection of the backbone and a variety of 333 
primary amines (most of them commercially available) can be incorporated.[97] Monodisperse PoPs of 100 334 
monomer units (Mn = 8,500 g mol
-1) have been synthesized by coupling together two submonomer-synthesized 50-335 
mers.[98] The submonomer method represents a relatively inexpensive route compared to the preparation of the 336 
corresponding α-peptides.[99] Microwave heating can be used to accelerate the submonomer synthesis and 337 
increases the efficiency of coupling sterically hindered and electrostatically deactivated amines.[100] An alternative 338 
approach for their synthesis is the (living) ring-opening polymerization of N-substituted N-carboxyanhydride (NCA) 339 
monomers in solution or from solid substrates.[94b, 96b, 101] This chain growth polymerization yields PoPs with degrees 340 
of polymerization >100, but with limited sequence control.[102] Their structural similarity compared to peptides, 341 
their resistance against protease, the proteolytic stability, the convenient synthesis and their superior 342 
biocompatibility make PoPs an interesting class of materials for a variety of applications, e.g. as transfection and 343 
therapeutic agents,[103] diagnostic agent[104] and lung surfactant mimetic.[105] Optionally, they can be incorporated 344 
into polypeptides at specific sites.[106] Luxenhofer and co-workers could recently show the degradation of PoPs via 345 
oxidative degradation under biologically relevant conditions.[107] This polymer class is not yet approved by the FDA.  346 
 347 
2.7 Poly(2-oxazoline)s 348 
Concerning biocompatible, hydrophilic polymers, poly(2-oxazoline)s (POx) gained increasing attention.[15] This class 349 
of polymers was introduced in 1966 by four independent research groups.[35, 108] The polymers are prepared by a 350 
cationic ring-opening polymerization (CROP) of 2-substituted oxazolines resulting in repeating amide functionalities 351 
at the interface between polymer backbone and side chain. Since 2004, the microwave assisted synthesis is most 352 
commonly used to shorten reaction times from days to minutes.[109] As the CROP is not as sensitive as most anionic 353 
polymerization methods, the production of POx in a lab scale is comparably convenient, and a large variety of 354 
possible functionalization strategies can be applied.[110] Besides the variation of start- and end-groups, the 355 
2-substitution of the monomer can be modulated within the borders of tolerated functionalities in a CROP. The 356 
achievable molar mass strongly depends on the used monomer. POx derivatives bearing short side chains (methyl 357 
or ethyl) are reported to be biocompatible[111] and even feature a stealth effect similar to PEG 358 
(see Chapter 3.1.2),[112] which turns these polymers into highly favorable materials for biomedical applications.[113] 359 
By the incorporation of longer side chains, the solubility behavior can be tailored creating systems being 360 
thermoresponsive or water insoluble.[114] Just as PEG, POx is not biodegradable. A degradation of the amide group 361 
leads to an abstraction of the side group rather than a decomposition of the backbone and, hence, the formation of 362 
linear poly(ethylene imine) (see Chapter 2.2). Since 2016, poly(2-ethyl-2-oxazoline) is approved by the FDA as 363 
indirect additive used in food contact substances (21 CFR 175.105).  364 
 365 
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2.8 Poly(N-acrylamide)s 366 
Poly(N-acrylamide)s describe a polymer class that bear amide functionalities in the side chain. There is a large 367 
variety of monomers commercially available, however, the most commonly applied and studied polymers are 368 
doubtlessly poly(N-(2-hydroxypropyl)methacrylamide) and poly(N-isopropylacrylamide). Furthermore, poly(2-369 
acrylamido-2-methylpropane sulfonate) is utilized. 370 
Poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) is a hydrophilic, chemically and hydrolytically stable, 371 
biocompatible polymer, often described simply as “HPMA” in literature. Moreover, it mimics living tissue and 372 
features a well-established safety profile in the human body. Its hydroxyl group functionalities allow the convenient 373 
conjugation of drugs and targeting molecules. However, PHPMA-based polymers are nonbiodegradable, which 374 
limits their use for some pharmaceutical applications.[115] Otherwise, they are hydrophilic and known to be non-375 
toxic in the rat, even at higher doses (30 g kg-1).[116] PHPMA can be synthesized by conventional free radical 376 
polymerization of N-(2-hydroxypropyl) methacrylamide or by several controlled radical polymerization techniques 377 
including atom transfer radical polymerization (ATRP) and reversible addition-fragmentation chain transfer (RAFT) 378 
polymerization.[117] Other techniques include the post-polymerization modification of poly(pentafluorophenyl 379 
methacrylate) (PPFMA), which contains activated ester side chains, by reacting with 1-amino-2-propanol.[118] 380 
Compared to the free radical polymerization, controlled radical polymerization techniques provide access to a vast 381 
number of macromolecular architectures including PHPMA copolymers with improved control over the molar mass 382 
and dispersity.[119] Despite the extensive research effort spent on PHPMA, none of the materials has yet been 383 
approved by the FDA. 384 
Poly(N-isopropylacrylamide) (PNIPAAm) is one of the most intensively studied temperature responsive polymers 385 
of the past four decades.[120] The PNIPAAm homopolymer exhibits a lower critical solution temperature (LCST) of 386 
around 33 °C in aqueous solution, which is close to the body temperature.[121] In addition, the LCST of PNIPAAm can 387 
be easily tuned by copolymerizing various functional monomers to alter the polymer backbone.[122] When the 388 
temperature is lower than the LCST, PNIPAAm is water soluble due to a complex H-bond network along the 389 
PNIPAAm chains. In contrast, at temperatures above the LCST PNIPAAm becomes water insoluble because of the 390 
destroyed H-bond network and the release of water molecules.[123] Due to this reversible transition in water, its 391 
good biocompatibility and low toxicity, PNIPAAm-based polymers are found in numerous biological and biomedical 392 
applications including controlled drug release, tissue engineering, bio-detection, bio-separation, smart microfluidic 393 
devices and biochips.[123-124] However, PNIPAAm is not biodegradable which limits its use in some pharmaceutical 394 
applications.[125] PNIPAAm can be synthesized by a variety of polymerization techniques including conventional free 395 
radical polymerization, ATRP, and RAFT polymerization of N-isopropylacrylamide.[120a, 126] Although an enormous 396 
progress has been made, to the best of our knowledge, there is no FDA approval of PNIPAAm-based materials, nor 397 
are there any materials under clinical investigation for drug delivery. 398 
 399 
2.9 Polyphosphoesters 400 
Polyphosphoesters are constructed by repeating phosphoester groups (-POR’-O-R-O-)n in the main chain. They can 401 
be subdivided into polyphosphites, polyphosphonates, polyphosphoramidates and polyphosphates.[127] 402 
Among them, polyphosphates (PP) (R’ = OR1) represent the most important class of polymers, due to their 403 
structural similarity with nucleic and teichoic acids.[128] Inorganic PPs are salts or esters of polymeric oxoanions built 404 
on tetrahedral phosphate (PO4) units and occur as linear or branched forms, or cyclic ring structures. They are 405 
commonly synthesized by dehydration of orthophosphate (PO4
3-) at an elevated temperature. Other methods 406 
include an olefin metathesis reaction via an acyclic diene and the ring-opening metathesis polymerization.[129] 407 
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A variety of synthetic methods has been summarized by Wang et al..[130] PP can be found in all bacterial, fungal, 408 
plant or animal life forms. PP was first isolated from yeast by Lieberman[131] in 1888 and has been reviewed 409 
frequently since the 80’s.[132] The numerous and different biological functions and their biocompatibility have made 410 
these materials the subject of several research areas investigating the substitution for adenosine triphosphate 411 
(ATP) in kinase reactions,[133] chelation of metals,[134] or their role in the physiological regulation of growth, 412 
development, stress, and deprivation.[135] PPs allow for numerous opportunities of modifications due to the 413 
pentavalent nature of the phosphorus atoms. Examples for such modifications are the introduction of 414 
double[136]/triple bonds,[137] hydroxy[138] and amine groups[139] to the side chain or polymer backbone. Since Yan and 415 
co-workers reported the synthesis of highly pure hyperbranched polyphosphates (HBPPs) via the self-condensing 416 
ring-opening polymerization, this method attracted considerable attention.[140] The convenient modification of the 417 
side group of the cyclic phosphate monomers resulted in a variety of structures and functionalities.[128] 418 
Well-defined PPs with approximately 30,000 g mol-1 (Mn) can be synthesized with dispersities Ð < 1.1
[141] while also 419 
high molar mass PPs are possible (Mn = 150,000 g mol
-1).[142] Under physiological conditions, PPs can degrade into 420 
non-toxic, low molar mass species through the hydrolysis or enzymatic cleavage of the phosphate bond. The FDA 421 
classifies chosen PPs used in food under the GRAS status. They can be found in all types of food including baby 422 
food, meat, seafood and cheese according to the stipulated rules (food industry: < 5000 pm,[143] meat: 423 
< 0.5% weight of the final product[144]). Polyphosphates have shown to stabilize the protein structure, form a 424 
surface layer coagulated protein around meat or to retain the natural moisture of seafood. 425 
 426 
2.10 Polysiloxanes 427 
Materials composed of a backbone of alternating silicon and oxygen atoms with two alkyl or aryl moieties attached 428 
to the tetravalent silicon (-R2Si-O-) are generally referred to as silicon polymers.
[145] They can be considered as 429 
hybrid materials due to the combination of polar inorganic siloxane bonds (-Si-O-) in the backbone and organic alkyl 430 
or aryl side chains. Since the invention of the so-called “Direct Synthesis” of methylchlorosilane by Rochow and 431 
Müller (also called “Müller-Rochow-Process”) in the early 1940s, polysiloxanes have been prepared industrially. 432 
This large scale production of silicon polymers is realized by an equilibration polymerization of cyclic and linear 433 
oligosiloxanes in the presence of an acid or a base as catalyst.[146] The method enables easy scale-up and cost 434 
effective production. However, it does not provide a good control over molar masses of the polymers and their 435 
dispersity. Only with the development of an ionic ring-opening polymerization using cyclic oligosiloxanes as 436 
monomers, well-defined polysiloxanes with defined molar masses and narrow dispersities became accessible.[147] 437 
Compared to the carbon-based polymers, silicon polymers feature superior physical and chemical properties in 438 
terms of thermal and oxidative stability, as well as flexibility combined with a low thermal glass transition 439 
temperature.[148]  440 
Poly(dimethylsiloxane) (PDMS), for pharmaceutical applications better known as “dimethicone”, bears two methyl 441 
groups on each silicon atom and represents the most prominent member of the silicone family. It is used in various 442 
pharmaceutical applications due to its excellent biocompatibility, low toxicity, optical transparency, gas 443 
permeability, high thermal stability, elasticity and low production costs.[149] However, due to the extreme 444 
hydrophobicity, PDMS-based materials suffer from low wettability and biofouling problems.[150] In consequence, 445 
increasing concerns arise about the safety of PDMS polymers in long term applications in blood contacting 446 
environments. To overcome these limitations, the focus of recent silicon related research has been concentrated 447 
on modifications to enhance the hydrophilicity and anti-fouling capability.[151] PDMS is not biodegradable in 448 
processes occurring in vivo; however, it slowly degrades within the environment to yield silica, carbon dioxide and 449 
water as non-toxic degradation products.[152] The FDA approved the use of PDMS in foods (except milk), cosmetic 450 
and pharmaceutical products (21 CFR 173.340). 451 
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2.11 Poly(vinyl ester/alcohol/ether)s 452 
Poly(vinyl esters/alcohols/ethers) are all based on the polymerization of a vinyl group linked to an adjacent oxygen 453 
group. Poly(vinyl ester)s comprise polymer species, which are mainly prepared by free radical polymerization of 454 
vinyl esters. Technically important is poly(vinyl acetate) (PVAc). More than one decade ago, the preparation of 455 
well-defined PVAc by controlled radical polymerization (Mn = 50,000 g mol
-1, Ð < 1.4) by “macromolecular design 456 
via interchange of xanthate”/reversible addition-fragmentation chain-transfer (MADIX/RAFT) polymerization 457 
became popular.[153] PVAc reveals a glass transition temperature (Tg) around room temperature. Since it is rather 458 
brittle below the Tg, plasticizers are usually added for improved flexibility. The homopolymer is often applied as 459 
adhesive in water-based emulsions. To overcome its stiffness, PVAc is often copolymerized with other monomers. 460 
Furthermore, PVAc can be partially or fully hydrolyzed to obtain the water-soluble poly(vinyl alcohol) (PVA). 461 
It cannot be prepared by polymerization of the respective monomer vinyl alcohol since it is unstable. Depending on 462 
the length of the initial PVAc and the degree of hydrolysis under acidic or alkaline conditions, PVA with molar 463 
masses (Mn) from 20,000 to 400,000 g mol
-1 can be obtained with varying solubility, tensile strength and 464 
adhesiveness.[154] It has a number of desirable properties like mechanical strength and high elasticity that make it a 465 
useful pharmapolymer. The hydroxyl groups are suitable for cross-linking (e.g. with ethylene glycol 466 
diglycidyl ether[155] or glutaraldehyde[156]) to create hydrogel networks with low or high swelling behavior in water. 467 
They have been well-established as drug delivery carriers. The FDA approved PVA for various uses, e.g. as indirect 468 
food additive in products, which are in contact with food (21 CFR 177.1670), as diluent in color additive mixtures 469 
for coloring shell eggs (21 CFR 73.1) and as ophthalmic demulcent (21 CFR 349.12).[154] Several microorganisms are 470 
able to degrade PVA as well as PVAc through enzymatic processes. The degradation by human enzymes has not 471 
been reported so far. The copolymer poly(ethylene-co-vinyl acetate) (PEVA) is often used in drug delivery research 472 
to slowly release a compound. Furthermore, it reveals only little or no reaction after implantation. 473 
Since 1930, poly(vinyl ether)s (PVE) have been produced on an industrial scale. PVEs are polymers bearing the 474 
functional ether group in the side chain. They are made from the respective vinyl ethers via chain-growth 475 
polymerization. The functional versatility of the starting material allows the incorporation of alkyl or amine 476 
moieties. Different synthesis routes and industrial processes are described in literature.[157] Probably the most 477 
important PVE is the amphipathic butyl- and amine modified one (PBAVE) that has shown remarkable 478 
performances in trial experiments. 479 
 480 
2.12 Poly(N-vinyl amide)s 481 
Poly(N-vinyl amide)s describe a polymer class that comprises amide functionalities in the side chain. Compared to 482 
poly(N-acryl amide)s, the amide group is linked to the polymer backbone through the nitrogen atom. The most 483 
prominent representative is poly(vinyl pyrrolidone) (PVP). 484 
Linear PVP was first synthesized by Reppe in 1939 as one of the numerous products originating from acetylene 485 
chemistry. It is a water soluble, non-ionic, biocompatible and stable polymer, which is not metabolized by the 486 
organism.[158] In the very beginning during World War II, it was mainly used as plasma expander.[159] Today, it is well 487 
established in several products of cosmetic and pharmaceutical industry, e.g. as binder in pills. A special feature of 488 
PVP, also known as “povidone”, is its possibility to form strong hydrogen bonds, which also explains its good 489 
solubility properties in water. Furthermore, the hydrogen bond formation enables complexation of polar 490 
compounds which increases the water solubility and the bioavailability, as reported for acetaminophen.[160] 491 
The complex formation constants as well as solubility properties were furthermore determined for several other 492 
substances.[161] It could be shown that PVP, similar to PEG, increases the water solubility and blood circulation time 493 
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for liposomes.[162] PVP is approved by the FDA for numerous applications, e.g. in food for human consumption 494 
(21 CFR 173.55). A reported method to synthesize PVP in laboratory scale is MADIX/RAFT polymerization. 495 
In industrial scale, it is synthesized by free radical polymerization in most cases, whereat a broad range of molar 496 
masses can be obtained. The commercially available polymers comprise ranges (Mw) from 2,000 to 497 
2,500 × 103 g mol-1.[163] In order to achieve high molar masses, a polymerization in aqueous solution is commonly 498 
applied using hydrogen peroxide as initiator. Organic solvents generally lead to low molar mass PVP. 499 
Using hydrogen peroxide as initiator, the solvent for the polymerization is of high importance for the final product, 500 
since it is responsible for the polymer end group. Other possibilities to create different functional endgroups 501 
include the usage of suitable transfer agents or specific chain capping agents. Post modifications are also possible 502 
but difficult to control, and the products are hard to purify. Another way to alter or to improve the polymer 503 
properties of PVP is copolymerization.[160] The synthesis is performed by radical polymerization in an organic 504 
solvent similar to the synthesis of the linear homopolymer. A frequently used comonomer is vinyl acetate 505 
(polymer: copovidone). The amount of vinyl acetate increases the hygroscopicity of the product, allowing the 506 
preparation of less brittle films, which is preferable for the use as soluble binder or film-forming agent.[161] 507 
One opportunity to obtain water insoluble PVP is cross-linking, resulting in so-called crospovidone. The ways to 508 
synthesize cross-linked PVP are versatile, reaching from the use of cross-linking agents or cross-linking monomers 509 
to subsequent cross-linking with peroxides. A well-known way to obtain highly cross-linked products is the so-called 510 
“popcorn polymerization”. This method uses either an alkali hydroxide, yielding some bifunctional monomers, or a 511 
small amount of bifunctional monomers for cross-linking.[161, 164] The mechanism of this polymerization method is 512 
not well-determined, since it was primary observed as a side reaction in radical polymerization processes. It could 513 
be found that this polymerization starts by a highly reactive nucleus initiating the whole process, similar to the 514 
formation of popcorn.[165] Infrared measurements revealed that there is no structural difference between the 515 
cross-linked PVP obtained by popcorn polymerization and the linear PVP, but a difference was observed for 516 
chemically cross-linked PVP. Therefore the cross-linking of PVP via popcorn polymerization is essentially of a 517 
physical nature.[161] The cross-linked PVP is widely used in beverage and pharmaceutical industry. The good 518 
adsorptive properties are used to remove polyphenols or azo dyes from beverages. A rather well-known example in 519 
the pharmaceutical industry is the PVP-iodine complex which is used as disinfectant, also known as betaisodona 520 
and with several other trade names. Furthermore, crospovidone shows beneficial disintegration properties, thus it 521 
is used as additive in tablets promoting their break up and, therefore, speed up the drug release from solid dosage 522 
forms.[161, 166] 523 
 524 
2.13 Poly(allylamine)s 525 
Poly(allylamine) (PAAm) is a cationic polymer obtained from the radical or cationic polymerization of allylamine. 526 
While the backbone contains no nitrogen, as described for poly(ethylene imine), the polymer side chain contains 527 
primary amine groups which can be converted into secondary or tertiary amine functionalities. This turns PAAm 528 
into a highly promising gene delivery agent.[167] Poly(allylamine hydrochloride) in combination with an anionic 529 
polyelectrolyte (e.g. poly(styrene sulfonate)) can be used to form layer-by-layer adsorbed films.[168] 530 
 531 
2.14 Poly((meth)acrylate)s 532 
Poly(acrylate)s and poly(methacrylate)s are synthetic polymers of acrylic and methacrylic acids or their esters, 533 
respectively.[169] They are prepared on an industrial scale by free radical polymerization applying a variety of 534 
different methods, which include bulk, solution, suspension, and emulsion polymerization.[170] 535 
Poly(meth)acrylates can also be synthesized by various controlled radical polymerization techniques, which allow 536 
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a better control over molar mass, dispersity, polymer composition, and polymer architecture compared to 537 
free radical polymerization.[171] Poly(methacrylate)s generally display a higher glass transition temperature (Tg) and 538 
a lower decomposition temperature than the corresponding poly(acrylate)s.[172] The properties of 539 
poly(meth)acrylates can conveniently be tuned by varying the molecular structure of the ester side chain. These 540 
modifications enable access to polymers spanning the whole range from water to oil soluble or from brittle to 541 
elastic. The FDA has approved the safety of poly(meth)acrylates in several pharmaceutical applications, e.g. as basic 542 
components of food contact surfaces (21 CFR 177.1010). 543 
Poly(acrylic acid) (PAA) and poly(methacrylic acid) (PMAA), bearing a carboxylic acid unit on every second carbon 544 
atom of the main chain, are water soluble, weak anionic polyelectrolytes.[173] Besides their linear form they can be 545 
cross-linked by several cross-linking agents. The backbone of PAA and PMAA are not biodegradable, but they 546 
exhibit a low toxicity and excellent biocompatibility.[160] In aqueous solution, PAA and PMAA display a reversible 547 
coil-to-globule transition at pH 5. At lower pH values, these polymers undergo a transition to a compact globular 548 
conformation. However, if the pH value is increased, the chains expand into a fully solvated coil conformation due 549 
to the ionization of the carboxyl groups.[174] This reversible ionization of PAA and PMAA enables the formulation of 550 
pH- and ionic strength responsive materials. For instance, PAA-based hydrogels swell rapidly when placed in an 551 
aqueous environment due to the ionization of carboxyl groups. This feature makes PAA and its sodium salt 552 
(poly(sodium acrylate)) the most prominent materials for super absorbers, which are applied in diapers and 553 
membranes for hemodialysis or ultrafiltration.[175] Concerning drug delivery applications, PAA provides sufficient 554 
flexibility and excellent bioadhesion properties. Hence, they are frequently used for oral and mucosal contact 555 
applications such as tablets, oral suspensions and bioadhesives. An advantage of PAA is the convenient 556 
modification of the carboxyl side chains with alcohols or amines to introduce additional functionalities. 557 
In consequence, drugs and/or bioactive molecules can easily be attached to the PAA backbone in accordance with 558 
the concept of Ringsdorf.[176] Poly(2-hydroxyethyl methacrylate) (PHEMA) represents another water soluble, 559 
biocompatible poly(methacrylate) modified with hydroxyl functionalities in each repeating unit. These hydroxyl 560 
groups enable the material to form strong hydrogen bonds and make it very hydrophilic without need for charged 561 
side chains. As a consequence, PHEMA is often used as the main material for contact lenses. Moreover, the 562 
hydroxyl functionality of PHEMA can further be modified in post-polymerization reactions to conjugate any bio-563 
active molecule. 564 
Poly(methyl methacrylate) (PMMA) represents probably one of the best-known poly(methacrylate)s containing a 565 
methyl ester functionality at the side chain, which makes this material hydrophobic and non-soluble in water. 566 
PMMA was first developed in 1928 by Röhm, Chalmers and Bauer. The first commercial product was brought to the 567 
market in 1933 by the Rohm and Haas company under the trademark “Plexiglas®”.[177] In the following years, 568 
PMMA rapidly became the most important plastic glass due to its excellent transparency and ease of production. 569 
Concerning pharmaceutical applications, PMMA is characterized by an excellent biocompatibility, convenient 570 
processability, low toxicity, minimal inflammatory reactions with tissues, and low production costs.[178] Being 571 
nonbiodegradable and fracture resistant, it is an essential material for implant materials, in particular in case of 572 
long term applications. PMMA-based materials have further found application in dermal fillers, bone cements, 573 
intraocular lenses and membranes in dialyzers for hemodialysis.[179] However, there are some limitations to the use 574 
of PMMA, which are related to its brittleness and shrinkage, the generation of voids during processing steps, a lack 575 
of adherence to bone tissue, and the heat created by the exothermic reaction during cement polymerization, which 576 
can damage bone tissue.[180] To overcome these problems, alternative poly(meth)acrylates are currently under 577 
investigation, in particular for use as long term implant materials. One example is poly(n-butyl methacrylate) 578 
(PBMA), which possesses a butyl ester at the side chain. This material features a lower toxicity, a higher fracture 579 
toughness, and a better fatigue life, while reducing the exothermic effects compared to PMMA.[181] 580 
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Another important modification of poly(methacrylate) is poly(2-dimethylaminoethyl methacrylate) (PDMAEMA), 581 
which contains an ionizable tertiary amine group. In water it may be protonated and becomes a weak cationic 582 
polyelectrolyte depending on the pH value. The pKa value of the polymer depends on the composition as well as 583 
the molar mass, whereas values between 7 and 8 have been reported. Additionally, PDMAEMA exhibits LCST 584 
behavior in water depending on the molar mass of the polymer and the pH value of the solution.[182] However, the 585 
positive charge on the polymer causes these materials to be quite cytotoxic, which, in combination with the lack of 586 
biodegradability, limits its use in pharmaceutical applications.[183] Concerning drug delivery systems, the monomer 587 
DMAEMA is so far only applied as comonomer in combination with other methacrylates or methacrylic acid to 588 
modulate the overall charge and create a defined pattern for dissolution at specific pH values. Apart from changing 589 
the ester functionality or its alkyl moiety, physicochemical properties of the poly(meth)acrylates can also be altered 590 
by copolymerizing different functional monomers and by varying the monomer composition of the polymers. 591 
Incorporating the ionizable segments in the backbone of the polymers, such as amine and/or carboxyl groups, can 592 
render a tunable pH-dependent water solubility to the corresponding polymers. Accordingly, they are used for 593 
pH-dependent drug release applications due to salt formation.[184] These copolymers are more commonly known as 594 
EUDRAGIT® polymers in pharmaceutical industry and described in Chapter 3. 595 
Furthermore, in addition to hydrogen and methyl groups, some other functionalities can be installed on the 596 
α-position of the acrylic backbone. For instance, acrylates with a nitrile group are called cyanoacrylates. 597 
Various alkyl groups can be added to the ester group, e.g. methyl, butyl, or hexyl. Cyanoacrylates polymerize 598 
rapidly in the presence of traces of water by an anionic polymerization mechanism to corresponding 599 
poly(cyanoacrylate)s. Therefore, they are commonly used as instant adhesives or “superglues”.[185] For medical 600 
adhesive applications, cyanoacrylates with long alkyl groups are preferred since poly(cyanoacrylate)s with short 601 
groups can irradiate the tissues. Poly(cyanoacrylate)s, in particular poly(isobutyl cyanoacrylate) and 602 
poly(isohexyl cyanoacrylate), have also been used in drug delivery applications. The installation of the heavier 603 
element fluorine on the α-position results in α-fluoroacrylates. Poly(α-fluoroacrylate)s can be obtained by the free 604 
radical polymerization of the α-fluoroacrylate.[186] Compared to the conventional (meth)acrylates these polymers 605 
exhibit better thermal and chemical stabilities. These polymers are mainly used for optical applications, but also 606 
found to be useful in cross-linked copolymers as polymer sequestrant. 607 
 608 
2.15 Polyacrylonitriles 609 
Polyacrylonitriles (PAN) are synthetic, semicrystalline organic polymers consisting of nitrile units attached to the 610 
carbon backbone. First synthesized in 1930 by Fikentscher and Heuck (IG Farben, Ludwigshafen),[187] it took more 611 
than 16 years for establishing the large scale production of PAN (brand name Orlon®) by Du Pont®.[188] Commercial 612 
PAN with high molar mass is synthesized by free radical polymerization of acrylonitrile. As a result, the control of 613 
the molar mass distribution is limited and high dispersities are obtained (Mn < 10
6 g mol-1, Ð > 3). More controlled 614 
processes like the ATRP and the RAFT polymerization enable the control of the molar mass distribution for molar 615 
masses (Mn) up to 100,000 g mol
-1 (ATRP[189]: Ð < 1.3; RAFT[190]: 60,000 g mol-1, Ð = 1.2 to 1.4). In many cases, 616 
various vinyl monomers are copolymerized to modify the structure for final applications.[191] Anionic polymerization 617 
has been applied for the polymerization of PAN as well,[192] but this method results in branched structures, which 618 
affects the mechanical behavior of the PAN.[193] In general, the active nitrile groups in PAN can be converted to 619 
other functional groups like carboxyls (via hydrolysis)[194] and amines (via reduction),[195] which subsequently 620 
facilitate further modifications. Recently, Nataraj et al. reviewed the application of PAN-based nanofibers in various 621 
fields.[196] Several investigations have demonstrated that the relatively poor biocompatibility of the conventional 622 
PAN could be improved by bulk or surface modification.[197] Another simple and low-cost alternative modification is 623 
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blending.[198] The FDA approved the use of PAN in the production of semi-rigid and rigid acrylic plastics, which are 624 
intended for use in contact with food (21 CFR 177.1010). 625 
 626 
2.16 Polyurethanes 627 
Discovered 75 years ago, polyurethanes (PU) represent a versatile polymer class based on a modular structure 628 
which is generated by the combination of a variety of polyols and isocyanates as building blocks.[199] The urethane 629 
groups are formed in the polymer backbone by the polyaddition of respective isocyanates and alcohol groups. 630 
The chemical nature of the building blocks, the reaction sequence as well as the ratio of the OH/isocyanate 631 
components determines the properties of the polymers. Polyols with molar masses (Mn) larger than 1,000 g mol
-1 632 
are used to make soft and elastic PUs (e.g. PEG-diols) while short chains result in hard, rigid PUs (e.g. dipropylene 633 
glycol). The latter can be further supported by cross-linkages. The most common used isocyanates are aromatic 634 
diisocyanates (e.g. toluene and methylene diphenyl diisocyanate) since they reveal higher reactivity compared to 635 
aliphatic isocyanates (e.g. hexamethylene diisocyanates). Often the reaction of three components, in particular a 636 
diisocyanate, a bifunctional polyol and a dihydroxy chain extender, is described to form linear, segmented 637 
copolymers consisting of alternating hard and soft segments. The structural diversities and tailorable properties 638 
(e.g. biodegradability, blood compatibility, hydrophilicity) make these materials extremely versatile for 639 
bioapplications and other high-tech products.[200] Doubtless, the most prominent application for PUs are foams of 640 
different nature. The FDA approved PU resins for use as basic components of food contact surfaces 641 
(21 CFR 177.1680). Other materials, which are closely related to PUs, are polyureas (often summarized as 642 
polyurethanes); these are the product of the addition of isocyanates with amines.[201] In general PUs for biomedical 643 
applications are mainly found in gels of various sizes. 644 
 645 
2.17 Polystyrenes 646 
Polystyrenes (PS) are synthetic aromatic polymers made from the styrene monomers. The first commercially 647 
available polymers were manufactured by the company I. G. Farben in 1931.[202] The most prominent applications 648 
are the PS foams. Pioneering work on its polymerization was done by Natta (1960) and Ishihara (1986) who 649 
reported the synthesis of iso- (phenyl groups on the same side) and syndiotactic polystyrenes (phenyl groups on 650 
alternating sides of the backbone). The latter is commonly prepared in a so-called Ziegler-Natta-polymerization.[203] 651 
This kind of polymerization uses metallocene catalysts in order to control the orientation of the monomer in the 652 
moment of addition.[204] Further synthesis routes comprise radical, anionic as well as cationic polymerization. 653 
The syndiotactic PS exhibits a crystallization rate, which is around two orders of magnitude larger than the isotactic 654 
form. Several routes for the synthesis of functional materials are described in literature, comprising in situ 655 
functionalization, post-polymerization modification or the application of pre-functionalized monomers.[205] 656 
For instance, the introduction of sulfonic acid groups in the para-position of the benzene ring turns the resulting PS 657 
into the water soluble poly(styrene sulfonic acid). Different cross-linking agents have been incorporated into the 658 
PS resins, including the most commonly applied divinylbenzene, but also other monomers have been used to adjust 659 
different solvation properties (e.g. dimethacrylate, tetraethylene glycol).[206] Basically, PS is hard and rather brittle 660 
and occurs in the solid or foam state. It is a widely used plastic for packaging where hygiene is important. Above its 661 
glass transition temperature (100 °C) it becomes liquid, while cooling down results in rigidity again. Using this 662 
temperature behavior, PS can be processed via extrusion, molding or vacuum forming.[207] PS is approved by the 663 
FDA as food packaging material (21 CFR 177.1640) updated in 2013 by the Plastics Foodservice Packaging 664 
Group.[208] 665 
19 
 
2.18 Polyanhydrides 666 
Polyanhydrides are commonly obtained by the dehydration reaction between diacids by either melt 667 
polycondensation or solution polymerization to form the functional group (-O-CO-R-CO-). Different structures, their 668 
characterization and biocompatibility have extensively been reviewed.[209] The polymers were prepared with the 669 
intention to obtain a material that should degrade within the time range of their application due to the presence of 670 
the most reactive functional group available for degradation on the basis of passive hydrolysis.[210] They degrade 671 
in vivo into non-toxic monomer counterparts, which can be eliminated from the body as metabolites. High molar 672 
mass polyanhydrides (Mn up to 30,000 g mol
-1) can be synthesized by utilizing heterogenic coordination 673 
catalysts.[211] Often used monomers are the naturally occurring sebacic acid (poly(sebacic 674 
acid), FDA: 21 CFR 175.105) and the 1,3-bis(4-carboxyphenoxy)-propane (poly(bis-(p-carboxyphenoxy)propane). 675 
While aromatic polyanhydrides can fragment after exposure to water, resulting in a rapid release of water-soluble 676 
drugs, copolymers prepared from fatty acids (e.g. sebacic acid) show controlled degradation rates from days to 677 
years. The copolymer poly(styrene-co-maleic anhydride) was approved by the FDA as indirect food additive for use 678 
as articles or components of articles that contact food items (21 CFR 177.1820).  679 
Containing the functional groups in the side chain, poly(maleic anhydride) represents another form of 680 
polyanhydrides made from maleic anhydride in the presence of free radical catalysts and various organic bases, 681 
among others.[212] It is mainly used as comonomer, e.g., for the polymerization with styrene (poly(styrene-co-maleic 682 
anhydride)). A unique feature is the preparation of almost perfectly alternating copolymers which are the first 683 
polymers that were used for drug conjugates. 684 
 685 
2.19 Polyolefins 686 
Polyolefins describe a class of polymers obtained from a simple alkene (olefin) as monomer. These materials are 687 
produced in million ton scales and are the most common plastics used in commodity products. Besides radical 688 
processes or the frequently used coordination polymerization, the living alkene polymerization method catalyzed 689 
by transition metal complexes is becoming more and more popular to synthesize polyolefins with a precise molar 690 
mass control as well as a wide array of polymer architectures.[213] Their properties are mainly determined by their 691 
molar mass and degree of crystallinity (from liquid-like to rigid plastics). All practical or commercial relevant 692 
polyolefines are poly-α-olefins. The FDA approved poly(ethylene) for use as basic component of food contact 693 
surfaces (21 CFR 177.1520). It represents the simplest representative and most common plastic, which is made 694 
from ethylene in the presence of the Ziegler-Natta catalyst.[214] 695 
Further often used olefins are poly(isobutylene) (by cationic polymerization of isobutylene),[215] the non-reactive 696 
fluoropolymer poly(vinylidene fluoride) (PVDF) (by radical polymerization of vinylidene difluoride)[216] and 697 
poly(hexafluoropropylene) (PHFP). Bisfunctional polyolefins like poly(octa-1,7-diene) can be used for cross-linking 698 
reactions to obtain network architectures. 699 
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Table 2. Overview of polymer classes that exhibit pharmaceutical relevance. 700 
POLYMER CLASS STRUCTURE R NAME (ABBREVIATION) WATER SOLUBILITY BIODEGR.
[a]
 (Y/N) 
APPLICATION  
(see corresponding chapter) 
Polyether  
H Poly(ethylene glycol) (PEG) Good N 
Polymer-drug conjugates, solid 
colloidal dispersions, polyplexes, 
microgels, hydrogels, solid implants 
and inserts, matrix excipients 
CH3 Poly(propylene glycol) (PPG) LCST ~ 50 °C N 
Solid colloidal dispersions, polyplexes, 
matrix excipients, polymeric drugs 
OH Poly(glycerol) (PG) Good N Future prospects 
CH2Cl 
Poly(epichlorohydrin) 
(Poly(chlormethyl)oxiran) 
No N Polymeric drugs 
 
 Poly(ketal) (PK) Dependent on R
2
 Y Future prospects 
Poly(ethylene imine) 
 
H 
Linear poly(ethylene imine)  
(LPEI) 
Good for > 70 °C N 
Polyplexes, hydrogels, future 
prospects 
CH2CH2NHR 
Branched poly(ethylene 
imine)  
(BPEI) 
Good N 
Polyplexes, hydrogels, future 
prospects 
Polyester 
 
 Poly(caprolactone) (PCL) Degradation Y Drug-eluting stents, future prospects 
 
H Poly(glycolic acid) (PGA) Degradation Y 
Solid colloidal dispersions, hydrogels, 
solid implants and inserts, drug-
eluting stents, future prospects 
CH3 
Poly(lactic acid) (PLA) 
(i.e. PDLLA, PLLA and PDLA) 
Degradation Y 
Solid colloidal dispersions, hydrogels, 
solid implants and inserts, drug-
eluting stents, future prospects 
 
 Poly(oxalate) (PO) Degradation Y Future prospects 
 
(CH2)4 
Poly(butylene terephthalate) 
(PBT) 
Degradation 
(> 60 °C) 
Y Microgels 
Polycarbonate 
 
  Good Y Future prospects 
Poly(amino acid)  
H Poly(γ-glutamic acid) (PGluA) Good Y 
Polymer-drug conjugates, future 
prospects 
 Poly(γ-glutamate) (PGlu) Good Y Solid colloidal dispersions, nanogels 
 
 Poly(lysine) Good Y Polyplexes, future prospects 
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 α-Poly(aspartate) (PAs) Good Y Solid colloidal dispersions 
Poly(peptoid) 
 
 (PoP) Good Y Future prospects 
Poly(2-oxazoline) 
 
 (POx) 
Good 
(only for CH3, C2H5) 
N 
Polymer-drug conjugates, future 
prospects 
Poly(N-acrylamide) 
 
R
1 
= H;  
R
2 
= CH(CH3)2 
Poly(N-isopropylacrylamide) 
(PNiPAAm) 
Depending on temp. N Future prospects 
R
1 
= CH3;  
R
2 
= CH2CH(CH3)(OH) 
Poly(N-(2-hydroxypropyl)-
methacrylamide) (PHPMA) 
Good N 
Polymer-drug conjugates, future 
prospects 
Polyphosphoester 
 
R
2
 = OR Poly(phosphate) (PP) Good 
Y 
(Depend. on R
2
) 
Future prospects 
Polysiloxane 
 
R
1
,R
2
 = CH3 
Poly(dimethylsiloxane) 
(PDMS, dimethicone) 
No N 
Hydrogels, solid implants and inserts, 
matrix excipients, future prospects 
Poly(vinyl 
ester/alcohol/ether) 
 
COCH3 Poly(vinyl acetate) (PVAc) Good Y 
Solid implants and inserts, drug-
eluting stents, Future prospects 
 
 Poly(vinyl alcohol) (PVA) Good Y 
Microgels, solid implants and inserts, 
solid oral dosage forms, 
matrix excipients 
 
 Poly(vinyl ether) (PVE) No N Polymer-drug conjugates 
Poly(N-vinyl amide) 
 
 Poly(vinyl pyrrolidone) (PVP) Good N 
Hydrogels, drug-eluting stents, matrix 
excipients, future prospects 
Poly(allylamine) 
 
 (PAAm) Good ? Polymeric drugs, future prospects 
Poly(acrylate) 
 
R
1 
= H; R
2
 = H Poly(acrylic acid) (PAA) Good N 
Hydrogels, matrix excipients, future 
prospects 
R
1 
= H; R
2 
= CH3 Poly(methyl acrylate) No N Solid oral dosage forms 
R
1
 = H; R
2
 = C2H5 Poly(ethyl acrylate) No N Solid oral dosage forms 
R
1 
= F; R
2 
= H Poly(2-fluoroprop-2-enoate) Good N Polymeric drugs 
Poly(methacrylate) 
 
R = H 
Poly(methacrylic acid) 
(PMAA) 
Good N 
Microgels, solid oral dosage forms, 
future prospects 
R = CH3 
Poly(methyl methacrylate) 
(PMMA) 
No N 
Solid implants and inserts, solid oral 
dosage forms, matrix excipients, 
future prospects 
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R = C4H9 
Poly(n-butyl methacrylate) 
(PBMA) 
No N Drug-eluting stents, matrix excipients 
R = CH2CH2N(CH3)2 
Poly(dimethylaminoethyl 
methacrylate) (PDMAEMA) 
Good N 
Solid oral dosage forms, matrix 
excipients, future prospects 
R = CH2CH2N(C2H5)2 
Poly(diethylaminoethyl 
methacrylate) (PDEAEMA) 
Depending on 
pH value 
N Solid oral dosage forms 
R = CH2CH2N(CH3)3
+
 
Poly(trimethylammonioethyl 
methacrylate chloride) 
(PTMAEMA) 
Depending on 
pH value 
N Solid oral dosage forms 
R = CH2CH2OH 
Poly(2-hydroxyethyl 
methacrylate) (PHEMA) 
Good 
(low molar masses) 
N Hydrogels 
Poly(cyanoacrylate) 
 
R = CH2CH(CH3)2 Poly(isobutyl cyanoacrylate) No N Solid colloidal dispersions  
R = (CH2)3CH(CH3)2 Poly(isohexyl cyanoacrylate) No N Solid colloidal dispersions  
Polyacrylonitrile 
 
 (PAN) 
Good  
(in aq. inorganic salt 
solutions) 
N Hydrogels, future prospects  
Polyurethane 
 
 (PU) No Y Hydrogels, solid implants and inserts 
Polystyrene 
 
H (PS) No N 
Polymer-drug conjugates, drug-
eluting stents, polymeric drugs, 
future prospects 
SO3H Poly(styrene sulfonic acid) Good N Polymeric drugs 
[-CHCH2]n Poly(divinylbenzene) No N Polymeric drugs 
Polyanhydride 
 
 Poly(sebacic acid) Decomposition Y Solid implants and inserts 
 
 
Poly(bis-(p-carboxy-
phenoxy)propane) 
Decomposition Y Solid implants and inserts 
 
 Poly(maleic anhydride) Decomposition N 
Polymer-drug conjugates, future 
prospects 
Polyolefin 
 
R
1
 = H; R
2
 = H Poly(ethylene) No N 
Solid implants and inserts, drug-
eluting stents 
R
1
 = CH3; R
2
 = CH3 Poly(isobutylene) No N Drug-eluting stents 
R
1 
= F; R
2 
= F 
Poly(vinylidene fluoride) 
(PVDF) 
No N Drug-eluting stents 
 
 Poly(octa-1,7-diene) No N Polymeric drugs 
 
 
Poly(hexafluoropropylene) 
(PHFP) 
No N Drug-eluting stents 
[a]
 Biodegradability in this review designates the potential of polymer chain cleavage by enzymes or proteases (Y = yes, N = no).701 
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3. Polymers in pharmaceutical applications 702 
The following chapter describes different forms of applications of pharmapolymers which are already available on 703 
the market or currently undergoing clinical trials. The current clinical status and the respective NTC number 704 
(clinicaltrials.gov identifier) usually refer to the official webpage https://clinicaltrials.gov/. In some cases, the 705 
availability and the approved indication of use for the applied materials vary between countries. The described 706 
forms of appearance include polymer-drug conjugates, drug carrier systems in scales ranging from nano- to 707 
macroscopic size, polymers as coatings and matrix excipients as well as polymeric drugs. 708 
 709 
3.1 Polymer-drug conjugates 710 
The conjugation to polymers is a well-established technique to improve the properties of therapeutically active 711 
substances. In the last decades, numerous polymers have been tested for this purpose. The cytostatic agents that 712 
have been mainly used for preparing polymer-drug conjugates are doxorubicin (DOX), camptothecin (CPT), 713 
paclitaxel (TXL) and platinum complexes (Figure 1), but also other, more specialized drugs are conjugated. 714 
 715 
716 
 717 
Figure 1. Schematic representation of the structures of the most common cytostatic agents used for preparing polymer-drug conjugates. 718 
A) Literature reported conjugation sites (marked in red) and B) selected examples for platinum complexes. 719 
 720 
3.1.1 PEG conjugates  721 
One of the first and probably the most well-known example is the attachment of poly(ethylene glycol) (PEG), also 722 
called PEGylation. In drug delivery, PEGylation can be subdivided into three categories: The attachment of PEG to 723 
proteins, to small drug molecules and to other polymers. The latter is often related to the formation of 724 
nanocarriers, which are described in detail in Chapter 3.2. With the attachment of PEG chains, some of the 725 
beneficial properties of this polymer are transferred to the pharmacological active compounds, which can improve 726 
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the accessibility of drugs in biological systems.[15, 217] Pioneered by Davis and his colleagues, the first PEGylation was 727 
successfully demonstrated on a protein.[10a] The initial goal was the protection from destruction during the delivery 728 
process. As an unexpected finding, the authors observed that the PEGylation improved the pharmacokinetic and 729 
pharmacodynamics of the protein.[218] Similar observations are found for small drug molecules, which often suffer 730 
from poor solubility and, therefore, low bioavailability. The attachment of PEG strongly improves their properties 731 
by adapting the beneficial properties of the PEG polymer. 732 
PEGylation of proteins. Since the first PEGylation of a protein, a variety of accessible functional groups on protein 733 
surfaces has been explored as potential linking sites. In general, the functionalization with PEG introduces several 734 
advantageous properties compared to the native protein. PEGylated proteins show an improved pharmacokinetic 735 
and pharmacodynamic, which is related to an increased water solubility, an increased stability, shielding from 736 
metabolic enzymes, a reduced immunogenicity and retarded renal clearance (due to stealth behavior) leading to an 737 
elongated blood circulation time.[11b] Depending on the molar mass of the attached PEG chains, the clearance by 738 
the kidneys can also be circumvented.[15, 218-219] The conjugation additionally reduces the immunogenicity of the 739 
native protein, increases its stability and prolongs the biological half-life which helps to reduce the frequency of 740 
administration. In the last decade, several new conjugation methods have been developed, allowing a more 741 
effective and selective attachment of PEG polymers. The PEGylation techniques of proteins can be separated into 742 
first and second generation.[220] The first generation is performed using short PEGs (Mn = 5,000 to 12,000 g mol
-1) 743 
being randomly bound to the protein surface. A disadvantage when using a PEG-diol is the formation of a high 744 
content of protein dimers, trimers and even fully cross-linked materials. In consequence, the α-methylated mPEGs 745 
are preferred to avoid this problem, although minor contaminations with PEG-diol are still present.[221] As activation 746 
agents or linkers between the protein and the PEG chains, cyanuric chloride, tresyl chloride and many more 747 
compounds are applied.[11a, 222] The second generation of PEGylation improved the selectivity of the attachment to 748 
specific areas of the protein while reducing the influences on the protein structure. Common groups for 749 
functionalization are maleimide targeting free thiol groups, NHS activated acids reacting with amines, 750 
benzotriazoles, which create a pH-responsive linkage, and aldehydes such as propionaldehyde. Furthermore, 751 
second generation PEGs allow an easier purification and removal of remaining PEG-diol, e.g. in the case of PEG with 752 
activated acids up to 97% of the remaining diol content can be removed by ion-exchange chromatography.[218] 753 
PEGylation techniques forming disulfide bridges enable the site specific PEGylation to the few free cysteine 754 
residues on the protein surface, which minimizes the loss of biological activity, but preserves the low 755 
immunogenicity. A rather new method is described by DeFrees et al. called glycopegylation. This method basically 756 
uses enzymes for N-acetylgalactosamine (GalNAc) glycosylation at specific serine and threonine residues, which 757 
subsequently conjugate to salic acid conjugated PEG by enzymatic transfer.[223] These improvements on the 758 
conjugation methods allow the synthesis of drug conjugates with well-defined amounts of PEG and selective 759 
binding to non-active parts of the protein.[224] A more detailed overview on different protein PEGylation techniques 760 
is given by Roberts et al..[11d]  761 
Considering the above mentioned improvements on the synthesis, in particular the excellent selectivity of 762 
conjugation and the general benefits like the improved pharmacokinetics, it is not surprising that a number of 763 
PEGylated proteins already entered the market and several new materials are in clinical trials. Overall, thirteen 764 
different PEGylated proteins are nowadays approved and commercialized (Table 3). The first clinically approved 765 
PEGylated protein drug was the enzyme Adagen® (Enzon Pharmaceuticals). After its approval, several other 766 
PEGylated protein drugs found their way to commercialization and entered clinical trials within a short period of 767 
time. A milestone in the pharmaceutical development was certainly the approval of Macugen®, being the first 768 
approved aptamer used as therapeutic agent in humans.[225] The latest protein drug that has been approved by the 769 
Food and Drug Administration (FDA, Nov. 2015) is the PEGylated full length Factor VIII (Adynovate®) for use in 770 
patients aged 12 years and older suffering from haemophilia A and.[226] Once approved by the FDA or European 771 
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Medicines Agency (EMA), established PEGylated proteins are investigated in clinical trials. Due to the large number 772 
of clinical studies, only a selection of investigated diseases can be found in Table 3. 773 
 774 
Table 3. PEGylated proteins and small drugs on the market approved by the FDA and EMA as well as their use for other diseases. 775 
TRADE NAME CONJUGATE  INDICATION/USE MANCUFACTURER 
Mn (PEG) (g mol
-1
)  
[# of PEGs/drug molecule] 
CURRENT  
CLINICAL TRIALS ON … 
PROTEIN 
Adagen® 
PEG-Adenosine 
Deaminase 
SCID
[a]
 
Enzon 
Pharmaceuticals 
5,000 
[11 to 17] 
Severe combined 
immunodeficiency disease 
Oncaspar® PEG-Asparaginase  Leukaemia 
Enzon 
Pharmaceuticals 
5,000 
[69 to 82] 
Various cancers (neoplasms, 
multiple myeloma) 
PegIntron®, 
ViraferonPeg® 
PEG-Interferon-α2b Hepatitis C Schering-Plough 
12,000 
[1] 
Hepatitis B, various cancers 
(e.g. fallopian tube-, ovarian-, 
peritoneal cavity cancer, 
neoplasm, melanoma), HIV 
Infection 
PEG-Interferon-α2a  Hepatitis C Hoffman-La Roche 
40,000 
[1 branched] 
Hepatitis B, various cancers 
(e.g. kidney cancer, leukemia), 
HIV infection 
Somavert® 
PEG-Human growth 
hormone mutein 
antagonist 
Acromegaly Pfizer  
5,000 
[4 to 6] 
Different neoplasms 
(colorectal, lung, breast, 
prostatic) 
Neulasta® PEG-G-CSF
[b]
 Neutropenia Amgen® 
20,000 
[1] 
Various cancers  
(e.g. breast cancer) 
Macugen® 
(Pegaptanib) 
PEG-anti-VEGF 
aptamer 
WARMD 
OSI 
Pharmaceuticals/ 
Pfizer  
40,000 
[1 branched] 
Wet age related macular 
degeneration 
Mircera® PEG-Erytropoietin AACKD Hoffman-La Roche 
30,000 
[1] 
Various cancers  
(e.g. breast, prostate cancer, 
lymphoma, neoplasms) 
Cimzia® PEG-anti-TNF Fab
[c]
 
Rheumatoid 
arthritis & 
Crohn's disease 
(RACD) 
UCB Cares® 
40,000 
[1 branched] 
RACD  
Krystexxa® 
(Pegloticase) 
PEG-Uricase  Chronic gout Horizon Pharma 
10,000 
[9 per homo-tetramer (4)] 
Chronic kidney disease stage 5 
Omontys® Peginesatide AACKD Affymax/Takeda
[d]
 
40,000 
[1 branched] 
Anaemia associated with 
chronic kidney disease 
Lonquex® 
(Lipegfilgrastim) 
Glycopegylated  
G-CSF 
Neutropenia
[e]
 TEVA 
20,000 
[1] 
Various cancers (e.g. breast, 
ovarian cancer) 
Plegridy® 
PEG-interferon beta 
1a  
Relapsing 
multiple sclerosis 
(RMS) 
Biogen
TM
 
20,000 
[1] 
RMS 
Adynovate® 
PEG-Factor VIII 
(full-length 
Coagulation Factor 
VIII) (BAX 855) 
Haemophilia A
[a]
 Shire 
20,000 
[2] 
Different blood diseases  
(von Willebrand Disease, 
thrombosis) 
SMALL DRUG 
Moventig®  
(EU: Movantik®) 
(Naloxegol) 
PEG-Naloxone
[b]
 
Opioid-induced 
constipation 
AstraZeneca 
< 1,000  
[1] 
 
[a]
 Only approved by the FDA, 
[b] 
G-CSF: Granulocyte-colony stimulating factor, 
[c] 
approved for different disease in U.S. and E.U. (Nektar®), 776 
[d]
 withdrawn by Takeda, 
[e] 
Only approved by the EMA. 777 
 778 
Selected PEGylated protein drugs in clinical trials. Due to the high number of materials in clinical trials, we only like 779 
to highlight a few materials in late stages of clinical testing (phase III) used for different kinds of diseases (Table 4). 780 
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Inherent bleeding disorder due to a deficiency or dysfunction of coagulation proteins is called haemophilia (A in 781 
case of Factor VIII, B in case of Factor IX). The only treatment of haemophilia patients is the intravenous injection of 782 
the deficient coagulation factors, prophylactic or in case of acute trauma. A drawback of native coagulates is their 783 
short half-life (FVIII 8: 12 h, FIX 18: 24 h) and the resulting frequent need for administration. In comparison, 784 
PEGylated FVIII and FIX show extended half-life and increased blood concentration after injection.[227] Besides the 785 
FDA approved PEGylated recombinant Factor VIII several other products are currently undergoing clinical trials 786 
including PEGylated Factor IX proteins. These drugs differ mainly in the way of PEG-binding, the chain length of the 787 
PEG or the modification of the protein (mutant Factor VIII (K1804C)).[227b, 227c, 228] The aim of these modifications is 788 
of course an increased activity.[229] Two conjugates are currently undergoing clinical trials in phase III (N8-GP and 789 
N9-GP).[230] The effects of these products are discussed in detail in literature.[227c, 231] Age related macular 790 
degeneration (AMD) is a medical condition causing blurred or impeded vision on focused objects, which in case of 791 
the more common wet AMD is related to the formation of abnormal blood vessels in the middle part of the retina. 792 
Initiated by the approval of the previously mentioned Macugen®, further PEGylated protein aptamers are under 793 
investigation, such as Fovista®. In contrast to Macugen®, Fovista® is developed to inhibit the platelet-derived 794 
growth factor (PDGF) and, therefore, the formation of abnormal vessel growth. For the treatment of AMD, it is 795 
combined with ranibizumab, an anti-Vascular Endothelial Growth Factor (anti-VEGF), and just passed the clinical 796 
trials phase II and entered phase III showing significantly improved results compared to native ranibizumab.  797 
Patients with an inactive recombinant phenylalanine ammonia lyase suffer from an enrichment of phenylalanine 798 
(Phe) or hyperphenylalaninemia, which is mainly caused by a recessive gene disorder and results in mental 799 
retarding, if not recognized and treated timely.[232] A possible treatment is an enzyme substitution therapy. 800 
However, injections of pure phenylalanine ammonia-lyase (PAL) have only a short half-life and low activity in gastric 801 
secretions. In consequence, research focused on the development of more efficient forms realized by site-directed 802 
mutagenesis and PEG modifications. As a result, the concentration of Phe in blood could be decreased significantly 803 
and the symptoms are diminished.[233] Another PEGylated protein that reached phase III clinical trials is 804 
Peglispro,[234] a PEGylated insulin for the application as long term drug for diabethis mellitus patients. It could be 805 
shown that Peglispro has improved pharmakokinetic and pharmakodynamic profiles and, preferentially, hepatic 806 
versus peripheral action compared to insulin glargine. Nevertheless, end of 2015 the development of the project 807 
was discontinued by the supplier Lilly due to late stage observations regarding liver fat changes leading to 808 
unresolved questions.[235] 809 
 810 
Table 4. PEGylated proteins under active clinical trials in phase III. 811 
NAME PEGYLATED PROTEIN INDICATION/USE MANUFACTURER 
Mn (PEG) (g mol
-1
)  
[# of PEGs/drug molecule] 
IDENTIFIER 
NUMBER 
N8-GP 
Glycopegylated recombinant 
coagulation Factor VIII (K1804C) 
Haemophilia A Novo Nordisk® 40,000 [1] NCT01489111 
N9-GP PEGylated recombinant Factor IX Haemophilia B Novo Nordisk® 40,000 [1] NCT02141074 
Fovista® 
PEGylated anti-platelet-derived 
growth factor  
Age related macular 
degeneration 
Ophthotech/ 
Nektar® 
40,000 [1 branched] e.g. NCT01944839 
Pegvaliase 
PEGylated recombinant PAL 
enzyme
[a]
 
Phenylketonuria BioMarin® 20,000 [1] NCT01819727 
[a]
 PAL: Phenylalanine ammonia lyase. 812 
 813 
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PEGylation of small molecule drugs. In comparison to proteins, small molecules provide only a limited number of 814 
reactive side chains that are suitable for modifications. The lack of functional side groups in linear PEGs makes the 815 
coupling capacity of small molecules a critical issue. In order to improve the loading capacity, different 816 
architectures were investigated, e.g. forked, multi-arm, star-like and dendritic or branched polymers for the 817 
conjugation of small molecule drugs.[236] [217b, 237] Despite the immense research effort, it took a comparably long 818 
time for PEGylated small molecule drugs to enter the market. Small molecule drugs, such as antitumor agents, 819 
often suffer from poor solubility, high toxicity, rapid excretion and untargeted biodistribution. Therefore, 820 
conjugation of PEG represents an obvious way to improve their profiles. However, until now PEG-Naloxone 821 
(Moventig®) is, to the best of our knowledge, the first and only marketed PEGylated small molecule drug (approved 822 
by FDA and EMA) (Table 3). PEG-Naloxone is applied for treatment of opioid-induced constipation and approved for 823 
adult patients with chronic non-cancer pain.[217a] Being approved in 2014, Moventig® entered the market 824 
comparably late considering that PEGylation of proteins is performed for decades. Li et al. summarized 20 to 25 825 
PEGylated small molecules at different stages of development and several research examples which show that 826 
PEGylated small molecules principally have improved properties. However, those examples failed in clinical trials 827 
due to a reduced activity, an inherent instability or their toxicity.[237b] Nevertheless, with the first approval of a 828 
PEGylated small drug we are confident that further examples will follow. 829 
A list of PEGylated small molecule drugs undergoing clinical trials is given in Table 5. NKTR-181 is a PEGylated 830 
agonist for the µ-opioid receptor developed by Nektar®. Currently, it undergoes clinical trials in phase III.[238] 831 
Modified opoids are the most common medication types to treat chronic pain. In preclinical and clinical trials, the 832 
PEG modified drug revealed a slower uptake by the central nervous system (CNS) due to a reduced crossing of the 833 
blood-brain barrier (BBB), resulting in fewer CNS related side effects.[239] The aim of NKTR-181 is the treatment of 834 
patients with chronic low back pain (SUMMIT-07).[240] 835 
Etirinotecan pegol comprises the prodrug irinotecan which is conjugated to a 20,000 g mol-1 four arm PEG by a 836 
degradable linker. Irinotecan is widely used as chemotherapeutical agent.[241] After enzymatic hydrolysis of the 837 
linker, it metabolizes into SN38, a potent topoisomerase I inhibitor and the active moiety of irinotecan, resulting in 838 
a 1000-fold increased activity in comparison to irinotecan itself.[242] The conjugation to PEG using slowly 839 
hydrolysable linkers based on esters aims at an application as long-acting agent with continuous and targeted drug 840 
release. In consequence, the concentration of SN38 is reduced in the plasma and undesired side effects are 841 
diminished.[243] As a result of the beneficial properties observed in phase II, Etirinotecan pegol is now undergoing 842 
clinical trials in phase III for advanced breast cancer and brain metastases in the US (OnzealdTM).[243] In addition to 843 
this trial, further studies in different stages are currently ongoing to test its use for other cancerous diseases. 844 
In phase II of clinical trials, toxic side-effects associated with common chemotherapies appeared less frequent or 845 
were completely absent.[244] These preliminary results make etirinotecan pegol an attractive and interesting 846 
candidate for chemotherapies in the future. Other PEGylated small molecules produced by Nektar® are in earlier 847 
stages of clinical trials (I and II), including EZN-2208 for advanced solid tumors/lymphoma, and NKTR-171 for 848 
neuropathic pain.[238, 245] 849 
 850 
Table 5. PEGylated small molecule drugs undergoing active clinical trials. 851 
NAME 
PEGYLATED 
DRUG 
INDICATION/USE MANUFACTURER 
Mn (PEG) (g mol
-1
)  
[# of PEGs/drug molecule] 
STATUS 
NKTR-181 n.a. Neuropathic pain Nektar® < 1,000 
Phase III  
(e.g. NCT01619839) 
NKTR-102 
(US: Onzeald
TM
) 
Etirinotecan 
pegol (SN38) 
Several cancer Nektar® 20,000 [1 four-arm] 
Phase III  
(e.g. NCT01492101) 
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Figure 2. Schematic representation of the 
chemical structure of poly(styrene-co-maleic 
anhydride/acid/ester). 
EZN-2208 SN38 Several cancer Enzon Pharmaceuticals 40,000 [1 four-arm] 
Phase II  
(e.g. NCT00520637) 
NKTR-171 n.a. Neuropathic pain Nektar® < 1,000 Phase I
[246]
 
n.a.: not applicable. 852 
 853 
3.1.2  Non-PEG conjugates 854 
Some limitations of PEGylation have emerged specifically including an increased occurrence of immunogenic 855 
reactions and the accumulation in tissues which is a result of the nondegradability.[247] Hypersensitivity has been 856 
observed in some cases, which diminishes the benefits of PEGylation in case of some patient populations.[248] 857 
Even though PEG is not biodegradable, degradation occurred under certain circumstances (light, heat etc.) with the 858 
possibility of a build-up of toxic side products while stored.[15] Nevertheless, PEG is currently still the most tested 859 
and best understood polymer available with the longest clinical track record, but research efforts have increased to 860 
develop alternative materials addressing these limitations of PEG and adding further functionalities to 861 
polymer-drug conjugates. The number of potential alternatives for PEGylation has increased tremendously in the 862 
last years.[249] Requirements for potential substitutes for PEG include a high water-solubility, non-toxicity, 863 
non-immunogenicity, low accumulation during a therapy and clearance from the body.[250] Besides natural 864 
polymers such as heparin, dextran, chitosan, hyaluronic acid and human serum albumin, several synthetic polymers 865 
have emerged as suitable conjugate alternatives to PEG. In the following chapter we focus on these synthetic PEG 866 
alternatives and summarize all materials which entered clinical trials or the market already (Table 6). 867 
Poly(styrene-co-maleic anhydride). The conjugation of poly(styrene-co-maleic anhydride) to the antitumor protein 868 
neocarzinostatin (SMANCS) was the first clinically approved polymer-drug conjugate (Zinostatin Stimalmer®) and is 869 
to this date the only non-PEG polymer-protein therapeutic that made it to 870 
the market. Maeda et al. reported the synthesis of SMANCS in the late 871 
1970’s. The copolymer consisting of styrene and maleic anhydride (SMA) 872 
was partially modified (30 to 50%) with butanol which was found to 873 
provide considerable hydrophobicity (Figure 2). Once added into aqueous 874 
solution, the residual anhydrides open and quickly form the acid. The 875 
modified SMA polymer chains were covalently linked to neocarzinostatin 876 
(NCS).[251] This characteristic enables dispersion in the phase-contrast 877 
agent lipiodol used in lymphangiography and, therefore, local 878 
administration through the feeding artery of the primary cancer, in particular liver cancer, of patients.[252] With the 879 
aid of X-ray, a precise localization of SMANCS to tumor tissue became realizable. Preclinical studies revealed the 880 
highest tumor-blood ratio (> 2.500) of the prodrug location ever reported for targeting approaches.[253] 881 
Maeda mentioned for the first time the importance of passive tumor targeting by the “enhanced permeability and 882 
retention effect” (EPR effect) describing that molecules of certain sizes (Mn = 30,000 to 50,000 g mol
-1)[254] tend to 883 
accumulate preferentially in tumor tissue not in normal tissue.[255] Recently, lipiodol has been proven to be 884 
essential for the anti-tumor activity of SMANCS.[256] The protein conjugate successfully passed the clinical phases 885 
with high response rates (36 to 40%).[257] SMANCS received its approval for the market in 1990 (Japan) as part of 886 
the treatment of hepatocellular carcinoma and is distributed by Astellas Pharma (formerly Yamanouchi).[258] 887 
The highest chance of success is given in a 'patient-individualized treatment' (dose per tumor size/area) and 888 
follow-up treatments are only administered if the tumor is not regressing. Despite the efforts made to develop 889 
novel polymer carriers, the modified copolymer SMA remains the only commercialized synthetic alternative to PEG. 890 
However, a few other types of polymers or their drug conjugates, respectively, have been evaluated in clinical 891 
studies and mainly comprise poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) and poly(glutamic acid) (PGluA). 892 
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Poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA). Testing conjugates of the PHPMA with anthracyclines, the 893 
homopolymers and respective copolymers were found to be chemically inert in biological media and showed no 894 
immunogenic response.[259] The first polymer-drug conjugate that entered clinical trials was the PHPMA conjugate 895 
PK1 (FCE28068), which included doxorubicin (DOX) covalently bound by a tetrapeptide linker.[116] The peptide 896 
(Gly-Phe-Leu-Gly) is stable in the plasma, but can be cleaved off by lysosomal enzymes of tumor cells[260] enabling 897 
the controlled release of the DOX within the tumor cell.[261] In addition, the conjugate has shown to concentrate 898 
within the solid tumor models of rats.[262] After phase I studies revealed signs of activity and a 5-fold decrease in 899 
toxicity compared to the pure anthracycline,[116] phase II trials on application for breast, non-small cell lung and 900 
colon cancer were initiated. Positive responses were indicated for breast and for non-small cell lung, while none 901 
were observed in case of colorectal cancer. A related compound to PK1, named PK2 (FCE28069), was modified by 902 
incorporation of a galactosamine group, which was designed to increase the uptake in liver tumor cells by 903 
interaction with the asialoglycoprotein receptor. After the PHPMA-DOX-galactosamine conjugate was investigated 904 
in preclinical studies,[263] the phase I trial revealed that the maximum tolerated dose (MTD) was reduced to 905 
approximately half the value of PK1, although the molar mass and the loading ratio were similar.[264] An increased 906 
uptake due to the hepatic targeting was confirmed by planar imaging and single photon emission computed 907 
tomography (SPECT) with 123I-labeled PK2, while the conjugate without galactosamine (PK1) revealed no effect. 908 
However, despite showing promising results, both clinical studies (PK1 and PK2) were discontinued for undisclosed 909 
reasons. 910 
For decades, platinum complexes have represented a major class of chemotherapeutics, which have been used for 911 
the treatment of solid tumors. Although numerous different Pt analogues have been investigated in preclinical and 912 
clinical studies, cis-, carbo-, and oxaliplatin are the only metal-based anticancer agents in routine clinical use. 913 
Recently, the drug conjugates AP5280 and AP5286 have entered clinical trials. A diamine platinum(II) (AP5280) or a 914 
diaminocyclohexane platinum(II) (AP5286) moiety, respectively, are bound to a dicarboxylate ligand that is linked 915 
to PHPMA via the tetrapeptide spacer Gly-Phe-Leu-Gly.[265] This cathepsin B sensitive linker has already been 916 
mentioned for PK1 and PK2. For AP5280, preclinical studies revealed a high antitumor efficiency and increased MTD 917 
compared to the established clinical standards cis- and carboplatin.[266] In the case of AP5286, we can only refer to a 918 
handful of references that claim phase I trials that are currently ongoing.[236, 267] Abeona Therapeutics 919 
(formerly Access Pharmaceuticals) has decided to focus on a third generation polymer which is based on an 920 
improved polymer carrier.[115] ProLindacTM (AP5346) represents a 25,000 g mol-1 (Mw) polymer delivery vehicle 921 
based on PHPMA, to which a diaminocyclohexane (DACH) platinum is conjugated.[268] The pH-sensitive linker causes 922 
a more rapid release of the platinum in environments of low pH value, as it is typically found in many tumor sites. 923 
ProLindacTM is currently in clinical development phase II in cancer patients with solid tumors. The phase I/II 924 
monotherapy study on patients with recurrent ovarian cancer has been completed and demonstrated efficiency 925 
and safety.[268-269] This opens the field for further clinical studies of ProLindacTM in combination with other 926 
chemotherapeutic agents, e.g. TXL.[270] Two other PHPMA conjugates, which entered clinical phase I trials, are 927 
bound to TXL or CPT, respectively. In the case of TXL (PNU-166945), the drug is conjugated to the PHPMA backbone 928 
via the previously mentioned enzymatically degradable tetrapeptide linker. One patient with advanced breast 929 
cancer had a partial response. The study had to be discontinued due to severe neurotoxic effects observed in 930 
additional rat studies.[271] PNU-166148 is a copolymer consisting of HPMA, very few units of 931 
N-(2-hydroxypropyl)methacryloyl glycinamide and methacrylamide units, to which CPT is bound through the 932 
degradable Gly-6-amino-hexanoyl-Gly spacer (Figure 3). The conjugate was developed by Pharmacia and Upjohn to 933 
overcome problems in the clinical delivery of CPT, which are related to the limited solubility of the active form 934 
(closed lactone ring) or the poor activity of the more soluble open ring form. With conjugation of the closed form of 935 
CPT to the copolymer, the solubility was maintained while the drug can be released by the pH-dependent or 936 
enzymatic degradation of the linker. There are three different phase I studies described in literature.[272] 937 
30 
 
The obtained results revealed changes in the pharmacokinetics of CPT with a prolonged half-life for both carrier-938 
bound and released-CPT. However, the studies lacked answers to 939 
potential pharmacodynamic benefits, and revealed no sign of 940 
significant antitumor activity. The toxicities of the studied conjugates 941 
were similar to the pure compound CPT. Therefore, Pharmacia and 942 
Upjohn decided to discontinue further clinical development of 943 
PNU-166148. 944 
All PHPMA conjugates which have been investigated in clinical 945 
studies are exclusively applied for cancer treatment. Although 946 
PHPMA is well-established as a biocompatible drug carrier and a 947 
promising alternative to PEG, protein conjugates of this polymer 948 
class are less developed. However, in recent years, the research on 949 
PHPMA copolymers for the treatment of non-cancerous diseases has increased tremendously (see Chapter 4). 950 
These innovative and promising developments in the rational design, synthesis, and evaluation of novel PHPMA 951 
copolymer-drug conjugates have been highlighted elsewhere.[273] 952 
Poly(glutamic acid) (PGluA). PGluA represents a well-established type of polymer which frequently appears in 953 
clinical studies. The conjugate with TXL (CT-2103) is one of the few successful polymer-drug conjugates to date 954 
which is known under the name OpaxioTM (formerly as XyotaxTM, CTI BioPharma). It has already successfully 955 
finished phase III trials where it proved its efficacy against ovarian and non-small cell lung cancer in combination 956 
with other standard chemotherapeutics.[274] OpaxioTM features an extremely high loading capacity (~37 wt% TXL) 957 
compared to other polymer conjugates. Key advantages of the material are the inherent biodegradability of the 958 
polymer backbone and the related release of TXL or its derivatives in vitro and in vivo by enzymatic cleavage in the 959 
presence of cathepsin B.[275] In 2006, CTI BioPharma planned a new phase III study of 1,500 women suffering from 960 
ovarian cancer with the aim to improve survival rates. Two years later, CTI announced that the European Medicines 961 
Agency (EMA) has accepted to review CTI's Marketing Authorization Application for OpaxioTM for first-line 962 
treatment of patients with non-small cell lung cancer.[276] We expect that OpaxioTM will be on the market for the 963 
treatment of different types of cancer in the near future. In a similar manner, CPT was conjugated to 964 
PGluA (CT-2106) and the polymer-drug conjugate has already finished a phase I study (advanced solid 965 
malignancy).[277] According to an exclusive record, a phase II study on the treatment of advanced metastatic ovarian 966 
cancer was completed, but no results were published so far (NCT00291837).  967 
Poly(2-oxazoline)s (POx). The conjugation of the FDA-approved dopamine agonist, rotigotine (high affinity for the 968 
subclass of dopamine receptors in the brain that mediate dopamine signaling), to a poly(2-ethyl-2-oxazoline) 969 
(PEtOx) backbone (SER-214) resulted in a stimulant, which displayed an impressive efficacy in vivo.[278] The 970 
continuous dopaminergic stimulation profile provided by SER-214 represents a powerful tool in the treatment of 971 
the Parkinson’s disease. In October 2015, Serina Therapeutics started to recruit participants for a clinical phase I 972 
study (NCT02579473). Serina Therapeutics is furthermore offering a versatile POx-platform (POZTM) for multiple 973 
applications in drug delivery.[279] 974 
Poly(vinyl ether) (PVE). Arrowhead Pharmaceuticals follows a concept 975 
of covalent attachment of the genetic material to the polymer 976 
backbone with triggered intracellular release. This platform is named 977 
Dynamic PolyConjugate (DPC). DPCs are composed of an amphipathic 978 
butyl- and amine PVE (PBAVE, Figure 4) that has shown the best 979 
transfection performance in trial and error experiments.[280] To this 980 
backbone, GalNAc as hepatic targeting ligand and PEG are attached as 981 
 
Figure 4. Schematic representation of the 
chemical structure of the amphipathic butyl- and 
amine poly(vinyl ether) (PBAVE). 
 
 
Figure 3. Schematic representation of the chemical 
structure of the camptothecin(CPT)-conjugate of the 
copolymer PNU-166148. 
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well as a siRNA that is linked via a disulfide bond.[281] Once taken up by a cell, PEG and GalNAc are split off and the 982 
membrane-disrupting PBAVE is exposed to promote the endosomal escape (Figure 5). The siRNA is then released in 983 
the cytosol under the existing reducing conditions. ARC-520, ARC-521 and ARC-AAT are the formulations in clinical 984 
trials for the treatment of liver related diseases that are based on the DPC platform. 985 
 986 
 987 
 988 
Figure 5. The proposed mechanism of siRNA delivery. A) Schematic representation of the siRNA Dynamic PolyConjugate (DPC), its cellular 989 
uptake, disassembly in the low pH environment of the endosome, and release of the siRNA into the cytoplasm of the target cell 990 
(CDM = Carboxylated dimethyl maleic acid); B) mechanism of pH-sensitive CDM chemistry and the structures of the CDM derivatives used in this 991 
study. Depicted is the reaction of CDM with free tertiary amines on the polymer, which is reversible under acidic conditions. Reprinted from [281] 992 
with permission of National Academy of Sciences, Copyright (2017). 993 
 994 
Table 6. Synthetic polymer-drug conjugates in clinical trials (PEG-alternatives). 995 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Zinostatin Stimalmer® 
(SMANCS) 
Poly(styrene-co-
maleic anhydride) 
NeoCardioStatin 
Hepatocellular 
carcinoma 
Astellas Pharma Market 
PK1, FCE28068 PHPMA DOX 
Lung and breast 
cancers 
Pfizer  
Phase II  
(NCT00003165, Disc.) 
PK2, FCE28069 PHPMA 
DOX-
Galactosamine 
Hepatocellular 
carcinoma 
Pfizer  
Phase I
[264]
 
(Disc.) 
AP5280  
 
AP5286 
PHPMA 
Carboplatin 
platinate 
Various cancers 
 
Various cancers 
Abeona Therapeutics 
 
Abeona Therapeutics 
Phase I/II
[282]
 
 
Phase I
[236]
 
ProLindac™, AP5346 PHPMA DACHplatin 
Ovarian, melanoma & 
colorectal cancers 
Abeona Therapeutics 
Phase II 
(NCT00415298) 
PNU-166945 PHPMA TXL 
Various cancers 
(Breast cancer) 
Pfizer 
Phase I
[271]
 
(Disc.) 
PNU-166148 PHPMA CPT (MAG) Various cancers Pfizer 
Phase I 
(NCT00004076, Disc.) 
OPAXIO™, CT-2103, 
Paclitaxel poliglumex, 
(formerly Xyotax™) 
PGluA TXL 
Lung, ovarian, 
colorectal, breast & 
esophageal cancers 
CTI BioPharma Market 
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CT-2106 PGluA CPT 
Colorectal, lung & 
ovarian cancers 
CTI BioPharma 
Phase II 
(NCT00291837) 
SER-214 POx Rotigotine Parkinson's Disease Serina Therapeutics 
Phase I 
(NCT02579473) 
ARC-AAT PBAVE siRNA 
Liver disease 
associated with 
alpha-1 antitrypsin 
deficiency 
Arrowhead 
Pharmaceuticals 
Phase II  
(NCT02900183) 
ARC-520 PBAVE siRNA Hepatitis B 
Arrowhead 
Pharmaceuticals 
Phase II  
(e.g. NCT02065336, 
NCT02738008)  
ARC-521 PBAVE siRNA Hepatitis B 
Arrowhead 
Pharmaceuticals 
Phase I  
(NCT02797522) 
DOX: doxorubicin, DACH: diaminocyclohexane, TXL: paclitaxel, MAG: (20-O-(N-methacryloyl-glycyl-aminohexanoyl-glycyl)), CPT: camptothecin. 996 
 997 
3.2 Micro- and nanoparticulate drug carriers 998 
Polymeric micro- and nanoparticulate drug carriers for active pharmaceutical ingredients (APIs) have been in the 999 
focus of intense research since the mid 90’s. In the best case, the API is protected during the delivery and released 1000 
in a controlled way at the targeted site, which reduces the required frequency of administration, the therapeutic 1001 
dose, and the possibility of adverse side effects, reducing issues related to patients’ compliance.[283] The term 1002 
‘microparticle’ by definition refers to particles with dimensions between 100 nm and 100 µm, while particles are 1003 
called ‘nanoparticles’ if their size ranges from 1 to 100 nm.[284] However, several materials are considered as 1004 
nanoparticles in literature although they slightly exceed the defined limit, but still exhibit similar properties. 1005 
Therefore, we do not strictly comply with the given definition, but subdivide the materials according to their 1006 
properties or the route of administration, respectively. Nevertheless, the size of all mentioned nanoparticles does 1007 
not exceed 500 nm, which is still accepted.[284] 1008 
In the context of this review, the terms polymeric micro- and nanoparticles summarize stable solid dispersions 1009 
(prepared by emulsion polymerization of monomers or direct dispersion of premade polymers), which also include 1010 
polymeric micelles (including cross-linked micelles) or vesicles (often called polymersomes) as well as modified 1011 
liposomes, and polymer-based micro- and nanogels, but also polyplexes. The latter are formed by electrostatic 1012 
interactions between genetic materials (DNA, siRNA, mRNA) and cationically charged hydrophilic polymers in 1013 
solution. The different sizes of nano- and microparticles obviously influence their properties as for example 1014 
nanoparticles have a reduced tendency to aggregate in comparison to microparticles. Concerning drug delivery 1015 
applications, the size influences key parameters like the distribution within the body, the ability to cross biological 1016 
barriers, or the uptake into cells. Larger microparticles, for example, need to be delivered directly to the site of 1017 
action, but they also remain at this location and act as a depot releasing their payload over weeks, e.g. by slow 1018 
degradation of the microparticles. On the contrary, nanoparticles distribute in the body and cross barriers, but they 1019 
are also able to penetrate into leaky vascular tissue usually observed in tumors and inflamed sites.[285] 1020 
Moreover, they are small enough to enter cells via pinocytosis, which is the “cell drinking” of any cell type, while 1021 
microparticles are only taken up by phagocytosis. As a consequence of these variations in the properties, the 1022 
question of the right size of the drug delivery vehicle strongly depends on the application and the route of 1023 
administration. The most common way of administration is certainly the oral uptake. The main challenges for 1024 
particulate carriers are the protection of the drug during the harsh conditions in the gastrointestinal (GI) tract and 1025 
the transport through the GI epithelium including a mucus layer as additional barrier.[286] For the direct targeting of 1026 
the GI barrier layers itself, particles of about 2 µm reveal the best adsorption after oral application.[283] 1027 
Smaller nanoparticles are found to cross these barriers, but for a more detailed understanding the area of oral 1028 
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administration of nanosized materials still requires significant basic research.[287] In pulmonary administrations, 1029 
particles around 5 µm penetrate deeply in the smaller airways of the lung, which is well-suitable for topical 1030 
treatment.[288] In contrast, 1 to 2 µm particles are able to deposit in the capillary-rich alveoli, where systemic drug 1031 
delivery is targeted. Nanoparticles can be exhaled if they are not immobilized by aggregation or in suspension as 1032 
droplets. In the case of an intravitreal, subcutaneous or intramuscular administration, microspheres are preferably 1033 
in the order of 10 to 250 μm to avoid uptake by macrophages while minimizing inflammatory reactions. 1034 
For local administration in the brain, the microspheres should not be larger than 100 μm to preserve the structure 1035 
of the brain. Considering intravenous nanotherapies, particles should preferably have a size below 200 nm to 1036 
increase the circulation time in the blood stream and avoid filtration by the spleen or clearance by renal 1037 
excretion.[289] The probably most difficult route of administration is the transport through the skin, which 1038 
represents a natural barrier against particle penetration if not damaged.[290] Common nano- and microparticles 1039 
(above 10 nm) are not able to cross the stratum corneum, but may accumulate in the hair follicles (300 to 600 nm 1040 
sized particles).[291] An overview of these different routes of administration and the suitable size range is given in 1041 
Figure 6. 1042 
 1043 
  1044 
Figure 6. Overview of different routes of administration of micro- and nanoparticulate drug carriers; GI: gastrointestinal tract. 1045 
 1046 
3.2.1 Solid colloidal dispersions 1047 
Microparticle dispersions. For the local and continuous delivery of APIs, injections of degradable microparticles 1048 
certainly are the most commonly chosen route of administration. The particles are usually produced by emulsion 1049 
techniques, i.e. the polymer and the drug are dissolved in a suitable organic solvent and the mixture is suspended 1050 
in water, while the solvent is evaporated by continuous stirring. 1051 
Additional surfactants such as PVA might be added to stabilize the 1052 
resulting particles. Besides the classic procedure more 1053 
sophisticated double (multiple) emulsion techniques were 1054 
developed for example to encapsulate water soluble compounds, 1055 
but also other methods like spray drying or precipitation 1056 
 
Figure 7. Schematic representation of the chemical 
structure of poly(lactic-co-glycolic acid) (PLGA). 
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techniques are applied.[292] As polymers poly(lactide acid) and the copolymer poly(lactic-co-glycolic acid) (PLGA, 1057 
Figure 7) are the most accepted and also approved materials for microparticle formation. The tunable 1058 
biodegradability of the polymer (by varying molar mass, structure (end-group) and composition 1059 
(lactic acid/glycolide ratio)) and morphology of the particles enables PLA/PLGA to be easily engineered regarding 1060 
their aimed distribution and release profiles. Marketed products of PLGA microparticles include long-acting dosage 1061 
forms with in vivo life-times ranging from 2 to 80 weeks if administered as a gluteal intramuscular or abdominal 1062 
subcutaneous depot for peptides, proteins but also small molar mass drugs.[293] Table 7 provides an overview of 1063 
marketed PLGA microparticle products (no other polymers are used in marketed microparticle formulations) 1064 
treating various diseases such as cancer and psychological disorders. They are also used in dentistry as local 1065 
antibiotics and in animal husbandry for deworming. 1066 
An innovative route of administration is the in situ formation of biodegradable matrices after the liquid carrier 1067 
(e.g. DMSO) has diffused quickly from the polymeric solution towards surrounding tissue. Risperidone ISM® 1068 
represents a PLGA microparticle releasing risperidone for the treatment of schizophrenia. Clinical phase II trials 1069 
have been successfully performed (NCT02086786).[294] 1070 
 1071 
Table 7. List of marketed controlled release parenteral microspheres based on PLGA. 1072 
TRADE NAME DRUG INDICATION/USE MANUFACTURER
[a] 
Risperdal Consta®  Risperidone Schizophrenia Janssen 
Zoladex® LHRH agonists Prostate cancer AstraZeneca 
Lupron Depot®,  
Eligard®, 
Enantone®/Trenantone® 
Leuprolide Prostate cancer 
AbbVie, 
TOLMAR Pharmaceuticals, 
Takeda 
Decapeptyl®,  
Trelstar®, 
Pamorelin® 
Triptorelin Prostate cancer 
Ferring Pharmaceuticals, 
Allergan
TM
, 
Ipsen Pharma 
Profact Depot®,  
Suprefact Depot® 
Buserelin Prostate cancer, endometriosis  Sanofi 
Bydureon® Exenatide Diabetis AstraZeneca 
Sandostatin® LAR,  
Somatuline® LA 
Octreotide Acromegaly, diarrhea Novartis 
Nutropin Depot® Somatropin Growth hormone deficiency Genentech/Alkermes® (disc.) 
Vivitrol® Naltrexone Opioid- & alcohol dependence Alkermes® 
Arestin® Minocycline HCl Peridontal disease Valeant® (disc.) 
Longrange® Eprinomectine Parasitic disease Merial (Sanofi) 
[a] 
Selection thereof. 1073 
 1074 
The versatility and unique properties of PLGA and PLA certainly promote the domination of the market of these 1075 
materials considering microparticles for drug delivery. As a consequence, it is no surprise that further 1076 
developments, which are currently in clinical trials, are also based almost exclusively on these polymers. To the 1077 
best of our knowledge, only two alternatives have at least entered the stage of clinical testing. The first one is a 1078 
microparticulate formulation consisting of paclitaxel and a biodegradable polyphosphoester (NCT00005046). 1079 
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The polymer is a copolymer of short PLA oligomers and ethyl phosphate (P(DAPG-EOP)) (Figure 8).[295] 1080 
The microparticles (Paclimer®) were injected into the peritoneal cavity for treatment of recurrent ovarian 1081 
cancer.[296] The study (phase I) verified the beneficial properties of the 1082 
material ensuring a controlled and continuous release over more than 1083 
eight weeks. However, the presence of polymer filaments after several 1084 
months indicated a slow degradation and caused a marked 1085 
inflammatory response. The second one is the microsphere Retin-A 1086 
Mikro® (Valeant®), which is based on the Microsponge® technology 1087 
comprising styrene, divinylbenzene and methyl methacrylate and the 1088 
starting material ethylene glycol dimethacrylate in its polymer 1089 
backbone.[297] Tretinoin is encapsulated in the polymer in the 1090 
application form of a skin cream that slowly releases the active medication to treat acne vulgaris. 1091 
Amphiphilic block copolymer micelles. Polymeric micelles are created by dispersion of a block copolymer 1092 
consisting of a hydrophobic and a hydrophilic domain. The block-like and amphiphilic structure is essential for 1093 
polymeric micelles and their self-assembly behavior.[284] In contrast to small molecule surfactants, polymeric 1094 
micelles often seem to be not dynamic, which means that there is almost no exchange of polymer molecules 1095 
between the aggregates, and the polymeric micelles are kinetically frozen.[298] However, in most cases these 1096 
exchange dynamics are simply not investigated as the experiments require long acquisition times (up to several 1097 
days or weeks) to provide a detectable signal. According to its definition, polymeric micelles are still in an 1098 
equilibrium with its dissolved polymer chain.[284] Consequently, the formation and stability of the micelles depend 1099 
on the concentration. However, with increasing size of the hydrophobic block this equilibrium can be shifted 1100 
towards the formation of micelles, and the 1101 
critical micelle concentration (CMC) might be 1102 
below the detection limit.[299] Nevertheless, a 1103 
common concept to overcome any stability 1104 
issues related to polymeric micelles is the cross-1105 
linking of the micellar core, which ideally can be 1106 
used to covalently entrap the API.[300] The 1107 
research and development of polymeric micelles 1108 
has a very strong focus on cancer therapy. The 1109 
toxic and undesirable side effects of 1110 
chemotherapeutic agents are supposed to be 1111 
diminished by using these nanoparticulate carrier 1112 
systems.[301] The low lymphatic drainage of 1113 
tumors and the highly vasculature tumor tissue results in an enhanced penetration and retention (EPR) effect of 1114 
the micelles, which consequently yields a passive targeting of tumor tissue. Even more efficient is the use of 1115 
micelles bearing targeting moieties, which allow selective recognition of specific receptors that are overexpressed 1116 
in cancer cells. Recently published review articles cover the outcomes of clinical research and also show the results 1117 
of preclinical studies in terms of polymeric nanoparticles in cancer therapy.[301-302] However until now, none of 1118 
these formulations reached FDA approval for cancer therapy. Only one micellar delivery system is on the South 1119 
Korean market (Table 8).[303] Genexol® PM is a paclitaxel encapsulating polymeric micelle consisting of a block 1120 
copolymer of methoxy-PEG and poly(D,L-lactic acid) (Figure 9A).[304]  1121 
Nevertheless, a considerable number of micellar systems are currently undergoing clinical trials in various stages. In 1122 
the following, we provide an overview of the various materials, which are clinically tested, and exemplarily describe 1123 
the applications where these materials are in latest stage of clinical trials. In general, most of these micellar 1124 
 
Figure 9. Schematic representation of the chemical structures of the block 
copolymers of A) methoxy-PEG and poly(D,L-lactic acid) (Genexol® PM); B) 
PEG and esterified PAs (4-phenyl-1-butanol) (NK105); C) PEG and PPG (also 
called Pluronic®, SP1049C). 
 
Figure 8. Schematic representation of the 
chemical structure of the copolymer consisting 
of short PLA oligomers and ethyl phosphate 
(P(DAPG-EOP)). 
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formulations are also in preclinical/clinical trials for treatment of other cancerous diseases, which shows the 1125 
potential of polymeric nanoparticles in cancer therapy in future. A good example is the block copolymer PEG-b-PLA 1126 
which is identical to the material used in Genexol® PM. This polymer is further used for the formulation of 1127 
docetaxel encapsulating PEG-b-PLA polymeric micelles with similar sizes (20 to 50 nm) named Nanoxel®-PM, which 1128 
is in clinical phase I.[305] Other materials also take advantage of the generally accepted use of PEG for the 1129 
hydrophilic block. In contrast, a variety of different polymers is used for the hydrophobic block. NK105 uses a block 1130 
copolymer of PEG and partially hydrophobized poly(aspartate) (PAs) (esterification of the carboxylic groups with 1131 
4-phenyl-1-butanol, Figure 9B) for the delivery and release of docetaxel.[306] SP1049C is a mixture of non-ionic 1132 
PEG-block-PPG-block-PEG copolymers (Pluronic® L61, Pluronic® F127, Figure 9C) that form a micelle to encapsulate 1133 
doxorubicin.[307] SP1049C has the state as an orphan drug for gastric cancer as approved by the FDA.  1134 
With the effort to improve the specifity of nanoparticles, targeted strategies were developed and already entered 1135 
clinical trials. BIND-014 is the outcome of a combinatorial library of nanoparticles based on PEG-b-PLA and 1136 
PEG-b-PLGA that encapsulate docetaxel and bear a prostate-specific membrane antigen (PSMA) on the micelle 1137 
surface. PSMA is a tumor antigen preferentially expressed on prostate cancer cells and vasculature of non-prostate 1138 
solid tumors.[308] The PSMA substrate analog inhibitor S,S-2-(3-(5-amino-1-carboxypentyl)-ureido)-pentanedioic acid 1139 
(ACUPA) is covalently attached to a PEG-b-PLA. A mixture of PEG-b-PLA and PEG-b-PLA-ACUPA is finally used for the 1140 
micelle formation in a microfluidic supported emulsion/solvent evaporation process. BIND-014 was the best 1141 
performing candidate in terms of particle size, drug loading, targeting ligand density, PEG/PLA ratio and so on. The 1142 
same technology (Accurins® technology) was recently used to deliver a selective Aurora B kinase inhibitor, 1143 
AZD2811, that induces apoptosis in tumor cells.[309] Increased encapsulation efficiency and reduced drug leakage 1144 
could be achieved by simple ion pairing of AZD2811 and are currently tested in phase 1 studies. Preclinical studies 1145 
using the same Accurins® portfolio involve BIND-510 (encapsulated drug: Vincristine, PEG-b-PLA with PSMA 1146 
targeting) and others as proposed by BIND Therapeutics.[310] A critical point is that the physical entrapment of drugs 1147 
can be associated with drug leakage before reaching the side of action.  1148 
Therefore, the covalent attachment via labile linkers to the polymer backbone can be advantageous. A popular 1149 
system is a block copolymer of PEG and polyglutamate. The polyaminoacid is able to complex different platinum 1150 
complexes, which renders the polymer amphiphilic. NC-6004 is delivering cis-platin and already entered clinical 1151 
phase III. The same concept is applied for NC-4016 in phase I, using 1,2-diaminocyclohexane platinum (DACHplatin) 1152 
to modify PEG-b-PGlu block copolymers. Also other anti-cancer drugs were covalently attached to the PGlu block: 1153 
NK012 is functionalized with SN-38, a camptothecin derivative, and completed clinical phase II for the treatment of 1154 
breast and lung cancer. A similar system using poly(amino acid) is NK911, with DOX covalently linked to the carboxy 1155 
groups of the copolymers of PEG and PAs. NK911 revealed less stability and more drug release but also higher 1156 
accumulation at other cell regions compared to liposomal doxorubicin (Doxil®).[311] Clinical phase I finished in 2004 1157 
and did not recruit for phase II until now. There are only few examples of materials in clinical trials that are not 1158 
aiming at the treatment of cancer. SEL-068 is a PEG-b-PLGA-based micelle loaded with peptides for the treatment 1159 
of nicotine addiction.[312] This nicotine vaccine creates nicotine specific antibodies that bind free nicotine and 1160 
prevent it from crossing the BBB. The same particle platform (Synthetic Vaccine Particle (SVPTM)) is used for the 1161 
design of SEL-110 in antigen-specific immunotherapy. SEL-110 is loaded with specific protein- or peptide antigens 1162 
and rapamycin and aims to prevent unwanted anti-drug-antibodies from forming.[313] 1163 
 1164 
Table 8. List of active clinical trials using amphiphilic block copolymer micelles. 1165 
TRADE NAME POLYMER SYSTEM  DRUG INDICATION/USE MANUFACTURER STATUS 
Genexol® PM 
(US: Cynviloq
TM
, IG-001)  
PEG-b-PLA Docetaxel 
Breast, lung, ovarian 
cancer 
Samyang 
Biopharm 
Market  
(South Korea) 
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Nanoxel®-PM 
(Docetaxel-PNP) 
PEG-b-PLA Docetaxel Solid tumors 
Samyang 
Biopharm 
Phase I 
(NCT02274610) 
NK105 PEG-b-PAs Docetaxel Gastric, breast cancer NanoCarrier® 
Phase III  
(NCT01644890) 
SP1049C 
PEG-b-PPG-b-PEG 
(Pluronic® L61, F127
[a]
) 
DOX Adenocarcinoma Supratek Pharm Phase II
[307]
 
BIND-014  
(Accurins® technology)  
PEG-b-PLGA,  
PEG-b-PLA 
Docetaxel  Solid tumors 
BIND 
Therapeutics/ 
Pfizer 
Phase II  
(e.g. NCT01812746, 
NCT01792479,) 
AZD2811 
(Accurins® technology) 
PEG-b-PLA AZD2811  Solid tumors AstraZeneca 
Phase I  
(NCT02579226) 
NC-6004 PEG-b-PGlu Cisplatin Solid tumors NanoCarrier® 
Phase III  
(NCT02043288 ) 
NC-4016 PEG-b-PGlu DACHplatin Solid tumors NanoCarrier® Phase I
[314]
 
NK012 PEG-b-PGlu SN-38 
Breast, lung, 
colorectal cancer 
Nippon Kayaku 
Phase II  
(e.g. NCT00951613, 
NCT00951054) 
NK911 PEG-b-PAs DOX 
Pancreatic, colorectal 
cancer 
n.a. Phase I
[311]
 (disc.) 
SEL-068 PEG-b-PLGA 
TLR agonist and T 
cell helper peptide 
Nicotine addiction 
Selecta 
Biosciences 
Phase I 
(NCT01478893 ) 
SEL-110 PEG-b-PLGA 
Rapamycin, peptide 
antigen 
Production of anti-
drug antibodies, 
unwanted immune 
response 
Selecta 
Biosciences 
Phase I  
(NCT02648269 ) 
DOX: doxorubicin, DACH: diaminocyclohexane; 
[a]
 L = liquid, F = flake/solid, the first one or two digits (in a three-digit number) in the code, 1166 
multiplied by 300, indicates the approximate molar mass of the PPG block and the last digit of this code × 10 provides the percentage PEG 1167 
content; n.a.: not applicable. 1168 
 1169 
Nanoparticle dispersions. Besides the large number of micellar structures made from amphiphilic block copolymers 1170 
only few systems have entered clinical studies, which are solid nanoparticle dispersions prepared by 1171 
nanoprecipitation or emulsion polymerization (Table 9). CRLX101 is a nanoparticle formulation consisting of a 1172 
statistical copolymer based on β-cyclodextrin and PEG, that is hydrophobized by conjugation of CPT to the 1173 
cyclodextrin ring via an acid labile glycine linker.[315] The current studies are recruiting participants for several 1174 
clinical studies in cancer therapy, which shows the potential of this formulation as novel nanomedical device. 1175 
CRLX301 has recently started phase IIa and uses the same polymer platform as CRLX101 but with docetaxel as 1176 
active agent.[316] While the previously mentioned system is still stabilized by the amphiphilic character of the 1177 
polymer, DOX-Transdrug is a solid nanoparticle dispersion that is produced by emulsion polymerization of isohexyl 1178 
cyanoacrylate in the presence of DOX. DOX-Transdrug is used for the treatment of liver cancer by local injection via 1179 
the hepatic artery and has recently entered clinical phase III. This system was also successfully applied to pass the 1180 
BBB for the therapy of glioblastomas as observed in rats.[317] Another acrylate-based nanocarrier is prepared in a 1181 
comparable way resulting in mitoxantrone (dihydroxyanthracenedione, DHAD) encapsulating poly(isobutyl 1182 
cyanoacrylate) nanoparticles (DHAD-PBCA-NP). The formulation shows good efficacy in treating liver cancer and, 1183 
thus, enhances the survival period.[318] DHAD-PBCA-NP reached clinical phase II but did not continue since 2009. 1184 
 1185 
Table 9. List of active clinical trials using nanoparticle dispersions. 1186 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
CLRX101  
(IT-101)  
P(EG-co-cyclodextrin) CPT 
Lung cancer, renal cell 
carcinoma 
Cerulean
TM
 
Phase II  
(e.g. NCT02010567, 
NCT02769962) 
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CRLX301 P(EG-co-cyclodextrin) Docetaxel Solid tumors Cerulean
TM
 
Phase I/IIa 
(NCT02380677) 
Livatag®  
(DOX-Transdrug) 
Poly(isohexyl cyanoacrylate) 
coated with Tween 80  
DOX Liver cancer Onxeo 
Phase III  
(NCT01655693) 
DHAD-PBCA-NP Poly(isobutyl cyanoacrylate) Mitoxantrone Liver cancer n.a. Phase II
[318]
 (Disc.) 
CPT: campthothecin, DOX: doxorubicin; n.a.: not applicable. 1187 
 1188 
Modified liposomes. Liposomes are structurally slightly different species also using polymers in a nanoparticular 1189 
device. They are composed of phospholipids, which self-assemble into lipid bilayers (able to incorporate lipophilic 1190 
molecules) surrounding an aqueous core (able to incorporate hydrophilic molecules).[319] For improving the desired 1191 
properties, the phospholipids can be covalently modified with polymers or targeting functions resulting in surface 1192 
modified liposomes. For example, PEG is generally used to improve the circulation and drug retention. In addition 1193 
to the stealth effect, PEG is acting as spacer molecule between lipid structures and targeting functions. Besides 1194 
Doxil® being the most prominent example of a PEG-containing liposome on the market[320] there are also 1195 
Lipodox®,[321] Oncodox® PEG[322] and LipoplatinTM[323] showing good performances in cancer treatment with DOX 1196 
and cisplatin, respectively, as APIs (Table 10). The heat-responsive liposomal formulation ThermoDox® is now 1197 
recruiting patients for a phase III study of PEGylated liposomal DOX. 1198 
 1199 
Table 10. List of PEG-modified liposomes on the market or in active clinical trials in phase III. 1200 
TRADE NAME DRUG INDICATION/USE MANUFACTURER STATUS 
Doxil® 
(Caelyx®) 
DOX 
Ovarian cancer,  
AIDS-related Kaposi's sarcoma, multiple myeloma 
Janssen Market 
Lipodox® DOX 
Metastatic carcinoma of the ovary, metastatic breast cancer, AIDS 
related Kaposi’s Sarcoma 
Sun Pharma Market 
Oncodox® PEG DOX Ovarian cancer, breast cancer, AIDS related Kaposi’s Sarcoma Ciplamed Market 
Lipoplatin
TM
 Cisplatin 
Pancreatic cancer, head and neck cancer, mesothelioma, breast 
cancer, non-cell lung cancer 
Regulon Phase III
[324]
 
ThermoDox® DOX Primary liver cancer, breast cancer Celsion 
Phase III 
(NCT02112656) 
DOX: doxorubicin. 1201 
 1202 
3.2.2 Polyplexes 1203 
The delivery of small molecules either encapsulated or conjugated to yield apoptosis in cancer cells is only one 1204 
strategy in cancer therapy. The pharmaceutical industry also holds promise on gene therapy. However, to transport 1205 
genetic material such as plasmid DNA (pDNA), short interfering RNA (siRNA) and messenger RNA (mRNA) into body 1206 
cells these structures must be protected against degradation and shielded to avoid clearance. A common way is the 1207 
complexation of the negatively charged genetic material with cationically charged polymers via electrostatic 1208 
interactions. The result is a so-called polyplex, which ideally should mimic the nature of viruses and result in 1209 
efficient gene delivery and transfection without showing an immune response. Poly(ethylene imine) (PEI) and its 1210 
variations are among the most studied materials for this purpose. In contrast to other cationic polymers, linear and 1211 
branched PEI are capable of mediating endosomal escape, which is essential for transfection.[325] Other prominent 1212 
examples are poly(L-lysine) or poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA).[326] In general, it can be said 1213 
that only pDNA and RNA therapeutics passed preclinical studies so far for clinical trials.[325, 327]  1214 
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Different PEI formulations and modifications that all resolved general toxicity issues of PEI in vitro and in vivo reveal 1215 
encouraging results in clinical phases (Table 11). SNS01-T is a jetPEI® formulation, i.e. a linear PEI dissolved in a 1216 
special buffer system. Although the precise composition is undisclosed, it is expected to have a molar mass (Mn) of 1217 
about 22,000 g mol-1. The polyplex contains both a B-cell-specific expression pDNA and a siRNA, which suppresses 1218 
hypusinated eIF5A. A reduction of eIF5A levels was found to sensitize myeloma cells to apoptosis.[328] CYL-02 is also 1219 
based on jetPEI® as transfection agent and in clinical phase II for pDNA delivery. It strongly inhibits tumor 1220 
progression and dissemination of pancreatic cancer after intratumoral administration using endoscopic 1221 
ultrasound.[329] A promising intravenously administered system is a polyplex of the pDNA BC-819 with PEI. 1222 
BC-819/PEI targets cancer cells that generally express the H19 gene, which activates Diphtheria Toxin A (DTA) and 1223 
leads to cell death, whereas healthy cells that are also exposed to the pDNA are not affected. In 2016, BC-819 was 1224 
announced to commence phase III.[330] In addition, BioCancell developed a dual-DTA expression system named 1225 
BC-821, which is a pDNA that is again transfected with PEI and switches the distinct promoters H19 and IGF2-P4.[331] 1226 
The dual expression system may have the benefit of enhanced cancer cell toxicity and a higher chance that at least 1227 
one of the promoters will be active in any tumor. A further pDNA PEI-based formulation in clinical trials is EGEN-1228 
001. It contains a cholesterol modified low molar mass branched PEI that is also PEGylated.[332] EGEN-001 is 1229 
designed for direct injection into cancerous tissue where it increases the local concentration of interleukin 12 1230 
(IL-12) in the tumor microenvironment. IL-12 has several functions, amongst them it is known to potentiate 1231 
antitumoral functions of the host immune system.[333] The delivery of a RNA sequence is also in the focus of Celsion 1232 
by using the TheraSilence™ technology platform.[334] In general, the intrinsic cytotoxicity of PEI is a serious problem 1233 
in the transfer to a FDA approved PEI-based product. 1234 
The benefit of non-viral siRNA delivery is to selectively silence gene expression in vivo. The first targeted (siRNA) 1235 
nanoparticle formulation in clinical trials is denoted as CALAA-01.[335] The polymer matrix is a cationic cyclodextrin 1236 
containing polymer prepared by polycondensation of a diamine-functionalized cyclodextrin and dimethyl 1237 
suberimidate leading to a polyamidine. Adamantyl functionalized PEG with and without human transferrin ligands 1238 
is complexed with the cyclodextrin moieties for steric stabilization and also for the targeting ability of the 1239 
polyplexes. CALAA-01 completed phase I in 2012 but did not proceed further. However, this study was the first 1240 
evidence that systemically administered siRNA induces RNA interferences in humans.[336] 1241 
In the early days of gene therapy, the discovery of interferon caused much excitement. Various forms of interferon 1242 
are produced by virally infected cells and interfere with further viral growth and, thus, show promise in antitumor 1243 
and antiviral therapy. The synthetic double-stranded RNA (dsRNA), an interferon that consists of a pair of 1244 
polyinosinic and polycytidylic acids, is condensed with poly(L-lysine) and supplemented with 1245 
carboxymethylcellulose to form Hiltonol®.[337] Probably the first clinical study using this system was already 1246 
conducted in 1978.[338] Nowadays, there are many clinical trials of Poly-ICLC for various types of cancer. 1247 
However, Poly-ICLC is also in clinical trials to test its efficacy as adjuvant (to boost the immune response) in 1248 
HIV-infected patients. A further polylysine-based polyplex is a PEGylated version that demonstrated an effect for 1249 
cystic fibrosis patients after administration of the complexed pDNA carrying the cystic fibrosis transmembrane 1250 
regulator-encoding gene to the nasal mucosa in an early phase I study.[339] 1251 
Although cancer is certainly the most prominent disease to be treated by polyplex-based gene delivery, the 1252 
treatment of other human diseases can also benefit of the approach if applied at the right site or by using targeting 1253 
functions. The DermaVir patch is a topical application of a pDNA, encoding the entire HIV genome minus the 1254 
integrase gene that is formulated with mannosylated jet-PEI® in a glucose solution.[340] For this purpose, the 1255 
stratum corneum needs to be interrupted to deliver the polyplex to the Langerhans cells to be transported to the 1256 
lymph nodes in order to express the HIV antigens. The DermaVir therapeutic vaccination completed phase II but did 1257 
not proceed further maybe due to infection risks of the skin. A different pDNA vaccination that already started 1258 
phase III trials is ASP0113. It is designed to suppress the activation of the cytomegalovirus (CMV) in transplant 1259 
recipients. It basically consists of two plasmids encoding CMV glycoprotein B and phosphoprotein 65, respectively, 1260 
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formulated with poloxamer, a triblock PEG-b-PPG-b-PEG (CRL1005), and a mixture of alkyl-1261 
benzyldimethylammonium chlorides (BAK, alkyl chains: C12, C14, C16, C18).[341] The hydrophobic cationic 1262 
surfactant BAK and the hydrophilic CRL1005 self-assemble with the pDNA into nanoparticles.  1263 
 1264 
Table 11. List of active clinical trials using polyplexes. 1265 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
SNS01-T LPEI (jetPEI®) 
pDNA,  
siRNA 
Multiple myeloma Sevion Therapeutics 
Phase II  
(NCT01435720) 
CYL-02 LPEI (jetPEI®) pDNA Pancreatic adenocarcinoma InvivoGen 
Phase II  
(NCT02806687) 
BC-819/PEI  
(DTA-H19) 
BPEI DNA 
Bladder cancer, ovarian 
cancer, 
pancreatic adenocarcinoma 
BioCancell 
Phase II  
(NCT00595088) 
EGEN-001  
(GEN-1) 
Cholesterol and  
PEG-modified PEI 
DNA 
Ovarian, tubal, colorectal 
peritoneal cancer 
GOG® Foundation 
Phase II  
(NCT01118052) 
CALAA-01 
Cationic cyclodextrin, 
adamantane modified PEG  
siRNA  Solid tumors 
Calando 
Pharmaceuticals 
Phase I  
(NCT00689065) (disc.) 
Hiltonol®  
(Poly-ICLC)  
Polylysine,  
carboxymethyl cellulose 
dsRNA 
Brain tumor, non-small cell 
lung cancer, skin cancer, 
breast cancer 
 
 
HIV 
Oncovir 
Phase II  
(e.g. NCT01984892, 
NCT02423863) 
 
Phase I/II 
(NCT02071095) 
DermaVir 
(LC002) 
Mannosylated LPEI 
(jetPEI®) 
DNA HIV vaccine Genetic Immunity 
Phase II  
(NCT00711230) 
ASP0113  
(VCL-CB01,  
formerly TransVax®) 
PEG-b-PPG-b-PEG, 
(CRL1005) 
DNA CMV vaccine Vical 
Phase III  
(NCT01877655) 
pDNA: plasmid deoxyribonucleic acid, siRNA: small interfering ribonucleic acid, dsRNA: double-stranded ribonucleic acid, CMV: cytomegalovirus. 1266 
 1267 
3.2.3  Micro-/Nanogels 1268 
 1269 
Microgels. ‚Microgels‘ (IUPAC name) are defined as hydrogel microparticles (also mentioned as ‘microhydrogels’ or 1270 
‘hydrogel microspheres’) formed by water soluble polymers which are physically or chemically cross-linked. In 1271 
physical gels, the cross-linking points of the network are formed by non-covalent or supramolecular interactions, 1272 
such as hydrogen bonds, ionic or hydrophobic interactions, respectively. On the other side covalent bonds form the 1273 
links of the network in chemical gels, i.e. cross-linking of ready polymers on functional groups or polymerization of 1274 
multivalent monomers. These three-dimensional networks fill the size gap between dendrimers/polymers 1275 
(10 to 20 nm) and macroscopic hydrogels (see Chapter 3.3.1) comprising sizes from 100 nm to 100 μm according to 1276 
the definition of microparticles.[342] Microgel systems possess high capacity for drug loading, are mostly 1277 
biocompatible, and can be modified for biodegradability, which represent the key points to design an effective drug 1278 
delivery system. Their structure features some key advantages in comparison to dendritic systems including their 1279 
superior swelling behavior, the opportunity to introduce responsive modalities, and the presence of suitable gaps 1280 
for encapsulation of other compounds (without the need of a chemical attachment). Besides their application as 1281 
drug delivery systems, they have shown promising potential for use in adjacent fields such as diagnostics, antiviral 1282 
compounds, and embolic therapies.[343] Microgel-based formulations for drug delivery have shown significant 1283 
enhancements in effectiveness and safety considering certain anti-cancer drugs or other pharmaceutically active 1284 
compounds, which was confirmed by numerous in vivo studies. Despite this progress, only very few microgels have 1285 
been explored in clinical studies and several safety issues have to be overcome. The challenges in terms of cargo 1286 
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delivery and their efficient clearance once they have accomplished their mission in vivo demand careful 1287 
engineering of the microgels. This remains challenging due to the complexity of the systems and the unique 1288 
structural features. To date, there are only three microgel systems based on synthetic polymers that are approved 1289 
for use as drug delivery system. They are all used in the treatment of hepatocellular carcinoma (Table 12). 1290 
DC Bead® is an embolic hydrogel microsphere product that is capable of being 1291 
loaded with anthracycline drugs just before administration in a transarterial 1292 
chemoembolization (TACE) procedure. TACE is a minimally invasive 1293 
(non-surgical) procedure performed by an interventional radiologist. In this 1294 
process, the microgel is not just delivering the drug, but also occludes the 1295 
arteries supplying the tumor. DC Bead® is composed of a biocompatible PVA 1296 
hydrogel, which has been modified with the ionic monomer sodium 1297 
2-acrylamido-2-methylpropanesulfonate (AMPS, Figure 10). The latter enables 1298 
the electrostatic loading and delivery of chemotherapeutic drugs. The beads 1299 
are produced by an inverse emulsion polymerization and are available in sizes 1300 
from 100 to 900 μm.[344] Injected into the local artery, the formulation occludes the blood flow to the target tissue 1301 
and delivers a local and sustained dose of the drug directly to the tumor. DC Bead® is approved as anti-tumor 1302 
formulation with doxorubicin (DEBDOX™)[345] and irinotecan (DEBIRI™).[346] Current research is focusing on an 1303 
increase of the drug doses of administered drug.[347] In addition, the microbeads can be loaded with idarubicin 1304 
(IDASPHERE II) by the interaction of the positively charged protonated amine group of idarubicin hydrochloride 1305 
with the sulphonate of the DC Beads®.[348] They are currently in randomized phase II studies. Special radiopaque 1306 
beads (RO Beads), which are also based on the DC Bead® platform, have been investigated to not only be 1307 
pharmacologically active, but allow the imaging of the active site in a rabbit VX2 liver tumor model by X-ray scans. 1308 
These RO Beads were covalently modified with a triiodobenzyl group to allow a better traceability in comparison to 1309 
DC beads® which were loaded with a soluble contrast agent.[349] The first commercially available RO bead, LC Bead 1310 
LUMI™, was cleared by the FDA for the chemoembolization of hypervascular tumors and arteriovenous 1311 
malformations.[350]  1312 
Other commercialized microgels include the Tandem® microspheres, which are spherical, biocompatible, non-1313 
resorbable hydrogel cores based on cross-linked poly(methacrylic acid) (PMAA).[351] They are subdivided into two 1314 
classes of microspheres, Oncozene® and Embozene®, which are both available in a size range from 40 to 100 μm. 1315 
The latter features an additional outer layer of CeloNova’s proprietary Polyzene®-F, a 1316 
poly(bis(trifluoroethoxy)phosphazene) (Figure 11), which is introduced to enhance biocompatibility and reduce 1317 
inflammation. These materials have been optimized for loading with a variety of drugs (Table 12). Current studies 1318 
focus on the use of DOX (NCT02141906) or idarubicin,[352] loaded in the Oncozene® microspheres. HepasphereTM 1319 
represents another hydrogel microsphere, which is approved for clinical use and commercially available (in the 1320 
range from 30 to 200 μm). In general, DOX is loaded into a polymer network of poly(vinyl alcohol-co-acrylic 1321 
acid).[353] The microsphere binds drugs with the same mechanism as 1322 
DC Bead®, using carboxylate instead of sulfonate groups. Recent 1323 
developments in the treatment of hepatocellular carcinoma with 1324 
HepasphereTM were summarized by Malagari et al..[354] LifePearl® is a 1325 
PEG-based embolization hydrogel that can be loaded with 1326 
chemotherapeutic agents to treat primary hyper vascular tumors or 1327 
liver metastasis. The microspheres are biocompatible, hydrophilic, 1328 
and precisely calibrated.[355]  1329 
A new injectable formulation for the delivery of IFN-α 2b is Locteron®, which is one of the few systems for 1330 
continuous release of proteins that reached late-stage clinical trials. It is a microparticulate formulation 1331 
encapsulating a protein which is suspended in an injection vehicle prior to subcutaneous administration. 1332 
 
Figure 11. Schematic representation of the chemical 
structure of poly(bis(trifluoroethoxy)phosphazene) 
(Polyzene®-F). 
 
 
Figure 10. Schematic representation of 
the chemical structure of P(VA-co-2-
acrylamido-2-methylpropane sulfonate). 
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The technology is based on PolyActive® – a variety of biodegradable poly(ether ester) segmented copolymers based 1333 
on PEG and PBT. The polymers absorb water up to 65% of their weight resulting in a hydrogel network. 1334 
Biolex Therapeutics announced that its remaining asset (phase III) for the treatment of hepatitis C virus (HCV) and 1335 
hepatitis B virus (HBV) is finally commercialized.[356] 1336 
 1337 
Nanogels. When the size of microgels is in submicron range 1338 
(1 to 100 nm), they are usually specified as nanogels 1339 
(‘nanohydrogels’, ‘hydrogel nanospheres’).[357] Although 1340 
significant effort has been dedicated into their research,[358] 1341 
there is only a limited number of nanogel systems under 1342 
clinical investigations that are based on synthetic polymers. 1343 
A new gel-based approach with the ability to form a depot 1344 
(Medusa®) has been developed by Flamel Technologies 1345 
(today: Avadel Pharmaceuticals). It enables a controlled 1346 
drug release within an adjustable time ranging from one day up to one week without the often observed initial 1347 
burst effect or a decreasing activity. The formulation will be administered as a subcutaneous injection. The polymer 1348 
platform is based on poly(α-glutamate) (hydrophilic), where vitamin E is grafted onto (Figure 12). The resulting 1349 
amphiphilic polymer spontaneously forms stable nanogels (20 to 50 nm) when dissolved in water due to the 1350 
hydrophobic domains of vitamin E.[359] Different cargos (e.g. peptide, protein, small molecule) can be loaded into 1351 
the nanogel simply by mixing the two components, and the uptake into the nanogel is solely based on non-1352 
covalent, hydrophobic and electrostatic interactions. The formulations with several therapeutic proteins (e.g. IL-2, 1353 
IFN-α 2b and IFN-β 1a) revealed a release period of one week in animal models.[360] Clinical phase I trials were 1354 
performed on the application of the interferon IFN-α 2b, which was administered to patients with genotype 1 1355 
hepatitis C virus (HVC), and the outcomes were compared to the established treatment with the respective 1356 
PEGylated interferon PegIntron® (Table 3). The study demonstrated a favorable antiviral activity and safety profile 1357 
using the Medusa® technology.[361] A phase II study followed (over a period of 12 weeks) in order to compare this 1358 
formulation to PegIntron®, which was combined with ribavirin.[362] Currently, Avadel Pharmaceuticals explores the 1359 
product Medusa® exenatide, which is called a once-a-week formulation. After successful preclinical studies on the 1360 
administration to minipigs (June 2014), the company reported the completion of phase 1b trials for type 2 diabetes 1361 
mellitus.[363] 1362 
 1363 
Table 12. Micro- and nanogels based on synthetic polymers on the market or in clinical trials. 1364 
TRADE NAME SUBNAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Microgel 
DC Bead®  
(US: LC Bead®) 
DEBDOX™ P(VA-co-AMPS) DOX 
Malignant 
hypervascular 
tumor 
BTG Market 
DEBIRI™ P(VA-co-AMPS) Irinotecan 
Metastatic 
colorectal cancer 
BTG Market 
IDASPHERE II P(VA-co-AMPS) Idarubicin Liver cancer 
Federation Franco-
phone de Cancer-
ologie Digestive 
Phase II 
(NCT02185768) 
Tandem® 
Oncozene® PMAA 
DOX, 
epirubicin,  
idarubicin,  
irinotecan 
Neurovascular 
arteriovenous 
malformations, 
hypervascular 
tumors 
CeloNova 
BioSciences 
Market 
Embozene®  PMAA + Polyzene®-F Market 
 
Figure 12. Schematic representation of the chemical structure 
of vitamin E-grafted poly(α-glutamate) (α-PGlu). 
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HepaSphere
TM
 
(US: QuadraSphere®) 
 Poly(VA-co-AA) DOX 
Hepatocellular 
carcinoma 
Merit Medical® Market 
LifePearl®  PEG 
DOX, 
irinotecan 
Hyper vascular 
tumor, 
liver metastasis 
Terumo Market 
PolyActive® 
Locteron® 
(OctoPlus) 
PEG-b-PBT 
(Multiblocks) 
IFN-α 2b Hepatitis C virus Biolex Therapeutics 
Phase III 
(NCT00863239) 
Nanogel 
Medusa®
 
 
 
α-PGlu grafted with  
vitamin E 
IL-2,  
IFN-α 2b, 
IFN-β 1a, 
exenatide 
Various cancers, 
viral infections 
Avadel 
Pharmaceuticals 
Phase I/II
[363]
 
DOX: doxorubicin. 1365 
 1366 
3.3 Macroscopic drug carriers 1367 
3.3.1 Hydrogels 1368 
Hydrogels. Hydrogels represent macroscopic, hydrophilic polymer networks, which are able to absorb water or 1369 
aqueous biological fluids in amounts ranging up to multiple times of their own mass. In analogy to microgels, they 1370 
can be subdivided by their type of cross-linking, i.e. chemical or physical cross-linking. Hydrogels are able to imitate 1371 
natural living tissue more than any other class of synthetic biomaterials due to their high water content, soft 1372 
consistency and porosity. Undoubtedly, their most advanced application field is their usage as contact lenses, in 1373 
particular in form of soft lenses. However, the relatively low drug loading capacity and the burst release upon 1374 
ocular administration is a challenge that has to be overcome. To date, no drug loaded contact lens is on the market. 1375 
An advanced alternative to frequent application of eye drops for steroid therapy is the hydrogel punctum plug 1376 
DextenzaTM. The dexamethasone loaded depot for ophthalmic drug delivery is based on branched PEG and 1377 
represents the first sustained release ophthalmic product that entered phase III trials (Table 13).[364] As cross-linker, 1378 
a molecule with four arms is used bearing complimentary 1379 
reactive sites on each end which are not further described in 1380 
literature. Very recently, Ocular TherapeutixTM announced 1381 
positive results from this clinical trial for the treatment of post-1382 
surgical ocular inflammation and pain.[365] It is placed through the 1383 
punctum (natural opening in the eye lid) into the lacrimal 1384 
canaliculus and allows a controlled delivery of corticosteroid to 1385 
the eye (Figure 13). After an application period of four weeks, the 1386 
hydrogel degrades and liquefies through bulk hydrolysis[366] and 1387 
naturally exits the nasolacrimal system. Besides the treatment of 1388 
post-operative inflammation, as well as allergic conjunctivitis 1389 
(phase III), the system is studied in phase II trials to treat the 1390 
inflammatory dry eye disease.  1391 
Besides ocular applications, hydrogels represent a promising platform for injection into the human body which 1392 
facilitates the well-controlled administration of drugs at the desired rate and site. An overview of recent patent 1393 
applications has been given by Calo and Khutoryanskiy.[367] A successful example for a hydrogel-based (non-ocular) 1394 
drug delivery system is the vaginal insert Propess® (US: Cervidil®) used to induce cervical ripening, which is on the 1395 
market since 1995. The network consists of polyurethane (PU) obtained from the cross-linking of PEG-diol and 1396 
diisocyanates units (Figure 14) and releases the previously loaded drug dinoprostone continuously over a period of 1397 
12 h. This release is induced by the swelling of the hydrogel when it is placed in the moist vaginal environment.[368] 1398 
 
Figure 13. The hydrogel plug Dextenza
TM
 (loaded with 
dexamethasone to treat inflammatory dry eye disease) is 
placed through the punctum (natural opening in the eye 
lid) into the lacrimal canaliculus and allows a controlled 
delivery of corticosteroid too the eye. 
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Based on a similar polymer system, Moraxen® represents a hydrogel 1399 
that features a slow, controlled release of morphine sulfate over a 1400 
whole day and is mainly used to relieve pain related to end-stage 1401 
cancer.[369] It is used for rectal delivery, but it is not considered a 1402 
classic suppository. The hydrogel is rather a reservoir type device 1403 
which has to be removed and replaced if needed due to the lack of 1404 
biodegradability. In 2008, Marillion Pharmaceuticals and 1405 
Cytokine PharmaSciences announced that they signed a license 1406 
agreement concerning the delivery system Pilobuc™, which is a buccal insert containing pilocarpine for the 1407 
treatment of symptoms associated with primary and secondary Sjögren’s syndrome, e.g. xerostomia.[370] 1408 
Pilobuc™ is based on a PU hydrogel system, which is an adaption of the marketed products Propess® and 1409 
Moraxen®.[371] It is placed between the buccal mucosa and gingiva at the back of the mouth.[371] In 2015, the phase 1410 
II trial for the treatment of xerostomia has been discontinued.[372] A second controlled release system for vaginal 1411 
delivery is Mysodelle®/Myspess® (US: Misodel®), which is based on a similar cross-linked system, synthesized from 1412 
PEG, 1,2,6-hexanetriol and dicyclohexylmethane-4,4’-diisocyanate. The drug misoprostol, which is applied for the 1413 
induction of labor, is released from a reservoir over a period of 24 h. The product is equipped with a withdrawal 1414 
tape that enables rapid removal when active labor begins.[373] The product Supprelin® LA is a hydrogel system that 1415 
is used as subcutaneous insert. The system acts as a reservoir and releases histrelin acetate 1416 
(gonadotropin-releasing hormone agonist) for the treatment of children with central precocious puberty. The drug 1417 
decreases the luteinizing hormone levels and the serum concentration of sex steroids. The formulation is composed 1418 
of 2-hydroxyethyl methacrylate (HEMA), 2-hydroxypropyl methacrylate, trimethylolpropane trimethacrylate, 1419 
benzoin methyl ether, di(4-tert-butylcyclohexyl) peroxydicarbonate (Perkadox-16) and Triton X-100 (non-ionic 1420 
surfactant).[374] Histrelin acetate is continuously delivered over a period of 12 months until the implant has to be 1421 
removed as it is nonbiodegradable.[375] Another subcutaneous insert based on a similar polymer reservoir release 1422 
system of histrelin acetate is Vantas®,[376] which is indicated to treat the symptoms of advanced prostate cancer. 1423 
Aquamere® and Aquatrix® II are types of hydrogel-based devices, which are produced by Hydromer®. 1424 
The trademark Aquamere® comprises several hydrogels based on poly(vinyl pyrrolidone) (PVP) containing 1425 
PU segments acting as cross-linker.[377] The materials are mainly used for topical applications, but some are applied 1426 
in oral drug delivery systems. The product line includes four different polymer types (H-, A-, C- and S-series) which 1427 
contain various comonomers to adjust the properties of the final hydrogel. The H-series products are solutions of 1428 
PVP and hydrophilic PU that facilitate high viscosity, superb film formation properties and excellent compatibility. 1429 
Based on the same polymer system as the H-series, the A-series exhibits polymers that are dispersed in ethanol for 1430 
quick drying. The C-series products of cationic grafted PDMAEMA/PVP copolymers and hydrophilic PU have 1431 
excellent adhesion and greater substantivity to skin and hair than H-series while maintaining excellent film forming 1432 
properties. The S-series contains unique silicone-based copolymers of dimethiconylacrylate/PVP and hydrophilic 1433 
PU, exhibiting a low viscosity and silky feel without oily residue. As a consequence, they are used for applications 1434 
where sheen or tack reduction is required. The products under the trademark Aquatrix® II are sold as two separate 1435 
aqueous solutions, forming a hydrogel upon mixing and result in superior cohesive and elastic properties. One part 1436 
is a solution of PVP in water and the other one contains either chitosan or PEI depending on the specific 1437 
product.[378] The resulting network can be loaded with active cosmetic and pharmaceutical ingredients by addition 1438 
to the aqueous solution prior to the gel formation. Another hydrogel system, Hypan® is based on a segmented 1439 
copolymer structure consisting of hard blocks (PAN sequences, good mechanical properties) and soft blocks 1440 
(hydrophilic derivatives of acrylic acid obtained by controlled partial hydrolysis of PAN, good water binding 1441 
capability) whereby more than one block of each kind is present per chain.[379] Hypan® hydrogels are used for the 1442 
treatment of colon diseases and various cancers. The materials can be processed by extrusion and injection 1443 
molding, which represent rather unusual methods considering hydrogels. Hypan® is produced and sold by 1444 
 
Figure 14. Schematic representation of the 
chemical structure of polyurethane (orange: 
urethane unit) obtained by a diol (i.e. PEG-diol) and 
a diisocyanate (R
1
 = aliphatic, aromatic moiety). 
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Hymedix.[380] SQZ GelTM is a hydrogel system for oral medication composed of chitosan and PEG, which allows a 1445 
pH-sensitive release of diltiazem hydrochloride to treat hypertension.[369, 381] In the basic environment of the gut, 1446 
the swollen network shrinks and releases the drug. 1447 
Smart HydrogelTM is a blend of the polymers PAA and PEG-b-PPG-b-PEG (Pluronic®) that forms a gel when it is 1448 
warmed to body temperature. Once injected at the desired body surface, it gels and enables a constant dosing of 1449 
drugs in situ for hours.[382] Increasing temperatures result in the aggregation of the hydrophobic ends of adjacent 1450 
Pluronic®-PAA molecules and, therefore, the formation of micelles. In this conformation, the hydrophilic ends 1451 
connect with each other to form a network that provides rigidity and structure to the mixture.[383] An intensely 1452 
investigated thermo-gelling hydrogel is the OncogelTM system, which is a network loaded with paclitaxel (TXL). It is 1453 
currently investigated for its application in the treatment of different cancer types.[384] As an example, it has been 1454 
proven to be effective in the treatment of malignant gliomas in rat models.[385] The physically cross-linked hydrogel 1455 
by itself is known under the trade name ReGel® and consists of an amphiphilic triblock copolymer 1456 
(PLGA-b-PEG-b-PLGA).[386] The system is soluble at low temperatures (< 15 °C), but upon injection into the body, 1457 
ReGel® forms a gelled depot. The temperature increase towards the critical gelation temperature results in 1458 
hydrophobic interactions of the PLGA segments and a strong micellar aggregation.[387] As a consequence, the 1459 
entrapped active compounds are released for systemic/local delivery over several weeks. OncoGelTM has been 1460 
evaluated in clinical studies on solid tumors[388] and in combination with radiotherapy on esophageal cancer.[389] 1461 
A recent phase IIb study failed as it showed no impact on the tumor in patients with esophageal cancer. Based on 1462 
these results, BTG has discontinued its clinical studies and its search for new partners to further develop 1463 
OncoGelTM.[390] Nevertheless, they will continue studies on ReGel® as a drug delivery technology. 1464 
 1465 
Table 13. Hydrogels based on synthetic polymers on the market or in clinical trials. 1466 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
DEXTENZA™ PEG Dexamethasone 
Post-operative 
inflammation, 
allergic conjunctivitis 
 
Ocular 
Therapeutix
TM 
 
Phase III
[364] 
 
Inflammatory dry eye 
disease 
Ocular 
Therapeutix
TM
 
Phase II
[364] 
Propess® 
(US: Cervidil®) 
PU (PEG-diol) 
Dinoprostone, 10 mg 
(prostaglandin E2/PGE2)  
Induction of labor 
Ferring 
Pharmaceuticals 
Market 
Moraxen® PU (PEG-diol) Morphine sulfate End-stage cancer pain BTG, PAION Market 
Pilobuc
TM
 PU (PEG-diol) Pilocarpine 
Sjögren’s syndrome 
(Xerostomia) 
Ferring 
Pharmaceuticals 
Phase II
[372]
 
(Disc.) 
Mysodelle®, 
Myspess® 
(US: Misodel®)  
PU (PEG-diol) 
Misoprostol, 200 µg 
(prostaglandin E1/PGE1) 
Induction of labor 
Ferring 
Pharmaceuticals 
Market 
Supprelin® LA 
2-Hydroxyethyl/propyl 
methacrylate, 
trimethylolpropane 
trimethacrylate 
Histrelin acetate 
Treatment of children with 
central precocious puberty 
Endo® Market 
Vantas® 
2-Hydroxyethyl/propyl 
methacrylate, 
trimethylolpropane 
trimethacrylate 
Histrelin acetate Advanced prostate cancer Endo® Market 
46 
 
Aquamere® 
PVP and PVP-grafted 
copolymers  
(cl
[a]
: PU segments) 
(H-, A-, C-, S-series) 
Broad range of cosmetic 
& drug ingredients 
Topical and oral drug 
delivery 
Hydromer® Market 
Aquatrix® II 
PVP (cl: Chitosan), 
PVP (cl: PEI) 
Broad range of cosmetic 
& drug ingredients 
Drug delivery matrices  
(i.e. transdermal) 
Hydromer® Market 
Hypan®
 Multiblocks of  
PAN-b-PAA 
[b] Colon diseases, various 
cancers 
Hymedix Market 
SQZ Gel™ PEG, Chitosan (blend) Diltiazem Hypertension BTG, Macromed Market 
Hycore-V™, 
Hycore-R™ 
Not discclosed Metronidazole 
Vaginal and rectal 
infections 
BTG , PAION Market 
Smart Hydrogel™ PAA, Pluronic® (blend) 
Broad range of drug 
ingredients 
Drug delivery matrices MedLogic Global Market 
OncoGel
TM
 
PLGA-b-PEG-b-PLGA 
(ReGel®) 
TXL 
Esophageal cancer 
 
 
Recurrent glioma 
BTG 
Phase IIb
[390]
 
(disc.) 
 
Phase I/II 
(NCT00479765) 
TXL: paclitaxel; 
[a]
 cl = cross-linker; 
[b] 
Hymedix has developed a line of seven products for the chronic wound care market. Which of them are 1467 
used for drug delivery applications has not been described in publicly available resources.
[380]
 1468 
 1469 
3.3.2 Solid implants and inserts 1470 
Solid drug delivery devices, which are implanted or simply inserted into natural orifices, possess several advantages 1471 
over parenteral or oral dosage forms. Besides the site specific drug administration and, hence, significantly lower 1472 
doses of the applied drugs, implantable or insertable devices usually allow a sustained and continuous release of 1473 
the therapeutic agents. Furthermore, the medication by implantable devices guarantees a better patient 1474 
compliance and acceptance than frequent injections or the taking of several pills a day. In this chapter, we focus on 1475 
passive delivery devices that provide continuous release over time periods ranging from weeks to several years 1476 
without the need for replenishment. These systems are particularly applied for the delivery of highly potent drugs, 1477 
which work at low doses such as hormones. Numerous commercial systems are available for applications ranging 1478 
from the prevention of HIV and the treatment of glaucoma to various methods for contraception. 1479 
Vaginal inserts. Currently, five different vaginal rings are commercially available (Table 14). For decades, silicone 1480 
elastomers (PDMS-based) are used for their fabrication due to the low weight, high flexibility and excellent 1481 
biocompatibility of these materials. Estring® and Femring® are used for 1482 
hormone replacement therapy, whereas Progering® represents a 1483 
contraceptive. Fertiring® combines both applications. The only commercialized 1484 
vaginal ring that is based on poly(ethylene-co-vinyl acetate) (PEVA, Figure 15) is 1485 
NuvaRing® for contraception. Numerous vaginal rings based on PDMS are 1486 
currently under clinical investigations, which are not only used for 1487 
contraception but also as prevention for sexually transmitted diseases. 1488 
MilprosaTM and NES/EE already went through clinical phase III and are close to 1489 
commercialization. The most advanced microbicide ring, dapivirine (DPV) Ring-004, was designed for HIV 1490 
prevention and is in phase III trials.[391] Different rings for the controlled and simultaneous delivery of preventives 1491 
for HIV (maraviroc, levonorgestrel) have recently entered clinical phase I. UPA-CVR, a vaginal ring releasing 1492 
ulipristal acetate, is already investigated in clinical phase II studies.[392] The trend goes towards multifunctional 1493 
applicable drug reservoirs. The dual protection vaginal ring of CONRAD is currently in phase I trials. It consists of 1494 
two segments, which are based on different aliphatic polyether-based PUs from the Tecoflex® family (variable in 1495 
 
Figure 15. Schematic representation of 
the chemical structure of 
poly(ethylene-co-vinyl acetate) (PEVA). 
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hardness and hydrophilicity based on varying contents of PEG and poly(tetramethylene ether glycol) (PTMEG)). 1496 
The system is optimized to deliver a high flux of tenofovir (HIV/herpes prevention) from one segment and a low flux 1497 
of levonorgestrel (contraception) from the other.[393] Another polyurethane-based ring entering clinical trials is 1498 
VR101, which releases glycerin to counteract vaginal dryness. Currently, the Population Council is developing a 1499 
PEVA ring for simultaneous delivery of medivir-150 (targets HIV), carrageenan (targets human papilloma virus (HPV) 1500 
and herpes simplex virus-2 (HSV-2)), zinc acetate (targets HIV and HSV-2) and levonorgestrel (targets unintended 1501 
pregnancy).[394] 1502 
Another option for reliable contraception is the insertion of an intrauterine device (IUD, Figure 16). The hormonal 1503 
IUD’s are usually made of PDMS (Table 14). The levonorgestrel-releasing 1504 
system Mirena® was approved by the FDA in 2000, after it had been used in 1505 
Europe since 1991. A new version of Mirena®, called Skyla® (U.K.: Jaydess®), 1506 
which is based on the same mechanism of action, was introduced to the US 1507 
market in 2013. It features a smaller size and a reduced dose of the released 1508 
hormone levonorgestrel. The latest IUD entering the market (Liletta®) was 1509 
approved by the FDA in 2015 and exhibits similar characteristics (shape and 1510 
dose of released levonorgestrel) compared to Mirena®. Intrauterine copper 1511 
contraceptives (e.g. Paragard®) are not described herein, although their 1512 
monofilament threads and T-frames are usually made of polyethylene (PE). 1513 
 1514 
Table 14. Vaginal inserts on the market and selected inserts in clinical trials. 1515 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
VAGINAL RING 
Estring® PDMS 17β-Estradiol 
Hormone replacement 
(menopause) 
Pfizer Market 
Femring®  PDMS 
17β-Estradiol-3-
acetate 
Hormone replacement 
(menopause) 
Allergan Market 
Progering®  PDMS Progesterone Contraception 
Population Council, 
Grünenthal 
Market  
(South America) 
Fertiring®  PDMS Progesterone 
Contraception & 
hormone replacement 
(menopause)  
Population Council, 
Grünenthal 
Market 
NuvaRing® PEVA 
Etonogestrel & 
ethinyl estradiol 
Contraception Merck & Co. Market 
Milprosa
TM
 PDMS Progesterone Contraception Ferring Pharmaceuticals Phase III
[395]
 
NES/EE PDMS 
Nestorone® (NES) & 
ethinyl estradiol 
Contraception Population Council 
Phase III finished 
(NCT00455156) 
NES/E2 PDMS 
Estradiol & 
nestorone® (NES) 
Contraception Population Council 
Phase II 
(NCT02626208) 
DPV-Ring PDMS 
Dapivirine (DPV),  
(DPV Ring-004) 
 
DPV/ 
levonorgestrel 
DPV/maraviroc 
HIV prevention IPM 
 
Phase III finished
[396]
 
 
Phase I  
(NCT02855346) 
Phase I 
(NCT01363037) 
 
Figure 16. Schematic representation of an 
intrauterine device (IUD). 
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UPA-CVR PDMS Ulipristal acetate Contraception 
HRA Pharma,  
Population Council 
Phase II
[392]
 
Dual protection 
PU, PEG & PTMEG 
(Tecoflex
TM
, Lubrizol 
Corp.) 
Levonorgestrel, 
tenofovir 
Contraception & 
HIV/herpes prevention 
CONRAD 
Phase I 
(NCT02235662) 
VR101 PU Glycerin Vaginal dryness 
J3 Bioscience 
(formerly ViroPan) 
Phase 0 
(NCT02029053) 
INTRAUTERINE DEVICE 
Mirena® PDMS Levonorgestrel Contraception 
Bayer,  
Population Council 
Market  
(as Levosert® in GB) 
Skyla® PDMS Levonorgestrel Contraception Bayer 
Market 
(as Jaydess® in GB) 
Liletta® 
(LNG20) 
PDMS Levonorgestrel Contraception 
Allergan, 
Odyssea Pharma 
Market 
 1516 
Subcutaneous implants. An effective contraception can further be accomplished by subcutaneous implants which 1517 
are implanted at the inside of the upper arm (Figure 17) and continuously release hormones into the blood. 1518 
After discontinuing the production of Norplant® (silicone capsules 1519 
containing levonorgestrel),[397] Norplant® II (Jadelle®) was 1520 
developed, which consists of small rods based on PDMS (Table 15). 1521 
Once inserted, Norplant® II lasts up to 5 years. Utilizing the same 1522 
mechanism of action, Sino-Implant II (two thin, flexible silicone 1523 
rods) represents one of the most effective birth control products 1524 
with annual pregnancy rates below 1%.[398] The product is 1525 
considered for four years of use, so far.[399] Another type of 1526 
subdermal implant is Nexplanon®, which is based on a PEVA 1527 
copolymer. Nexplanon® reveals two main advantages compared to 1528 
its predecessor Implanon®, which is replaced gradually: 1529 
I) The easier insertion that avoids placing the implant too deep 1530 
under the skin; II) the rod allows localization via X-ray since it is radiopaque due to the addition of 15 mg barium 1531 
sulphate.[400] Despite showing great promise for being another contraceptive alternative, the development of 1532 
PCL-based Capronor releasing levonorgestrel was abandoned in the 1990s due to skin irritation and stability in 1533 
storage issues. Furthermore, there were concerns about removal of the device and a long release tail.[401] 1534 
However, the single, tubular implant was able to achieve up to one year of ovulation suppression. [402] Very 1535 
recently, the FDA approved another implant based on PEVA, called Probuphine®, which is the first device for the 1536 
continuous release of buprenorphine. It is used for the maintenance treatment of opioid dependence as part of a 1537 
complete treatment program including counseling and psychosocial support. Probuphine® consists of four rods that 1538 
are implanted under the skin on the inside of the upper arm and provides treatment for six months.[403] VC-01TM is a 1539 
subcutaneous implant currently under clinical investigation (phase I/II) to treat diabetes type I. It is composed of 1540 
ViaCyte’s Encaptra® drug delivery technology (made of undisclosed polymers[404]) and is used to deliver human 1541 
embryonic stem cells (pancreatic PEC-01TM cells).  1542 
 1543 
 1544 
 
Figure 17. Schematic representation of the 
implantation of a subcutaneous implant. Reprinted 
from Acta Cir. Bras. 2009, 24, 7-12. with permission of 
Creative Commons Corporation (2009). 
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Table 15. Subcutaneous implants on the market and in clinical trials. 1545 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Jadelle® 
(Norplant® II) 
PDMS Levonorgestrel Contraception 
Bayer,  
Population Council 
Market (not in US) 
Sino-Implant II PDMS Levonorgestrel Contraception 
Shanghai Dahua 
Pharmaceuticals 
Market 
(as Zarin®, Fem-plant®, 
Trust®, Simplant® etc. 
registered in 24 countries) 
Nexplanon® PEVA Etonogestrel Contraception Merck & Co. Market 
Capronor PCL Levonorgestrel Contraception RTI International Phase II
[401]
 (disc.) 
Probuphine® PEVA Buprenorphine HCl Opioid dependence 
Titan & Braeburn
TM
 
Pharmaceuticals 
Market 
VC-01
TM
 
undisclosed 
(Encaptra®) 
PEC-01
TM
 cells
[a]
 Diabetes type 1 ViaCyte 
Phase I/II 
(NCT02239354)  
[a]
 Embryonic stem cell–derived precursors of insulin-producing beta cells. 1546 
 1547 
Ocular implants and inserts. Implantable or insertable devices are 1548 
well-established for the local treatment of eye diseases. Ocusert® Pilo was one 1549 
of the first ocular delivery devices and represents an ocular insert, which is 1550 
placed in the lower cul-de-sac of the eye to be used for the treatment of 1551 
glaucoma (Table 16).[405] It contains a core reservoir consisting of pilocarpine and 1552 
alginic acid and a framework of hydrophobic poly(ethylene-co-vinyl acetate) 1553 
(PEVA) membrane that regulates diffusion of pilocarpine. However, the product 1554 
has been withdrawn from the market, which is mainly related to the difficulties 1555 
(in particular for elderly people) replacing the insert.[406] The first intravitreal 1556 
implant was Vitrasert®. This ganciclovir pellet was used for the treatment of 1557 
cytomegalovirus retinitis. The antiviral medication is coated by nondegradable 1558 
layer of impermeable PEVA, which is sandwiched in between two permeable layers of PVA. This design enables a 1559 
well-controlled rate of release of the drug by the diffusion only through the areas where no impermeable material 1560 
is present. As a consequence, reimplantation is necessary after 5 to 8 months.[407] Due to market forces, Vitrasert® 1561 
has not been produced since 2014, and all remaining implants have passed their expiration dates.[408] 1562 
Retisert® followed as the second generation of reservoir-based implants, which are used for treatment of chronic 1563 
noninfectious uveitis (Figure 18).[409] This implant for sustained release consists of a silicon laminate and PVA 1564 
coating, which control the release of fluocinolone acetonide (FA). Further studies have proven the potential of this 1565 
device in the treatment of edema (caused by diabetes) and central retinal vein occlusions.[410] Another implant for 1566 
the delivery of FA and the treatment of diabetic macular edema is Iluvien®. 1567 
This rod-like device is based on polyimide tubes (Figure 19) with a PVA 1568 
membrane at the caps. Due to its small size, it can remain in the cavity even 1569 
after the whole drug has been released. A similar, small rod-like device, which is 1570 
injected into the white of the eye, is Ozurdex®. This system is designed to 1571 
deliver the corticosteroide dexamethasone also applied for the treatment of 1572 
macular edema. In contrast to previous devices, the use of degradable PLGA 1573 
allows the dissolution of the implant and, therefore, eliminates the need of 1574 
surgically removal. Another biodegradable PLGA-based implant is Surodex®, which is a rod-shaped device inserted 1575 
into the anterior chamber after a cataract surgery in order to control postoperative inflammation.[407] 1576 
 
Figure 18. Schematic representation 
of the reservoir-based Retisert® 
implant. 
 
Figure 19. Schematic representation 
of the chemical structure of 
polyimides. 
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Further ophthalmic inserts (e.g. I-vationTM or HeliosTM), which are currently under clinical investigations, have been 1577 
nicely reviewed elsewhere.[407, 411] 1578 
 1579 
Table 16. Ocular implants and inserts on the market and in clinical trials. 1580 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Ocusert® Pilo PEVA Pilocarpine 
Treatment of 
glaucoma 
Johnson & Johnson, 
Alza Cooperation 
Market 
(withdrawn) 
Vitrasert® 
PVA, PEVA 
(Versa
TM
 platform) 
Ganciclovir 
Cytomegalovirus 
retinitis 
Auritec Pharmaceuticals 
Market 
(withdrawn) 
Retisert® 
PVA, PDMS 
(Versa
TM
 platform) 
Fluocinolone 
acetonide 
Chronic non-
infectious uveitis 
Valeant® (Bausch & Lomb), 
Auritec Pharmaceuticals 
Market 
Iluvien® Polyimide, PVA 
Fluocinolone 
acetonide 
Diabetic macular 
edema 
AlimeraSciences Market 
Ozurdex® 
PLGA 
(Novadur®) 
Dexamethasone 
Diabetic macular 
edema 
Allergan Market 
Surodex® 
PLGA, hydroxypropyl 
methylcellulose 
Dexamethasone 
Postcataract surgery 
inflammation 
Oculex Pharmaceuticals 
Market (China, 
Singapore, etc.) 
I-vation
TM
 PMMA, PEVA 
Triamcinolone 
acetonide 
Diabetic macular 
edema 
SurModics 
Phase II finished 
(NCT00692614) 
Helios
TM
 PDMS Bimatoprost 
Intraocular pressure 
(IOP)-lowering 
ForSight
TM
 VISION5 
Phase II 
(NCT02537015) 
* PLGA 
Brimonidine 
tartrate 
Retinitis pigmentosa Allergan 
Phase II 
(NCT00661479) 
Age-related macular 
degeneration 
Allergan 
Phase II 
(NCT00658619) 
* No trade name listed. 1581 
 1582 
Implants for deeper tissue. While the majority of implantable devices comprises subcutaneous or ocular systems, 1583 
which do not require major surgery to be applied, replaced or removed, a few devices were developed to be 1584 
implanted into deeper tissue in the body (Table 17). Based on a biodegradable polymer (a copolymer of 1585 
bis-(p-carboxyphenoxy)propane and sebacic acid called 1586 
Polifeprosan 20) the Gliadel® wafer is approved for the 1587 
treatment of malignant glioma.[412] It is inserted into cavities 1588 
resulting after the surgical removal of the tumor in the brain 1589 
(Figure 20) and will be degraded by the body to release the 1590 
cytostatic drug carmustine. Another commercialized implant 1591 
for the application in deeper tissue is Propel® based on the 1592 
biodegradable polymer PLGA.[413] This steroid-eluting device is 1593 
implanted after surgery into the nose to assist in the treatment 1594 
of chronic sinusitis. 1595 
The presented implant systems reflect only a selection of currently commercially available systems. Besides, a large 1596 
pipeline of polymer-based implant delivery technologies has been studied in promising clinical trials. 1597 
The biodegradable implant siG12D-LODER™ (PLGA-based) is inserted into the tumor and releases a siRNA drug 1598 
against KRASG12D over four months. In combination with chemotherapy it is used as targeted therapy for locally 1599 
advanced pancreatic cancer (phase IIb).[414] RestoraTM represents a transmucosal PU steroid-eluting device[415] for 1600 
thirty day treatment of sinusitis (phase II/III).[416] In contrast, LiRIS® is a pretzel-shaped silicone tube that could be 1601 
inserted into the bladder, releasing lidocaine over two weeks in females with interstitial cystitis (phase II).[417] 1602 
 
Figure 20. Schematic representation of the inserted 
Gliadel® wafer (polymer system) in the brain. 
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 1603 
Table 17. Implants for deeper tissue on the market and in clinical trials. 1604 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER STATUS 
Gliadel® Wafer Polifeprosan 20
[a]
 Carmustine Malignant glioma Arbor Pharmaceuticals Market  
Propel® PLGA, PEG 
Mometasone 
furoate 
Chronic sinusitis Intersect® ENT Market 
siG12D-LODER™ PLGA (Loder
TM
) 
siRNA therapeutic 
(KRASG12D) 
Pancreatic tumor Silenseed 
Phase IIb 
(NCT01676259) 
Restora
TM
 PU Steroid Sinusitis SinuSys
TM
 
Phase II/III 
(NCT02627794)  
LiRIS® PDMS Lidocaine 
Interstitial cystitis/ 
bladder pain 
syndrome 
Allergan 
Phase II 
(e.g. NCT01475253, 
NCT01824303) 
 
[a]
 Polifeprosan 20 (poly[bis (p-carboxy-phenoxy)] propane and sebacic acid). 1605 
Several companies are working continuously on new technologies (e.g. MedidurTM, DebioStarTM, Duros®, 1606 
MedLaunchTM), which can be used as polymer platform for different drugs. Implanted drug-eluting stents are 1607 
described in Chapter 3.4.2 as the polymers are used as coatings in that case. Implanted devices built up from 1608 
hydrogel networks, e.g. Supprelin® LA and Vantas®, are described in Chapter 3.3.1. 1609 
 1610 
3.4 Coatings 1611 
3.4.1 Solid oral dosage forms 1612 
Despite the complexity of the related uptake mechanism, oral administration of pharmaceutical compounds is the 1613 
preferred route for the drug delivery applications due to the ease of ingestion, the avoidance of painful procedures, 1614 
its versatility, the high patient compliance, reduced sterility constraints, and flexibility of dosage form design 1615 
(e.g. solids: Powder, granules, capsules).[418] In addition, the oral uptake allows patients to conveniently 1616 
self-administer drugs without the need of any health care professionals.[419] But the oral delivery of 1617 
pharmaceuticals remains challenging for several reasons: I) The typical transit time in the gut (from mouth to anus) 1618 
is about 30 hours, which limits the use of drugs that aim at longer dosing times;[420] II) the physiological parameters 1619 
and the biological environment of the gastrointestinal (GI) tract can vary quite significantly from one stage to the 1620 
next. For example, the pH value of the saliva in the mouth is usually in the range of 5.8 and 7.4. Inside the stomach 1621 
the pH value decreases dramatically to 1 (extremely acidic) and increases back to 7 (neutral) in the bowels; 1622 
III) the food and beverage intake causes dynamic changes in the concentration of bile salts, lipids, carbohydrates 1623 
and digestive enzymes throughout the GI tract that can interact with the drug;[421] IV) finally, before reaching the 1624 
bloodstream, the drug has to overcome some anatomical obstacles including the degradative environment in the 1625 
lumen and traversing the mucosa and epithelial cells. However, one of the main concerns remains the patient 1626 
compliance considering the oral uptake of pharmaceuticals, in case the drugs have disagreeable taste and require 1627 
frequent dosing. As a result of these limitations, various functional coatings based on polymers have been designed 1628 
to improve the efficacy of the oral route of administration. These polymer coatings are mainly applied to solid 1629 
dosage forms, i.e. tablets, granulates and capsules, with the aim to achieve selective delivery of active ingredients 1630 
to a particular gastrointestinal (GI) tract, such as the small intestine or the large bowel, or to improve the patient 1631 
compliance by improving the odor or masking the taste. Since the established systems comprise proven and 1632 
versatile materials, there doesn’t exist an immediate need for new polymer systems.  1633 
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Polymer coatings for site specific delivery. The release of a drug at a specific site in the GI guarantees an optimized 1634 
uptake into the blood stream or activity of the delivered active ingredient at the desired side, but avoids 1635 
complications with other parts of the tract. Several polymer-based coatings have been developed to target various 1636 
sites of the GI. An enteric polymer coating prevents the release of the drug in the gastric environment and 1637 
facilitates the release in the small intestine or in the colon. This enables: I) The protection of the stomach from 1638 
some drugs, which may cause stomach ulcers, such as aspirin, diclofenac 1639 
and naproxen; II) the protection of special pharmaceutical compounds 1640 
such as proton pump inhibitors (PPIs) (e.g. omeprazole or pantoprazole) 1641 
against the acidic environment in the stomach, and, III) the targeting of 1642 
the small intestine or colon.[422] Enteric coatings contain carboxylic acid 1643 
groups, which remain in an unionized (protonated) form at low pH values 1644 
and, therefore, are insoluble in the acidic aqueous environment of the 1645 
stomach.[169] However, as the pH value increases in the small intestine, the 1646 
carboxylic acids become deprotonated (negatively charged), which results in the dissolution of the polymers in the 1647 
intestinal fluid.[423] Table 18 summarizes marketed poly(meth)acrylate copolymers, which are used for enteric 1648 
coatings, including their chemical composition, product form and the pH value at which they become soluble. 1649 
The critical pH value for dissolution of the polymers mainly depends on the content of the carboxylic acid and 1650 
esterified groups. The different dissolution properties of enteric coatings enable targeting specific areas of the 1651 
intestine. For example, EUDRAGIT® L100-55 and EUDRAGIT® L100 dissolve above pH value of 5.5 and 6.0, 1652 
respectively, and are used for targeting the small intestine, whereas EUDRAGIT® S100 and EUDRAGIT® FS 30D 1653 
(Figure 21) dissolve above pH value of 7.0 and are used for colon targeting.[424] In addition, the release of the 1654 
encapsulated drugs can further be controlled by the thickness of the coating material or simply by blending the 1655 
different enteric polymers in different ratios.[422] 1656 
 1657 
Table 18. Marketed poly(meth)acrylates as enteric coatings. 1658 
TRADE NAME PRODUCT FORM POLYMER SYSTEM DISSOLUTION pH MANUFACTURER 
EUDRAGIT® L 100-55 Powder 
Poly(MAA-co-ethyl acrylate) 1:1 
Soluble > pH 5.5 Evonik 
EUDRAGIT® L 30D-55 Aqueous dispersion 30% 
Kollicoat® MAE 30 DP Aqueous dispersion 30% 
Soluble > pH 5.5 BASF 
Kollicoat® MAE 100 P Powder 
EUDRAGIT® L 100 Powder 
Poly(MAA-co-MMA) 1:1 Soluble > pH 6.0 Evonik 
EUDRAGIT® L 12.5 Organic solution 12.5% 
EUDRAGIT® S 100 Powder 
Poly(MAA-co-MMA) 1:2 Soluble > pH 7.0 Evonik 
EUDRAGIT® S 12.5 Organic solution 12.5% 
EUDRAGIT® FS 30D Aqueous dispersion 30% Poly(MAA-co-methyl acrylate-co-MMA) 7:3:1 Soluble > pH 7.0 Evonik 
 1659 
Apart from enteric coatings, sustained release coating polymers releasing the drug over time can also be used for 1660 
modified/controlled release applications. These polymers lack ionizable groups and they are not soluble in the 1661 
entire GI tract. However, they can swell with exposure to the gastrointestinal fluids and, consequently, release the 1662 
active ingredients by a diffusion-controlled mechanism. These polymer coatings are mainly used in prolonged-1663 
action dosage forms. EUDRAGIT® RL and RS, which contain 10% or 5% quaternary ammonium groups, respectively, 1664 
 
Figure 21. Schematic representation of the 
chemical structure for the copolymer 
poly(MAA-co-methyl acrylate-co-MMA), 
named EUDRAGIT® FS 30D. 
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as well as the neutral EUDRAGIT® NE and NM, which are the copolymers of ethyl acrylate and methyl methacrylate, 1665 
are preferred coating materials for a sustained release. Table 19 includes marketed poly(meth)acrylate based 1666 
copolymers which are used for sustained release coatings and their chemical composition as well as dissolution 1667 
properties. 1668 
 1669 
Table 19. Various marketed poly(meth)acrylates for sustained release. 1670 
TRADE NAME PRODUCT FORM POLYMER SYSTEM  PROPERTIES ADVANTAGES 
EUDRAGIT® RL 30 D Aqueous dispersion 30% 
Poly(ethyl acrylate-co-MMA-co-
TMAEMA) 1:2:0.2 
Insoluble, 
high permeability, 
pH-independent swelling 
Customized release 
profiles by 
combination of RL 
and RS grades in 
different ratios, 
suitable for matrix 
structures 
EUDRAGIT® RL PO Powder 
EUDRAGIT® RL 100 Granules 
EUDRAGIT® RL 12.5 Organic solution 12.5% 
EUDRAGIT® RS 30 D Aqueous dispersion 30% 
Poly(ethyl acrylate-co-MMA-co-
TMAEMA) 1:2:0.1 
Insoluble, low permeability, 
pH-independent swelling 
EUDRAGIT® RS PO Powder 
EUDRAGIT® RS 100 Granules 
EUDRAGIT® RS 12.5 Organic solution 12.5% 
EUDRAGIT® NE 30 D Aqueous dispersion 30% 
Poly(ethyl acrylate-co-MMA-co-
TMAEMA) 2:1:0 
Insoluble, low permeability, 
pH-independent swelling 
No plasticizer 
required, highly 
flexible, suitable for 
matrix structures 
EUDRAGIT® NE 40 D Aqueous dispersion 40% 
EUDRAGIT® NM 30 D Aqueous dispersion 30% 
TMAEMA = trimethylammonioethyl methacrylate chloride. 1671 
 1672 
Polymer coatings for odor or taste masking. Polymer coatings are also applied to protect the sensitive ingredients 1673 
from environmental influences such as light and moisture or to mask the unpleasant taste of the formulations.[169, 1674 
425] Methacrylates containing tertiary amino groups are commonly applied for masking the taste and moisture 1675 
protection (Table 20). These pH-responsive polymer coatings take advantage of the differences in pH values 1676 
between the oral cavity (pH 5.8 to 7.4) and the stomach (pH 1 to 3.5).[426] The polymers are insoluble in water at the 1677 
neutral pH value of the saliva. Therefore, they suppress the release of the drug, which usually exhibit an unpleasant 1678 
taste, and the diffusion of water molecules to the core of the system protecting any moisture sensitive ingredients. 1679 
However, they become protonated and water-soluble at acidic conditions resulting in the release of the content in 1680 
the stomach or in the small intestine. 1681 
 1682 
Table 20. Marketed pH-responsive poly(meth)acrylates as protective coatings. 1683 
TRADE NAME PRODUCT FORM POLYMER SYSTEM  DISSOLUTION pH MANUFACTURER 
EUDRAGIT® E 100 Granules 
Poly(BMA-co-DMAEMA-co-MMA) 1:2:1 Soluble ˂ pH 5.0 Evonik EUDRAGIT® E 12.5 Organic solution 12.5% 
EUDRAGIT® E PO Powder 
Kollicoat® Smartseal 30D Aqueous dispersion Poly(MMA-co-DEAEMA
[a]
) 7:3 
Soluble ˂ pH 5.0; 
Stable in saliva 
BASF 
[a]
 DEAEMA= diethylaminoethyl methacrylate. 1684 
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Apart from these pH-responsive methacrylates, some other water soluble synthetic polymers, including vinyl 1685 
polymers and hydrophilic copolymers, are also applied for masking unpleasant tastes or protecting against 1686 
moisture (Table 21). These polymers do not contain any ionic groups, which decreases the risk of chemical 1687 
interactions with any other ingredient of the formulation.[425] 1688 
 1689 
Table 21. Marketed water soluble synthetic polymers as protective coatings. 1690 
TRADE NAME PRODUCT FORM POLYMER SYSTEM MANUFACTURER 
Kollidon® Powder PVP BASF 
Kollicoat® IR Powder PVA-PEG-graft copolymer BASF 
Kollicoat® Protect Powder PVA-PEG-graft copolymer (Kollicoat® IR), PVA BASF 
Opadry® AMB Powder PVA Colorcon® 
Moreover, the previously mentioned enteric polymers (see Table 18) and coatings for sustained release 1691 
(see Table 19) can also be used for taste masking and moisture protection if they provide a sufficient suppression of 1692 
the drug release in the mouth and prevent moisture to pass into the formulation. However, to realize the desired 1693 
fast drug release after swallowing, relatively thin coatings are applied.[425] Table 22 represents selected examples of 1694 
commercialized drug formulations which are coated with EUDRAGIT® polymers. 1695 
 1696 
Table 22. Examples for marketed dosage forms coated with EUDRAGIT® polymers. 1697 
TRADE NAME POLYMER SYSTEM DRUG INDICATION/USE MANUFACTURER 
Clipper® EUDRAGIT® L 100-55 
Beclometasone 
dipropionate 
Inflammatory bowel disease Chiesi 
Colo-Pleon® EUDRAGIT® L 100-55 Sulfasalazine Inflammatory bowel disease Sanofi-Aventis 
Entocort® EUDRAGIT® L 100-55 Budesonide Inflammatory bowel disease Prometheus Lab. 
Salofalk® EUDRAGIT® L 100 Mesalazine Inflammatory bowel disease Dr. Falk Pharma 
Ipocol® EUDRAGIT® S 100 Mesalazine Inflammatory bowel disease Sandoz 
Budenofalk® 
EUDRAGIT® S 100 & 
EUDRAGIT® L 100 
Budesonide Inflammatory bowel disease Dr. Falk Pharma 
Premique® EUDRAGIT® NE 30 D 
Conjug. estrogens & 
medroxyprogesterone 
acetate (MPA) 
Hormone replacement therapy for 
estrogen deficiency symptoms in 
postmenopausal women within an intact 
uterus 
Pfizer 
Nutrizym 22 EUDRAGIT® L 30 D Pancreatin BP 
Symptomatic relief of pancreatic exocrine 
insufficiency such as in fibrocycstic 
disease of the pancreas & chronic 
pancreatitis 
Merck Serono 
Convulex® CR EUDRAGIT® RL 30 D Sodium valproate Epilepsy and bipolar disorder G. L. Pharma GmbH 
Amisulpride film-
coated tablets 
EUDRAGIT® E 100 Amisulpride Acute & chronic schizophrenic disorders 
Lek Pharmaceuticals D. D., 
Salutas Pharma GmbH 
Adanif® XL EUDRAGIT® E Nifedipine 
Hypertension, prophylaxis of chronic 
stable angina pectoris 
Focus Pharmaceuticals 
 1698 
 1699 
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3.4.2 Drug-eluting stents 1700 
Coronary artery disease (CAD) is a heart disease, which 1701 
is considered to be one of the leading causes of death 1702 
worldwide.[427] The lining of the coronary arteries, 1703 
which guarantee the blood supply to heart muscle, 1704 
becomes harder and stiffer, and, finally, the artery’s 1705 
diameter is narrowed due to the accumulation of 1706 
plaque on their inner walls (atherosclerosis). The 1707 
percutaneous transluminal coronary angioplasty 1708 
(PTCA) is a well-established method to counteract the 1709 
symptoms of the CAD. However, this treatment is not 1710 
sufficient as the risks of early abrupt closure, intimal 1711 
hyperplasia and late restenosis are considerably high, if it is not accompanied by further therapies.[428] An early 1712 
approach to overcome these limitations resulted in the development of bare metal stents (BMS).[429] BMS are 1713 
devices, which are first inserted in the narrowed coronary artery by an inflatable catheter. At the side of action, the 1714 
BMS gets expanded by the attached balloon and acts as a mechanical scaffold to recover the original dimensions of 1715 
the vessel (Figure 22).[430] Despite an initial improvement, the implantation of the BMS commonly results in an in-1716 
stent restenosis (ISR) due to the migration of vascular smooth cells within the stents.[431] The first attempts to 1717 
prevent this restenosis by systematic drug delivery systems failed. As a consequence, focus was set on the 1718 
development of drug-eluting stents (DES). These systems carry an antiproliferative drug, which is incorporated into 1719 
a polymer coating of the BMS. The drugs are directly released at the injured sites to prevent the ISR by the 1720 
suppression of the neointimal growth.[432] The first generation of DES comprises the sirolimus-eluting stent 1721 
(Cypher®) and the paclitaxel-eluting stent (Taxus®), which are made of a stainless steel (SS) scaffold coated with the 1722 
polymers poly(n-butyl methacrylate) (PBMA) and poly(ethylene-co-vinyl acetate) (PEVA) or poly(styene-b-1723 
isobutyelene-b-styrene) (PSIBS), respectively. The application of these modified stents resulted in a remarkable 1724 
reduction of the usually occurring restenosis. However, safety concerns have been raised regarding the possibility 1725 
of late stent thrombosis in case of a long term use.[433] In recent years, a second generation of DES has been 1726 
developed with the aim to improve the efficacy and the long term 1727 
safety of the stents. For this purpose, stent frames with thinner 1728 
struts were introduced, and novel, more effective drugs were 1729 
incorporated compared to the first generation DES. Similar to the 1730 
first generation, these DES still use synthetic, nonbiodegradable 1731 
polymers such as PBMA, PEVA, PSIBS, poly(hexafluoropropylene) 1732 
(PHFP), and poly(vinylidene fluoride) (PVDF), sometimes in 1733 
combination with a phosphorylcholine polymer (PCh) 1734 
(Figure 23),[434] as coating materials of a metal surface. Table 23 1735 
summarizes all DES approved by the FDA that use polymer 1736 
coatings.[428-429, 431, 435] Keeping in mind that the above mentioned 1737 
polymers are nonbiodegradable, these coatings remain on the 1738 
stent even after the drug is fully released, which may induce local 1739 
hypersensitivity, inflammation and delayed vascular healing 1740 
resulting in the development of late stent thrombosis.[436]  1741 
 1742 
 
Figure 22. General mechanism of the insertion of a stent. A) Insertion 
of the stent by an inflatable catheter; B) expansion of the stent by the 
attached ballon; C) removal of the ballon. 
 
 
Figure 23. Schematic representation of the chemical 
structure of an exemplary phosphorylcholine 
polymer (PCh, PC technology
TM
). 
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Table 23. Drug-eluting stents (DES) with nonbiodegradable polymers as coating materials on the market or in clinical trials. 1743 
TRADE NAME 
STENT 
PLATFORM
[a]
 
POLYMER SYSTEM DRUG DRUG RELEASE (DAYS) MANUFACTURER APPROVAL 
Cypher® SS PEVA, PBMA, PCh Sirolimus  
40% (5);  
85% (30);  
100% (90) 
Cordis Corporation FDA
[b]
 
Taxus® SS 
Poly(styrene-b-
isobutylene-b-styrene) 
TXL <10% (28) Boston Scientific FDA 
Promus 
PREMIER
TM
 
Pt-Cr 
PBMA, 
poly(vinylidene-co-
hexafluoropropylene) 
Everolimus  
71% (28);  
100% (120) 
Boston Scientific FDA 
Xience V® Co-Cr 
PBMA, 
poly(vinylidene-co-
hexafluoropropylene) 
Everolimus  
80% (28);  
100% (120) 
Abbot Vascular FDA 
Endeavor® Co-Cr PCh Zotarolimus  
75% (2);  
95% (15);  
100% (28) 
Metronic FDA 
Endeavor® 
Resolute 
Co-Cr 
Blend of PVP, poly(hexyl 
methacrylate)-co-PVP-
co-PVAc and PBMA-co-
PVAc (BioLinx) 
Zotarolimus  
50% (7);  
70% (28);  
100% (31) 
Metronic FDA 
Firebird2®  Co-Cr 
Poly(styrene-butylenes-
styrene)  
Sirolimus 
50% (7);  
90% (30) 
Essen Technology 
(Beijing) 
Phase IV 
(NCT01257373) 
TXL: paclitaxel; 
[a]
 Pt-Cr: platinum chromium, SS: stainless steel, Co-Cr: cobalt chromium; 
[b]
 FDA approved stents also have CE approvals. 1744 
 1745 
These issues have promoted the recent development of stents coated with fully biodegradable polymers such as 1746 
PLGA and PLA. A successful example is the everolimus-eluting stent, which consist of a platinum chromium (Pt-Cr) 1747 
platform coated with a biodegradable PLGA copolymer. A summary of FDA and CE approved DES based on 1748 
biodegradable polymers are listed in Table 24.[429, 437] 1749 
 1750 
Table 24. Drug-eluting stents (DES) with biodegradable polymers as coating materials. 1751 
TRADE NAME 
STENT 
PLATFORM
[a]
 
POLYMER SYSTEM DRUG 
DRUG RELEASE 
(DAYS) 
MANUFACTURER STATUS 
Synergy
TM
 Pt-Cr PLGA Everolimus  
50% (60);  
100% (90) 
Boston Scientific FDA
[b]
 
Axxess
TM
 Nitinol PLA Biolimus A9  45% (30) Biosensors CE 
BioMatrix Flex
TM
 SS PLA Biolimus A9  45% (30) Biosensors CE 
Nobori® SS PLA Biolimus A9  45% (30) Terumo CE 
Supralimus® SS PLLA-PLGA-PCL-PVP Sirolimus  100% (48) SMT CE 
Orsiro Co-Cr PLLA + silicon carbide Sirolimus  
50% (30);  
80% (90) 
Biotronik CE 
BioMime
TM
 Co-Cr PLLA + PLGA Sirolimus  100% (30) Meril CE 
Inspiron® Co-Cr PLLA, PDLLGA Sirolimus  
60% (10);  
100% (45) 
Scitech Medical 
Phase IV 
(NCT01856088) 
Firehawk® Co-Cr PDLLA Sirolimus  90% (90) MicroPort Medical CE 
DESyne® BD Co-Cr PLA Novolimus
TM
  90% (90) Elixir® CE 
MiStent SES® Co-Cr PLGA Sirolimus 
100% (270) 
(sustained 
release) 
Micell Technologies CE 
Tivoli® Co-Cr PLGA Sirolimus  
50% (7);  
80% (28) 
Essen Technology 
(Beijing) 
Phase III 
(NCT02448524) 
[a]
 Pt-Cr: platinum chromium, SS: stainless steel, Co-Cr: cobalt chromium; 
[b]
 FDA approved stents also have CE approvals.  1752 
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Although the above mentioned efforts have increased the efficacy and lifetime of stents, it has to be kept in mind 1753 
that even after the degradation of the polymer coatings the metal scaffold (BMS) remains in the artery, which still 1754 
might cause restenosis.[438] As a consequence, the development of fully biodegradable stents has gained 1755 
considerable attention. Several fully degradable DES have been investigated clinically or are still in clinical trials, but 1756 
so far only the evorolimus-eluting stent AbsorbTM is FDA approved and the NovolimusTM-eluting DESolve® is CE 1757 
approved for commercial use in coronary patients (Table 25).[429, 439] In addition to these fully degradable systems, 1758 
dual drug-eluting stents (DDES) are tested to deliver both anti-proliferative and pro-healing agents reducing the 1759 
occurrence of stent thrombosis. Although some of the DDES have shown promising results in clinical trials, the 1760 
Combo stent (OrbusNeich) is the only marketed DDES, which has CE approval. Combo stent uses stainless steel as 1761 
stent platform and elutes the sirolimus and CD-34 antibody as drugs from a biodegradable polymer matrix that 1762 
achieves the complete release within 30 days. Unfortunately, the chemical formulation of the used polymer matrix 1763 
is not specified. Moreover, since the DDES in clinical trials are either polymer free or use no synthetic polymers, 1764 
readers are referred to literature for more information.[429] 1765 
 1766 
Table 25. Drug-eluting stents (DES) with fully biodegradable scaffolds and coatings. 1767 
TRADE NAME 
STENT 
PLATFORM 
POLYMER 
SYSTEM 
DRUG DRUG RELEASE (DAYS) MANUFACTURER STATUS 
Absorb
TM
 PLLA PDLLA Evorolimus  80% (28) Abbot Vascular FDA approval 
DESolve® PLLA PLLA Novolimus
TM
 100% (180 to 270) Elixir® CE approval 
Dreams I Mg
[a]
 PLGA TXL 100% (90) Biotronik 
Phase 0 
(NCT01168830) 
Dreams II Mg PLLA Sirolimus n.a. Biotronik 
Phase 0 
(NCT01960504) 
ReZolve2 PTD-PC
[b]
 n.a. Sirolimus Majority of drug (90) REVA 
Clinical study
[c] 
(NCT01845311) 
[a] 
Mg, magnesium; 
[b] 
PTD-PC, poly-tyrosine-derived polycarbonate; 
[c]
 status not clear; n.a.: not applicable. 1768 
 1769 
3.5 Polymers as matrix excipients  1770 
Besides the previously described application forms, several synthetic polymers are added to pharmaceutical dosage 1771 
forms. By definition they have to be inactive ingredients (all materials other than the API) in final drug products to 1772 
belong to the so-called excipients.[440] The FDA provides an online database comprising all inactive ingredients 1773 
approved for certain formulations for their particular route of administration, amount and concentration (also the 1774 
polymers used for coatings, e.g., several Eudragit® products, can be found here, see Chapter 3.4.1).[441] 1775 
Excipients have undergone a paradigm shift from being “inert ingredients” to “functional ingredients”. For instance, 1776 
polymers on one hand act as binders in tablets, capsules and granules, as solubilizing, lyophilizing, wetting or taste 1777 
masking agents[442] but also as mucoadhesives.[443] They are referred to provide sustained release of drugs, to 1778 
solubilize and protect them from degradation or to enhance their bioavailability. They ensure mucus permeability 1779 
of the formulation and enhance the probability for the drug to permeate epithelial barriers (intestinal, nasal, 1780 
pulmonary).[444] Thus, in fact they are used to modulate the overall efficacy of a drug and are, therefore, major 1781 
components in so-called modified release (MR) drug delivery systems. Based on the solubility and permeability of 1782 
an API, a Biopharmaceutical Classification System (BCI) has been introduced grouping the APIs into 4 classes 1783 
(I to IV).[445] According to FDA, an API is for instance highly soluble when its highest clinical dose strength is soluble 1784 
in 250 mL of aqueous media over a pH range of 1 to 7.5 at 37.5 °C, and it is considered to be highly permeable if the 1785 
absorption of an orally administered dose in humans is > 90% when determined using mass balance or in 1786 
comparison to an intravenous reference dose.[446] Such API is referred to as a class I API and can be more easily 1787 
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delivered via e.g. an oral dosage form. For class II drugs (low solubility and high permeability) different formulation 1788 
strategies have to be applied to deliver them orally, e.g. as polymeric amorphous solid dispersion.[447] Related to 1789 
this, polymer matrix excipients can be classified as hydrophilic or hydrophobic matrices. The class of hydrophilic 1790 
matrices is dominated by different celluloses (most often hydroxypropyl methylcellulose, HPMC) and polysorbates 1791 
(both not subject of this review), but also PVP and PEG as synthetic polymers are used.  1792 
Due to the vast number of products on the market containing synthetic polymers as matrix excipients, herein only 1793 
an impression of the most superficial functions of each polymer class is provided followed by an arbitrary selection 1794 
of commercially available dosage forms. Often polymers can be included into formulations to fulfill several tasks 1795 
depending on the formulation technology. Therefore, assignment of a certain polymer or polymer class to a 1796 
particular function, dosage form or manufacturing process is difficult since it can perform different functions in 1797 
different dosage forms (Table 26). 1798 
Eudragit®. Different poly(methacrylate)s (Eudragits®) are most frequently applied as synthetic hydrophobic 1799 
matrices.[448] For instance, Eudragit® NE 30 D can serve as a coating material or can be processed into a tablet 1800 
formulation acting as matrix (with up to 20 wt%), e.g. by wet granulation or direct compression of powders. 1801 
The drug and other excipients are partially impregnated with the polymer. Subsequent compression results in 1802 
embedment of the drug in a sponge-like network of thin polymer layers. The polymer network controls the 1803 
penetration of digestive fluid into the tablet as well as the diffusion of the dissolved drug through the pores. In this 1804 
way, a time controlled release and pH value independent formulation for sustained-release formulation can be 1805 
realized. Eudragit® E PO (EE) is a cationic copolymer based on dimethylaminoethyl methacrylate, butyl 1806 
methacrylate, and methyl methacrylate (for exact composition, see Table 20). It is soluble in gastric fluid up to pH 5, 1807 
thus the drug release can be controlled to occur only in acidic environment. It is frequently used as a coating agent 1808 
due to its film forming capability, but also finds application as a binder in tablets prepared by direct compression in 1809 
10% to 50% concentration. The coating of solid oral dosage forms is highlighted separately in Chapter 3.4.1. 1810 
Carbomer. “Carbomers” (Carbopol™) are high molar mass poly(acrylic acid)s (PAA), sometimes cross-linked with 1811 
small amounts of allyl ethers of polyalcohols. The different numbers in the labels of carbomers (934, 934p, 1812 
940, 941) denote their different molecular sizes as well as the use of benzene during the manufacturing process. 1813 
If benzene is not used during the manufacture, carbomers of type a, b or c are distinguished according to the 1814 
viscosity of their solutions in water. They are most commonly used in cosmetic industry but also in tablet 1815 
formulations, in particular for oral mucoadhesive controlled drug delivery systems.[449] Carbomers can absorb large 1816 
amounts of water, thus increasing in volume up to 1,000 times to form gels and thick solutions that are stable and 1817 
resistant to spoilage. Usually, carbomers are provided as a dried, white powder. Carbomers are considered to be 1818 
generally regarded as safe by the FDA, although high concentrations may lead to eye and skin irritation. 1819 
Polycarbophil. Poly(acrylic acid) cross-linked with divinyl glycol is named polycarbophil. It is a bulk-forming laxative 1820 
that increases the amount of water in stools to make them softer and easier to pass. Polycarbophil is used to treat 1821 
constipation and to help to maintain regular bowel movements. It has been developed as pharmaceutical polymer 1822 
with superior bioadhesive properties used in the field of controlled drug delivery systems. It could be used as a 1823 
highly efficient thickener, bioadhesive agent, suspending aid and emulsion stabilizer when dispersed in water or 1824 
other polar solvents.[450] Polycarbophil can also be used as a controlled release polymer in oral solid dose 1825 
applications (e.g. Striant®). Typical usage levels for achieving controlled release characteristics in tablets 1826 
manufactured by aqueous granulation are 5 wt% to 10 wt%, depending on the drug properties, co-excipients and 1827 
processing parameters. 1828 
Dimethicone. Poly(dimethylsiloxane) (PDMS) is widely used under the name “dimethicone”’ as lubricant and 1829 
conditioning agent, but is also present in tablet capsules (e.g. Keflex®). An orally administered dosage form is the 1830 
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over-the-counter drug “simethicone” (mixture of 90% to 99% of PDMS with siliciumdioxide, see Chapter 3.6). 1831 
It is also used as excipient in tablets and capsules (e.g. Antara®). The presence of PDMS was found in many 1832 
registered drugs, including familiar ones such as AugmentinTM, Maalox®, and VapoSteamTM, just to name a few 1833 
examples. 1834 
Poly(ethylene glycol) (PEG). PEG is frequently used as stealth polymer covalently coupled to drugs (Chapter 3.1) or 1835 
in micro- and nanoparticulate drug delivery systems (Chapter 3.2),[15] but also as matrix excipients in oral and 1836 
parenteral dosage forms and more.[451] PEG is mainly added to solubilize poorly water soluble drugs to enhance 1837 
their bioavailability and to reduce inter-subject variability of plasma concentrations. In particular, clear liquid PEG 1838 
with low molar masses (Mn) of 300 to 600 g mol
-1 is frequently used to solubilize poorly water soluble drugs in soft 1839 
gelatin or HPMC capsules for oral application (e.g. Cetirizine capsules) and for almost all parenteral formulations 1840 
(e.g. Robaxin®, Ativan®). PEG with molar masses (Mn) exceeding 4,000 g mol
-1 is found in hard shell capsules, which 1841 
is related to the administered drugs and the required stability of the capsules during passage.[452] Another reason is 1842 
that the solubility of most drugs in PEG drops significantly upon dilution with water (leading to re-precipitation of 1843 
the drug). Therefore, also surfactants are often added, which reduce the risk of precipitation of the drug from the 1844 
PEG solution (e.g. phosphadidylcholine or polysorbat 80). Other solubility enhancers are further added to increase 1845 
the solubility of drugs in PEG. These are commonly used ionizing agents; for acidic compounds (e.g. ibuprofen or 1846 
naproxen) bases are added and for basic compounds (e.g. thioridazin or ranitidine) acids. Furthermore, hydrophilic 1847 
polymers (e.g. povidone or cellulose derivatives) are added for the same reason. Administration of capsules results 1848 
in increased rates of absorption and faster achievement of maximum plasma concentration, as shown for instance 1849 
for the Ibuprofen containing soft gel capsules Spalt-Liqua® compared to a standard tablet formulation.[453] 1850 
PEG (i.e. PEG 1000 and PEG 540) serves as a formulation base for some suppositories to dissolve the active 1851 
substance in order to allow enhanced bioavailability by facilitating effective and complete release of the active 1852 
substance in the body. Rather high molar mass PEGs are used to coat suppositories, providing elasticity and 1853 
lubricity. 1854 
Poloxamer. Poloxamers represent another important group in the field of polymer excipients, which are triblock 1855 
amphiphilic copolymers of the structure PEG-b-PPG-b-PEG (also known as Pluronic® from BASF). They are used for 1856 
drug delivery as formulation excipients. They act as surfactants, emulsifying agents, solubilizing agents, dispersing 1857 
agents, and as in vivo absorbance enhancers. They are also used in topical dosage forms, rectal suppositories, for 1858 
the modification of the surface of hydrophobic drugs,[454] for drug delivery,[455] as micelles and micellar drug 1859 
formulations for gene delivery,[456] and as components in formulations for transdermal drug delivery.[457] Because of 1860 
the different customized block-lengths in the copolymers various poloxamers exist. Due to their inertness, a few 1861 
poloxamers are on the rather tight list of excipients that were officially approved by the European Pharmacopoeia 1862 
as well as the U.S. Pharmacopoeia even for human parenteral administration acting as dispersing, emulsifying and 1863 
coemulsifying excipient, as tablet lubricant or wetting agent. 1864 
Poly(vinyl pyrrolidone) (PVP). PVP, also known as “povidone”, is used in the pharmaceutical industry as a synthetic 1865 
polymer vehicle for dispersing and suspending drugs. It has multiple uses, including as a binder for tablets and 1866 
capsules, a film former for ophthalmic solutions, to aid in flavoring liquids and chewable tablets, and as an adhesive 1867 
for transdermal systems. In oral dosage forms it is also added as a wicking agent to facilitate the entry of water to 1868 
the inner surface of the core of the tablet by the formation of channels. A wide range of vinyl pyrrolidone 1869 
homopolymers (povidone k12 to k90) with different molar masses are also available from BASF under the name 1870 
Kollidon®. The k number refers to the mean molar mass of the PVP. The polymers with higher k-values (i.e. k90) are 1871 
not usually administered by injection since their high molar masses prevent excretion by the kidneys and lead to 1872 
accumulation in the body. The best-known example of PVP formulations is povidone-iodine, an important 1873 
disinfectant. “Crospovidones” (polyplasdones, polyvinylpolypyrrolidone) are synthetic, insoluble, cross-linked 1874 
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homopolymers of N-vinyl-2-pyrrolidone. They are insoluble in water, though they still absorb water and swell very 1875 
rapidly generating a swelling force. As a consequence, they are used as disintegrants and dissolution agents for 1876 
solid oral dosage forms and are even effective for poorly soluble dosage forms. Such orally disintegrating tablets 1877 
have emerged as one of the novel solid oral dosage forms with the potential to deliver a wide range of drug 1878 
candidates.[458] PolyplasdoneTM XL crospovidone (Ashland) is a commonly used polyplasdone. 1879 
Poly(vinyl alcohol). Poly(vinyl alcohol) (PVA) as a water-soluble synthetic polymer is used to increase viscosity in 1880 
pharmaceuticals but also as a lubricant and protectant in ophthalmic preparations (known as “artificial tears”).[459] 1881 
PVA is often found in over-the-counter eye redness and eye lubricant drops (Liquifilm Tears). PVA is the lubricant, 1882 
and works by providing moisture to the eye, which helps to relieve dryness and protects the eye from becoming 1883 
more irritated sometimes in combination with, for instant, phenylephrine. 1884 
 1885 
Table 26. Selected examples of synthetic polymers as matrix excipients. 1886 
TRADE NAME POLYMER SYSTEM 
PREDOMINANT DOSAGE 
FORMS USED IN … 
FUNCTION IN DOSAGE FORMS AS  
MATRIX EXCIPIENT 
Eudragit® P(MAA-co-MMA) Oral Film former, tablet binder, tablet diluent 
Carbomer/Carbopol
TM
 PAA Ophthalmic 
Mucoadhesive , viscosity enhancer, thickening 
agent 
Polycarbophil 
Poly(acrylic acid) cross-linked with 
divinyl glycol 
Oral, vaginal gels Mucoadhesive 
Dimethicone PDMS Oral Antifoaming agent, emollient 
Poly(ethylene glycol) PEG Oral, parenteral, rectal 
Ointment base, plasticizer, solvent, suppository 
base, tablet and capsule lubricant, mucoadhesive, 
tablet binder, thickening agent 
Poloxamer/Pluronic® PEG-b-PPG-b-PEG Parenteral 
Dispersing agent, emulsifying and coemulsifying 
agent, solubilizing agent, tablet lubricant, wetting 
agent, non-ionic surfactant 
Povidone PVP Oral, ophthalmic 
Disintegrant, dissolution aid, suspending agent, 
tablet binder 
Crosspovidone 
Polyvinylpolypyrrolidone  
(highly cross-linked povidone) 
Oral Tablet disintegrant 
Copolyvidone P(VP-co-VAc) Oral Film-former, granulating agent, tablet binder 
Poly(vinyl alcohol) PVA Ophthalmic Viscosity enhancer, lubricant & protectant 
 1887 
3.5.1 Oral dosage forms 1888 
Oral drug delivery combines several advantages and is, as already described, the most frequently used route for 1889 
introducing drugs into the body.[460] The drug absorption depends on different factors making this process a 1890 
complex one. One important issue is the solubility of the API’s in the GI fluids to enable oral absorption (see coating 1891 
of solid oral dosage forms, Chapter 3.4.1). Indeed, more than 50% of potential new drug candidates are expected to 1892 
be lipophilic and have poor aqueous solubility.[461] In recent years, polymeric excipients have been widely used to 1893 
overcome low solubility and formulation difficulties. Furthermore, various new solid formulations have been 1894 
developed using technologies that involve polymer excipients. Selected examples of commercial oral drug 1895 
formulations containing different synthetic polymers as matrix excipients are summarized in Table 27. Further oral 1896 
products containing PEGs are nicely summarized by Gullapalli et al..[451a] 1897 
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Table 27. Selected examples of oral drug formulations on the market containing different synthetic polymers as matrix excipients. 1898 
NAME DRUG
[a]
 POLYMER SYSTEM INDICATION/ USE MANUFACTURER 
Diethylpropion Diethylpropion hydrochloride 
Carbomer homopolymer 
type a 
Treatment of obesity (anorexiant) Lannett 
Metformin Metformin hydrochloride Carbopol® 974P NF 
Blood sugar control in people with type 
2 diabetes 
Aurobindo 
Pharma Limited 
Alfuzosin Alfuzosin hydrochloride 
Carbomer homopolymer 
type b 
Benign prostatic hyperplasia 
Aurobindo 
Pharma Limited 
Macrobid® Nitrofurantoin Carbomer 934
[b]
 Urinary tract infection 
Norwich 
Pharmaceuticals 
Striant® Testosterone Polycarbophil Treatment of hypogonadism 
Columbia 
Laboratories 
Keflex® Cephalexin Dimethicone 
Bacterial infection, skin or soft tissue 
infection, bladder infection, upper 
respiratory tract infection 
Advancis 
Pharmaceutical 
Antara® Fenofibrate Simethicone 
Lowering high cholesterol & 
 triglyceride levels in the blood 
Lupin 
Zarontin® Ethosuximide PEG 400
[c]
 
Prevention and control of a certain type 
of seizure 
Pfizer 
Advil® Ibuprofen PEG 600 
Pain relief for headaches, migraines & 
minor arthritis 
Pfizer 
Lybrel® 
Ethinyl estradiol/ 
levonorgestrel 
PEG 400, PEG 1450 
Abnormal uterine bleeding, birth 
control, ovarian cysts, endometriosis, 
polycystic ovary syndrome 
Wyeth 
Augmentin
TM
 Amoxicillin/clavulanic acid 
PEG 4000, PEG 6000,  
dimethicone 
Antibiotic (beta-lactamase inhibitors) 
for short term treatment of a wide 
range of infections caused by bacteria 
GlaxoSmithKline 
Lipofen® Fenofibrate PEG 8000, PEG 20000 
Primary hypercholesterolemia,  
mixed dyslipidemia, severe 
hypertriglyceridemia 
Cipher
TM
 
Maalox® 
Aluminium & magnesium 
hydroxide/calcium carbonate 
Simethicone 
Acid indigestion, heartburn & 
sour stomach 
Novartis 
VapoSteam
TM
 Camphor PDMS, poloxamer 124
[d]
 Cold symptoms Vick 
Alprazolam Alprazolam 
Poloxamer 188  
(Pluronic F 68) 
Anxiety, panic disorder, depression, 
tinnitus, dysautonomia 
TEVA 
Accretropin
TM
 
Somatropin  
(recombinant human growth 
hormone (r-hGH)) 
Poloxamer 188 
(Pluronic F 68) 
Pediatric growth hormone deficiency, 
Turner syndrome 
Cangene 
Corporation 
Famciclovir 
Famciclovir (guanosine 
analogue antiviral drug) 
Poloxamer 407  
(Pluronic F 127 NF) 
Herpes zoster, herpes simplex Apotex 
Endocet® Acetaminophen/oxycodone Povidone Chronic pain Endo® 
Naproxen Naproxen Povidone 
Back pain, ankylosing spondylitis, 
sciatica, bursitis, tendonitis 
TEVA 
Cetirizine Cetirizine hydrochloride Povidone k29/32 Allergic rhinitis, urticaria Northstar Rx LLC 
Tinidazole Tinidazole Povidone k12 
Bacterial vaginitis, trichomoniasis, 
giardiasis, amebiasis 
Roxane 
Laboratories 
Adenovirus 
vaccine 
 Plasdone C (PVP) Adenovirus type 4 & type 7 vaccination Barr Labs 
Isoptin® SR Verapamil hydrochloride PEG, Povidone 
Cluster headaches, migraine 
prevention, arrhythmia, high blood 
pressure 
Ranbaxy 
Pharmaceuticals 
Opana® ER Oxymorphone PVA, PEG Narcotic analgesic Endo® 
BuPROPion Bupropion hydrochloride 
PVA, copovidone, 
povidone 
SSRI induced sexual dysfunction, major 
depressive disorder, anxiety 
Actavis 
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[a] 
All mentioned drugs are used in various drug formulations. However, in most cases they do not comprise a polymeric matrix excipient; 1899 
[b]
 carbomer codes (e.g. 934) are an indication of molar mass and the specific components of the polymer; 
[c] 
PEG # (e.g. PEG 400) indicates the 1900 
average molar mass of the specific PEG (i.e. 400 g mol
-1
); 
[d] 
the first two digits code the molar mass of the PPG core, and the last digit codes the 1901 
PEG content. 1902 
 1903 
3.5.2 Parenteral dosage forms 1904 
Parenteral dosage forms describe all forms of administration avoiding any part of the gastrointestinal tract. 1905 
The advantages of parenteral injection through the skin or other external boundary tissue are immediate systemic 1906 
drug availability and rapid onset of action, as well as a long-term drug delivery by the formation of a depot or 1907 
reservoir at the injection site. The sustained release of the drugs results from its long-acting property and its 1908 
residence in the blood stream or the bone. However, the use of excipients for injectable drugs is more limited than 1909 
for oral administration.[462] The application of novel excipients or the increase of their established concentration 1910 
requires additional safety studies, which impedes the continuous progress of novel matrix excipients. 1911 
Therefore, the well-established PEG is still the method of choice for polymeric excipients (Table 28).[451a] 1912 
In comparison to compounds that are soluble and stable in a PEG vehicle (formulation as solution), insufficient 1913 
solubility requires the formulation as suspension. Therefore, higher molar mass PEGs are used as suspending 1914 
agents (viscosifying) to prevent setting of the dispersed material and to maintain homogeneity. 1915 
 1916 
Table 28. Selected examples of parenteral drug formulations on the market containing PEG as matrix excipients. 1917 
TRADE NAME DRUG POLYMER SYSTEM INDICATION/ USE MANUFACTURER 
Solutions 
VePesid® Etoposide PEG 300
[a]
 Antineoplastic Bristol-Myers Squib 
Robaxin® Methacarbamol PEG 300 
CNS depressant,  
musculoskeletal relaxant 
Wyeth 
Busulfex®  
(Myleran®) 
Busulfan PEG 400 
Preparatory regimen prior to 
allogeneic hematopoietic progenitor 
stem cell transplantation 
Otsuka Pharmaceutical 
Ativan® Lorazepam PEG 400 Antianxiety, anticonvulsant Biovail Laboratories 
Persantine® Dipyridamole PEG 600 Coronary vasodilator 
Boehringer Ingelheim 
(disc.) 
Extended-release suspensions 
Bioclate
TM
 
Antihemophilic  
factor VIII 
PEG 3350 
Prevention of bleeding episodes in 
persons with hemophilia A, control 
the bleeding related to surgery or 
dentistry in a person with hemophilia 
Baxter Healthcare, 
Genetics Institute 
Depo-Provera® 
Medroxyprogesterone 
acetate 
PEG 3350 Contraception Pfizer 
Depo-Medrol Lidocaine® 
Methylprednisolone 
acetate, lidocaine 
PEG 3350 
Osteoarthritis, rheumatoid arthritis, 
acute & subacute bursitis 
Pfizer 
Aristocort® Forte Triamcinolone PEG 3350 
Asthma, atopic dermatitis, drug 
hypersensitivity reactions 
Sandoz 
Invega Sustenna® Paliperidone palmitate PEG 4000 Schizophrenia Janssen 
[a] 
PEG # (e.g. PEG 300) indicates the average molar mass of the specific PEG (i.e. Mn = 300 g mol
-1
). 1918 
 1919 
3.5.3 Rectal, vaginal and urethral dosage forms 1920 
Suppositories. Suppositories are one type of solid dosage forms and can be administered rectal,[463] vaginal,[464] and 1921 
to a much lesser extent, urethral. Although there are different suppository types, the systemic absorption is limited 1922 
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to the rectal absorption, while the other two forms are mainly intended for local action. The rectal route is the 1923 
method of choice if the oral dosage is not possible because of nausea, incapability of swallowing, or if the patient is 1924 
unconscious. Different advantages and disadvantages of rectal administration have been nicely summarized by 1925 
Vora and AliChisty.[463] The suppositories should melt or dissolve in the respective fluids in order to release the 1926 
drug. Depending on the drug and the site of action different “suppository bases” are used, mainly fatty and 1927 
oleaginous bases as well as water soluble and water miscible bases. Whereas the former ones are mostly derived 1928 
from cocoa butter (also cottonseed oil, vegetable oils) the latter ones contain reasonable amounts of various PEGs 1929 
of different molar masses (Table 29).[463] Certain PEG polymers may be used singly as suppository bases, but more 1930 
commonly, formulas call for compounds of two or more molar masses mixed in various proportions as needed to 1931 
yield a finished product of satisfactory hardness and dissolution time. Since the water miscible suppositories 1932 
dissolve in body fluids and need not be formulated to melt at body temperature, they can be formulated with much 1933 
higher melting points and thus may be safely stored at room temperature. 1934 
 1935 
Table 29. Selected examples of suppositories on the market containing PEG as matrix excipients. 1936 
TRADE NAME DRUG POLYMER SYSTEM INDICATION/ USE MANUFACTURER 
Rectal 
THE MAGIC BULLET
TM
 Bisacodyl PEG Relief of occasional constipation Concepts in Confidence, USA 
Acephen
TM
 Acetaminophen PEG 100 stearate
[a]
 
Reduction of fever, relieve minor aches, 
pains & headache 
G & W Laboratories 
Indocin® Indomethacin PEG 3350,PEG 8000 
Severe rheumatoid arthritis, ankylosing 
spondylitis, osteoarthritis, gouty arthritis 
G & W Laboratories 
Numorphan® Oxymorphone PEG 1000, PEG 3350 Relief of moderate to severe pain Endo® 
Vaginal 
AVC Sulfanilamide PEG 400, PEG 3350 Treatment of Candida albicans infections Monarch 
Encare® Nonoxynol-9 PEG Contraception Thompson Medical 
Endometrin® Progesterone PVP Help to become & stay pregnant Ferring 
Urethral 
MUSE® Alprostadil PEG 1450, PEG 400 Treatment of erectile dysfunction (male) Meda Pharmaceuticals 
[a] 
PEG # (e.g. PEG 100) indicates the average molar mass of the specific PEG (i.e. Mn = 100 g mol
-1
). 1937 
 1938 
Gels. Gels have been established as useful dosage form for vaginal applications of different drugs endowed with 1939 
moisturizing and lubrication effect, physiological pH restoring effect, as contraceptive, and as labor inducer.[465] 1940 
They represent semi-solid systems comprising small amounts of solid, dispersed in a large volume of liquid. 1941 
Gels show several advantages over other vaginal drug delivery systems such as higher bioavailability, safety, 1942 
versatility, and economical savings.[466] Among the common natural derivatives (cellulose, chitosan etc.), 1943 
PAA derivatives are mainly used as synthetic polymeric excipients (Table 30). Thanks to the high content in water, 1944 
gels based on mucoadhesive polymers, without addition of drugs, are proposed for moisturization of the vagina in 1945 
cases of vaginal dryness. Such Vaginal gels contain polycarbophil that forms the basis of well-consolidated 1946 
marketed products (e.g. Replens®, Miphil®).[467] 1947 
 1948 
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Table 30. Selected examples of vaginal gels on the market containing different synthetic polymers as matrix excipients. 1949 
TRADE NAME DRUG POLYMER SYSTEM INDICATION/ USE MANUFACTURER 
Zidoval® Metronidazole Carbomer 974P
[a]
 Bacterial vaginosis Meda Pharmaceuticals 
Metrogel® Metronidazole Carbomer 934P 
Inflammatory papules & pustules of 
rosacea 
Galderma 
Replens®  Polycarbophil Vaginal dryness Church & Dwight 
RepHresh® 
(Miphil®) 
 Polycarbophil Vaginal dryness, bacterial vaginosis Sanol 
Advantage S Nonoxynol-9 Carbomer 934P, polycarbophil Contraception Columbia Laboratories 
Crinone® Progesterone Carbomer 934P, polycarbophil 
Infertile women with progesterone 
deficiency, secondary amenorrhea 
Watson 
Conceptrol® Nonoxynol-9 Povidone Contraception Revive 
[a] 
Carbomer codes (e.g. 974P) are an indication of molar mass and the specific components of the polymer. 1950 
 1951 
3.5.4 Ophthalmic dosage forms 1952 
Typically, gels with high water content but with certain viscosity are applied in ophthalmic drug formulations. 1953 
To impart a high viscosity and a water content > 90%, in particular carbomers/carbopolsTM[468] and poloxamers[469] 1954 
are used (Table 31). The polymers have to prolong the contact time on the ocular surface and to slow down the 1955 
drug elimination. Eye drops represent an alternative dosage form to achieve therapeutic concentrations of drugs in 1956 
ocular tissues. Thereby, the topical administration is effective for molecules with poor ocular uptake or poor 1957 
efficacy-to-safety ratio when given systematically. The poor bioavailability and therapeutic response exhibited by 1958 
conventional ophthalmic solutions due to pre-corneal elimination of the drug may be overcome by the use of in situ 1959 
gel forming systems. In situ gelling systems increase the viscosity by changing the pH value or temperature in the 1960 
pre-corneal region and lead to an increase of drug bioavailability by slowing drainage. Poloxamers possess thermal 1961 
gelling properties and are frequently included in ophthalmic formulations to improve the ocular bioavailability of 1962 
drugs by increasing the viscosity.[470] Future prospects are the delivery of peptides and proteins with the help of 1963 
stimuli-responsive polymers.[471] 1964 
 1965 
Table 31. Selected examples of ophthalmic drug formulations on the market containing different synthetic polymers as matrix excipients. 1966 
TRADE NAME DRUG POLYMER SYSTEM DOSAGE FORM INDICATION/ USE MANUFACTURER 
Pilopine HS® 
Pilocarpine 
hydrochloride 
Carbopol 940 Gel 
Control intraocular 
pressure 
Alcon 
Laboratories 
Zirgan® Ganciclovir Carbomer Gel 
Acute herpetic keratitis 
(dendritic ulcers) 
Bausch & Lomb 
RESTASIS® Cyclosporine Carbomer copolymer type A Emulsion Chronic dry eye Allergan 
AzaSite® Azithromycin 
Poloxamer 407/ 
polycarbophil (DuraSite®) 
Solution Bacterial conjunctivitis Akorn 
ALREX® 
loteprednol 
etabonate 
Povidone Suspension 
Seasonal allergic 
conjunctivitis 
Bausch & Lomb 
Refresh Redness 
Relief® 
Phenylephrine 
hydrochloride 
PVA Solution Eye redness & dryness Allergan 
 1967 
 1968 
 1969 
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3.6 Polymeric drugs 1970 
 1971 
Polymers that act as pharmaceutically active ingredients are relatively rare. Besides several attempts already in the 1972 
1960s, poly(ethylene sulfonate) and poly(maleic anhydride-co-divinylether) (DIVEMA) were studied for their 1973 
effects, e.g. as anti-tumor agents, but failed due to toxicity issues. The pharmaceutical industry remarked strong 1974 
doubts that a polymer can be a therapeutic agent in diseases where small molecules failed.[472] Major concerns 1975 
were the presumably high dispersity (Ð) and the structural heterogeneity, in particular with regard to regulatory 1976 
issues. However, in the last years a new market grew up with polymeric drugs that are approved and have defined 1977 
and well-characterized structural features. The polymer characteristics but also the administration routes strongly 1978 
influence the therapeutic effect of the polymeric drugs. 1979 
 1980 
Polymeric sequestrants. One field of application is the removal of detrimental species from the gastrointestinal (GI) 1981 
tract in a selective manner. Such polymeric sequestrants work as therapeutic agents and are able to bind and 1982 
subsequently eliminate harmful species that were either ingested or produced by the human body itself. These 1983 
polymers are usually ion exchange resins in the form of hydrogels that are not adsorbed by the GI tract. For the 1984 
treatment of hyperkalemia (i.e. high levels of potassium ions in the serum, which can cause abnormal heart 1985 
rhythms and other health problems), a sodium polystyrene sulfonate (Kayexalate®) is used as cation-exchange resin 1986 
since decades (Table 32).[473] However, the high levels on resulting sodium may cause other critical effects.[474] 1987 
Recently, Valtessa® was approved as a new medication to treat hyperkalemia.[475] This cross-linked polymer based 1988 
on calcium 2-fluoroprop-2-enoate, divinylbenzene and octa-1,7-diene (also named patiromer) with a calcium-1989 
sorbitol counterion is established as a formulation of 100 µm beads.  1990 
Patients suffering from chronic or end-stage renal diseases often have elevated serum phosphate concentrations 1991 
(hyperphosphatemia) that can be treated with sevelamer hydrochloride marketed under the brand name Renagel®, 1992 
which is a poly(allylamine) cross-linked with epichlorohydrin (Figure 24).[476] Comparing to this, Renvela®, 1993 
a sevelamer carbonate, shows fewer side effects. Bile acid sequestrants are one strategy in the treatment of 1994 
elevated cholesterol levels. Cholestyramine (quarternized ammonium groups attached to poly(styrene-co-1995 
divinylbenzene)) and colestipol (copolymer of diethylenetriamine and epichlorohydrin) are polymeric therapeutics 1996 
that bind bile acid, which is necessary for the production of cholesterol 1997 
in the liver, but both therapeutics lack on low clinical efficiency.[477] 1998 
Besides diverse other amine containing cross-linked polymers that 1999 
entered clinical trials, Colestilan (poly(2-methylimidazol-co-2000 
(chlormethyl)oxiran) and Colesevelam hydrochloride (poly(allylamine) 2001 
with 1-chloro-2,3-epoxypropane, (6-(allylamino)-2002 
hexyl)trimethylammonium chloride and N-allyldecylamine) are already 2003 
on the market and show better performances as bile acid sequestrants 2004 
for the treatment of hypercholesterolemia.[478] Micronized 2005 
crospovidone can be used in the treatment of diarrhea based on its 2006 
ability to form complexes with toxins.[164b] 2007 
For binding and removing toxins, originating e.g. from bacteria, such 2008 
ion exchange resins are not efficient enough. More specific binding sides are necessary to reach multivalency. 2009 
Tolevamer®, a high molar mass poly(styrene sulfonic acid), is such a toxin binder that is used to treat diarrhea.[479] 2010 
However, this alternative to antibiotics failed in final clinical trials. The concept of multivalency is also used in 2011 
research for the treatment of viruses, but none of them did reach the market yet. For example, specific peptides, 2012 
that are conjugated to different polymer backbones, are able to protect cells from the anthrax toxin action.[480] 2013 
A linear poly(acrylamide) bearing the C-glycoside of sialic acid shows antiviral activity against the influenza virus.[481] 2014 
As preventional medicine for HIV infections, a naphthalene sulfonate polymer (PRO-2000®) was developed but also 2015 
 
Figure 24. Schematic representation of the 
chemical structure for sevelamer, a 
poly(allylamine) cross-linked with epichlorohydrin 
(hydrochloride: Renagel®, carbonate: Renvela®). 
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failed in clinical phase studies.[482] The development of fat binding hydrogel-like polymers for the treatment of 2016 
human obesity is also a growing area of research. Such polymers should inhibit fat hydrolysis and absorb 2017 
unhydrolyzed fat droplets. They are based on e.g. poly(acrylamide)s, poly(meth)acrylates and other polymers that 2018 
contain both cationic and hydrophobic moieties.[483] An even higher efficiency is aimed by additional conjugation of 2019 
a lipase inhibitor to the polymer backbone (GT 389-255).[484] 2020 
Dimethicone (PDMS) and Espumisan® (dimethicone compounded with 4 to 7% silicone dioxide) are used as active 2021 
pharmaceutical ingredients (API) in medicinal products such as chewable tablets, granulations, tablets, capsules, 2022 
suspensions and drops.[485] These polymers are used in gastroenterology to relieve flatulence, tension in stomach, 2023 
bowel colic and gastric ulceration due to their anti-foaming and anti-flatulent properties.[486] 2024 
Moreover, simethicone can be used prior to upper GI endoscopy to reduce the amount of air bubbles and foam.[487] 2025 
This increases the visibility during the procedure and provides the possibility of more accurate evaluation of the 2026 
mucosa and consequently decreases the endoscopy duration. 2027 
 2028 
Synthetic analogues of antigens. There are basically only very few polymeric drugs that are not related to 2029 
sequestration of small molecules. They act as synthetic analogues of specific disease-associated antigens for 2030 
systemic therapy. The first developed drug as such is glatiramer acetate (also known and marketed as Copaxone®). 2031 
Glatiramer acetate is a copolymer of four L-amino acids (alanine, lysine, glutamic acid, and tyrosine in a molar ratio 2032 
of 4.2 : 3.4 : 1.4 : 1.0) that are randomly copolymerized in a ring-opening polymerization of the corresponding 2033 
amino acid anhydrides.[488] Glatiramer acetate acts via immunomodulation of pathways involved in the 2034 
pathogenesis of multiple sclerosis. However, the complete mode of action is not yet fully understood. 2035 
Patients suffering from multiple sclerosis demonstrate a significant decrease in the number of relapses and rate of 2036 
progression when treated with glatiramer acetate. A recent study also shows a reduction of symptoms in patients 2037 
with the Rett syndrome.[489] There was also a clinical trial where age-related macular degeneration could 2038 
successfully be treated with glatiramer acetate.[490] The most recent research goes to other poly(amino acid) 2039 
combinations that might also show a high potential as drugs for modulating immune responses.[491] 2040 
 2041 
Miscellaneous polymeric drugs. Another polymeric drug is the commonly used highly purified non-ionic surfactant 2042 
poloxamer 188, a block copolymer consisting of PEG-b-PPG-b-PEG (Pluronic® F-68). It is used in treating sickle cell 2043 
disease to reduce inflammation and pain.[492] Clinical trials showed rheologic, cytoprotective, anti-adhesive and 2044 
antithrombotic effects that help to reduce the overall duration of painful episodes of patients suffering from the 2045 
sickle cell disease. The trials passed phase III (NCT00004408) but the drug (Flocor®) did not come to the market yet. 2046 
An innovative approach is the PolyHealTM technology, using negatively charged microspheres (~ 5 µm). They consist 2047 
of nonbiodegradable, medical grade polystyrene (PS) in a suspension of serum-free nutrient medium. Cells and 2048 
macromolecules are able to attach to the surface of the microspheres and to participate in the wound healing 2049 
process. Further polymer-based wound healing dressings have been nicely summarized by Ghadi et al..[493] 2050 
 2051 
Table 32. Selected examples of polymeric drugs on the market. 2052 
TRADE NAME POLYMER SYSTEM INDICATION/USE MANUFACTURER 
Kayexalate® 
Cross-linked sodium poly(styrene 
sulfonate) 
Hyperkalemia Sanofi 
Valtessa® 
Cross-linked calcium 2-fluoroprop-2-
enoate, divinylbenzene, octa-1,7-diene 
(patiromer) 
Hyperkalemia Relypsa 
Renagel® 
Cross-linked poly(allylamine) 
(sevelamer hydrochloride)  
Hyperphosphatemia Sanofi (Genzyme) 
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Renvela® 
Cross-linked poly(allylamine) 
(sevelamer carbonate) 
Hyperphosphatemia Sanofi (Genzyme) 
BindRen® 
(Colestilan) 
Cross-linked poly(2-methylimidazol-co-
(chlormethyl)oxiran) 
Hypercholesterolemia Mitsubishi Tanabe Pharma 
Welchol®, Cholestagel® 
(Colesevelam)  
Cross-linked poly(allylamine) Hypercholesterolemia Sanofi (Genzyme) 
Espumisan® PDMS (simethicone) Flatulence Berlin-Chemie 
Copaxone® Glatiramer acetate Multiple sclerosis TEVA 
PolyHeal
TM
 PS Wound healing TEVA 
 2053 
4. Future prospects and concluding remarks 2054 
Besides the previously described systems on the market or in clinical trials, a large variety of polymer-based 2055 
materials are currently under preclinical investigations, and these materials show immense potential concerning 2056 
drug delivery applications. In the following chapter, we highlight a few exemplarily chosen systems used for 2057 
pharmaceutical applications, which in our opinion hold an enormous potential and will certainly be in forthcoming 2058 
clinical studies.  2059 
Polymer-drug conjugates. Although polymer-drug conjugates are under investigation for several decades now, the 2060 
research interest in this field is still unabated. PEGylation has certainly dominated the area so far, but increasing 2061 
concerns about its immunogenicity have promoted the development of new polymers and their conjugates. Some 2062 
of these materials already reached the stage of clinical testing (conjugates of poly(N-(2-2063 
hydroxypropyl)methacrylamide (PHPMA), poly(2-oxazoline) (POx), see Chapter 3.1.2), and based on their 2064 
performance more conjugates are currently in preclinical studies. The latest investigations, however, focused on 2065 
the development of biodegradable polymers such as polyphosphoesters to substitute the nondegradable PEG. In 2066 
the following some of the most promising systems are described. 2067 
Nondegradable polymers for drug conjugates. Among the vinyl based materials prepared by radical 2068 
polymerizations PHPMA had certainly the highest impact on the area of polymer-drug conjugates. Due to the good 2069 
compatibility and shielding capacity it is no surprise that more studies are ongoing. Besides the previously 2070 
described drug conjugations, PHPMA has, e.g., successfully been conjugated to NPC1161 (8-[(4-amino-1-2071 
methylbutyl) amino]-5-[3,4-dichlorophenoxy]-6-methoxy-4-methylquinoline), an 8-aminoquinoline analog with 2072 
anti-leishmanial activity, and already passed successfully preclinical studies (in vivo).[494] In combination with 2073 
N-acetylmannosamine (ManN) in the side chains, this polymer conjugate represents a promising candidate for 2074 
clinical studies with reduced toxicity and increased efficiency of anti-leishmanial drugs for the treatment of visceral 2075 
leishmaniasis. Mannose-grafted systems allow a selective delivery of anti-leishmanial drugs and a maximization of 2076 
the potential of the drug to destroy the parasite at the site where it resides by mimicking the invasion process 2077 
(mannose-dependent receptor-mediated endocytosis). 2078 
Further candidates based on vinyl polymers, which are close to be tested in clinical studies, rely on established 2079 
systems, such as the Dynamic PolyConjugate (DPC) products: ARC-F12 (thrombosis, angioedema, inhibits the 2080 
production of factor 12), ARC-LPA (cardiovascular diseases, reduces the production of apolipoprotein A), and 2081 
ARC-HIF2 (clear cell renal cell carcinoma, first candidate to target tissue outside of the liver).[495]  2082 
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During the last two decades, the class of POx has gained increasing attention for biomedical and drug delivery 2083 
applications. Besides the already mentioned first POx conjugate (SER-214) under clinical investigations, several 2084 
studies deal with the conjugation to drugs or proteins. The first report on a protein coupled to POx was published in 2085 
1990 by Miyamata et al..[496] Preparing POx with a carboxylic acid as end-group allowed to attach the polymer to 2086 
amine groups of the protein (lysine groups) using DCC/NHS chemistry. Other publications also show the increasing 2087 
thermal stability,[497] as well as a decreasing rate of aggregation[498] using POx ligated proteins. The coupling of 2088 
carboxy functionalized POx using NHS chemistry is the most common reaction for protein conjugation,[499] 2089 
alongside using pyromelitic anhydride,[500] CuAAc,[501] reductive amination,[499b] native chemical ligation,[502] or the 2090 
direct reaction of a protein with the living chain end of the polymerization.[503] Luxenhofer et al. recently 2091 
summarized poly(2-oxazoline) drug and protein conjugates in different stages of their preclinical investigations.[113b] 2092 
An interesting feature of POx is the versatility of the various types of oxazolines allowing to alter the properties and 2093 
functionalities of the resulting polymers. For example, it was demonstrated that the cellular uptake can be 2094 
influenced by the choice of the oxazoline monomer and architecture[499a, 503] and in vivo investigations showed a 2095 
low immune response, as well as an increased circulation of 2096 
POxylated proteins.[504] Besides these protein conjugates, POx 2097 
was also conjugated to small molecule drugs in order to alter 2098 
their pharmacokinetics. The anticancer drug Ara-C[498] as well 2099 
as the antibiotic ciprofloxacin[505] showed similar behavior 2100 
when conjugated to PEtOx as comparable PEG conjugates. In 2101 
summary, it seems that in terms of biocompatibility and 2102 
pharmacokinetic POxylation and PEGylation have very similar 2103 
effects,[506] however, from a synthetic point of view the 2104 
properties of POx can be altered with relative ease compared 2105 
to PEG, just by changing the type of monomer used rendering 2106 
POx a highly versatile tool. 2107 
A further alternative are zwitterionic polymers, that are 2108 
mainly represented by polycarboxybetaine, polysulfobetaine 2109 
and poly(methacryloyloxyethyl phosphorylcholine) 2110 
(Figure 25). They are postulated to partially substitute the 2111 
current benchmark polymer for protein conjugates, PEG, and 2112 
to take a key role in the future of protein therapeutics.[507] 2113 
These polymers are able to maintain the stability of proteins 2114 
without diminishing their binding affinity, which represents a major improvement over the current PEGylation 2115 
technique. An interesting example for this class of polymers is the hyperbranched copolymer poly(3-ethyl-3-2116 
(hydroxymethyl)oxetane)-co-(carboxybetaine) which is used as a biomimetic material in drug delivery carriers.[508] 2117 
Another promising candidate is poly(carboxybetaine methacrylate) that was modified with the charged drug 2118 
DOX.[509] The resulting conjugate features a low cytotoxicity, prolonged circulation time and a controlled release of 2119 
DOX under mild acid conditions. Studies on tumor-bearing mice showed a tumor-inhibition rate of 55% without 2120 
resulting in any body weight loss which usually accompanies this treatment. As previously mentioned, zwitterionic 2121 
polymers are very promising materials to maintain the bioactivity of proteins. In this context, Chen and co-workers 2122 
synthesized a zwitterionic block copolymer poly(methyl acrylic acid-b-sulfobetaine methacrylate) to modify a 2123 
protein drug (uricase).[510] They demonstrated that the stability of the enzyme is improved without causing any 2124 
destructive effects on its bioactivity by the conjugation of a zwitterionic copolymer with a short poly(methyl acrylic 2125 
acid) block. 2126 
 
Figure 25. Schematic representation of the chemical 
structures of zwitterionic polymers: A) Poly(carboxybetaine) 
(R5 = COO
-
) and poly(sulfobetaine) (R5 SO3
-
); B) 
poly(methacryloyloxyethyl phosphorylcholine). 
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Degradable polymers for drug conjugates. Undoubtedly, the degradability in biological relevant environment or 2127 
at least the possibility for excretion of the applied polymers is a key aspect for their application in drug delivery. 2128 
As a consequence, the nondegradable nature of many polymer conjugates using PEG or PHPMA has certainly 2129 
hindered their progression towards market approval, although many of them have progressed into clinical 2130 
development. Despite the efficiency of these materials, the safety of their administration is of utmost importance, 2131 
and therefore it would not be surprising, if biodegradable polymer conjugates will have a much higher probability 2132 
of clinical success. 2133 
Polyphosphoesters (PPE) represent a promising class of polymers which is not only biocompatible, but also 2134 
degradable under physiological conditions. These alternatives have already been proposed as PEG substitutes in 2135 
polymeric prodrugs.[130, 132d, 511] The simple and versatile adjustment of the hydrophobicity and polyvalence by 2136 
attachment of different pendant ester groups of the variation of the backbone in PPEs allows the formation of fully 2137 
biodegradable polymer-drug or -protein conjugates (“PPEylation”[512]) as well as the encapsulation of different 2138 
drugs (e.g. low-molar-mass drugs, proteins, DNA, and plasmids) depending on the functionalities of the polymers. 2139 
Recently, Zhang et al. presented a novel drug system containing ultra-high levels of drug loading via covalent 2140 
attachment.[513] In this case, PEG-b-PPE-based paclitaxel (TXL) drug conjugates were synthesized by organocatalyst-2141 
promoted ring-opening polymerization (ROP) followed by click-reaction-based conjugation of PTX to the PPE block 2142 
of the copolymer. The resulting amphiphilic polymer forms micelles with a loading capacity of 65 wt% of PTX and 2143 
demonstrated to be effective against several cancer cell lines. In another study, dual pH-sensitive nanoparticles 2144 
(PPC-Hyd-DOX-DA) have been designed, which are able to reverse their surface charges when exposed to tumor 2145 
tissue to facilitate cell uptake.[514]  2146 
Polymers based on repeating ester units are another potential biodegradable class of polymers which is intensively 2147 
investigated for polymer-drug conjugate approaches and also possesses a wide range of functionalities and 2148 
properties.[515] Among them, polycarbonates have recently received 2149 
much attention for protein/peptide conjugation.[516] Hedrick and co-2150 
workers demonstrated the synthesis of functional polycarbonates by 2151 
ROP starting from the monomer pentafluorophenyl 5-methyl-2-oxo-2152 
1,3-dioxane-5-carboxylate (MTC-OC6F5, Figure 26). The active 2153 
pentafluorophenyl esters enable a substitution with suitable 2154 
nucleophiles such as alcohols and amines and, thus, the 2155 
functionalization with other active groups.[517] The versatility of this 2156 
approach was demonstrated by the preparation of numerous 2157 
functional polycarbonates, which are of particular relevance to 2158 
polymer-drug conjugates, including polycarbonates with PEG,[516] 2159 
hydroxyl-containing[518] and zwitterionic side-chains.[519] Recently, Cheng et al. reported an in vivo efficacy for the 2160 
first example of a polymeric therapeutic based on polycarbonates for the treatment of systemic methicillin-2161 
resistant Staphylococcus aureus (MRSA) infection. Other novel functional nanocarriers for biomedical applications 2162 
have been extensively reviewed by numerous research groups, highlighting these polycarbonate-based degradable 2163 
alternatives to PEG with minimal toxicity.[518, 520] 2164 
Micro- and nanoparticulate drug carriers. Although polymer-drug conjugates have certainly made a huge impact in 2165 
the research area of synthetic pharmapolymers, great promises have been expected from particulate drug carrier 2166 
systems. The versatility and diversity of potential materials used for their preparation allows a flexible design with 2167 
tailor made properties, which has certainly resulted in the success of various systems in clinical trials or on the 2168 
market. However, several issues still have to be addressed and the potential of these systems has by far not been 2169 
fully exploited. The transfer of degradability to nondegradable polymers often represents a missing link between 2170 
the design of advanced materials and their use in biomedical applications. To fulfill the criteria of degradability 2171 
 
Figure 26. Schematic representation of the chemical 
structure of pentafluorophenyl 5-methyl-2-oxo-1,3-
dioxane-5-carboxylate (MTC-OC6F5). 
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appropriate units have to be integrated into the main chain during the synthesis. Another big issue in the 2172 
application of particles, in particular microparticles, for drug delivery is the initial burst release.[521] This problem 2173 
can be overcome by choosing the optimal conditions for the formulation processing or by changing the properties 2174 
of the drug or the polymer itself to prevent polymer-drug separation. Doubtless, the main challenge is the targeted 2175 
delivery that is necessary for cancer and some other diseases to perform better than conventional medications. 2176 
An analysis of over 100 cancer studies has shown that in the average only 0.7% of injected particles reach their 2177 
targets.[522] And what is more surprising, this number did not change within the last 10 years. Reasons for this are 2178 
the increased immunogenicity and plasma protein adsorption in vivo, which masks the targeting molecules and also 2179 
results in decreased blood circulation times.[301] Consequently, targeted nanoparticles behave with the same or less 2180 
efficacy than untargeted particles. Even the often studied EPR effect only yielded poor delivery efficiency and 2181 
shows the lack of ‘proof-of-concept’ studies to be translated to patient care.[522] A better understanding of the in 2182 
vivo nanoparticle transport is necessary and can be accomplished by quantitative analysis with subsequent 2183 
collection of all the information in databases including organization and interpretation of the data also with the 2184 
help of computational tools. Such open excess databases are already established and supported by several 2185 
programs (e.g. DaNa2.0[523] and Cancer Nanomedicine Repository[524]). Only a translation from research to the 2186 
patient might stimulate the application of nanotechnology for treating human diseases as promised. 2187 
Solid colloidal dispersions. One strategy is the use of copolymers of PLGA and PEG making the particles more 2188 
hydrophilic and in consequence more suitable for protein delivery.[525] The hydrophilic domains facilitate a slow and 2189 
controlled release by diffusion. Further improvements on the release profiles and an additional increase in the 2190 
loading capacity could be achieved by a triblock copolymer system consisting of PLGA, PEG and poly(allyl glycidyl 2191 
ether); the latter can also be used to conjugate targeting ligands.[526] Several other systems based on these classic 2192 
release mechanisms of drugs (diffusion through water filled pores, diffusion through the polymer matrix, osmotic 2193 
pumping, and erosion) encapsulated in polymeric nano- and microparticles are currently still under intensive 2194 
investigation in in vitro, in vivo and preclinical studies.[527] However, besides these systems rapid progress has been 2195 
made in the development of stimuli-responsive nano- and microparticles as smart alternatives within the last 2196 
years.[528] In this case, the release can be triggered by internal (coming from the cells/tissue itself) or external 2197 
(coming from outside) stimuli. Such triggers can for example be temperature, light, ultrasound, pH-value, redox 2198 
environment, or specific biomolecules and enzymes.[528] The development of more efficient targeting structures 2199 
may further improve the efficiency of nano-/microparticles. For example, particles carrying siRNA and targeting 2200 
molecules are able to simultaneously attack numerous pathways.[529] The given examples display only a small 2201 
fraction of the numerous systems in development. The wide field of polymeric materials with countless variations 2202 
in constitution, conformation, configuration, and molar mass will definitely yield nano- and microparticles that have 2203 
the potential to show efficacy beyond the current products in clinical stages and on the market. However, a 2204 
translation from bench to bedside is more cost- and time efficient if the polymeric material is already used in 2205 
pharmaceutical products.[308] An interesting study shows the beneficial properties of doxorubicin (DOX) loaded 2206 
PLGA microparticles that could be used in transarterial chemoembolization (TACE) instead of recently developed 2207 
PLGA based microgels.[530] Such PLGA microparticles allow a re-entry into the tumor feeding arteries after an initial 2208 
TACE trial combined with higher drug release rates. A further important step is the development of a robust and 2209 
scalable process for the fabrication of micro-/nanoparticles with reproducible quality and the subsequent GMP 2210 
(good manufacturing practice) production in kilogram quantities. 2211 
An interesting alternative to PLGA is poly(caprolactone) (PCL), which has a slower degradation rate than PLGA 2212 
(up to one year), a high permeability for the diffusion of small molecules and does not generate an acidic 2213 
environment after degradation often causing the destabilization of proteins.[531] Up to now, PCL is most commonly 2214 
used in tissue engineering. Its use as therapeutic molecule delivery system is still limited since PCL carriers reveal in 2215 
many cases low encapsulation efficiency, burst release and low bioactivity. In contrast, besides its beneficial slow 2216 
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degradation rate, PCL is a rubbery at room temperature, which allows high permeability for many drugs. In recent 2217 
years, PCL-materials have been intensively investigated in in vitro and in vivo biocompatibility and efficiency studies 2218 
in order to deliver drugs, genetic materials and proteins. They have been nicely reviewed by Venkatraman and 2219 
co-workers.[532] One example is the encapsulation of chloramphenicol in PCL-Pluronic® composite nanoparticles 2220 
(CAM-PCL-NP). These systems exhibited significantly enhanced anti-MRSA (methicillin-resistant Staphylococcus 2221 
aureus) activity against ten clinical isolates of MRSA strains. Compared to free-chloramphenicol treatment, the 2222 
in vivo study of CAM-PCL-NPs in MRSA-infected burn-wound mice models revealed quicker efficiency in MRSA 2223 
clearance and an improved survival rate.[533] Preclinical studies of a further formulation named NC-6300 show 2224 
promising results in mice and are now under way for clinical studies in Japan.[534] In NC-6300, epirubicin is attached 2225 
via an acide-labile hydrazone bond to PEG-PAs, which can be beneficial due to a better controlled release kinetic. 2226 
Further attempts are also in the development of targeted drug delivery systems, which was already shown, 2227 
e.g. by attaching several anti-TF antibodies resulting in an enhanced antitumor activity against TF-high expressing 2228 
human pancreatic cancer cells, a subunit toolbox with insensibly large possible combinatorial combinations of 2229 
desired bio-functionality and evolutionary optimization techniques.[535] 2230 
Polyplexes. Cationic polymers have already been bloomed over years as non-viral vectors in gene therapy. 2231 
They show tremendous potential in treating different types of cancer and genetic disorders without using 2232 
conventional drugs. One approach is to develop alternative gene delivery platforms by creating higher ordered 2233 
macromolecular structures such as multi-component supramolecules or 2D and 3D scaffolds.[536] Another approach 2234 
is to enhance existing vector platforms (e.g. by functionalization). For instant, the successful clinical application of 2235 
the gold standard poly(ethylene imine) (PEI) for gene delivery depends mainly on three factors: I) The enhancement 2236 
of the transfection efficiency; II) the reduction of toxicity, 2237 
and, III) the ability of the vectors to overcome numerous 2238 
biological barriers after systemic or local administration. 2239 
Current research is focusing on the design of 2240 
biodegradable[537] and more biocompatible derivatives[538] by 2241 
modifying the PEI backbone. Very recently, our group 2242 
introduced a new generation of linear PEI (3rd generation, 2243 
Figure 27) bearing multiple functional groups comprising 2244 
cationic functionalities, cell viability increasing functional 2245 
groups as well as a third group of functionalities which can be 2246 
used, e.g., for targeting molecules.[38] One promising opportunity is the conjugation of glutathione moieties to the 2247 
cationic backbone which enables the transport of genetic materials and, simultaneously, the passage through an 2248 
hCMEC/D3 endothelial cell layer mimicking the highly selective blood-brain barrier (BBB) within a microfluidically 2249 
perfused biochip.[539] Cationic methacrylate copolymers are another upcoming polymer platform able to interact 2250 
with genetic material. Poly(2-dimethylaminoethyl methacrylate) (PDMAEMA) has shown promising gene 2251 
transfection activity due to its cationic character.[540] Jiang and co-workers synthesized PEGylated PDMAEMA/DNA 2252 
polyplexes for efficient brain-targeted gene delivery in mice. As mentioned for phosphates, inorganic safe materials 2253 
will add an important basis for composites with synergistic functions.[541] 2254 
Microgels. The importance of degradability has also been recognized for the design of carrier gels and, in 2255 
particular, micro- and nanosized structures. One quite established example is a PEG microgel, which contains 2256 
degradable PLGA sequences. Injecting them into the cavity of sheep shoulder joint, the new PEG-hydrogel 2257 
microspheres were compared to nondegradable microgels with regard to location, degradation and 2258 
inflammation.[542] The degradable microgel offers several advantages over the nondegradable material considering 2259 
drug delivery in synovial tissue as it reduces the intensity of inflammatory reactions triggered in synovium. 2260 
An interesting strategy for the continuous in vivo expression of a protein is the direct delivery of an ex vivo modified 2261 
 
Figure 27. Schematic representation of the general chemical 
structure for the 3
rd
 generation LPEI which describes the 
presence of multiple functional units comprising cationic 
functionalities (blue), cell viability increasing functional 
groups (black) as well as further functionalities (orange, 
e.g. targeting molecules). 
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cell encapsulated in a gel structure to shield it from the immune system. Sonnet et al. have developed a 2262 
PEG-diacrylate (PEGDA) microgel with allogeneic carrier cells transduced with an adenovirus expressing BMP2 for 2263 
bone regeneration.[543] The PEGylated microsphere system shields the cell and, thus, suppresses the destructive 2264 
inflammatory processes. Within 3 weeks, a 5 mm long femur defect in a rat model was healed completely through 2265 
secretion of 100-fold lower levels of protein compared to similar studies using recombinant protein. For the future, 2266 
this class of injectables opens the macroscopic functional embodiment space staying close to a minimal invasive 2267 
paradigm replacing larger drug eluting devices. 2268 
Nanogels. Besides the already discussed Medusa® technology (Chapter 3.2.3), the only nanogel examples that 2269 
have been evaluated under clinical trials are based on a polysaccharide structure, e.g. cholesterol-bearing 2270 
pullulan (CHP) network,[544] which are described elsewhere.[545] However, researchers still consider tailored nanogel 2271 
systems as a very promising platform for drug delivery applications.[546] Recent successful studies prove the 2272 
efficiency of nanogels by targeting multiple immune cell subsets in the draining lymph nodes.[547] In contrast to 2273 
other gel materials, these systems are fabricated by the synthesis of mesoporous silica (MS) particles (200 nm) as 2274 
templates and subsequent infiltration with pyridine dithioethylamine (PDA) modified poly(methacrylic acid) 2275 
(PMAA-PDA). The infiltration of cysteamine (SH) modified PMAA (PMAASH) leads to a cross-linking by disulfide 2276 
exchange followed by template removal. Further PEGylation of these PMAA nanogels did not affect their cellular 2277 
association in vitro, but improved their lymphatic drainage in vivo (mice). 2278 
Similar to other nanoparticulate systems, the integration of stimuli responsive polymers promises access to carriers 2279 
with local control of the cargo release. Recently, a new type of dual-responsive nanogel with tunable volume phase 2280 
transition temperature and redox-labile properties was investigated.[548] The nanogel system is constructed from a 2281 
copolymer based on vinylcaprolactam (VCL) and HPMA cross-linked with N,N′-bis(acryloyl)cystamine (P(VCL-s-s-2282 
HPMA)). The hydrophilicity of the nanogel allows a stable blood circulation at 37 °C. A higher temperature of the 2283 
tumor tissue forces the nanogel to turn into a hydrophobic state which enhances its cell uptake. Upon the entrance 2284 
into the tumor cells, a redox-triggered degradation of the nanogel (due to the presence of disulfide bonds) leads to 2285 
a burst drug release. In vivo studies (A549 tumor-bearing mice) revealed that these nanogels can significantly limit 2286 
the tumor growth with no side effects to normal tissues. These results underline the immense potential of the dual-2287 
responsive biodegradable nanogels for cancer therapy. Many other nanogel systems have been investigated in vivo 2288 
based on polymers such as PMAA (drugs: DOX/TXL[549]), PEG (siRNA[550]), PEI (AZT 5′-triphosphate[551]), PEG-b-PGluA 2289 
(17-AAG/DOX[552]; cisplatin/TXL[553]) and PMEO3MA-b-PPFPMA (siRNA
[554]). Considering the ongoing effort for the 2290 
development of such carrier systems, we are certain that first nanogel materials will soon enter clinical trials. 2291 
 2292 
Macroscopic drug carriers. They probably represent the most versatile application forms of pharmapolymers 2293 
comprising the wide range of hydrogels and solid implants and inserts. The general trend is towards the creation of 2294 
multiple functional systems. In our opinion, in particular the application of hydrogel systems will change 2295 
significantly. Sensor and conditional release/activity can be established and are already shown for vaccination on 2296 
animal trial stage.[555] 2297 
 2298 
Hydrogels. The most common application form for hydrogels is certainly their use in contact lenses, but 2299 
surprisingly they are not used as drug delivery vehicles so far, which is probably related to the loss of lens quality 2300 
accompanied with the release. The recent development of new techniques to design contact lenses enables an 2301 
extended drug release over a few weeks without any significant impact on the lens properties. Compared to 2302 
alternative eye drops, these contact lenses revealed safety, efficacy and increased bioavailability in in vivo 2303 
studies.[556] Corresponding contact lenses, placed on the cornea, release drugs into the post-lens (between lens and 2304 
cornea) and reveal a prolonged contact time with the cornea.[557] The increased efficiency (35× higher than delivery 2305 
with drops[558]) allows the delivery of drugs over extended time periods (which eliminates the need for multiple 2306 
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dosing) while decreasing side effects since less drug amount is needed. Further ocular applications are the 2307 
development of hydrogels based on poly(2-hydroxyethyl methacrylate) (PHEMA)[559] or poly(dimethyl siloxane) 2308 
(PDMS),[560] which may serve as drug delivery agents for the anterior segment of the eye. The latter is also used for 2309 
punctual plugs releasing cyclosporine A for a period of 3 months.[561] In the last years, immense effort has been put 2310 
into the development of devices for ocular drug delivery,[562] and we are convinced that suitable systems will enter 2311 
the market soon. 2312 
A real innovation is the non-hormonal contraceptive “Reversible inhibition of sperm under guidance” (RISUG®, 2313 
Figure 28) for men developed by Guha and co-workers based on poly(styrene-co-maleic anhydride).[563] 2314 
It represents a long acting and reversible alternative to a 2315 
vasectomy as the polymer can be flushed with another 2316 
injection of a dissolver.[564] It has been patented in several 2317 
countries including India, China and the United States. While 2318 
clinical phase III is already ongoing in India,[565] the Parsemus 2319 
Foundation began to develop a similar polymer contraceptive 2320 
inspired by RISUG® for the rest of the world in 2010 2321 
(VasalgelTM).[566] After one year of successful in vivo studies, 2322 
they recently announced the start of first clinical trials in the 2323 
second half of 2017 and a commercial launch in 2018.[567] 2324 
Besides the classic hydrogels, the development of so-called 2325 
interpenetrating polymer networks (IPN) has expended 2326 
enormously in the field of controlled release and targeted drug delivery in the last decades.[568] Introduced in 1960 2327 
by Miller,[569] IPN’s are defined as “polymers comprising two or more networks which are at least partially 2328 
interlaced on a molecular scale but not covalently bonded to each other and cannot be separated unless chemical 2329 
bonds are broken” (IUPAC[570]). They represent a subgroup of physical gels. The blending of natural and/or synthetic 2330 
polymers opens the field for the design of new controlled release systems for a variety of drugs and broadens the 2331 
range of their properties.[571] IPNs reveal several advantages like an excellent swelling behavior, improved 2332 
responsiveness and mechanical strength, which play an important role in drug delivery systems and differentiate 2333 
them from single networks (such as hydrogels). Even if in vitro and in vivo data have been extensively studied and 2334 
reviewed,[568, 571-572] and the number of patents on this technology is increasing frequently, IPN drug-loaded systems 2335 
have not found their way into clinical studies up to now, and, hence, commercialization, so far. Their complexity 2336 
due to the combination of various different properties has hindered a major breakthrough in pharmaceutical 2337 
applications so far. The current research is still at the academic level, but in our opinion, IPNs are expected to 2338 
receive much more attention in the future. 2339 
Coatings. Colon specific drug delivery has gained considerable attention not only considering colon associated 2340 
diseases but also for the safe delivery of therapeutic peptides and proteins to the blood stream as the activity of 2341 
proteolytic enzymes is far lower compared to the upper GI tract.[573] The marketed dosage forms that aim the site 2342 
specific delivery of the drugs usually depend on the pH variations in the GI tract. However, the pH value difference 2343 
between the small intestine and the colon is not high enough. This limits the efficient colon targeting in particular 2344 
when the distal colon is targeted. Therefore, to achieve an efficient colon targeting, variations in the environment 2345 
comparing the small and the large intestine are exploited in several in vivo studies, which include changes in the 2346 
pH value, the different microbial enzymatic activity, the fluctuating intraluminal pressure or the transit time. 2347 
Dosage forms which are coated with innovative colon targeting polymers have been extensively reviewed 2348 
elsewhere.[574] However, it should be noted that novel polymers with unknown safety data always require 2349 
additional safety assessment. Therefore, most of these studies use polymers with well-established safety profiles 2350 
 
Figure 28. The work principle of “Reversible inhibition of 
sperm under guidance” (RISUG®): A) The hydrogel is 
injected into the vas deferens connected to each testicle; 
B) it coats the wall of the vas deferens. When sperm gets 
into contact with the wall it becomes unable to swim. 
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for coatings. Hence, we do not envisage new marketed dosage forms with novel complex polymeric coatings in 2351 
near future. 2352 
 2353 
5. Concluding remark 2354 
The presented review attempted to provide a comprehensive overview of the current state of synthetic polymers 2355 
used for drug delivery applications, so-called ‘pharmapolymers’. Within the last decades, the impact of synthetic 2356 
polymers has resulted in tremendous advances in chemical synthesis and analysis. The contribution highlights the 2357 
current market situation and clinical status of respective polymers while paying attention to underlying chemical 2358 
structures. In addition, we highlight upcoming trends in the development of new pharmapolymers, which in our 2359 
opinion will have a tremendous impact on the market situation soon. However, we also summarize the obstacles 2360 
these materials still have to overcome to the market for drug delivery applications. Our review comprises a detailed 2361 
description of the most important polymer classes and their fields of application. Application forms like 2362 
polymer-drug conjugates, drug carrier systems in scales ranging from nano- to macroscopic size, polymers as 2363 
coatings and matrix excipients as well as polymeric drugs are described. We hope that providing a link between the 2364 
properties and structures of these systems and their area of application helps scientists from different research 2365 
fields where the systems are often just known by their trade names or abbreviations. 2366 
 2367 
Acknowledgements 2368 
We acknowledge funding from the collaborative research center ChemBioSys (SFB 1127) by the German Science 2369 
Foundation (DFG) and from the Thüringer Ministerium für Wirtschaft, Wissenschaft, und Digitale Gesellschaft 2370 
(TMWWDG, ProExzellenz II, NanoPolar). M.G. is grateful for the funding by the DFG (GO 1100/4-1) and JB thanks 2371 
the DFG for granting a fellowship (BR 4905/2-1). Furthermore, we thank Dr. Matthias Hartlieb for helpful 2372 
comments. 2373 
 2374 
Keywords 2375 
Pharmapolymers • drug delivery • market • clinical trials • structure-activity relationships 2376 
 2377 
75 
 
References 2378 
 2379 
[1] A. S. Hoffman, J. Control. Release 2008, 132, 153-163. 2380 
[2] K. E. Uhrich, S. M. Cannizzaro, R. S. Langer, K. M. Shakesheff, Chem. Rev. 1999, 99, 3181-3198. 2381 
[3] a) P. J. Flory, J. Am. Chem. Soc. 1940, 62, 1561-1565; b) M. Szwarc, Nature 1956, 178, 1168-1169. 2382 
[4] A.-L. Brocas, C. Mantzaridis, D. Tunc, S. Carlotti, Prog. Polym. Sci. 2013, 38, 845-873. 2383 
[5] S. Penczek, M. Cypryk, A. Duda, P. Kubisa, S. Słomkowski, Prog. Polym. Sci. 2007, 32, 247-282. 2384 
[6] R. Hoogenboom, Polyethers and Polyoxazolines, in Handbook of ring-opening polymerization 2385 
(Eds.: P. Dubois, O. Coulembier, J.-M. Raquez), Wiley-VCH, 2009, pp. 141-164. 2386 
[7] a) B. Obermeier, F. Wurm, C. Mangold, H. Frey, Angew. Chem. Int. Ed. 2011, 50, 7988-7997; b) C. 2387 
Mangold, F. Wurm, H. Frey, Polym. Chem. 2012, 3, 1714-1721; c) M. J. Barthel, T. Rudolph, S. 2388 
Crotty, F. H. Schacher, U. S. Schubert, J. Polym. Sci., Part A: Polym. Chem. 2012, 50, 4958-4965. 2389 
[8] R. Kjellander, E. Florin, J. Chem. Soc., Faraday Trans. 1 1981, 77, 2053-2077. 2390 
[9] S. N. S. Alconcel, A. S. Baas, H. D. Maynard, Polym. Chem. 2011, 2, 1442-1448. 2391 
[10] a) A. Abuchowski, T. van Es, N. C. Palczuk, F. F. Davis, J. Biol. Chem. 1977, 252, 3578-3581; b) A. 2392 
Abuchowski, J. R. McCoy, N. C. Palczuk, T. van Es, F. F. Davis, J. Biol. Chem. 1977, 252, 3582-3586. 2393 
[11] a) F. M. Veronese, Biomaterials 2001, 22, 405-417; b) F. M. Veronese, G. Pasut, Drug Discovery 2394 
Today 2005, 10, 1451-1458; c) G. Pasut, F. M. Veronese, Adv. Drug Delivery Rev. 2009, 61, 1177-2395 
1188; d) M. J. Roberts, M. D. Bentley, J. M. Harris, Adv. Drug Delivery Rev. 2012, 64, 116-127. 2396 
[12] a) A. L. Klibanov, K. Maruyama, V. P. Torchilin, L. Huang, FEBS Lett. 1990, 268, 235-237; b) G. 2397 
Blume, G. Cevc, Biochim. Biophys. Acta Biomembr. 1990, 1029, 91-97. 2398 
[13] S. Schöttler, G. Becker, S. Winzen, T. Steinbach, K. Mohr, K. Landfester, V. Mailänder, F. R. Wurm, 2399 
Nat. Nanotechnol. 2016, 11, 372-377. 2400 
[14] a) V. P. Torchilin, V. S. Trubetskoy, Adv. Drug Delivery Rev. 1995, 16, 141-155; b) C. Monfardini, F. 2401 
M. Veronese, Bioconjugate Chem. 1998, 9, 418-450. 2402 
[15] K. Knop, R. Hoogenboom, D. Fischer, U. S. Schubert, Angew. Chem. Int. Ed. 2010, 49, 6288-6308. 2403 
[16] a) A. Bendele, J. Seely, C. Richey, G. Sennello, G. Shopp, Toxicol. Sci. 1998, 42, 152-157; b) D. G. 2404 
Rudmann, J. T. Alston, J. C. Hanson, S. Heidel, Toxicol. Pathol. 2013, 41, 970-983. 2405 
[17] D. A. Herold, K. Keil, D. E. Bruns, Biochem. Pharmacol. 1989, 38, 73-76. 2406 
[18] a) A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N. M. Rafique, C. R. Alving, F. M. Muggia, Ann. 2407 
Oncol. 2003, 14, 1430-1437; b) J. Szebeni, Toxicology 2005, 216, 106-121. 2408 
[19] S. Dai, K. C. Tam, Langmuir 2004, 20, 2177-2183. 2409 
[20] S. Saeki, N. Kuwahara, M. Nakata, M. Kaneko, Polymer 1976, 17, 685-689. 2410 
[21] J. R. Fowles, M. I. Banton, L. H. Pottenger, Crit. Rev. Toxicol. 2013, 43, 363-390. 2411 
[22] M. Schömer, C. Schüll, H. Frey, J. Polym. Sci., Part A: Polym. Chem. 2013, 51, 995-1019. 2412 
[23] P. Kubisa, J. Polym. Sci., Part A: Polym. Chem. 2003, 41, 457-468. 2413 
[24] R. K. Kainthan, E. B. Muliawan, S. G. Hatzikiriakos, D. E. Brooks, Macromolecules 2006, 39, 7708-2414 
7717. 2415 
[25] M. A. Quadir, R. Haag, J. Control. Release 2012, 161, 484-495. 2416 
[26] A. Thomas, S. S. Müller, H. Frey, Biomacromolecules 2014, 15, 1935-1954. 2417 
[27] a) B. Klajnert, W. Walach, M. Bryszewska, A. Dworak, D. Shcharbin, Cell Biol. Int. 2006, 30, 248-2418 
252; b) R. K. Kainthan, J. Janzen, E. Levin, D. V. Devine, D. E. Brooks, Biomacromolecules 2006, 7, 2419 
703-709. 2420 
[28] M. I. Ul-Haq, B. F. L. Lai, R. Chapanian, J. N. Kizhakkedathu, Biomaterials 2012, 33, 9135-9147. 2421 
[29] K. Maruyama, S. Okuizumi, O. Ishida, H. Yamauchi, H. Kikuchi, M. Iwatsuru, Int. J. Pharm. 1994, 2422 
111, 103-107. 2423 
[30] O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, J. P. Behr, Proc. 2424 
Natl. Acad. Sci. U.S.A. 1995, 92, 7297-7301. 2425 
76 
 
[31] a) W. T. Godbey, K. K. Wu, A. G. Mikos, J. Control. Release 1999, 60, 149-160; b) W. T. Godbey, 2426 
M. A. Barry, P. Saggau, K. K. Wu, A. G. Mikos, J. Biomed. Mater. Res. 2000, 51, 321-328. 2427 
[32] U. Lungwitz, M. Breunig, T. Blunk, A. Göpferich, Eur. J. Pharm. Biopharm. 2005, 60, 247-266. 2428 
[33] G. D. Jones, A. Langsjoen, S. M. M. C. Neumann, J. Zomlefer, J. Org. Chem. 1944, 09, 125-147. 2429 
[34] K. A. Gibney, I. Sovadinova, A. I. Lopez, M. Urban, Z. Ridgway, G. A. Caputo, K. Kuroda, Macromol. 2430 
Biosci. 2012, 12, 1279-1289. 2431 
[35] a) T. Kagiya, S. Narisawa, T. Maeda, K. Fukui, J. Polym. Sci. Part B 1966, 4, 441-445; b) D. A. 2432 
Tomalia, D. P. Sheetz, J. Polym. Sci., Part A: Polym. Chem. 1966, 4, 2253-2265. 2433 
[36] a) R. Tanaka, I. Ueoka, Y. Takaki, K. Kataoka, S. Saito, Macromolecules 1983, 16, 849-853; b) L. 2434 
Tauhardt, K. Kempe, K. Knop, E. Altuntaş, M. Jäger, S. Schubert, D. Fischer, U. S. Schubert, 2435 
Macromol. Chem. Phys. 2011, 212, 1918-1924. 2436 
[37] a) T. Saegusa, H. Ikeda, H. Fujii, Macromolecules 1972, 5, 108; b) T. Saegusa, S. Kobayashi, A. 2437 
Yamada, Macromolecules 1975, 8, 390-396. 2438 
[38] T. Bus, C. Englert, M. Reifarth, P. Borchers, M. Hartlieb, A. Vollrath, S. Hoeppener, A. Traeger, U. 2439 
S. Schubert, J. Mater. Chem. B 2017, 5, 1258-1274. 2440 
[39] K. Aoi, A. Motoda, M. Ohno, K. Tsutsumiuchi, M. Okada, T. Imae, Polym. J. 1999, 31, 1071-1078. 2441 
[40] a) J. H. Jeong, S. H. Song, D. W. Lim, H. Lee, T. G. Park, J. Control. Release 2001, 73, 391-399; b) H. 2442 
M. L. Lambermont-Thijs, J. P. A. Heuts, S. Hoeppener, R. Hoogenboom, U. S. Schubert, Polym. 2443 
Chem. 2011, 2, 313-322; c) H. P. C. Van Kuringen, J. Lenoir, E. Adriaens, J. Bender, B. G. De Geest, 2444 
R. Hoogenboom, Macromol. Biosci. 2012, 12, 1114-1123. 2445 
[41] M. Jaeger, S. Schubert, S. Ochrimenko, D. Fischer, U. S. Schubert, Chem. Soc. Rev. 2012, 41, 4755-2446 
4767. 2447 
[42] a) A.-C. Albertsson, I. Varma, Adv. Polym. Sci. 2002, 157, 1-40; b) Q. Chen, G. Thouas, 2448 
Biomaterials: A Basic Introduction, CRC Press (Taylor & Francis Group), Boca Raton, Florida, 2014. 2449 
[43] B. Azimi, P. Nourpanah, M. Rabiee, S. Arbab, J. Eng. Fiber. Fabr. 2014, 9, 74-90. 2450 
[44] a) P. A. Gunatillake, R. Adhikari, Eur. Cells Mater. J. 2003, 5, 1-16; b) A. G. A. Coombes, S. C. Rizzi, 2451 
M. Williamson, J. E. Barralet, S. Downes, W. A. Wallace, Biomaterials 2004, 25, 315-325; c) V. R. 2452 
Sinha, K. Bansal, R. Kaushik, R. Kumria, A. Trehan, Int. J. Pharm. 2004, 278, 1-23; d) H. Sun, L. Mei, 2453 
C. Song, X. Cui, P. Wang, Biomaterials 2006, 27, 1735-1740; e) X. Wei, C. Gong, M. Gou, S. Fu, Q. 2454 
Guo, S. Shi, F. Luo, G. Guo, L. Qiu, Z. Qian, Int. J. Pharm. 2009, 381, 1-18. 2455 
[45] M. A. Woodruff, D. W. Hutmacher, Prog. Polym. Sci. 2010, 35, 1217-1256. 2456 
[46] M. Labet, W. Thielemans, Chem. Soc. Rev. 2009, 38, 3484-3504. 2457 
[47] C. Zhang, Biodegradable polyesters: Synthesis, properties, applications, in Biodegradable 2458 
polyesters, Wiley-VCH, 2015, pp. 1-24. 2459 
[48] K. Chavalitpanya, S. Phattanarudee, Energy Procedia 2013, 34, 542-548. 2460 
[49] a) A. Sarasam, S. V. Madihally, Biomaterials 2005, 26, 5500-5508; b) D. M. García Cruz, J. L. 2461 
Gomez Ribelles, M. Salmerón Sánchez, J. Biomed. Mater. Res. B 2008, 85, 303-313. 2462 
[50] a) J. C. Middleton, A. J. Tipton, Biomaterials 2000, 21, 2335-2346; b) V. Singh, M. Tiwari, Int. J. 2463 
Polym. Sci. 2010, 2010, 1-23; c) M. S. Lopes, A. L. Jardini, R. M. Filho, Procedia Eng. 2012, 42, 2464 
1402-1413. 2465 
[51] a) R. A. Jain, Biomaterials 2000, 21, 2475-2490; b) B. D. Ulery, L. S. Nair, C. T. Laurencin, J. Polym. 2466 
Sci., Part B: Polym. Phys. 2011, 49, 832-864; c) H. K. Makadia, S. J. Siegel, Polymer 2011, 3, 1377-2467 
1397; d) B. Behera, J. Med. Pharm. Innov. 2013, 1, 1-5; e) B. Azimi, P. Nourpanah, M. Rabiee, S. 2468 
Arbab, J. Eng. Fiber. Fabr. 2014, 9, 47-66. 2469 
[52] a) H. Tsuji, Macromol. Biosci. 2007, 7, 1299; b) P. Gentile, V. Chiono, I. Carmagnola, P. V. Hatton, 2470 
Int. J. Mol. Sci. 2014, 15, 3640-3659. 2471 
[53] W. H. Carothers, G. L. Dorough, F. J. v. Natta, J. Am. Chem. Soc. 1932, 54, 761-772. 2472 
77 
 
[54] C. C. Erbetta, R. J. Alves, J. M. Resende, R. F. Freitas, R. G. Sousa, J. Biomater. Nanobiotechnol. 2473 
2012, 3, 208-225. 2474 
[55] a) M. Jamshidian, E. A. Tehrany, M. Imran, M. Jacquot, S. Desobry, Compr. Rev. Food Sci. Food 2475 
Saf. 2010, 9, 552-571; b) C. Engineer, J. Parikh, A. Raval, Trends Biomater. Artif. Organs 2011, 25, 2476 
79-85. 2477 
[56] S. W. Shalaby, D. D. Jamiolkowski, US 4140678 A, 1980. 2478 
[57] a) S. J. Holland, B. J. Tighe, P. L. Gould, J. Control. Release 1986, 4, 155-180; b) J. Shin, K.-N. Yeh, J. 2479 
Appl. Polym. Sci. 1999, 74, 921-936; c) L. Finelli, N. Lotti, A. Munari, Eur. Polym. J. 2002, 38, 1987-2480 
1993; d) S. Kim, K. Seong, O. Kim, S. Kim, H. Seo, M. Lee, G. Khang, D. Lee, Biomacromolecules 2481 
2010, 11, 555-560. 2482 
[58] J. J. Garcia, S. A. Miller, Polym. Chem. 2014, 5, 955-961. 2483 
[59] A. Einhorn, Justus Liebigs Ann. Chem. 1898, 300, 135-155. 2484 
[60] H. Schnell, Angew. Chem. 1956, 68, 633-640. 2485 
[61] D. Fox, Polyesters: History, in High performance polymers: Their origin and development (Eds.: R. 2486 
B. Seymour, G. S. Kirshenbaum), Springer, 1986, pp. 67-70. 2487 
[62] a) D. J. A. Cameron, M. P. Shaver, Chem. Soc. Rev. 2011, 40, 1761-1776; b) H. Seyednejad, A. H. 2488 
Ghassemi, C. F. van Nostrum, T. Vermonden, W. E. Hennink, J. Control. Release 2011, 152, 168-2489 
176; c) Y. Zhang, H. F. Chan, K. W. Leong, Adv. Drug Delivery Rev. 2013, 65, 104-120. 2490 
[63] F. Suriano, O. Coulembier, J. L. Hedrick, P. Dubois, Polym. Chem. 2011, 2, 528-533. 2491 
[64] A. Cyriac, S. H. Lee, J. K. Varghese, E. S. Park, J. H. Park, B. Y. Lee, Macromolecules 2010, 43, 7398-2492 
7401. 2493 
[65] a) M. Taherimehr, P. P. Pescarmona, J. Appl. Polym. Sci. 2014, 131, 41141; b) R.-R. Ang, L. Tin Sin, 2494 
S.-T. Bee, T.-T. Tee, A. A. H. Kadhum, A. R. Rahmat, B. A. Wasmi, J. Cleaner Prod. 2015, 102, 1-17. 2495 
[66] K. Sehanobish, T. Pham, H. C. P. Bosnyak, in Polymeric Materials Encyclopedia, Vol. 8 (Ed.: J. C. 2496 
Salamone), CRC Press (Taylor & Francis Group), 1996, p. 5697. 2497 
[67] J. Xu, F. Prifti, J. Song, Macromolecules 2011, 44, 2660-2667. 2498 
[68] a) Y. Shibasaki, H. Sanada, M. Yokoi, F. Sanda, T. Endo, Macromolecules 2000, 33, 4316-4320; b) 2499 
C. Yang, Z. Y. Ong, Y.-Y. Yang, P. L. R. Ee, J. L. Hedrick, Macromol. Rapid Commun. 2011, 32, 1826-2500 
1833; c) S. M. Guillaume, Eur. Polym. J. 2013, 49, 768-779; d) R. P. Brannigan, A. Walder, A. P. 2501 
Dove, J. Polym. Sci., Part A: Polym. Chem. 2014, 52, 2279-2286. 2502 
[69] a) H. Wu, Y. Ji, Z. Li, X. Wang, Q. Zhang, S. Cui, W. Wu, J. Liu, K. Guo, J. Polym. Sci., Part A: Polym. 2503 
Chem. 2015, 53, 729-736; b) C. Yang, S. Q. Liu, S. Venkataraman, S. J. Gao, X. Ke, X. T. Chia, J. L. 2504 
Hedrick, Y. Y. Yang, J. Control. Release 2015, 208, 93-105. 2505 
[70] Z. Zhang, R. Kuijer, S. K. Bulstra, D. W. Grijpma, J. Feijen, Biomaterials 2006, 27, 1741-1748. 2506 
[71] a) M. Acemoglu, S. Bantle, T. Mindt, F. Nimmerfall, Macromolecules 1995, 28, 3030-3037; b) E. J. 2507 
Vandenberg, D. Tian, Macromolecules 1999, 32, 3613-3619. 2508 
[72] T. F. Al-Azemi, K. S. Bisht, Macromolecules 1999, 32, 6536-6540. 2509 
[73] F. Sanda, J. Kamatani, T. Endo, Macromolecules 2001, 34, 1564-1569. 2510 
[74] P. G. Parzuchowski, M. Jaroch, M. Tryznowski, G. Rokicki, Macromolecules 2008, 41, 3859-3865. 2511 
[75] R. C. Pratt, F. Nederberg, R. M. Waymouth, J. L. Hedrick, Chem. Commun. 2008, 114-116. 2512 
[76] J. Mindemark, T. Bowden, Polymer 2011, 52, 5716-5722. 2513 
[77] X. Zhang, Z. Zhong, R. Zhuo, Macromolecules 2011, 44, 1755-1759. 2514 
[78] a) Y. Shen, X. Chen, R. A. Gross, Macromolecules 1999, 32, 2799-2802; b) F. Suriano, R. Pratt, J. P. 2515 
K. Tan, N. Wiradharma, A. Nelson, Y.-Y. Yang, P. Dubois, J. L. Hedrick, Biomaterials 2010, 31, 2516 
2637-2645. 2517 
[79] a) T. J. Deming, Prog. Polym. Sci. 2007, 32, 858-875; b) Y. Shen, X. Fu, W. Fu, Z. Li, Chem. Soc. Rev. 2518 
2015, 44, 612-622. 2519 
78 
 
[80] a) A. Lavasanifar, J. Samuel, G. S. Kwon, Adv. Drug Delivery Rev. 2002, 54, 169-190; b) C. Li, Adv. 2520 
Drug Delivery Rev. 2002, 54, 695-713; c) Y. Bae, K. Kataoka, Adv. Drug Delivery Rev. 2009, 61, 2521 
768-784; d) S. F. M. van Dongen, H.-P. M. de Hoog, R. J. R. W. Peters, M. Nallani, R. J. M. Nolte, J. 2522 
C. M. van Hest, Chem. Rev. 2009, 109, 6212-6274; e) S. Hehir, N. R. Cameron, Polym. Int. 2014, 2523 
63, 943-954. 2524 
[81] H. Leuchs, Ber. Deutsch. Chem. Ges. 1906, 39, 857-861. 2525 
[82] a) H. R. Kricheldorf, Angew. Chem. Int. Ed. 2006, 45, 5752-5784; b) N. Hadjichristidis, H. Iatrou, 2526 
M. Pitsikalis, G. Sakellariou, Chem. Rev. 2009, 109, 5528-5578; c) C. Deng, J. Wu, R. Cheng, F. 2527 
Meng, H.-A. Klok, Z. Zhong, Prog. Polym. Sci. 2014, 39, 330-364. 2528 
[83] T. J. Deming, J. Polym. Sci., Part A: Polym. Chem. 2000, 38, 3011-3018. 2529 
[84] T. Aliferis, H. Iatrou, N. Hadjichristidis, Biomacromolecules 2004, 5, 1653-1656. 2530 
[85] a) I. Dimitrov, H. Schlaad, Chem. Commun. 2003, 2944-2945; b) J.-F. Lutz, D. Schütt, S. Kubowicz, 2531 
Macromol. Rapid Commun. 2005, 26, 23-28. 2532 
[86] H. Lu, J. Cheng, J. Am. Chem. Soc. 2007, 129, 14114-14115. 2533 
[87] a) C. He, X. Zhuang, Z. Tang, H. Tian, X. Chen, Adv. Healthcare Mater. 2012, 1, 48-78; b) H. Lu, J. 2534 
Wang, Z. Song, L. Yin, Y. Zhang, H. Tang, C. Tu, Y. Lin, J. Cheng, Chem. Commun. 2014, 50, 139-2535 
155. 2536 
[88] A. Ogunleye, A. Bhat, V. U. Irorere, D. Hill, C. Williams, I. Radecka, Microbiology 2015, 161, 1-17. 2537 
[89] I.-L. Shih, Y.-T. Van, M.-H. Shen, Mini-Rev. Med. Chem. 2004, 4, 179-188. 2538 
[90] S. Roweton, S. J. Huang, G. Swift, J. Environ. Polym. Degrad. 1997, 5, 175-181. 2539 
[91] P. S. Farmer, E. J. Ariens, Trends Pharmacol. Sci. 1982, 3, 362-365. 2540 
[92] R. J. Simon, R. S. Kania, R. N. Zuckermann, V. D. Huebner, D. A. Jewell, S. Banville, S. Ng, L. Wang, 2541 
S. Rosenberg, C. K. Marlowe, Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 9367-9371. 2542 
[93] a) K. Kirshenbaum, A. E. Barron, R. A. Goldsmith, P. Armand, E. K. Bradley, K. T. V. Truong, K. A. 2543 
Dill, F. E. Cohen, R. N. Zuckermann, Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4303-4308; b) R. N. 2544 
Zuckermann, Pept. Sci. 2011, 96, 545-555. 2545 
[94] a) J. W. Robinson, H. Schlaad, Chem. Commun. 2012, 48, 7835-7837; b) J. Sun, R. N. Zuckermann, 2546 
ACS Nano 2013, 7, 4715-4732; c) A. Birke, D. Huesmann, A. Kelsch, M. Weilbaecher, J. Xie, M. 2547 
Bros, T. Bopp, C. Becker, K. Landfester, M. Barz, Biomacromolecules 2014, 15, 548-557; d) K. 2548 
Klinker, R. Holm, P. Heller, M. Barz, Polym. Chem. 2015, 6, 4612-4623  2549 
[95] R. N. Zuckermann, J. M. Kerr, S. B. H. Kent, W. H. Moos, J. Am. Chem. Soc. 1992, 114, 10646-2550 
10647. 2551 
[96] a) R. M. J. Liskamp, D. T. S. Rijkers, J. A. W. Kruijtzer, J. Kemmink, ChemBioChem 2011, 12, 1626-2552 
1653; b) R. Luxenhofer, C. Fetsch, A. Grossmann, J. Polym. Sci., Part A: Polym. Chem. 2013, 51, 2553 
2731-2752; c) A. M. Rosales, R. A. Segalman, R. N. Zuckermann, Soft Matter 2013, 9, 8400-8414; 2554 
d) A. S. Knight, E. Y. Zhou, M. B. Francis, R. N. Zuckermann, Adv. Mater. 2015, 27, 5665-5691; e) 2555 
C. Secker, S. M. Brosnan, R. Luxenhofer, H. Schlaad, Macromol. Biosci. 2015, 15, 881-891. 2556 
[97] A. S. Culf, R. J. Ouellette, Molecules 2010, 15, 5282. 2557 
[98] H. K. Murnen, A. R. Khokhlov, P. G. Khalatur, R. A. Segalman, R. N. Zuckermann, Macromolecules 2558 
2012, 45, 5229-5236. 2559 
[99] S. M. Miller, R. J. Simon, S. Ng, R. N. Zuckermann, J. M. Kerr, W. H. Moos, Bioorg. Med. Chem. 2560 
Lett. 1994, 4, 2657-2662. 2561 
[100] a) H. J. Olivos, P. G. Alluri, M. M. Reddy, D. Salony, T. Kodadek, Org. Lett. 2002, 4, 4057-4059; b) 2562 
B. C. Gorske, S. A. Jewell, E. J. Guerard, H. E. Blackwell, Org. Lett. 2005, 7, 1521-1524. 2563 
[101] D. Zhang, S. H. Lahasky, L. Guo, C.-U. Lee, M. Lavan, Macromolecules 2012, 45, 5833-5841. 2564 
[102] a) M. Schneider, C. Fetsch, I. Amin, R. Jordan, R. Luxenhofer, Langmuir 2013, 29, 6983-6988; b) 2565 
N. Gangloff, C. Fetsch, R. Luxenhofer, Macromol. Rapid Commun. 2013, 34, 997-1001. 2566 
79 
 
[103] a) S. Lohan, G. S. Bisht, Mini Rev. Med. Chem. 2013, 13, 1073-1088; b) K. H. A. Lau, Biomater. Sci. 2567 
2014, 2, 627-633. 2568 
[104] a) C. M. Gao, A. Y. Yam, X. Wang, E. Magdangal, C. Salisbury, D. Peretz, R. N. Zuckermann, M. D. 2569 
Connolly, O. Hansson, L. Minthon, H. Zetterberg, K. Blennow, J. P. Fedynyshyn, S. Allauzen, PLoS 2570 
ONE 2010, 5, e15725; b) M. M. Reddy, R. Wilson, J. Wilson, S. Connell, A. Gocke, L. Hynan, D. 2571 
German, T. Kodadek, Cell 2011, 144, 132-142. 2572 
[105] a) S. L. Seurynck, J. A. Patch, A. E. Barron, Chem. Biol. 2005, 12, 77-88; b) N. J. Brown, J. 2573 
Johansson, A. E. Barron, Acc. Chem. Res. 2008, 41, 1409-1417. 2574 
[106] a) C. A. Olsen, ChemBioChem 2010, 11, 152-160; b) B.-C. Lee, R. N. Zuckermann, ACS Chem. Biol. 2575 
2011, 6, 1367-1374. 2576 
[107] J. Ulbricht, R. Jordan, R. Luxenhofer, Biomaterials 2014, 35, 4848-4861. 2577 
[108] a) W. Seeliger, E. Aufderhaar, W. Diepers, R. Feinauer, R. Nehring, W. Thier, H. Hellmann, Angew. 2578 
Chem. Int. Ed. 1966, 5, 875-888; b) T. G. Bassiri, A. Levy, M. Litt, J. Polym. Sci. Part B 1967, 5, 871-2579 
879. 2580 
[109] a) F. Wiesbrock, R. Hoogenboom, C. H. Abeln, U. S. Schubert, Macromol. Rapid Commun. 2004, 2581 
25, 1895-1899; b) K. Kempe, C. R. Becer, U. S. Schubert, Macromolecules 2011, 44, 5825-5842; c) 2582 
C. Englert, A. M. Schwenke, S. Hoeppener, C. Weber, U. S. Schubert, Adv. Polym. Sci. 2016, 274, 2583 
209-240. 2584 
[110] B. Guillerm, S. Monge, V. Lapinte, J.-J. Robin, Macromol. Rapid Commun. 2012, 33, 6000-6016. 2585 
[111] a) J. Kronek, Z. Kroneková, J. Lustoň, E. Paulovičová, L. Paulovičová, B. Mendrek, J. Mater. Sci.: 2586 
Mater. Med. 2011, 22, 1725-1734; b) R. Luxenhofer, G. Sahay, A. Schulz, D. Alakhova, T. K. 2587 
Bronich, R. Jordan, A. V. Kabanov, J. Control. Release 2011, 153, 73-82; c) M. Bauer, S. Schroeder, 2588 
L. Tauhardt, K. Kempe, U. S. Schubert, D. Fischer, J. Polym. Sci., Part A: Polym. Chem. 2013, 51, 2589 
1816-1821. 2590 
[112] a) M. C. Woodle, C. M. Engbers, S. Zalipsky, Bioconjugate Chem. 1994, 5, 493-496; b) S. Zalipsky, 2591 
C. B. Hansen, J. M. Oaks, T. M. Allen, J. Pharm. Sci. 1996, 85, 133-137. 2592 
[113] a) R. Hoogenboom, Angew. Chem. Int. Ed. 2009, 48, 7978-7994; b) R. Luxenhofer, Y. Han, A. 2593 
Schulz, J. Tong, Z. He, A. V. Kabanov, R. Jordan, Macromol. Rapid Commun. 2012, 1613-1631; c) 2594 
V. R. de la Rosa, J. Mater. Sci.: Mater. Med. 2014, 25, 1211-1225. 2595 
[114] C. Weber, R. Hoogenboom, U. S. Schubert, Prog. Polym. Sci. 2012, 37, 686-714. 2596 
[115] R. Duncan, M. J. Vicent, Adv. Drug Delivery Rev. 2010, 62, 272-282. 2597 
[116] P. A. Vasey, S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. H. Thomson, L. S. 2598 
Murray, T. E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, J. Cassidy, Clin. Cancer Res. 2599 
1999, 5, 83-94. 2600 
[117] a) J. Kopeček, H. Baẑilová, Eur. Polym. J. 1973, 9, 7-14; b) M. Teodorescu, K. Matyjaszewski, 2601 
Macromolecules 1999, 32, 4826-4831; c) C. W. Scales, Y. A. Vasilieva, A. J. Convertine, A. B. Lowe, 2602 
C. L. McCormick, Biomacromolecules 2005, 6, 1846-1850. 2603 
[118] a) M. Eberhardt, P. Théato, Macromol. Rapid Commun. 2005, 26, 1488-1493; b) M. I. Gibson, E. 2604 
Fröhlich, H.-A. Klok, J. Polym. Sci., Part A: Polym. Chem. 2009, 47, 4332-4345. 2605 
[119] B. S. Tucker, B. S. Sumerlin, Polym. Chem. 2014, 5, 1566-1572. 2606 
[120] a) M. Heskins, J. E. Guillet, J. Macromol. Sci. Chem. Ed. 1968, A2, 1441-1455; b) K. Dušek, D. 2607 
Patterson, J. Polym. Sci. Part. A-2 1968, 6, 1209-1216. 2608 
[121] a) H. Wei, S.-X. Cheng, X.-Z. Zhang, R.-X. Zhuo, Prog. Polym. Sci. 2009, 34, 893-910; b) A. Halperin, 2609 
M. Kröger, F. M. Winnik, Angew. Chem. Int. Ed. 2015, 54, 15342-15367. 2610 
[122] Z. M. O. Rzaev, S. Dinçer, E. Pişkin, Prog. Polym. Sci. 2007, 32, 534-595. 2611 
[123] T. Sun, G. Qing, Adv. Mater. 2011, 23, H57-H77. 2612 
[124] a) Y. Guan, Y. Zhang, Soft Matter 2011, 7, 6375-6384; b) Y. Lu, M. Ballauff, Prog. Polym. Sci. 2011, 2613 
36, 767-792; c) C. Li, Y. Ma, H. Niu, H. Zhang, ACS Appl. Mater. Interfaces 2015, 7, 27340–27350; 2614 
80 
 
d) L. D. Blackman, D. B. Wright, M. P. Robin, M. I. Gibson, R. K. O’Reilly, ACS Macro Lett. 2015, 4, 2615 
1210-1214; e) H. Hathaway, D. R. Alves, J. Bean, P. P. Esteban, K. Ouadi, J. Mark Sutton, A. T. A. 2616 
Jenkins, Eur. J. Pharm. Biopharm. 2015, 96, 437-441. 2617 
[125] H. M. Mansour, M. Sohn, A. Al-Ghananeem, P. P. DeLuca, Int. J. Mol. Sci. 2010, 11, 3298. 2618 
[126] a) F. Ganachaud, M. J. Monteiro, R. G. Gilbert, M.-A. Dourges, S. H. Thang, E. Rizzardo, 2619 
Macromolecules 2000, 33, 6738-6745; b) G. Masci, L. Giacomelli, V. Crescenzi, Macromol. Rapid 2620 
Commun. 2004, 25, 559-564. 2621 
[127] T. Steinbach, E. M. Alexandrino, C. Wahlen, K. Landfester, F. R. Wurm, Macromolecules 2014, 47, 2622 
4884-4893. 2623 
[128] J. Liu, W. Huang, Y. Pang, D. Yan, Chem. Soc. Rev. 2015, 44, 3942-3953. 2624 
[129] a) F. Marsico, M. Wagner, K. Landfester, F. R. Wurm, Macromolecules 2012, 45, 8511-8518; b) T. 2625 
Steinbach, E. M. Alexandrino, F. R. Wurm, Polym. Chem. 2013, 4, 3800-3806. 2626 
[130] Y.-C. Wang, Y.-Y. Yuan, J.-Z. Du, X.-Z. Yang, J. Wang, Macromol. Biosci. 2009, 9, 1154-1164. 2627 
[131] L. Lieberman, Ber. Chem.-Ges. 1888, 21, 598-607. 2628 
[132] a) I. S. Kulaev, V. M. Vagabov, Adv. Microb. Physiol 1983, 24, 83-171; b) A. Kornberg, J. Bacteriol. 2629 
1995, 177, 491-496; c) I. S. Kulaev, V. M. Vagabov, T. V. Kulakovskaya, The biochemistry of 2630 
inorganic polyphosphates, John Wiley & Sons, 1979; d) T. Steinbach, F. R. Wurm, Angew. Chem. 2631 
Int. Ed. 2015, 54, 6098-6108; e) X. Wang, H. C. Schröder, W. E. G. Müller, Biotechnol. J. 2016, 11, 2632 
11-30. 2633 
[133] a) A. Kornberg, S. R. Kornberg, E. S. Simms, Biochim. Biophys. Acta 1956, 20, 215-227; b) S. R. 2634 
Kornberg, Biochim. Biophys. Acta 1957, 26, 294-300. 2635 
[134] a) R. P. Elliott, R. P. Straka, J. A. Garibaldi, Appl. Microbiol. 1964, 12, 517-522; b) A. Momeni, M. J. 2636 
Filiaggi, Langmuir 2014, 30, 5256-5266. 2637 
[135] A. Kornberg, N. N. Rao, D. Ault-Riché, Annu. Rev. Biochem. 1999, 68, 89-125. 2638 
[136] J.-Z. Du, T.-M. Sun, S.-Q. Weng, X.-S. Chen, J. Wang, Biomacromolecules 2007, 8, 3375-3381. 2639 
[137] S. Zhang, A. Li, J. Zou, L. Y. Lin, K. L. Wooley, ACS Macro Lett. 2012, 1, 328-333. 2640 
[138] W.-J. Song, J.-Z. Du, N.-J. Liu, S. Dou, J. Cheng, J. Wang, Macromolecules 2008, 41, 6935-6941. 2641 
[139] J. Wang, H.-Q. Mao, K. W. Leong, J. Am. Chem. Soc. 2001, 123, 9480-9481. 2642 
[140] J. Liu, W. Huang, Y. Zhou, D. Yan, Macromolecules 2009, 42, 4394-4399. 2643 
[141] Y. Iwasaki, E. Yamaguchi, Macromolecules 2010, 43, 2664-2666. 2644 
[142] J. Libiszowski, K. Kałużynski, S. Penczek, J. Polym. Sci. Polym. Chem. Ed. 1978, 16, 1275-1283. 2645 
[143] J. A. Obritsch, D. Ryu, L. E. Lampila, L. B. Bullerman, J. Food Prot. 2008, 71, 1401-1405. 2646 
[144] A. S. Naidu, Natural food antimicrobial systems, CRC Press (Taylor & Francis Group), 2000. 2647 
[145] E. Yilgör, I. Yilgör, Prog. Polym. Sci. 2014, 39, 1165-1195. 2648 
[146] a) L. Wilczek, J. Chojnowski, Makromol. Chem. 1983, 184, 77-90; b) A. Mitra, D. A. Atwood, 2649 
Polysiloxanes & polysilanes, in Encyclopedia of inorganic chemistry (Ed.: R. B. King), John Wiley & 2650 
Sons, 2006. 2651 
[147] a) P. Cancouët, E. Daudet, G. Hélary, M. Moreau, G. Sauvet, J. Polym. Sci., Part A: Polym. Chem. 2652 
2000, 38, 826-836; b) A. Saxena, S. Rajaraman, M. Leatherman, Macromolecules 2007, 40, 752-2653 
755; c) M. D. Ninago, A. J. Satti, J. A. Ressia, A. E. Ciolino, M. A. Villar, E. M. Vallés, J. Polym. Sci., 2654 
Part A: Polym. Chem. 2009, 47, 4774-4783. 2655 
[148] A. Colas, Dow Corning, Life Sciences 2005. 2656 
[149] R. De Jaeger, M. Gleria, Inorganic Polymers, Nova Science Publishers, 2007. 2657 
[150] H. Zhang, M. Chiao, J. Med. Biol. Eng. 2015, 35, 143-155. 2658 
[151] a) H. Schmolke, S. Demming, A. Edlich, V. Magdanz, S. Büttgenbach, E. Franco-Lara, R. Krull, C.-P. 2659 
Klages, Biomicrofluidics 2010, 4, 44113; b) K. M. Kovach, J. R. Capadona, A. S. Gupta, J. A. Potkay, 2660 
J. Biomed. Mater. Res. A 2014, 102, 4195-4205; c) M. A. Rufin, J. A. Gruetzner, M. J. Hurley, M. L. 2661 
Hawkins, E. S. Raymond, J. E. Raymond, M. A. Grunlan, J. Mater. Chem. B 2015, 3, 2816-2825. 2662 
81 
 
[152] C. Stevens, Int. J. Cosmet. Sci. 1998, 20, 296-304. 2663 
[153] M. H. Stenzel, L. Cummins, G. E. Roberts, T. P. Davis, P. Vana, C. Barner-Kowollik, Macromol. 2664 
Chem. Phys. 2003, 204, 1160-1168. 2665 
[154] C. C. DeMerlis, D. R. Schoneker, Food Chem. Toxicol. 2003, 41, 319-326. 2666 
[155] I. Orienti, R. Trere, B. Luppi, F. Bigucci, T. Cerchiara, G. Zuccari, V. Zecchi, Arch. Pharm. 2002, 335, 2667 
89-93. 2668 
[156] S. M. More, R. V. Kulkarni, B. Sa, N. V. Kayane, J. Appl. Polym. Sci. 2010, 116, 1732-1738. 2669 
[157] G. Schröder, Poly(vinyl ethers), in Ullmann's encyclopedia of industrial chemistry, Wiley-VCH, 2670 
Weinheim, Germany, 2000. 2671 
[158] M. G. Tardajos, M. Nash, Y. Rochev, H. Reinecke, C. Elvira, A. Gallardo, Macromol. Chem. Phys 2672 
2012, 213, 529-538. 2673 
[159] W. Reppe, Angew. Chem. 1953, 65, 577-578. 2674 
[160] V. G. Kadajji, G. V. Betageri, Polymers 2011, 3, 1972. 2675 
[161] V. Bühler, Kollidon: Polyvinylpyrrolidone excipients for the pharmaceutical industry, BASF, 2676 
Ludwigshafen, Germany, 2008. 2677 
[162] a) V. P. Torchilin, J. Microencapsulation 1998, 15, 1-19; b) Z. Zhu, C. Xie, Q. Liu, X. Zhen, X. Zheng, 2678 
W. Wu, R. Li, Y. Ding, X. Jiang, B. Liu, Biomaterials 2011, 32, 9525-9535. 2679 
[163] F. Fischer, S. Bauer, Chem. Unserer Zeit 2009, 43, 376-383. 2680 
[164] a) F. Haaf, A. Sanner, F. Straub, Polym. J. 1985, 17, 143-152; b) M. B. Mohamed, M. K. Talari, M. 2681 
Tripathy, A. B. A. Majeed, Int. J. Drug Formulation Res. 2012, 3, 13-28. 2682 
[165] W. Strohmeier, P. Hartmann, Z. Naturforsch. B 1964, 19, 655. 2683 
[166] a) P. S. Mohanachandran, P. G. Sindhumol, T. S. Kiran, Int. J. Pharm. Sci. Rev. Res. 2011, 6, 105-2684 
109; b) R. Bala, S. Khanna, P. Pawar, Asian J. Pharm. Clin. Res. 2012, 5, 8-14; c) M. Mangal, S. 2685 
Thakral, M. Goswami, P. Ghai, Int. J. Pharm. Pharm. Sci. Res. 2012, 2, 26-35. 2686 
[167] M. Wytrwal, C. Leduc, M. Sarna, C. Goncalves, M. Kepczynski, P. Midoux, M. Nowakowska, C. 2687 
Pichon, Int. J. Pharm. 2015, 478, 372-382. 2688 
[168] J. M. C. Lourenço, P. A. Ribeiro, A. M. Botelho do Rego, F. M. Braz Fernandes, A. M. C. Moutinho, 2689 
M. Raposo, Langmuir 2004, 20, 8103-8109. 2690 
[169] K. Nollenberger, J. Albers, Int. J. Pharm. 2013, 457, 461-469. 2691 
[170] P. F. Holmes, M. Bohrer, J. Kohn, Prog. Polym. Sci. 2008, 33, 787-796. 2692 
[171] a) P. Kwiatkowski, J. Jurczak, J. Pietrasik, W. Jakubowski, L. Mueller, K. Matyjaszewski, 2693 
Macromolecules 2008, 41, 1067-1069; b) E. Yoshida, Colloid. Polym. Sci. 2011, 289, 1625-1630; c) 2694 
T. Yildirim, A. C. Rinkenauer, C. Weber, A. Traeger, S. Schubert, U. S. Schubert, J. Polym. Sci., Part 2695 
A: Polym. Chem. 2015, 53, 2711-2721. 2696 
[172] F. Fleischhaker, A. P. Haehnel, A. M. Misske, M. Blanchot, S. Haremza, C. Barner-Kowollik, 2697 
Macromol. Chem. Phys. 2014, 215, 1192-1200. 2698 
[173] K. Terao, Poly(acrylic acid) (PAA), in Encyclopedia of polymeric nanomaterials (Eds.: Shiro 2699 
Kobayashi, Klaus Müllen), Springer, Berlin, Heidelberg, Germany, 2014, pp. 1-6. 2700 
[174] T. Swift, L. Swanson, M. Geoghegan, S. Rimmer, Soft Matter 2016, 12, 2542-2549. 2701 
[175] J. E. Elliott, M. Macdonald, J. Nie, C. N. Bowman, Polymer 2004, 45, 1503-1510. 2702 
[176] a) A. Bernkop-Schnürch, C. Egger, M. Elhassan Imam, A. H. Krauland, J. Control. Release 2003, 93, 2703 
29-38; b) G. M. Eichenbaum, P. F. Kiser, A. V. Dobrynin, S. A. Simon, D. Needham, 2704 
Macromolecules 1999, 32, 4867-4878. 2705 
[177] S. Hochheiser, Rohm and Haas: History of a chemical company, University of Pennsylvania Press, 2706 
Philadelphia, Pennsylvania, 1986. 2707 
[178] U. Ali, K. J. B. A. Karim, N. A. Buang, Polym. Rev. 2015, 55, 678-705. 2708 
[179] a) F. Galli, S. Benedetti, U. Buoncristiani, M. Piroddi, C. Conte, F. Canestrari, E. Buoncristiani, A. 2709 
Floridi, Kidney Int. 2003, 64, 748-755; b) T. G. Tihan, M. D. Ionita, R. G. Popescu, D. Iordachescu, 2710 
82 
 
Mater. Chem. Phys. 2009, 118, 265-269; c) A. Gomaa, R. M. H. Lee, C. S. C. Liu, Eye 2011, 25, 2711 
1090-1093; d) M. Khandaker, M. B. Vaughan, T. L. Morris, J. J. White, Z. Meng, Int. J. Nanomed. 2712 
2014, 9, 2699-2712. 2713 
[180] A. Bhowmick, S. Banerjee, R. Kumar, P. Kundu, Biomedicine and Nanotechnology 2013, 254, 135-2714 
167. 2715 
[181] C. Migliaresi, L. Fambri, J. Kolarik, Biomaterials 1994, 15, 875-881. 2716 
[182] R. Yañez-Macias, I. Alvarez-Moises, I. Perevyazko, A. Lezov, R. Guerrero-Santos, U. S. Schubert, C. 2717 
Guerrero-Sanchez, Macromol. Chem. Phys. 2017, accepted. 2718 
[183] Y.-Z. You, D. S. Manickam, Q.-H. Zhou, D. Oupický, J. Control. Release 2007, 122, 217-225. 2719 
[184] T. Yildirim, A. Traeger, E. Preussger, S. Stumpf, C. Fritzsche, S. Hoeppener, S. Schubert, U. S. 2720 
Schubert, Macromolecules 2016, 49, 3856-3868. 2721 
[185] B. Burns, Polycyanoacrylates, in Encyclopedia of polymer science and technology (Ed.: H. F. 2722 
Mark), John Wiley & Sons, 2016, pp. 1-27. 2723 
[186] J. M. Cracowski, V. Montembault, D. Bosc, B. Améduri, F. Odobel, L. Fontaine, J. Polym. Sci., Part 2724 
A: Polym. Chem. 2009, 47, 1403-1411. 2725 
[187] H. Finkentscher, C. Heuck, DE 654989 C, 1930. 2726 
[188] H. R. Clyde, US 2404713 A, 1946. 2727 
[189] H. Dong, W. Tang, K. Matyjaszewski, Macromolecules 2007, 40, 2974-2977. 2728 
[190] M. Kopeć, P. Krys, R. Yuan, K. Matyjaszewski, Macromolecules 2016, 49, 5877-5883. 2729 
[191] a) P. Bajaj, K. Sen, S. H. Bahrami, J. Appl. Polym. Sci. 1996, 59, 1539-1550; b) P. Bajaj, T. V. 2730 
Sreekumar, K. Sen, J. Appl. Polym. Sci. 2001, 79, 1640-1652; c) D. F. Grishin, I. D. Grishin, Russ. 2731 
Chem. Rev. 2015, 84, 712. 2732 
[192] a) Y. Nakano, K. Hisatani, K. Kamide, Polym. Int. 1994, 35, 207-213; b) A. V. Novoselova, V. V. 2733 
Shamanin, L. V. Vinogradova, Polym. Sci. Ser. B Polym. Chem. 2009, 51, 205-211. 2734 
[193] H. Ono, K. Hisatani, K. Kamide, Polym. J. 1993, 25, 245-265. 2735 
[194] M. L. Gupta, B. Gupta, W. Oppermann, G. Hardtmann, J. Appl. Polym. Sci. 2004, 91, 3127-3133. 2736 
[195] N. Arsalani, R. Rakh, E. Ghasemi, A. A. Entezami, Iran. Polym. J. 2009, 18, 623-632. 2737 
[196] S. K. Nataraj, K. S. Yang, T. M. Aminabhavi, Prog. Polym. Sci. 2012, 37, 487-513. 2738 
[197] C. Dizman, D. O. Demirkol, S. Ates, L. Torun, S. Sakarya, S. Timur, Y. Yagci, Colloids Surf., B 2011, 2739 
88, 265-270. 2740 
[198] M. Amirilargani, A. Sabetghadam, T. Mohammadi, Polym. Adv. Technol. 2012, 23, 398-407. 2741 
[199] O. Bayer, H. Rinke, W. Siefken, L. Orthner, H. Schild, DRP 728981 (13. Nov. 1937), I. G. Farben, 2742 
Chem. Zbl., 1940. 2743 
[200] a) P. A. Gunatillake, R. Adhikari, G. P. Felton, Biodegradable polyurethanes: design, synthesis, 2744 
properties and potential applications, in Biodegradable polymers: Processing, degradation and 2745 
applications (Ed.: Gary P. Felton), Nova Science Publishers, Hauppauge (New York), 2011, pp. 2746 
431-470; b) G. T. Howard, Int. Biodeterior. Biodegrad. 2002, 49, 245-252; c) T. Thomson, 2747 
Polyurethanes as specialty chemicals: principles and applications, CRC Press (Taylor & Francis 2748 
Group), Boca Raton, Florida, 2005. 2749 
[201] K. Uhlig, Discovering polyurethanes, Carl Hanser, München, Germany, 1999. 2750 
[202] B. Tieke, Makromolekulare Chemie: Eine Einführung, John Wiley & Sons, 2014. 2751 
[203] a) G. Natta, P. Corradini, I. W. Bassi, Nuovo. Cima. 1960, 15, 68-82; b) N. Ishihara, T. Seimiya, M. 2752 
Kuramoto, M. Uoi, Macromolecules 1986, 19, 2464-2465. 2753 
[204] W. Kaminsky, Metalorganic catalysts for synthesis and polymerization: recent results by Ziegler-2754 
Natta and metallocene investigations, Springer Science & Business Media, Berlin, Germany, 2755 
1999. 2756 
[205] P. Zinck, F. Bonnet, A. Mortreux, M. Visseaux, Prog. Polym. Sci. 2009, 34, 369-392. 2757 
[206] C. A. McNamara, M. J. Dixon, M. Bradley, Chem. Rev. 2002, 102, 3275-3300. 2758 
83 
 
[207] J. Maul, B. G. Frushour, J. R. Kontoff, H. Eichenauer, K.-H. Ott, C. Schade, Polystyrene and styrene 2759 
copolymers, in Ullmann's encyclopedia of industrial chemistry, Wiley-VCH, 2000. 2760 
[208] http://plasticfoodservicefacts.com/Safety-of-Styrene-Based-Polymers-for-Food-Contact, last 2761 
accessed 16.01.2017. 2762 
[209] N. Kumar, R. S. Langer, A. J. Domb, Adv. Drug Delivery Rev. 2002, 54, 889-910. 2763 
[210] A. Göpferich, J. Tessmar, Adv. Drug Delivery Rev. 2002, 54, 911-931. 2764 
[211] A. J. Domb, R. Langer, J. Polym. Sci., Part A: Polym. Chem. 1987, 25, 3373-3386. 2765 
[212] N. G. Gaylord, J. Macromol. Sci., Rev. Macromol. Chem. 1975, C13, 235-261. 2766 
[213] G. J. Domski, J. M. Rose, G. W. Coates, A. D. Bolig, M. Brookhart, Prog. Polym. Sci. 2007, 32, 30-2767 
92. 2768 
[214] a) P. Cossee, J. Catal. 1964, 3, 80-88; b) G. Fink, R. Mülhaupt, H. H. Brintzinger, Ziegler Catalysts: 2769 
Recent Scientific Innovations and Technological Improvements, Springer, Berlin, Heidelberg, 2770 
Germany, 2012. 2771 
[215] J. E. Puskas, Y. Chen, Y. Dahman, D. Padavan, J. Polym. Sci., Part A: Polym. Chem. 2004, 42, 3091-2772 
3109. 2773 
[216] A. J. Lovinger, Poly(vinylidene fluoride), in Developments in crystalline polymers, Vol. 1 (Ed.: D. C. 2774 
Bassett), Springer, Dordrecht, Netherlands, 1982, pp. 195-273. 2775 
[217] a) A. Grigoletto, K. Maso, A. Mero, A. Rosato, O. Schiavon, G. Pasut, J. Drug Delivery Sci. Technol. 2776 
2016, 32, 132–141; b) P. Mishra, B. Nayak, R. K. Dey, Asian J. Pharm. Sci., 11, 337–348. 2777 
[218] J. M. Harris, R. B. Chess, Nat. Rev. Drug Discovery 2003, 2, 214-221. 2778 
[219] A. Kolate, D. Baradia, S. Patil, I. Vhora, G. Kore, A. Misra, J. Control. Release 2014, 192, 67-81. 2779 
[220] V. B. Damodaran, C. J. Fee, Eur. Pharm. Rev. 2010, 15, 18. 2780 
[221] a) A. Kozlowski, J. Milton Harris, J. Control. Release 2001, 72, 217-224; b) P. L. Turecek, M. J. 2781 
Bossard, F. Schoetens, I. A. Ivens, J. Pharm. Sci. 2016, 105, 460-475. 2782 
[222] a) I. Zundorf, T. Dingermann, Die Pharmazie 2014, 69, 323-326; b) M. A. Croyle, Q. C. Yu, J. M. 2783 
Wilson, Hum. Gene Ther. 2000, 11, 1713-1722. 2784 
[223] S. DeFrees, Z.-G. Wang, R. Xing, A. E. Scott, J. Wang, D. Zopf, D. L. Gouty, E. R. Sjoberg, K. 2785 
Panneerselvam, E. C. M. Brinkman-Van der Linden, R. J. Bayer, M. A. Tarp, H. Clausen, 2786 
Glycobiology 2006, 16, 833-843. 2787 
[224] a) S. Brocchini, A. Godwin, S. Balan, J.-w. Choi, M. Zloh, S. Shaunak, Adv. Drug Delivery Rev. 2008, 2788 
60, 3-12; b) G. Pasut, F. M. Veronese, J. Control. Release 2012, 161, 461-472. 2789 
[225] E. W. M. Ng, D. T. Shima, P. Calias, E. T. Cunningham, D. R. Guyer, A. P. Adamis, Nat. Rev. Drug 2790 
Discovery 2006, 5, 123-132. 2791 
[226] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472643.htm, last 2792 
accessed 16.01.2017. 2793 
[227] a) I. A. Ivens, A. Baumann, T. A. McDonald, T. J. Humphries, L. A. Michaels, P. Mathew, 2794 
Haemophilia 2013, 19, 11-20; b) M. V. Ragni, Drugs 2015, 75, 1587-1600; c) M. Laffan, Br. J. 2795 
Haematol. 2016, 172, 23-31; d) R. Stidl, S. Fuchs, M. Bossard, J. Siekmann, P. L. Turecek, M. Putz, 2796 
Haemophilia 2016, 22, 54-64. 2797 
[228] a) E. Blasko, L. Leong, D. S. Sim, L. Tang, E. Ho, J. Wu, K. Z. Kauser, B. Subramanyam, Blood 2014, 2798 
124, 1471-1471; b) T. T. Wynn, B. Gumuscu, J. Blood Med. 2016, 7, 121-128. 2799 
[229] H. R. Stennicke, M. Kjalke, D. M. Karpf, K. W. Balling, P. B. Johansen, T. Elm, K. Øvlisen, F. Möller, 2800 
H. L. Holmberg, C. N. Gudme, E. Persson, I. Hilden, H. Pelzer, H. Rahbek-Nielsen, C. Jespersgaard, 2801 
A. Bogsnes, A. A. Pedersen, A. K. Kristensen, B. Peschke, W. Kappers, F. Rode, L. Thim, M. 2802 
Tranholm, M. Ezban, E. H. N. Olsen, S. E. Bjørn, Blood 2013, 121, 2108-2116. 2803 
[230] a) P. W. Collins, G. Young, K. Knobe, F. A. Karim, P. Angchaisuksiri, C. Banner, T. Gürsel, J. 2804 
Mahlangu, T. Matsushita, E. P. Mauser-Bunschoten, J. Oldenburg, C. E. Walsh, C. Negrier, Blood 2805 
84 
 
2014, 124, 3880-3886; b) T. E. Coyle, M. T. Reding, J. C. Lin, L. A. Michaels, A. Shah, J. Powell, J. 2806 
Thromb. Haemost. 2014, 12, 488-496. 2807 
[231] F. Peyvandi, I. Garagiola, S. Seregni, J. Thromb. Haemost. 2013, 11, 84-98. 2808 
[232] a) M. J. de Groot, M. Hoeksma, N. Blau, D. J. Reijngoud, F. J. van Spronsen, Mol. Genet. Metab. 2809 
2010, 99, S86-S89; b) J. B. Hennermann, S. Roloff, C. Gebauer, B. Vetter, A. von Arnim-Baas, E. 2810 
Mönch, Mol. Genet. Metab. 2012, 107, 294-301. 2811 
[233] A. Bélanger-Quintana, A. Burlina, C. O. Harding, A. C. Muntau, Mol. Genet. Metab. 2011, 104, 2812 
S19-S25. 2813 
[234] C. Sorli, Am. J. Med., 127, S39-S48. 2814 
[235] T. Hirose, Diabetol. Int. 2016, 7, 16-17. 2815 
[236] R. Haag, F. Kratz, Angew. Chem. Int. Ed. 2006, 45, 1198-1215. 2816 
[237] a) X. Pang, H.-L. Du, H.-Q. Zhang, Y.-J. Zhai, G.-X. Zhai, Drug Discovery Today 2013, 18, 1316-1322; 2817 
b) W. Li, P. Zhan, E. De Clercq, H. Lou, X. Liu, Prog. Polym. Sci. 2013, 38, 421-444. 2818 
[238] M. Swierczewska, K. C. Lee, S. Lee, Expert Opin. Emerging Drugs 2015, 20, 531-536. 2819 
[239] http://fibromyalgianewstoday.com/2015/03/04/novel-drug-treats-chronic-pain-without-side-2820 
effects-danger-abuse/, last accessed 16.01.2017. 2821 
[240] http://www.nektar.com/pipeline/rd-pipeline/nktr-181, last accessed 16.01.2017. 2822 
[241] U. Hoch, C.-M. Staschen, R. K. Johnson, M. A. Eldon, Cancer Chemother. Pharmacol. 2014, 74, 2823 
1125-1137. 2824 
[242] A. Patnaik, K. P. Papadopoulos, A. W. Tolcher, M. Beeram, S. Urien, L. J. Schaaf, S. Tahiri, T. 2825 
Bekaii-Saab, F. M. Lokiec, K. Rezaï, A. Buchbinder, Cancer Chemother. Pharmacol. 2013, 71, 1499-2826 
1506. 2827 
[243] http://www.nektar.com/pipeline/rd-pipeline/onzeald, last accessed 16.01.2017. 2828 
[244] a) http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ 2829 
OncologicDrugsAdvisoryCommittee/UCM426178.pdf, last accessed 16.01.2017; b) E. A. Perez, A. 2830 
Awada, J. O'Shaughnessy, H. S. Rugo, C. Twelves, S.-A. Im, P. Gómez-Pardo, L. S. Schwartzberg, V. 2831 
Diéras, D. A. Yardley, D. A. Potter, A. Mailliez, A. Moreno-Aspitia, J.-S. Ahn, C. Zhao, U. Hoch, M. 2832 
Tagliaferri, A. L. Hannah, J. Cortes, Lancet Oncol. 2015, 16, 1556-1568. 2833 
[245] Z. Hong, Curr. Bioact. Compd. 2011, 7, 3-7. 2834 
[246] E. C. Emery, A. P. Luiz, J. N. Wood, Expert Opin. Ther. Targets 2016, 20, 975-983. 2835 
[247] a) E. M. Pelegri-O’Day, E.-W. Lin, H. D. Maynard, J. Am. Chem. Soc. 2014, 136, 14323-14332; b) Y. 2836 
Qi, A. Chilkoti, Curr. Opin. Chem. Biol. 2015, 28, 181-193. 2837 
[248] S. Shah, T. Prematta, N. F. Adkinson, F. T. Ishmael, J. Clin. Pharmacol. 2013, 53, 352-355. 2838 
[249] R. Duncan, Nat. Rev. Cancer 2006, 6, 688-701. 2839 
[250] A. Godwin, K. Bolina, M. Clochard, E. Dinand, S. Rankin, S. Simic, S. Brocchini, J. Pharm. 2840 
Pharmacol. 2001, 53, 1175-1184. 2841 
[251] a) H. Maeda, J. Takeshita, R. Kanamaru, Int. J. Pept. Protein Res. 1979, 14, 81-87; b) H. Maeda, M. 2842 
Ueda, T. Morinaga, T. Matsumoto, J. Med. Chem. 1985, 28, 455-461. 2843 
[252] N. Ohtsuka, T. Konno, Y. Miyauchi, H. Maeda, Cancer 1987, 59, 1560-1565. 2844 
[253] T. Konno, H. Maeda, Targeting chemotherapy of hepatocellular carcinoma, in Neoplasms of the 2845 
liver (Eds.: Kunio Okuda, Kamal G. Ishak), Springer, Tokyo, Japan, 1987, pp. 343-352. 2846 
[254] P. Caliceti, F. M. Veronese, Adv. Drug Delivery Rev. 2003, 55, 1261-1277. 2847 
[255] Y. Matsumura, H. Maeda, Cancer Res. 1986, 46, 6387-6392. 2848 
[256] H. Ishii, J. Furuse, M. Nagase, Y. Maru, M. Yoshino, T. Hayashi, Jpn. J. Clin. Oncol. 2003, 33, 570-2849 
573. 2850 
[257] T. Taguchi, T. Saito, J. Ota, I. Nakao, K. Ohashi, H. Nakamura, T. Konno, Gan to kagaku ryoho 2851 
1991, 18, 1665-1675. 2852 
[258] M. J. Vicent, R. Duncan, Trends Biotechnol. 2006, 24, 39-47. 2853 
85 
 
[259] a) B. Rihova, M. Bilej, V. Vetvicka, K. Ulbrich, J. Strohalm, J. Kopecek, R. Duncan, Biomaterials 2854 
1989, 10, 335-342; b) B. Rihova, K. Ulbrich, J. Kopecek, P. Mancal, Folia Microbiol. 1983, 28, 217-2855 
227. 2856 
[260] P. M. Loadman, M. C. Bibby, J. A. Double, W. M. Al-Shakhaa, R. Duncan, Clin. Cancer Res. 1999, 5, 2857 
3682-3688. 2858 
[261] P. Rejmanová, J. Kopeček, R. Duncan, J. B. Lloyd, Biomaterials 1985, 6, 45-48. 2859 
[262] J. Cassidy, R. Duncan, G. J. Morrison, J. Strohalm, D. Plocova, J. Kopecek, S. B. Kaye, Biochem. 2860 
Pharmacol. 1989, 38, 875-879. 2861 
[263] R. Duncan, L. C. Seymour, L. Scarlett, J. B. Lloyd, P. Rejmanová, J. Kopecek, Biochim. Biophys. Acta 2862 
1986, 880, 62-71. 2863 
[264] L. W. Seymour, D. R. Ferry, D. Anderson, S. Hesslewood, P. J. Julyan, R. Poyner, J. Doran, A. M. 2864 
Young, S. Burtles, D. J. Kerr, J. Clin. Oncol. 2002, 20, 1668-1676. 2865 
[265] E. Gianasi, M. Wasil, E. G. Evagorou, A. Keddle, G. Wilson, R. Duncan, Eur. J. Cancer 1999, 35, 2866 
994-1002. 2867 
[266] X. Lin, Q. Zhang, J. R. Rice, D. R. Stewart, D. P. Nowotnik, S. B. Howell, Eur. J. Cancer 2004, 40, 2868 
291-297. 2869 
[267] a) http://www.prnewswire.com/news-releases/access-expands-its-polymer-platinate-program-2870 
71728437.html, last accessed 16.01.2017; b) R. Tong, J. Cheng, Polym. Rev. 2007, 47, 345-381. 2871 
[268] D. P. Nowotnik, E. Cvitkovic, Adv. Drug Delivery Rev. 2009, 61, 1214-1219. 2872 
[269] D. P. Nowotnik, Curr. Bioact. Compd. 2011, 7, 21-26. 2873 
[270] https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020030-25, last accessed 2874 
16.01.2017. 2875 
[271] J. M. Meerum Terwogt, W. W. ten Bokkel Huinink, J. H. Schellens, M. Schot, I. A. Mandjes, M. G. 2876 
Zurlo, M. Rocchetti, H. Rosing, F. J. Koopman, J. H. Beijnen, Anticancer drugs 2001, 12, 315-323. 2877 
[272] a) N. E. Schoemaker, C. van Kesteren, H. Rosing, S. Jansen, M. Swart, J. Lieverst, D. Fraier, M. 2878 
Breda, C. Pellizzoni, R. Spinelli, M. G. Porro, J. H. Beijnen, J. H. M. Schellens, W. W. ten Bokkel 2879 
Huinink, Br. J. Cancer 2002, 87, 608-614; b) D. Bissett, J. Cassidy, J. S. de Bono, F. Muirhead, M. 2880 
Main, L. Robson, D. Fraier, M. L. Magnè, C. Pellizzoni, M. G. Porro, R. Spinelli, W. Speed, C. 2881 
Twelves, Br. J. Cancer 2004, 91, 50-55; c) F. M. Wachters, H. J. M. Groen, J. G. Maring, J. A. 2882 
Gietema, M. Porro, H. Dumez, E. G. E. de Vries, A. T. van Oosterom, Br. J. Cancer 2004, 90, 2261-2883 
2267. 2884 
[273] a) X.-M. Liu, S. C. Miller, D. Wang, Adv. Drug Delivery Rev. 2010, 62, 258; b) J. Kopeček, P. 2885 
Kopečková, Adv. Drug Delivery Rev. 2010, 62, 122-149. 2886 
[274] a) H. Ross, P. Bonomi, C. Langer, M. O'Brien, K. O'Byrne, L. Paz-Ares, A. Sandler, M. Socinski, F. 2887 
Oldham, J. Singer, J. Clin. Oncol. 2006, 24, abstr. 7039; b) C. J. Langer, K. J. O’Byrne, M. A. 2888 
Socinski, S. M. Mikhailov, K. Leśniewski-Kmak, M. Smakal, T. E. Ciuleanu, S. V. Orlov, M. Dediu, D. 2889 
Heigener, A. J. Eisenfeld, L. Sandalic, F. B. Oldham, J. W. Singer, H. J. Ross, J. Thorac. Oncol. 2008, 2890 
3, 623-630; c) M. E. R. O'Brien, M. A. Socinski, A. Y. Popovich, I. N. Bondarenko, A. Tomova, B. T. 2891 
Bilynsky˘ı, Y. S. Hotko, V. L. Ganul, I. Y. Kostinsky, A. J. Eisenfeld, L. Sandalic, F. B. Oldham, B. 2892 
Bandstra, A. B. Sandler, J. W. Singer, J. Thorac. Oncol. 2008, 3, 728-734. 2893 
[275] P. Bonomi, Expert Rev. Anticancer Ther. 2007, 7, 415-422. 2894 
[276] http://www.prnewswire.com/news-releases/european-regulatory-agency-accepts-cell-2895 
therapeutics-incs-marketing-authorization-application-for-xyotaxtm-for-lung-cancer-for-review-2896 
56983987.html, last accessed 16.01.2017. 2897 
[277] J. Homsi, G. R. Simon, C. R. Garrett, G. Springett, R. De Conti, A. A. Chiappori, P. N. Munster, M. K. 2898 
Burton, S. Stromatt, C. Allievi, P. Angiuli, A. Eisenfeld, D. M. Sullivan, A. I. Daud, Clin. Cancer Res. 2899 
2007, 13, 5855-5861. 2900 
86 
 
[278] K. L. Eskow Jaunarajs, D. G. Standaert, T. X. Viegas, M. D. Bentley, Z. Fang, B. Dizman, K. Yoon, R. 2901 
Weimer, P. Ravenscroft, T. H. Johnston, M. P. Hill, J. M. Brotchie, R. W. Moreadith, Mov. Disord. 2902 
2013, 28, 1675-1682. 2903 
[279] http://serinatherapeutics.com/, last accessed 16.01.2017. 2904 
[280] D. H. Wakefield, J. J. Klein, J. A. Wolff, D. B. Rozema, Bioconjugate Chem. 2005, 16, 1204-1208. 2905 
[281] D. B. Rozema, D. L. Lewis, D. H. Wakefield, S. C. Wong, J. J. Klein, P. L. Roesch, S. L. Bertin, T. W. 2906 
Reppen, Q. Chu, A. V. Blokhin, J. E. Hagstrom, J. A. Wolff, Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 2907 
12982-12987. 2908 
[282] J. M. Rademaker-Lakhai, C. Terret, S. B. Howell, C. M. Baud, R. F. de Boer, D. Pluim, J. H. Beijnen, 2909 
J. H. M. Schellens, J.-P. Droz, Clin. Cancer Res. 2004, 10, 3386-3395. 2910 
[283] V.-T. Tran, J.-P. Benoît, M.-C. Venier-Julienne, Int. J. Pharm. 2011, 407, 1-11. 2911 
[284] M. Vert, K.-H. Hellwich, M. Hess, P. Hodge, P. Kubisa, M. Rinaudo, F. Schué, Pure Appl. Chem. 2912 
2012, 84, 377-410. 2913 
[285] D. S. Kohane, Biotechnol. Bioeng. 2007, 96, 203-209. 2914 
[286] J. Renukuntla, A. D. Vadlapudi, A. Patel, S. H. S. Boddu, A. K. Mitra, Int. J. Pharm. 2013, 447, 75-2915 
93. 2916 
[287] A. C. Hunter, J. Elsom, P. P. Wibroe, S. M. Moghimi, Nanomed. Nanotechnol. Biol. Med. 2012, 8, 2917 
Supplement 1, S5-S20. 2918 
[288] F. Ungaro, I. d' Angelo, A. Miro, M. I. La Rotonda, F. Quaglia, J. Pharm. Pharmacol. 2012, 64, 2919 
1217-1235. 2920 
[289] K. Letchford, H. Burt, Eur. J. Pharm. Biopharm. 2007, 65, 259-269. 2921 
[290] T. W. Prow, J. E. Grice, L. L. Lin, R. Faye, M. Butler, W. Becker, E. M. T. Wurm, C. Yoong, T. A. 2922 
Robertson, H. P. Soyer, M. S. Roberts, Adv. Drug Delivery Rev. 2011, 63, 470-491. 2923 
[291] A. Firooz, S. Nafisi, H. I. Maibach, Int. J. Pharm. 2015, 495, 599-607. 2924 
[292] V. Lassalle, M. L. Ferreira, Macromol. Biosci. 2007, 7, 767-783. 2925 
[293] G. Singh, T. Kaur, R. Kaur, A. Kaur, Int. J. Pharm. Pharm. Sci. 2014, 1, 30-42. 2926 
[294] http://www.rovi.es/ficheros/notas/ingles/185i.pdf., last accessed 16.01.2017. 2927 
[295] W. Dang, I. R. Garver, DE 60023138 T2, 2006. 2928 
[296] D. K. Armstrong, G. F. Fleming, M. Markman, H. H. Bailey, Gynecol. Oncol. 2006, 103, 391-396. 2929 
[297] S. Kaity, S. Maiti, A. Ghosh, D. Pal, A. Ghosh, S. Banerjee, J. Adv. Pharm. Technol. Res. 2010, 1, 2930 
283-290. 2931 
[298] T. Nicolai, O. Colombani, C. Chassenieux, Soft Matter 2010, 6, 3111-3118. 2932 
[299] G. Riess, Prog. Polym. Sci. 2003, 28, 1107-1170. 2933 
[300] M. Talelli, M. Barz, C. J. F. Rijcken, F. Kiessling, W. E. Hennink, T. Lammers, Nano Today 2015, 10, 2934 
93-117. 2935 
[301] E. Pérez-Herrero, A. Fernández-Medarde, Eur. J. Pharm. Biopharm. 2015, 93, 52-79. 2936 
[302] Y. Min, J. M. Caster, M. J. Eblan, A. Z. Wang, Chem. Rev. 2015, 115, 11147-11190. 2937 
[303] C. Oerlemans, W. Bult, M. Bos, G. Storm, J. F. W. Nijsen, W. E. Hennink, Pharm. Res. 2010, 27, 2938 
2569-2589. 2939 
[304] http://www.samyangbiopharm.com/eng/productintroduce/injection01, last accessed 2940 
16.01.2017. 2941 
[305] S.-W. Lee, M.-H. Yun, S. W. Jeong, C.-H. In, J.-Y. Kim, M.-H. Seo, C.-M. Pai, S.-O. Kim, J. Control. 2942 
Release 2011, 155, 262-271. 2943 
[306] K. Kato, K. Chin, T. Yoshikawa, K. Yamaguchi, Y. Tsuji, T. Esaki, K. Sakai, M. Kimura, T. Hamaguchi, 2944 
Y. Shimada, Y. Matsumura, R. Ikeda, Invest. New Drugs 2012, 30, 1621-1627. 2945 
[307] J. W. Valle, A. Armstrong, C. Newman, V. Alakhov, G. Pietrzynski, J. Brewer, S. Campbell, P. 2946 
Corrie, E. K. Rowinsky, M. Ranson, Invest. New Drugs 2011, 29, 1029-1037. 2947 
87 
 
[308] J. Hrkach, D. Von Hoff, M. M. Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. 2948 
Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J. 2949 
J. Song, Y. H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, 2950 
P. W. Kantoff, N. H. Bander, C. Sweeney, O. C. Farokhzad, R. Langer, S. Zale, Sci. Transl. Med. 2951 
2012, 4, 128ra139-128ra139. 2952 
[309] S. Ashton, Y. H. Song, J. Nolan, E. Cadogan, J. Murray, R. Odedra, J. Foster, P. A. Hall, S. Low, P. 2953 
Taylor, R. Ellston, U. M. Polanska, J. Wilson, C. Howes, A. Smith, R. J. A. Goodwin, J. G. Swales, N. 2954 
Strittmatter, Z. Takáts, A. Nilsson, P. Andren, D. Trueman, M. Walker, C. L. Reimer, G. Troiano, D. 2955 
Parsons, D. De Witt, M. Ashford, J. Hrkach, S. Zale, P. J. Jewsbury, S. T. Barry, Sci. Transl. Med. 2956 
2016, 8, 325ra317. 2957 
[310] a) L. Cadzow, K. Arnold, D. Thrasher, J. Nolan, A. Horhota, E. Lewis-Clark, J. Wright, S. Low, Mol. 2958 
Cancer Ther. 2015, 14, C184; b) 2959 
http://www.businesswire.com/news/home/20150924005171/en/BIND-Therapeutics-2960 
Announces-Pfizer-Exercises-Option-Advance, last accessed 16.01.2017. 2961 
[311] Y. Matsumura, T. Hamaguchi, T. Ura, K. Muro, Y. Yamada, Y. Shimada, K. Shirao, T. Okusaka, H. 2962 
Ueno, M. Ikeda, N. Watanabe, Br. J. Cancer 2004, 91, 1775-1781. 2963 
[312] L. Pittet, D. Altreuter, P. Ilyinskii, C. Fraser, Y. Gao, S. Baldwin, M. Keegan, L. Johnston, T. 2964 
Kishimoto, J. Immunol. 2012, 188, 75.11. 2965 
[313] R. A. Maldonado, R. A. LaMothe, J. D. Ferrari, A. H. Zhang, R. J. Rossi, P. N. Kolte, A. P. Griset, C. 2966 
O'Neil, D. H. Altreuter, E. Browning, L. Johnston, O. C. Farokhzad, R. Langer, D. W. Scott, U. H. 2967 
von Andrian, T. K. Kishimoto, Proc. Natl. Acad. Sci. U.S.A. 2015, 112, E156-165. 2968 
[314] T. Ueno, K. Endo, K. Hori, N. Ozaki, A. Tsuji, S. Kondo, N. Wakisaka, S. Murono, K. Kataoka, Y. 2969 
Kato, T. Yoshizaki, Int. J. Nanomed. 2014, 9, 3005-3012. 2970 
[315] S. Eliasof, D. Lazarus, C. G. Peters, R. I. Case, R. O. Cole, J. Hwang, T. Schluep, J. Chao, J. Lin, Y. 2971 
Yen, H. Han, D. T. Wiley, J. E. Zuckerman, M. E. Davis, Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 2972 
15127-15132. 2973 
[316] D. Lazarus, S. Kabir, S. Eliasof, Cancer Res. 2012, 72, 5643. 2974 
[317] S. Wohlfart, A. S. Khalansky, C. Bernreuther, M. Michaelis, J. Cinatl Jr, M. Glatzel, J. Kreuter, Int. J. 2975 
Pharm. 2011, 415, 244-251. 2976 
[318] Q. Zhou, X. Sun, L. Zeng, J. Liu, Z. Zhang, Nanomed. Nanotechnol. Biol. Med. 2009, 5, 419-423. 2977 
[319] B. S. Pattni, V. V. Chupin, V. P. Torchilin, Chem. Rev. 2015, 115, 10938-10966. 2978 
[320] https://www.doxil.com/, last accessed 16.01.2017. 2979 
[321] http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm292721.htm, last accessed 2980 
16.01.2017. 2981 
[322] http://www.ciplamed.com/content/oncodox-peg-injection, last accessed 16.01.2017. 2982 
[323] G. P. Stathopoulos, Anti-Cancer Drugs 2010, 21, 732-736. 2983 
[324] G. P. Stathopoulos, D. Antoniou, J. Dimitroulis, P. Michalopoulou, A. Bastas, K. Marosis, J. 2984 
Stathopoulos, A. Provata, P. Yiamboudakis, D. Veldekis, N. Lolis, N. Georgatou, M. Toubis, C. 2985 
Pappas, G. Tsoukalas, Ann. Oncol. 2010, 21, 2227-2232. 2986 
[325] U. Lächelt, E. Wagner, Chem. Rev. 2015, 115, 11043-11078. 2987 
[326] Y. Lee, K. Kataoka, Adv. Polym. Sci. 2012, 95-134. 2988 
[327] a) R. Kanasty, J. R. Dorkin, A. Vegas, D. Anderson, Nat. Mater. 2013, 12, 967-977; b) H. Yin, R. L. 2989 
Kanasty, A. A. Eltoukhy, A. J. Vegas, J. R. Dorkin, D. G. Anderson, Nat. Rev. Genet. 2014, 15, 541-2990 
555. 2991 
[328] C. A. Taylor, Z. Liu, T. C. Tang, Q. Zheng, S. Francis, T.-W. Wang, B. Ye, J. A. Lust, R. Dondero, J. E. 2992 
Thompson, Mol. Ther. 2012, 20, 1305-1314. 2993 
[329] L. Buscail, B. Bournet, F. Vernejoul, G. Cambois, H. Lulka, N. Hanoun, M. Dufresne, A. Meulle, A. 2994 
Vignolle-Vidoni, L. Ligat, N. Saint-Laurent, F. Pont, S. Dejean, M. Gayral, F. Martins, J. Torrisani, O. 2995 
88 
 
Barbey, F. Gross, R. Guimbaud, P. Otal, F. Lopez, G. Tiraby, P. Cordelier, Mol. Ther. 2015, 23, 779-2996 
789. 2997 
[330] http://www.biocancell.com/lead-program/bc-819/, last accessed 16.01.2017. 2998 
[331] I. J. Matouk, D. Halle, M. Gilon, A. Hochberg, J. Transl. Med. 2015, 13, 1-12. 2999 
[332] J. G. Fewell, M. Matar, G. Slobodkin, S.-O. Han, J. Rice, B. Hovanes, D. H. Lewis, K. Anwer, J. 3000 
Control. Release 2005, 109, 288-298. 3001 
[333] R. D. Alvarez, M. W. Sill, S. A. Davidson, C. Y. Muller, D. P. Bender, R. L. DeBernardo, K. Behbakht, 3002 
W. K. Huh, Gynecol. Oncol. 2014, 133, 433-438. 3003 
[334] http://celsion.com/pages/pipeline, last accessed 16.01.2017. 3004 
[335] M. E. Davis, Mol. Pharmaceutics 2009, 6, 659-668. 3005 
[336] M. E. Davis, J. E. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, 3006 
A. Ribas, Nature 2010, 464, 1067-1070. 3007 
[337] H. B. Levy, G. Baer, S. Baron, C. E. Buckler, C. J. Gibbs, M. J. Iadarola, W. T. London, J. Rice, J. 3008 
Infect. Dis. 1975, 132, 434-439. 3009 
[338] A. S. Levine, H. B. Levy, Cancer Treat. Rep. 1978, 62, 1907-1912. 3010 
[339] M. W. Konstan, P. B. Davis, J. S. Wagener, K. A. Hilliard, R. C. Stern, L. J. H. Milgram, T. H. 3011 
Kowalczyk, S. L. Hyatt, T. L. Fink, C. R. Gedeon, S. M. Oette, J. M. Payne, O. Muhammad, A. G. 3012 
Ziady, R. C. Moen, M. J. Cooper, Hum. Gene Ther. 2004, 15, 1255-1269. 3013 
[340] F. Lori, J. Trocio, N. Bakare, L. M. Kelly, J. Lisziewicz, Vaccine 2005, 23, 2030-2034. 3014 
[341] a) J. Hartikka, A. Geall, V. Bozoukova, D. Kurniadi, D. Rusalov, J. Enas, J.-H. Yi, A. Nanci, A. Rolland, 3015 
J. Gene Med. 2008, 10, 770-782; b) M. A. Kharfan-Dabaja, T. Nishihori, Expert Rev. Vaccines 2015, 3016 
14, 341-350. 3017 
[342] A. L. Sisson, R. Haag, Soft Matter 2010, 6, 4968-4975. 3018 
[343] A. V. Kabanov, S. V. Vinogradov, Angew. Chem. Int. Ed. 2009, 48, 5418-5429. 3019 
[344] A. L. Lewis, M. V. Gonzalez, S. W. Leppard, J. E. Brown, P. W. Stratford, G. J. Phillips, A. W. Lloyd, 3020 
J. Mater. Sci. Mater. Med. 2007, 18, 1691-1699. 3021 
[345] G. Bruixola, R. García, F. Gomez, C. Escoín, L. Palomar, H. de la Cueva, J. J. Martínez, A. 3022 
Santaballa, Ann. Oncol. 2015, 26, iii6-ii9. 3023 
[346] O. K. Akinwande, P. Philips, P. Duras, S. Pluntke, C. Scoggins, R. C. Martin, Cardiovasc. Interv. 3024 
Radiol. 2015, 38, 361-371. 3025 
[347] A. L. Lewis, M. R. Dreher, V. O'Byrne, D. Grey, M. Caine, A. Dunn, Y. Tang, B. Hall, K. D. Fowers, C. 3026 
G. Johnson, K. V. Sharma, B. J. Wood, J. Mater. Sci. Mater. Med. 2016, 27, 13. 3027 
[348] M. Boulin, P. Hillon, J. P. Cercueil, F. Bonnetain, S. Dabakuyo, A. Minello, J. L. Jouve, C. Lepage, M. 3028 
Bardou, M. Wendremaire, P. Guerard, A. Denys, A. Grandvuillemin, B. Chauffert, L. Bedenne, B. 3029 
Guiu, Alimentary Pharmacology & Therapeutics 2014, 39, 1301-1313. 3030 
[349] R. Duran, K. Sharma, M. R. Dreher, K. Ashrafi, S. Mirpour, M. Lin, R. E. Schernthaner, T. R. 3031 
Schlachter, V. Tacher, A. L. Lewis, S. Willis, M. den Hartog, A. Radaelli, A. H. Negussie, B. J. Wood, 3032 
J.-F. H. Geschwind, Theranostics 2016, 6, 28-39. 3033 
[350] https://www.btgplc.com/media/press-releases/first-patient-treated-with-lc-bead-lumi-3034 
radiopaque-embolic-bead-supported-by-philips-live-image-guidance/, last accessed 16.01.2017. 3035 
[351] U. Fritz, O. Fritz, T. A. Gordy, R. Wojcik, J. Blummel, A. Kuller, US 9107850 B2, 2009. 3036 
[352] B. Guiu, A. Schmitt, S. Reinhardt, A. Fohlen, T. Pohl, M. Wendremaire, A. Denys, J. Blümmel, M. 3037 
Boulin, J. Vasc. Interv. Radiol. 2015, 26, 262-270. 3038 
[353] E. de Luis, J. I. Bilbao, J. A. G. J. Ciércoles, A. Martínez-Cuesta, A. de Martino Rodríguez, M. D. 3039 
Lozano, Cardiovasc. Interv. Radiol. 2008, 31, 367-376. 3040 
[354] K. Malagari, A. Pomoni, D. Filippiadis, D. Kelekis, Hepat. Oncol. 2015, 2, 147-157. 3041 
89 
 
[355] http://www.terumo-europe.com/en-emea/interventional-oncology/loco-regional-3042 
treatment/drug-elutable-microspheres-tace/lifepearl%C2%AE-microspheres, last accessed 3043 
16.01.2017. 3044 
[356] http://www.marketwired.com/press-release/biolex-sells-lex-system-to-synthon-and-initiates-3045 
sale-of-locteron-1653466.htm, last accessed 16.01.2017. 3046 
[357] J. Alemán, A. V. Chadwick, J. He, M. Hess, K. Horie, R. G. Jones, P. Kratochvíl, I. Meisel, I. Mita, G. 3047 
Moad, Pure Appl. Chem. 2007, 79, 1801-1829. 3048 
[358] a) M. Hamidi, A. Azadi, P. Rafiei, Adv. Drug Delivery Rev. 2008, 60, 1638-1649; b) K. S. Soni, S. S. 3049 
Desale, T. K. Bronich, J. Control. Release 2016, 240, 109-126. 3050 
[359] http://www.avadel.com/research-pipeline/innovative-technologies/medusa-/, last accessed 3051 
16.01.2017. 3052 
[360] Y. P. Chan, R. Meyrueix, R. Kravtzoff, F. Nicolas, K. Lundstrom, Expert Opin. Drug Deliv. 2007, 4, 3053 
441-451. 3054 
[361] L. Jorgensen, H. M. Nielson, Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, 3055 
Nucleic Acids and Vaccines, JohnWiley & Sons, West Sussex (U. K.), 2009. 3056 
[362] http://www.marketwired.com/press-release/flamel-technologies-medusar-formulated-3057 
interferon-alpha-demonstrates-favorable-antiviral-nasdaq-flml-1673013.htm, last accessed 3058 
16.01.2017. 3059 
[363] http://adisinsight.springer.com/drugs/800040952, last accessed 16.01.2017. 3060 
[364] http://www.ocutx.com/pipeline/dexamethasone-punctum-plug, last accessed 16.01.2017. 3061 
[365] https://www.drugs.com/clinical_trials/ocular-therapeutix-announces-successful-topline-results-3062 
both-inflammation-pain-primary-efficacy-17243.html, last accessed 16.01.2017. 3063 
[366] C. Blizzard, A. Desai, A. Driscoll, J. Ocul. Pharmacol. Ther. 2016, 32, 595-600. 3064 
[367] E. Caló, V. V. Khutoryanskiy, Eur. Polym. J. 2015, 65, 252-267. 3065 
[368] http://www.ferringusa.com/pi/cervidil., last accessed 16.01.2017. 3066 
[369] P. Gupta, K. Vermani, S. Garg, Drug Discovery Today 2002, 7, 569-579. 3067 
[370] http://www.businesswire.com/news/home/20080225005425/en/Marillion-Pharmaceuticals-3068 
Cytokine-PharmaSciences-Announce-License-Agreement, last accessed 16.01.2017. 3069 
[371] J. Gibson, J. A. Halliday, K. Ewert, S. Robertson, Br. Dent. J. 2007, 202, E17. 3070 
[372] http://adisinsight.springer.com/drugs/800020054, last accessed 16.01.2017. 3071 
[373] https://docetp.mpa.se/LMF/Misodel%20vaginal%20delivery%20system%20ENG%20PAR.pdf, last 3072 
accessed 16.01.2017. 3073 
[374] http://www.supprelinla.com/, last accessed 16.01.2017. 3074 
[375] L. A. Silverman, E. K. Neely, G. B. Kletter, K. Lewis, S. Chitra, O. Terleckyj, E. A. Eugster, J. Clin. 3075 
Endocrinol. Metab. 2015, 100, 2354-2363. 3076 
[376] http://www.vantasimplant.com/, last accessed 16.01.2017. 3077 
[377] http://www.hydromer.com/cosmetic/aquamere.pdf, last accessed 16.01.2017. 3078 
[378] http://www.hydromer.com/cosmetic/aquatrix.pdf, last accessed 16.01.2017. 3079 
[379] V. A. Stoy, J. Biomater. Appl. 1988, 3, 552-604. 3080 
[380] http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=711690, last 3081 
accessed 16.01.2017. 3082 
[381] R. C. Rathi, J. Bark, K. D. Fowers, SQZgelTM, in Modified-release drug delivery technology (Eds.: 3083 
M. J. Rathbone, J. Hadgraft, M. S. Roberts, M. E. Lane), CRC Press (Taylor & Francis Group), Salt 3084 
Lake City, Utah, 2008, pp. 153-162. 3085 
[382] https://hum-molgen.org/companies/profile.php3/413-gelmed, last accessed 16.01.2017. 3086 
[383] D. E. Newton, Chemistry of New Materials, Facts On File, New York, 2007. 3087 
[384] N. L. Elstad, K. D. Fowers, Adv. Drug Delivery Rev. 2009, 61, 785-794. 3088 
90 
 
[385] B. Tyler, K. D. Fowers, K. W. Li, V. R. Recinos, J. M. Caplan, A. Hdeib, R. Grossman, L. Basaldella, K. 3089 
Bekelis, G. Pradilla, F. Legnani, H. Brem, J. Neurosurg. 2010, 113, 210-217. 3090 
[386] G. Bonacucina, M. Cespi, G. Mencarelli, G. Giorgioni, G. F. Palmieri, Polymers 2011, 3, 779-811. 3091 
[387] M. McKenzie, D. Betts, A. Suh, K. Bui, L. D. Kim, H. Cho, Molecules 2015, 20, 20397-20408. 3092 
[388] S. J. Vukelja, S. P. Anthony, J. C. Arseneau, B. S. Berman, C. Casey Cunningham, J. J. Nemunaitis, 3093 
W. E. Samlowski, K. D. Fowers, Anticancer Drugs 2007, 18, 283-289. 3094 
[389] G. A. DuVall, D. Tarabar, R. H. Seidel, N. L. Elstad, K. D. Fowers, Anticancer Drugs 2009, 20, 89-95. 3095 
[390] http://www.scripintelligence.com/researchdevelopment/BTG-discontinues-paclitaxel-gel-after-3096 
Phase-IIb-failure-313595, last accessed 16.01.2017. 3097 
[391] http://ipmglobal.org/our-work/our-products/dapivirine-ring/phase-iii-results, last accessed 3098 
16.01.2017. 3099 
[392] http://pipeline.ctiexchange.org/products/upa-vaginal-ring, last accessed 16.01.2017. 3100 
[393] J. T. Clark, M. R. Clark, N. B. Shelke, T. J. Johnson, E. M. Smith, A. K. Andreasen, J. S. Nebeker, J. 3101 
Fabian, D. R. Friend, P. F. Kiser, PLoS ONE 2014, 9, e88509. 3102 
[394] S. R. Ugaonkar, A. Wesenberg, J. Wilk, S. Seidor, O. Mizenina, L. Kizima, A. Rodriguez, S. Zhang, K. 3103 
Levendosky, J. Kenney, M. Aravantinou, N. Derby, B. Grasperge, A. Gettie, J. Blanchard, N. 3104 
Kumar, K. Roberts, M. Robbiani, J. A. Fernández-Romero, T. M. Zydowsky, J. Control. Release 3105 
2015, 213, 57-68. 3106 
[395] http://www.tevapharm.com/news/phase_iii_study_of_teva_s_milprosa_progesterone_ 3107 
vaginal_ring_published_in_fertility_and_sterility_03_13.aspx, last accessed 16.01.2017. 3108 
[396] http://www.ipmglobal.org/content/ipms-dapivirine-ring-may-offer-significant-hiv-protection-3109 
when-used-consistently-new-data, last accessed 16.01.2017. 3110 
[397] D. Ramchandran, U. D. Upadhyay, Population Reports 2007, 1-19. 3111 
[398] A. Lendvay, R. Otieno-Masaba, S. K. Azmat, A. Wheeless, W. Hameed, B. T. Shaikh, S. Kuria, M. J. 3112 
Steiner, M. Chen, P. J. Feldblum, Contraception 2014, 89, 197-203. 3113 
[399] http://www.dahua-sh.com/, last accessed 16.01.2017. 3114 
[400] S. Palomba, A. Falbo, A. Di Cello, C. Materazzo, F. Zullo, Gynecol. Endocrinol. 2012, 28, 710-721. 3115 
[401] https://pipeline.ctiexchange.org/fillpdf?fid=105&nid=869, last accessed 16.01.2017. 3116 
[402] V. Halpern, R. M. Stalter, D. H. Owen, L. J. Dorflinger, A. Lendvay, K. H. Rademacher, 3117 
Contraception 2015, 92, 3-9. 3118 
[403] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm, last 3119 
accessed 16.01.2017. 3120 
[404] E. Dolgin, Nat. Med. 2014, 20, 9-11. 3121 
[405] http://www.medicinenet.com/pilocarpine-ophthalmic_ocular_system/article.htm, last accessed 3122 
16.01.2017. 3123 
[406] D. B. Troy, J. P. Remington, P. Beringer, Remington: The science and practice of pharmacy, 3124 
Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2006. 3125 
[407] J. Wang, A. Jiang, M. Joshi, J. Christoforidis, Mediators Inflammation 2013, 2013, 780634. 3126 
[408] W. A. Pearce, S. Yeh, H. F. Fine, Ophthalmic surgery, lasers & imaging retina 2016, 47, 103-107. 3127 
[409] A. C. Anselmo, S. Mitragotri, J. Control. Release 2014, 190, 15-28. 3128 
[410] M. Cabrera, S. Yeh, T. A. Albini, J. Ophthalmol. 2014, 2014, 5. 3129 
[411] a) Q. D. Nguyen, E. B. Rodrigues, M. E. Farah, W. F. Mieler, D. V. Do, Retinal 3130 
pharmacotherapeutics: Retinal pharmacotherapeutics, in Developments in ophthalmology (Ed.: 3131 
F. Bandello), Karger, 2016; b) N. Kuno, S. Fujii, Ocular Drug Delivery Systems for the Posterior 3132 
Segment: A Review, Retina Today May/June, 2012. 3133 
[412] http://www.gliadel.com/, last accessed 16.01.2017. 3134 
[413] http://propelopens.com/, last accessed 16.01.2017. 3135 
91 
 
[414] T. Golan, E. Z. Khvalevsky, A. Hubert, R. M. Gabai, N. Hen, A. Segal, A. Domb, G. Harari, E. B. 3136 
David, S. Raskin, Y. Goldes, E. Goldin, R. Eliakim, M. Lahav, Y. Kopleman, A. Dancour, A. Shemi, E. 3137 
Galun, Oncotarget 2015, 6, 24560-24570. 3138 
[415] http://www.drug-dev.com/Main/Back-Issues/ADVANCED-DELIVERY-DEVICES-Implantable-3139 
DrugEluting-1006.aspx, last accessed 16.01.2017. 3140 
[416] http://sinusys.com/, last accessed 16.01.2017. 3141 
[417] M. J. Cima, H. Lee, K. Daniel, L. M. Tanenbaum, A. Mantzavinou, K. C. Spencer, Q. Ong, J. C. Sy, J. 3142 
Santini, C. M. Schoellhammer, D. Blankschtein, R. S. Langer, J. Control. Release 2014, 190, 157-3143 
171. 3144 
[418] S. V. Sastry, J. R. Nyshadham, J. A. Fix, Pharm. Sci. Technol. Today 2000, 3, 138-145. 3145 
[419] M. W. Tibbitt, J. E. Dahlman, R. Langer, J. Am. Chem. Soc. 2016, 138, 704-717. 3146 
[420] G. Traverso, R. Langer, Nature 2015, 519, S19. 3147 
[421] a) F. Kong, R. P. Singh, J. Food Sci. 2008, 73, R67-R80; b) F. J. O. Varum, G. B. Hatton, A. W. Basit, 3148 
Int. J. Pharm. 2013, 457, 446-460. 3149 
[422] C. S. Leopold, Pharm. Sci. Technol. Today 1999, 2, 197-204. 3150 
[423] S. D. Hussan, R. Santanu, P. Verma, V. Bhandari, IOSR J. Pharm. 2012, 2, 5-11. 3151 
[424] a) S. Thakral, N. K. Thakral, D. K. Majumdar, Expert Opin. Drug Deliv. 2013, 10, 131-149; b) C. 3152 
Lautenschläger, C. Schmidt, D. Fischer, A. Stallmach, Adv. Drug Delivery Rev. 2014, 71, 58-76. 3153 
[425] S. Joshi, H. U. Petereit, Int. J. Pharm. 2013, 457, 395-406. 3154 
[426] T. Yoshida, T. C. Lai, G. S. Kwon, K. Sako, Expert Opin. Drug Deliv. 2013, 10, 1497-1513. 3155 
[427] M. A. Hanson, M. T. Fareed, S. L. Argenio, A. O. Agunwamba, T. R. Hanson, Prim. Care 2013, 40, 3156 
1-16. 3157 
[428] T. Hu, J. Yang, K. Cui, Q. Rao, T. Yin, L. Tan, Y. Zhang, Z. Li, G. Wang, ACS Appl. Mater. Interfaces 3158 
2015, 7, 11695-11712. 3159 
[429] Y. Huang, H. C. A. Ng, X. W. Ng, V. Subbu, J. Control. Release 2014, 193, 188-201. 3160 
[430] W. Khan, S. Farah, A. J. Domb, J. Control. Release 2012, 161, 703-712. 3161 
[431] J. Iqbal, J. Gunn, P. W. Serruys, Br. Med. Bull. 2013, 106, 193-211. 3162 
[432] A. E. Alahmar, A. D. Grayson, M. Andron, M. Egred, E. D. Roberts, B. Patel, R. K. G. Moore, K. 3163 
Albouaini, M. Jackson, R. A. Perry, Int. J. Cardiol. 2009, 132, 398-404. 3164 
[433] T. Palmerini, G. Biondi-Zoccai, D. Della Riva, A. Mariani, P. Genereux, A. Branzi, G. W. Stone, J. 3165 
Am. Coll. Cardiol. 2013, 62, 1915-1921. 3166 
[434] S. L. Chin-Quee, S. H. Hsu, K. L. Nguyen-Ehrenreich, J. T. Tai, G. M. Abraham, S. D. Pacetti, Y. F. 3167 
Chan, G. Nakazawa, F. D. Kolodgie, R. Virmani, N. N. Ding, L. A. Coleman, Biomaterials 2010, 31, 3168 
648-657. 3169 
[435] a) D. M. Martin, F. J. Boyle, Med. Eng. Phys. 2011, 33, 148-163; b) T. Tada, R. A. Byrne, S. Cassese, 3170 
L. King, S. Schulz, J. Mehilli, A. Schömig, A. Kastrati, Am. Heart J. 2013, 165, 80-86; c) B. D. Gogas, 3171 
M. McDaniel, H. Samady, S. B. I. King, Trends Cardiovasc. Med. 2014, 24, 305-313. 3172 
[436] A. M. Sammel, D. Chen, N. Jepson, Heart, Lung and Circulation 2013, 22, 495-506. 3173 
[437] a) G. G. Stefanini, B. Kalesan, P. W. Serruys, D. Heg, P. Buszman, A. Linke, T. Ischinger, V. Klauss, 3174 
F. Eberli, W. Wijns, M.-C. Morice, C. Di Mario, R. Corti, D. Antoni, H. Y. Sohn, P. Eerdmans, G.-A. 3175 
van Es, B. Meier, S. Windecker, P. Jüni, Lancet 2011, 378, 1940-1948; b) K. Upendra, B. Sanjeev, 3176 
Minerva Cardioangiol. 2012, 60, 23-31; c) P. A. Lemos, I. Bienert, Expert Rev. Med. Devices 2013, 3177 
10, 295-300; d) D. J. Kereiakes, I. T. Meredith, S. Windecker, R. Lee Jobe, S. R. Mehta, I. J. 3178 
Sarembock, R. L. Feldman, B. Stein, C. Dubois, T. Grady, S. Saito, T. Kimura, T. Christen, D. J. 3179 
Allocco, K. D. Dawkins, Circ. Cardiovasc. Interv. 2015, 8, e002372; e) L. O. Jensen, P. Thayssen, M. 3180 
Maeng, J. Ravkilde, H. S. Hansen, S. E. Jensen, H. E. Bøtker, K. Berencsi, J. F. Lassen, E. H. 3181 
Christiansen, Am. Heart J. 2015, 170, 210-215. 3182 
[438] W. Chen, T. C. J. Habraken, W. E. Hennink, R. J. Kok, Bioconjugate Chem. 2015, 26, 1277-1288. 3183 
92 
 
[439] B. D. Gogas, V. Farooq, Y. Onuma, P. W. Serruys, Hellenic J. Cardiol. 2012, 53, 301-309. 3184 
[440] https://www.drugs.com/inactive/, last accessed 16.01.2017. 3185 
[441] http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm, last accessed 16.01.2017. 3186 
[442] H. Sohi, Y. Sultana, R. K. Khar, Drug Dev. Ind. Pharm. 2004, 30, 429-448. 3187 
[443] B. Karolewicz, Saudi Pharm. J. 2016, 24, 525-536. 3188 
[444] K. Babiuch, M. Gottschaldt, O. Werz, U. S. Schubert, RSC Advances 2012, 2, 10427-10465. 3189 
[445] G. L. Amidon, H. Lennernas, V. P. Shah, J. R. Crison, Pharm. Res. 1995, 12, 413-420. 3190 
[446] http://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf., last accessed 16.01.2017. 3191 
[447] S. Baghel, H. Cathcart, N. J. O'Reilly, J. Pharm. Sci. 2016, 105, 2527-2544. 3192 
[448] O. M. Y. Koo, Pharmaceutical Excipients: Properties, Functionality, and Applications in Research 3193 
and Industry, John Wiley & Sons, 2016. 3194 
[449] a) A. K. Singla, M. Chawla, A. Singh, Drug Dev. Ind. Pharm. 2000, 26, 913-924; b) G. P. Andrews, T. 3195 
P. Laverty, D. S. Jones, Eur. J. Pharm. Biopharm. 2009, 71, 505-518. 3196 
[450] Z. Zhu, Y. Zhai, N. Zhang, D. Leng, P. Ding, Asian J. Pharm. Sci. 2013, 8, 218-227. 3197 
[451] a) R. P. Gullapalli, C. L. Mazzitelli, Int. J. Pharm. 2015, 496, 219-239; b) A. D'Souza A, R. Shegokar, 3198 
Expert Opin. Drug Deliv. 2016, 13, 1257-1275. 3199 
[452] E. T. Cole, D. Cadé, H. Benameur, Adv. Drug Deliv. Rev. 2008, 60, 747-756. 3200 
[453] T. Schettler, S. Paris, M. Pellett, S. Kidner, D. Wilkinson, Clin. Drug Investig. 2001, 21, 73-78. 3201 
[454] Q. T. Shubhra, J. Tóth, J. Gyenis, T. Feczkó, Polym. Rev. 2014, 54, 112-138. 3202 
[455] a) G. Dumortier, J. L. Grossiord, F. Agnely, J. C. Chaumeil, Pharm. Res. 2006, 23, 2709-2728; b) J. 3203 
J. Escobar-Chávez, M. López-Cervantes, A. Naik, Y. Kalia, D. Quintanar-Guerrero, A. Ganem-3204 
Quintanar, J. Pharm. Pharm. Sci. 2006, 9, 339-358. 3205 
[456] a) A. V. Kabanov, E. V. Batrakova, V. Y. Alakhov, J. Control. Release 2002, 82, 189-212; b) E. V. 3206 
Batrakova, A. V. Kabanov, J. Control. Release 2008, 130, 98-106. 3207 
[457] E. A. Yapar, O. Ynal, Trop. J. Pharm. Res. 2012, 11, 855-866. 3208 
[458] A. Al-Khattawi, A. R. Mohammed, Expert Opin. Drug Deliv. 2013, 10, 651-663. 3209 
[459] N. Krishna, F. Brow, Am. J. Ophthalmol. 1964, 57, 99-106. 3210 
[460] N. Debotton, A. Dahan, Med. Res. Rev. 2017, 37, 52-97. 3211 
[461] A. Dahan, J. M. Miller, AAPS J. 2012, 14, 244-251. 3212 
[462] C. G. Wermuth, D. Aldous, P. Raboisson, D. Rognan, The Practice of Medicinal Chemistry, 3213 
Academic Press, Elsevier Science, San Diego, California, 1996. 3214 
[463] L. Shargel, I. Kanfer, Generic drug product development: Specialty dosage forms, CRC Press 3215 
(Taylor & Francis Group), 2016. 3216 
[464] S. Garg, K. R. Tambwekar, K. Vermani, A. Garg, C. L. Kaul, L. J. Zaneveld, Pharm. Technol. 2001, 3217 
15. 3218 
[465] J. das Neves, M. F. Bahia, Int. J. Pharm. 2006, 318, 1-14. 3219 
[466] M. Justin-Temu, F. Damian, R. Kinget, G. Van Den Mooter, J. Womens Health (Larchmt.) 2004, 13, 3220 
834-844. 3221 
[467] C. M. Caramella, S. Rossi, F. Ferrari, M. C. Bonferoni, G. Sandri, Adv. Drug Delivery Rev. 2015, 92, 3222 
39-52. 3223 
[468] J. H. Guo, Drug Deliv. Technol. 2003, 3. 3224 
[469] D. R. Devi, P. Sandhya, B. N. V. Hari, J. Pharm. Sci. Res. 2013, 5, 159-165. 3225 
[470] H. Almeida, M. H. Amaral, P. Lobao, J. M. Lobo, Drug Discov. Today 2014, 19, 400-412. 3226 
[471] P. Mahlumba, Y. Choonara, P. Kumar, L. du Toit, V. Pillay, Molecules 2016, 21, 1002. 3227 
[472] P. Dhal, S. R. Holmes-Farley, C. Huval, T. Jozefiak, Adv. Polym. Sci. 2006, 192, 9-58. 3228 
[473] B. B. Gerstman, R. Kirkman, R. Platt, Am. J. Kidney Dis. 1992, 20, 159-161. 3229 
[474] Z. Harel, S. Harel, P. S. Shah, R. Wald, J. Perl, C. M. Bell, Am. J. Med. 2013, 126, 264.e269-224. 3230 
93 
 
[475] M. R. Weir, G. L. Bakris, D. A. Bushinsky, M. R. Mayo, D. Garza, Y. Stasiv, J. Wittes, H. Christ-3231 
Schmidt, L. Berman, B. Pitt, N. Engl. J. Med. 2015, 372, 211-221. 3232 
[476] E. A. Slatopolsky, S. K. Burke, M. A. Dillon, Kidney Int. 1999, 55, 299-307. 3233 
[477] W. H. Mandeville, D. I. Goldberg, Curr. Pharm. Des. 1997, 3, 15-28  3234 
[478] a) M. H. Davidson, Expert Opin. Pharmacother. 2007, 8, 2569-2578; b) T. Suzuki, K. Oba, Y. Igari, 3235 
N. Matsumura, K. Watanabe, S. Futami-Suda, H. Yasuoka, M. Ouchi, K. Suzuki, Y. Kigawa, H. 3236 
Nakano, J. Nippon Med. Sch. 2013, 80, 211-217. 3237 
[479] T. J. Louie, J. Peppe, C. K. Watt, D. Johnson, R. Mohammed, G. Dow, K. Weiss, S. Simon, J. F. John, 3238 
G. Garber, S.-C. Taber, D. M. Davidson, Clin. Infect. Dis. 2006, 43, 411-420. 3239 
[480] E. M. Nestorovich, S. M. Bezrukov, Expert Opin. Drug Discovery 2014, 9, 299-318. 3240 
[481] J. D. Reuter, A. Myc, M. M. Hayes, Z. Gan, R. Roy, D. Qin, R. Yin, L. T. Piehler, R. Esfand, D. A. 3241 
Tomalia, J. R. Baker, Bioconjugate Chem. 1999, 10, 271-278. 3242 
[482] J. Balzarini, L. Van Damme, Lancet 2007, 369, 787-797. 3243 
[483] D. Concagh, V. R. Garigapati, S. R. Holmes-Farley, C. C. Huval, T. H. Jozefiak, W. H. Mandeville, K. 3244 
K. Shackett, WO 2001005408 A1, 2001. 3245 
[484] I. Melnikova, D. Wages, Nat. Rev. Drug Discovery 2006, 5, 369-370. 3246 
[485] A. Colas, L. Aguadisch, Chim. Nouv. 1997, 15, 1779. 3247 
[486] K. Mojsiewicz-Pieńkowska, Review of current pharmaceutical applications of polysiloxanes 3248 
(silicones), in Handbook of polymers for pharmaceutical technologies (Eds.: V. K. Thakur, M. K. 3249 
Thakur), John Wiley & Sons, 2015, pp. 363-381. 3250 
[487] M. Ahsan, L. Babaei, A. Gholamrezaei, M. H. Emami, Diagn. Ther. Endosc. 2011, 2011, 4. 3251 
[488] N. J. Carter, G. M. Keating, Drugs 2012, 70, 1545-1577. 3252 
[489] A. Djukic, J. Feldman, H. P. Frey, J. Jankowski, R. Holtzer, S. Moshe, H. Muzumdar, S. Rose, R. 3253 
Shinnar, S. Shinnar, Eur. J. Paediatr. Neurol. 2015, 19, S8. 3254 
[490] G. Landa, O. Butovsky, J. Shoshani, M. Schwartz, A. Pollack, Curr. Res. 2008, 33, 1011-1013. 3255 
[491] J. Kovalchin, J. Krieger, M. Genova, K. Collins, M. Augustyniak, A. Masci, T. Hittinger, B. Kuca, G. 3256 
Edan, C. Braudeau, M. Rimbert, U. Patel, E. Mascioli, E. Zanelli, J. Neuroimmunol. 2010, 225, 153-3257 
163. 3258 
[492] E. P. Orringer, J. F. Casella, K. I. Ataga, M. Koshy, P. Adams-Graves, L. Luchtman-Jones, T. Wun, 3259 
M. Watanabe, F. Shafer, A. Kutlar, M. Abboud, M. Steinberg, B. Adler, P. Swerdlow, C. Terregino, 3260 
S. Saccente, B. Files, S. Ballas, R. Brown, S. Wojtowicz-Praga, J. M. Grindel, JAMA 2001, 286, 3261 
2099-2106. 3262 
[493] R. Ghadi, A. Jain, W. Khan, A. Domb, Wound Healing Biomaterials-Volume 2: Functional 3263 
Biomaterials 2016, 203. 3264 
[494] A. Nan, S. L. Croft, V. Yardley, H. Ghandehari, J. Control. Release 2004, 94, 115-127. 3265 
[495] http://arrowheadpharma.com/pipeline/, last accessed 16.01.2017. 3266 
[496] M. Miyamoto, K. Naka, M. Tokumizu, T. Saegusa, Macromolecules 1989, 22, 1604-1607. 3267 
[497] F. Manzenrieder, R. Luxenhofer, M. Retzlaff, R. Jordan, M. G. Finn, Angew. Chem. Int. Ed. 2011, 3268 
50, 2601-2605. 3269 
[498] A. Mero, G. Pasut, L. D. Via, M. W. M. Fijten, U. S. Schubert, R. Hoogenboom, F. M. Veronese, J. 3270 
Control. Release 2008, 125, 87-95. 3271 
[499] a) J. Tong, R. Luxenhofer, X. Yi, R. Jordan, A. V. Kabanov, Mol. Pharmaceutics 2010, 7, 984-992; b) 3272 
A. Mero, Z. Fang, G. Pasut, F. M. Veronese, T. X. Viegas, J. Control. Release 2012, 159, 353-361. 3273 
[500] a) S. Konieczny, C. P. Fik, N. J. H. Averesch, J. C. Tiller, J. Biotechnol. 2012, 159, 195-203; b) S. 3274 
Konieczny, C. Krumm, D. Doert, K. Neufeld, J. C. Tiller, J. Biotechnol. 2014, 181, 55-63. 3275 
[501] T. Lühmann, M. Schmidt, M. N. Leiske, V. Spieler, T. C. Majdanski, M. Grube, M. Hartlieb, I. 3276 
Nischang, S. Schubert, U. S. Schubert, L. Meinel, ACS Biomater. Sci. Eng. 2017, 3, 304–312. 3277 
94 
 
[502] M. Schmitz, M. Kuhlmann, O. Reimann, C. P. R. Hackenberger, J. Groll, Biomacromolecules 2015, 3278 
16, 1088-1094. 3279 
[503] W. H. Velander, R. D. Madurawe, A. Subramanian, G. Kumar, G. Sinai-Zingde, J. S. Riffle, C. L. 3280 
Orthner, Biotechnol. Bioeng. 1992, 39, 1024-1030. 3281 
[504] T. X. Viegas, M. D. Bentley, J. M. Harris, Z. Fang, K. Yoon, B. Dizman, R. Weimer, A. Mero, G. 3282 
Pasut, F. M. Veronese, Bioconjugate Chem. 2011, 22, 976-986. 3283 
[505] M. Schmidt, S. Harmuth, E. R. Barth, E. Wurm, R. Fobbe, A. Sickmann, C. Krumm, J. C. Tiller, 3284 
Bioconjugate Chem. 2015, 26, 1950-1962. 3285 
[506] M. Bauer, C. Lautenschlaeger, K. Kempe, L. Tauhardt, U. S. Schubert, D. Fischer, Macromol. 3286 
Biosci. 2012, 12, 986-998. 3287 
[507] B. Cao, Q. Tang, G. Cheng, J. Biomater. Sci., Polym. Ed. 2014, 25, 1502-1513. 3288 
[508] X. Wang, X. Sun, G. Jiang, R. Wang, R. Hu, X. Xi, Y. Zhou, S. Wang, T. Wang, J. Appl. Polym. Sci. 3289 
2013, 128, 3289-3294. 3290 
[509] Z. Wang, G. Ma, J. Zhang, W. Lin, F. Ji, M. T. Bernards, S. Chen, Langmuir 2014, 30, 3764-3774. 3291 
[510] W. Lin, H. Zhang, J. Wu, Z. Wang, H. Sun, J. Yuan, S. Chen, J. Mater. Chem. B 2013, 1, 2482-2488. 3292 
[511] Z. Zhao, J. Wang, H.-Q. Mao, K. W. Leong, Adv. Drug Delivery Rev. 2003, 55, 483-499. 3293 
[512] T. Steinbach, F. R. Wurm, Biomacromolecules 2016, 17, 3338-3346. 3294 
[513] S. Zhang, J. Zou, M. Elsabahy, A. Karwa, A. Li, D. A. Moore, R. B. Dorshow, K. L. Wooley, Chem. 3295 
Sci. 2013, 4, 2122-2126. 3296 
[514] J.-Z. Du, X.-J. Du, C.-Q. Mao, J. Wang, J. Am. Chem. Soc. 2011, 133, 17560-17563. 3297 
[515] E. Falco, M. Patel, J. Fisher, Pharm. Res. 2008, 25, 2348-2356. 3298 
[516] S. Tempelaar, L. Mespouille, O. Coulembier, P. Dubois, A. P. Dove, Chem. Soc. Rev. 2013, 42, 3299 
1312-1336. 3300 
[517] D. P. Sanders, K. Fukushima, D. J. Coady, A. Nelson, M. Fujiwara, M. Yasumoto, J. L. Hedrick, J. 3301 
Am. Chem. Soc. 2010, 132, 14724-14726. 3302 
[518] A. C. Engler, X. Ke, S. Gao, J. M. W. Chan, D. J. Coady, R. J. Ono, R. Lubbers, A. Nelson, Y. Y. Yang, 3303 
J. L. Hedrick, Macromolecules 2015, 48, 1673-1678. 3304 
[519] J. M. W. Chan, X. Ke, H. Sardon, A. C. Engler, Y. Y. Yang, J. L. Hedrick, Chem. Sci. 2014, 5, 3294-3305 
3300. 3306 
[520] a) Z. Y. Ong, K. Fukushima, D. J. Coady, Y.-Y. Yang, P. L. R. Ee, J. L. Hedrick, J. Control. Release 3307 
2011, 152, 120-126; b) J. Feng, R.-X. Zhuo, X.-Z. Zhang, Prog. Polym. Sci. 2012, 37, 211-236; c) W. 3308 
Chen, F. Meng, R. Cheng, C. Deng, J. Feijen, Z. Zhong, J. Control. Release 2014, 190, 398-414. 3309 
[521] S. D. Allison, Expert Opin. Drug Deliv. 2008, 5, 615-628. 3310 
[522] S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak, W. C. W. Chan, Nat. Rev. Mater. 3311 
2016, 1, 16014. 3312 
[523] http://www.nanopartikel.info/en/, last accessed 16.01.2017. 3313 
[524] http://inbs.med.utoronto.ca/cnr/, last accessed 16.01.2017. 3314 
[525] H. Otsuka, Y. Nagasaki, K. Kataoka, Adv. Drug Delivery Rev. 2003, 55, 403-419. 3315 
[526] R. Rietscher, J. A. Czaplewska, T. C. Majdanski, M. Gottschaldt, U. S. Schubert, M. Schneider, C.-3316 
M. Lehr, Int. J. Pharm. 2016, 500, 187-195. 3317 
[527] a) T. Sun, Y. S. Zhang, B. Pang, D. C. Hyun, M. Yang, Y. Xia, Angew. Chem. Int. Ed. 2014, 53, 12320-3318 
12364; b) N. Kamaly, B. Yameen, J. Wu, O. C. Farokhzad, Chem. Rev. 2016, 116, 2602-2663. 3319 
[528] M. Karimi, A. Ghasemi, P. S. Zangabad, R. Rahighi, S. M. M. Basri, H. Mirshekari, M. Amiri, Z. S. 3320 
Pishabad, A. Aslani, M. Bozorgomid, Chem. Soc. Rev. 2016, 45, 1457-1501. 3321 
[529] J. E. Zuckerman, M. E. Davis, Nat. Rev. Drug Discovery 2015, 14, 843-856. 3322 
[530] J. W. Choi, J.-H. Park, S. Y. Baek, D.-D. Kim, H.-C. Kim, H.-J. Cho, Colloids Surf., B 2015, 132, 305-3323 
312. 3324 
[531] D. Y. Wong, S. J. Hollister, P. H. Krebsbach, C. Nosrat, Tissue Engineer. 2007, 13, 2515-2523. 3325 
95 
 
[532] D. Mondal, M. Griffith, S. S. Venkatraman, Int. J. Polym. Mater. 2016, 65, 255-265. 3326 
[533] S. Kalita, B. Devi, R. Kandimalla, K. K. Sharma, A. Sharma, K. Kalita, A. C. Kataki, J. Kotoky, Int. J. 3327 
Nanomed. 2015, 10, 2971-2984. 3328 
[534] a) A. Takahashi, Y. Yamamoto, M. Yasunaga, Y. Koga, J.-i. Kuroda, M. Takigahira, M. Harada, H. 3329 
Saito, T. Hayashi, Y. Kato, T. Kinoshita, N. Ohkohchi, I. Hyodo, Y. Matsumura, Cancer Sci. 2013, 3330 
104, 920-925; b) Y. Matsumura, Jpn. J. Clin. Oncol. 2014, 44, 515-525. 3331 
[535] A. Sugaya, I. Hyodo, Y. Koga, Y. Yamamoto, H. Takashima, R. Sato, R. Tsumura, F. Furuya, M. 3332 
Yasunaga, M. Harada, R. Tanaka, Y. Matsumura, Cancer Sci. 2016, 107, 335-340. 3333 
[536] S. Y. Wong, J. M. Pelet, D. Putnam, Prog. Polym. Sci. 2007, 32, 799-837. 3334 
[537] a) C.-H. Ahn, S. Y. Chae, Y. H. Bae, S. W. Kim, J. Control. Release 2002, 80, 273-282; b) M. L. 3335 
Forrest, J. T. Koerber, D. W. Pack, Bioconjugate Chem. 2003, 14, 934-940; c) C. Englert, M. 3336 
Hartlieb, P. Bellstedt, K. Kempe, C. Yang, S. K. Chu, X. Ke, J. M. Garcıá, R. J. Ono, M. Fevre, R. J. 3337 
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ABSTRACT: In this study, we designed and investigated pH-
responsive nanoparticles based on different ratios of mono-
mers with primary, secondary or tertiary amino groups. For
this purpose, copolymers of methyl methacrylate (MMA) with
different compositions of amino methacrylates (2-(dimethyl-
amino)ethyl methacrylate (DMAEMA), 2-(tert-butylamino)ethyl
methacrylate (tBAEMA) and 2-aminoethyl methacrylate hydro-
chloride (AEMAHCI)) were synthesized using the reversible
addition-fragmentation chain transfer (RAFT) polymerization
process. The controlled nature of the radical polymerization
was demonstrated by kinetic studies. All copolymers show low
dispersities (-DM<1.2) with amino contents between 9 and
21 mol %. For the nanoparticle formation, nanoprecipitation
with subsequent solvent evaporation was used. All suspen-
sions were characterized by dynamic light scattering (DLS) and
scanning electron microscopy (SEM). Different initial condi-
tions of the formulations resulted in differently sized nanopar-
ticles that have monomodal size distributions, relatively
narrow polydispersity index (PDI) values and positive zeta
potential values. The pH-stability test results demonstrated
that, depending on the structure and amount of the amino con-
tent, the obtained nanoparticles reveal a reversible pH-
response, such as dissolution at acidic pH values. The ability of
the nanoparticles to encapsulate guest molecules was con-
firmed by pyrene fluorescence studies. The cytotoxicity assay
results showed that the nanoparticles did not have any signifi-
cant cytotoxic effect. VC 2015 Wiley Periodicals, Inc. J. Polym.
Sci., Part A: Polym. Chem. 2015, 53, 2711–2721
KEYWORDS: copolymerization; nanoparticles; nanoprecipitation;
pH-responsive polymers; pH-responsive nanoparticles; poly-
merization kinetics; RAFT polymerization; self-assembly
INTRODUCTION Stimuli-responsive polymeric nanoparticles
recently gained increasing attention due to their potential
applications in numerous fields, in particular for pharmaceu-
tical applications.1–3 Depending on the chemical composition,
such “smart” nanoparticles respond to external and/or inter-
nal stimuli by physicochemical changes driven by tempera-
ture,4 light,5 redox reaction,6 ultrasound,7 or pH value.8
Among these, pH-responsive nanoparticles are regarded as
highly promising vehicles for the selective delivery of phar-
maceutical agents to the diseased tissues. Due to the fact
that cancer cells have an abnormal acidic extracellular envi-
ronment,9 the pH-sensitivity of the matrix material can trig-
ger the release of the encapsulated drugs. Several pH-
responsive nanoparticle systems were reported to increase
the efficacy of anticancer drugs in cancer therapy.10–12 More-
over, a drug delivery vehicle with pH-responsive shedding
would be useful for endosomal escape due to the acidifica-
tion of the late endosome and lysosome.13
There are two main strategies to fabricate polymeric pH-
responsive nanoparticle systems. The first category com-
prises the nanoparticles prepared from polymers that have
pH-sensitive bonds, such as hydrazone or acetal bonds.14,15
The second category involves the nanoparticle formation
from polymers containing ionizable segments, such as amino
and/or carboxyl groups.16,17 Although there are several
methodologies to prepare polymeric nanoparticles,18 most of
the pH-responsive structures in literature are based on the
supramolecular self-assembly of copolymer micelles. How-
ever, the instability of the micelles below their critical
micelle concentration represents a serious drawback.19
Additional Supporting Information may be found in the online version of this article.
VC 2015 Wiley Periodicals, Inc.
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Moreover, uniform size and morphology of the assembled
structure is confined with block type copolymers that are
harder to synthesize compared to statistical copolymers,20
also in terms of upscaling.
In this study, a library of well-defined copolymers of methyl
methacrylate (MMA) with three amino comonomers with
ionizable segments (2-(dimethylamino)ethyl methacrylate
(DMAEMA), 2-(tert-butylamino)ethyl methacrylate (tBAEMA)
and 2-aminoethyl methacrylate hydrochloride (AEMAHCI))
were synthesized via RAFT polymerization (Scheme 1) to
obtain a novel pH-responsive drug delivery vehicle for the con-
trolled release of loaded pharmaceutical agents in acidic envi-
ronment.21 MMA was used as main monomer in the copolymer
chains due to the required hydrophobicity for the nanoparticle
formation. DMAEMA, tBAEMA, and AEMAHCI were used as
comonomers since their polymers act as weak polybases with
pKa values between 7.6 and 8.22–24 All nanoparticles were pre-
pared by means of nanoprecipitation25,26 of the synthesized
copolymers. To investigate a possible effect of the amino con-
tent on the pH-response of corresponding nanoparticles, the
copolymer composition was varied by using different monomer
feed ratios. Compared to the well-known pH-responsive sys-
tems, such as Eudragit E100,27 the main advantage of our
approach is the possibility to tune the nanoparticle’s size, solu-
bility, amino content and distribution of the amino moieties
along the polymer chain, which could improve loading and
release profiles of the pharmaceutical agents encapsulated.
EXPERIMENTAL SECTION
Materials
The monomers methyl methacrylate (MMA), 2-(N,N-dimethyla-
mino)ethyl methacrylate (DMAEMA), 2-(tert-butylamino)ethyl
methacrylate (tBAEMA) and 2-aminoethyl methacrylate hydro-
chloride (AEMAHCI) were purchased from Sigma Aldrich and
purified by stirring in the presence of inhibitor remover prior
to use. 2,20-Azobis(iso-butyronitrile) (AIBN) was purchased
from Acros and recrystallized from methanol prior to use.
4-Cyano-4-(phenylcarbonothioylthio) pentanoic acid (CPADB),
AmberlystV
R
A21, 1,3,5-trioxane, inhibitor remover and pyrene
were purchased from Sigma Aldrich. AlamarBlue was obtained
from Life Technologies. If not stated otherwise, cell culture
materials, cell culture media, and solutions were obtained from
PAA. All other chemicals were obtained from standard suppli-
ers and used without purification unless specified.
Instruments and Methods
Proton nuclear magnetic resonance (1H NMR) spectra were
recorded at room temperature in CDCl3 or CD3OD on a
Brucker Avance 300 MHz using the residual solvent reso-
nance as an internal standard. The chemical shifts are given
in ppm.
Gas chromatography (GC) measurements were performed on
a Shimadzu GC-2010 instrument.
Size-exclusion chromatography (SEC) measurements were
performed on two different setups: (SEC in CHCl3) Shimadzu
system equipped with a SCL-10A system controller, a LC-
10AD pump, a RID-10A refractive index detector and a
PSSSDV-linear S column (5 mm particle size; Polymer Stand-
ards Service GmbH, Mainz, Germany) at 40 8C using a chloro-
form, triethylamine and 2-propanol (94:4:2) mixture as eluent
at a flow rate of 1 mL min21. The system was calibrated with
PMMA standards (Mp5 410 to 88,000 g mol
21); (SEC in
DMAc) Agilent 1200 series equipped with a G1310A pump, a
G1315D DA detector, a G1362A RI detector, and PSS GRAM 30
Å/1000 Å (10 mm particle size) columns in series at 40 8C
using N,N-dimethylacetamide (DMAc) with 2.1 g L21 LiCl as
eluent at a flow rate of 1 mL min21. The system was cali-
brated with PMMA standards (Mp5 505 to 981,000 g mol
21).
Chlorine analysis was carried out on a Titrator TLalpha 20
instrument.
Dynamic light scattering (DLS) was performed on a Zetasizer
Nano ZS (Malvern Instruments, Herrenberg, Germany). After
an equilibration time of 180 s, 3 3 30 runs were carried out
at 25 8C (k5 633 nm). The counts were detected at an angle
of 1738. Each measurement was performed in triplicate. The
mean particle size was approximated as the effective (Z-aver-
age) diameter and the width of the distribution as the poly-
dispersity index of the particles (PDI) obtained by the
cumulants method assuming a spherical shape.
Electrophoretic light scattering was used to measure the elec-
trokinetic potential, also known as zeta potential. The mea-
surements were performed on a Zetasizer Nano ZS (Malvern
Instruments, Herrenberg, Germany) by applying laser Doppler
velocimetry. For each measurement, 10 runs were carried out
using the slow-field and fast-field reversal mode at 150 V.
Each experiment was performed in triplicate at 25 8C.
For scanning electron microscopy (SEM), 5 lL of the suspen-
sions were placed on a mica surface and dried overnight at
room temperature under atmospheric pressure. Afterwards,
images were taken using a Gemini 1530 type LEO field emis-
sion scanning electron microscope (Carl-Zeiss AG, Germany).
The samples were coated with a thin layer (4 nm) of platinum
via sputter coating using a Bal-TEC 020 HR Sputtering Coater.
For the cytotoxicity tests a Tecan Infinite 200 Pro fluores-
cence microplate reader (Crailsheim, Germany) was used.
The fluorescence spectra of pyrene solutions were recorded
on a Jasco FP-6500 fluorometer applying an excitation wave-
length of 335 nm. The emission spectra were recorded from
350 to 600 nm. The excitation and emission bandwidths
were 3.0 and 3.0 nm, respectively. For the pH-response test
of the nanoparticles a BioShake instrument (Analytik Jena
AG, Germany) was used.
Synthesis
RAFT Polymerization
MMA was copolymerized with three different amino metha-
crylates (DMAEMA, tBAEMA and AEMAHCI) using CPADB as
chain transfer agent (CTA) and AIBN as initiator. The initial
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monomer feed ratios of the monomers were varied whereas
the overall monomer to CTA ratio was kept constant at 100.
All polymerizations were carried out at 70 8C in an oil bath.
The copolymerizations with DMAEMA and tBAEMA (P1–P4)
were performed in a 2 M ethanolic solution. Methanol was
used as solvent for the copolymerizations with AEMAHCI
(P5–P6). The polymerization conditions are summarized in
Table 1. An exemplary RAFT copolymerization procedure
(Table 1, P1) is as follows: 30 g MMA (0.300 mol), 5.234 g
DMAEMA (0.033 mol), 930 mg CPADB (3.329 mmol), and
137 mg AIBN (0.832 mmol) were dissolved in ethanol in a
250 mL two-necked round-bottom flask equipped with a
magnetic stir bar. The total volume of the reaction mixture
was 166 mL. After degassing for 4 h by argon purging, the t0
sample for GC was taken and the flask was immersed in a pre-
heated oil bath under stirring at 70 8C. After 10 h, the poly-
merization was stopped by cooling to room temperature and
exposing to air. Monomer conversions were determined via
GC by using the reaction solvent (ethanol) as internal stand-
ard. The polymer was purified by precipitating in cold hexane
(approximately six times). The resulting pink colored polymer
was dried under high vacuum at room temperature until con-
stant weight to produce an overall yield of 40%. The number
average molar mass (Mn) and molar mass dispersities were
determined by two different SEC systems by using PMMA
standards. SEC in CHCl3: Mn5 6100 g mol
21 and -DM5 1.16.
SEC in DMAc: Mn5 6300 g mol
21 and -DM5 1.13.
1H NMR
(CDCl3, 300 MHz): d5 7.87, 7.52 and 7.36 (Ar-H, CPADB),
4.13 (AOCH2CH2NH(CH3)2), 3.60 (AOCH3), 2.64
(AOCH2CH2NH(CH3)2), 2.4–0.7 (backbone) ppm.
The degree of polymerization (DP) for each polymer was cal-
culated from the signal integrals in the 1H NMR spectrum of
the purified copolymer using the following equations:
DPMMA5
Iðpeak aÞ=3
I peak cð Þ=2 (1)
DPDMAEMA5
Iðpeak bÞ=2
I peak cð Þ=2 ; (2)
with I(a) corresponding to the integral of methyl proton
peaks of the MMA at 3.60 ppm, I(b) corresponding to the
integral of methylene proton peaks of the DMAEMA at 4.13
ppm, and I(c) corresponding to the integral of two aromatic
protons of the dithiobenzoate end group at 7.87 ppm. Molar
mass values were calculated by using the following equation:
Mn;NMR5 ðDPMMA3MMMAÞ1 ðDPDMAEMA3MDMAEMAÞ1MCTA;
(3)
in which the molar mass of the MMA, DMAEMA and RAFT
agent are 100.12, 157.21, and 279.38 g mol21, respectively.
Kinetic Study of the Polymerizations
During each polymerization, aliquots of 0.2 mL were taken
periodically from the reaction mixture by a syringe purged
with argon. From each sample, conversions were calculated
via GC (P1-P4) or 1H NMR (P5-P6) by using the reaction
solvents (P1-P4) or 1,3,5-trioxane (P5-P6) as internal stand-
ards. Molar masses and dispersities were determined via
SEC analysis (CHCl3, RI detection).
SCHEME 1 Schematic representation of the RAFT copolymerization of MMA with amino-functionalized methacrylates. [Color fig-
ure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
TABLE 1 RAFT Copolymerization Conditions of MMA (M1) and Corresponding Amino-Functionalized Methacrylates (M2)a
Entry M2 M1/M2/CTA/AIBN Solvent Polymerization Time [h]
P1 DMAEMA 90/10/1/0.25 Ethanol 10
P2 DMAEMA 80/20/1/0.25 Ethanol 10
P3 tBAEMA 95/5/1/0.25 Ethanol 13
P4 tBAEMA 85/15/1/0.25 Ethanol 10
P5b AEMAHCI 90/10/1/0.25 Methanol 9
P6b AEMAHCI 80/20/1/0.25 Methanol 10
a All polymerizations were carried out at total monomer concentrations
of 2 mol L21.
b Polymerization was carried out under reflux.
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Deprotonation of the Polymers
Ion exchange resin Amberlyst A21
VR
was used to deprotonate
P5 and P6. For a typical deprotonation reaction, P5 was dis-
solved in methanol, mixed with Amberlyst
VR
A21 and stirred
for 1 h at room temperature. Subsequently, the correspond-
ing polymer P7 was obtained by filtration, precipitation into
ice-cold hexane and by removal of the volatiles under
reduced pressure at room temperature. 1H NMR (CDCl3, 300
MHz): d5 7.87, 7.52, and 7.36 (Ar-H, CPADB), 4.00
(AOCH2CH2NH2), 3.60 (AOCH3), 2.97 (AOCH2CH2NH2), 2.5–
0.7 (backbone) ppm. SEC in CHCl3: Mn5 5300 g mol
21 and
-DM5 1.15, SEC in DMAc: Mn5 9000 g mol
21 and -DM5 1.10.
Elemental anal. found: C 58.31%, H 8%, N 1.73%, S 0.85%,
Cl 1.01%.
Preparation of the Nanoparticle Suspensions
For nanoprecipitation, the corresponding polymers (P1, P2,
P3, P4, P7, and P8) were dissolved in acetone at a concen-
tration of 1 or 10 mg mL21, respectively, and subsequently
added dropwise to deionized water under continuous stir-
ring at 500 rpm (acetone to water, AW method). For the
water to acetone (WA) method, deionized water was added
drop-wise to the acetone polymer solution under stirring at
500 rpm. The acetone/water (solvent/nonsolvent) ratio was
kept constant at 0.5 for all suspensions. After removal of the
acetone by stirring overnight at room temperature (GC anal-
ysis ensured complete removal of acetone), all suspensions
were diluted to the final volume of 10 mL. The nanoparticles
were characterized by DLS (performed in pure water) and
SEM without filtration.
pH-Response Test of the Nanoparticles
For the pH stability test of the nanoparticles (c5 0.3 mg
mL21), 0.0667 M acetate buffer (pH values 3.4, 4, 5, 6) and
0.0667 M tris buffer (pH values 7, 8, 9) were used. 500 mL
of nanoparticle suspensions were mixed with 500 mL of
buffer solutions in Eppendorf tubes and stored at 37 8C
while mixing at 200 rpm in a BioShake instrument. After
24 h, DLS and zeta potential measurements were performed
(particle concentration of 0.15 mg mL21 in all corresponding
buffer systems).
Fluorescence Spectroscopic Study of the Nanoparticles
1 mL stock solution of pyrene (6 3 1025 mol L21) in ace-
tone was added to 1 mL nanoparticle suspensions (0.15 mg
mL21 polymer concentrations) at various pH values. The
samples were incubated at 37 8C for 24 h to remove acetone
and to give a final pyrene concentration of 3 3 1025 mol
L21.
Cell Lines, Culture Conditions, and Cytotoxicity Test of
Nanoparticles
The L929 (CCL-1, ATCC) cell lines used in the cytotoxicity
experiments were maintained in DMEM culture media sup-
plemented with 10% fetal calf serum (FCS), 100 mg mL21
streptomycin and 100 IU mL21 penicilin. The cells were cul-
tured at 37 8C in humidified 5% CO2 atmosphere. The cyto-
toxicity was tested with L929 cells, as this sensitive cell line
is recommended by ISO10993-5 (n5 6). In detail, cells were
seeded at 10 cells per well in a 96-well plate and incubated
for 24 h. No cells were seeded in the outer wells. After-
wards, the media were replaced by fresh media and incu-
bated for 30 min. The nanoparticle suspensions were added
in the end concentration range from 10 to 1000 mg mL21,
and the cells were incubated at 37 8C for further 24 h. Sub-
sequently, the medium was replaced by fresh media and Ala-
marBlue as recommended by the supplier. After incubation
for 4 h, the fluorescence was measured at Ex 570/Em
610 nm, with untreated cells on the same well plate serving
as controls.
RESULTS AND DISCUSSION
A series of amino-functionalized PMMA based copolymers
was synthesized via RAFT polymerization due to its versatil-
ity and suitability for the synthesis of well-defined amino
methacrylate copolymers.28,29 Three different commercially
available amino methacrylates that have tertiary (DMAEMA),
secondary (tBAEMA) and protonated primary amine func-
tionalities (AEMAHCI) were used as comonomers. The uti-
lized CTA CPADB has previously been successfully applied to
mediate the RAFT polymerization of amino methacry-
lates.29,30 [M]/[CTA] was kept constant at a ratio of 100/1
with a monomer concentration of 2 mol L21 in order to
obtain relatively low molar mass polymers, considering the
increased toxicity of high molar mass polycations.31 Depend-
ing on previous research in our group, the [CTA]/[AIBN]
ratio was kept at 1/0.25 regarding polymerization rate and
control over the molar mass.32 All polymerizations were car-
ried out in ethanol at 70 8C, except for P5-P6, where metha-
nol under reflux was used as solvent because of the poor
solubility of AEMAHCI in ethanol. The primary amine con-
taining monomer AEMA can easily rearrange to its thermo-
dynamically more stable isomer 2-hydroxyethyl
methacrylamide, and the dithiobenzoate moiety of the CTA is
prone to an aminolysis reaction if the free amine monomer
is used.24 Thus, the hydrochloride salt of the monomer
AEMA was used for the polymerization. Two different initial
monomer feed ratios were applied for each copolymerization
to vary the amino content in the copolymers. The amino
methacrylate content in the copolymers was kept low (in
between 9 and 21) due to the required hydrophobicity of
the copolymers for the capability to form nanoparticles via
nanoprecipitation.
Kinetic Studies
The distribution of the amine functionality among the PMMA
chain might be an important parameter that could affect the
particle formation or structure. To obtain information about
the sequence arrangements of the monomers in the PMMA
based copolymer chains, kinetic studies were performed for
each copolymerization. The obtained data from the kinetic
studies of the RAFT copolymerizations of MMA with 10 mol%
comonomer (DMAEMA, tBAEMA and AEMAHCI, respec-
tively) are displayed in Figure 1. The corresponding data
derived from the kinetic studies with 20 mol% comonomer
content are given in the supporting information (Supporting
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Information Fig. S2). Analysis of the kinetic samples by
means of SEC in CHCl3 revealed monomodal molar mass dis-
tributions that shift to lower elution volumes throughout the
course of the polymerization (Supporting Information Fig.
S1). The molar mass Mn was found to increase linearly with
respect to the total monomer conversion (B, Fig. 1). These
results indicate the controlled nature of the RAFT
polymerization.
The semilogarithmic kinetic plots are linear (A, Fig. 1) for
both monomers in each copolymerization, indicating a
pseudo first order polymerization behaviour. At the begin-
ning of the DMAEMA and AEMAHCI polymerizations, induc-
tion periods of around 2 h were observed for each monomer,
which is often reported for RAFT polymerizations.33–36 How-
ever, for tBAEMA copolymerizations an increase in the induc-
tion period of the MMA was observed. This is due to the
selective addition of the tBAEMA to the growing polymer
chains at the beginning of the polymerizations.
The slopes of MMA and DMAEMA in the semilogarithmic
plot, which are directly proportional to the polymerization
rates of MMA and DMAEMA, respectively, are close to each
other, which indicates that both monomers are consumed at
close rates. In accordance to the results of the kinetic stud-
ies, the ratio of the monomers in the isolated copolymers is
similar to the initial monomer feed ratio. These results are
also in a good agreement with the reported reactivity ratios
of MMA and DMAEMA for the RAFT and free radical copoly-
merizations (rMMA  0.8, rDMAEMA  0.9).37,38 Therefore, it
can be concluded that MMA and DMAEMA arrange in the
polymer chain in a random sequence.
In contrast, the increased slope of the tBAEMA in the semilo-
garthmic plot reveals that tBAEMA is consumed faster than
MMA. Indeed, the compositions in the isolated polymers
deviated significantly from the initial monomer feed ratios in
favor of tBAEMA at moderate monomer conversions. The
reported relative reactivity ratios of MMA (rMMA  0.7) and
tBAEMA (rtBAEMA  1.4)39 for the free radical copolymeriza-
tion are in a good agreement with these results. Thus, it can
be concluded that the copolymers of MMA and tBAEMA dis-
play a gradient composition.40,41
To the best of our knowledge there are no relative reactivity
ratios reported for the copolymerization of MMA and
AEMAHCI. However, almost identical slopes of MMA and
AEMAHCI in the semilogarithmic plot hint towards a ran-
dom arrangement of the monomers along the polymer chain
for both 10 as well as 20 mol% AEMAHCI.
The kinetic plots for the copolymerizations of same mono-
mers with different initial monomer feed ratios revealed sim-
ilar results (Supporting Information Fig. S2).
Copolymer Synthesis and Characterization
Based on the results obtained from preliminary kinetic stud-
ies, the final copolymers were synthesized under similar con-
ditions with a total M/CTA of 100 aiming at 10 as well as
20% amino content for each monomer. All polymerizations
were stopped at moderate monomer conversions to exclude
undesired coupling reactions that could take place at higher
monomer conversions. Each purified polymer was character-
ized by 1H NMR spectroscopy and SEC measurements on
two systems (Table 2).
FIGURE 1 Kinetic studies of the RAFT copolymerization of MMA with 10 mol% comonomer DMAEMA (P1), tBAEMA (P3) and
AEMAHCI (P5). [M]/[CPADB]/[AIBN]5 100/1/0.25; [M]052 mol L21. Polymerization conditions for (P1 and P3): Solvent ethanol, T5 70
8C. Polymerization conditions for P5: Solvent methanol under reflux. (A) Semilogarithmic kinetic plots. (B) Mn and Mw/Mn evolution
with total monomer conversion. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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The compositions of the isolated copolymers (F(M1/M2),
Table 2) were calculated from the 1H NMR spectra by using
the integrals of appropriate signals derived from both como-
nomers (methyl proton signal “a” for MMA and methylene
proton signal “b” for the amino monomers in Fig. 2, see the
experimental section for details). Although DMAEMA and
AEMAHCI copolymers had close initial monomer feed ratios
and monomer compositions in the polymers, tBAEMA
copolymers revealed a composition drift. These results are in
accordance with the kinetic studies of the corresponding
monomers described above. However, by adjustment of the
corresponding monomer feed ratios it was possible to obtain
two sets of polymers that contained 10 and 20 mol% of
amine comonomer, respectively. All 1H NMR spectra clearly
indicate the presence of the dithiobenzoate end-groups
derived from the CTA (signals of the aromatic protons at
7.3–7.9 ppm) enabling an estimation of the DP for MMA and
for each amino methacrylate. The according number average
molar mass (Mn) values calculated by
1H NMR are in good
agreement with the theoretical values that were calculated
from the [monomer] to [CTA] ratio and the monomer con-
versions. It should be noted that the 1H NMR spectrum of
P6 was measured in methanol due to the insufficient solubil-
ity of P6 in CDCl3.
The isolated copolymers were analysed using two different
SEC systems, which both revealed monomodal traces for all
polymers with low dispersity values (-DM< 1.2) (Fig. 3, Sup-
porting Information Fig. S3, Table 2). In general, higher Mn
values were obtained from both SEC systems using PMMA
calibration compared to the Mn values calculated from the
1H NMR spectra. This is attributed to the difference in
hydrodynamic volumes of the polymers in both eluents that
TABLE 2 Selected Characterization Data of the MMA (M1) Copolymers with Corresponding Amino Methacrylates (M2)
Entry M2
f(M1/
M2)a
F(M1/
M2)b,c
Conv. (%)
M1 M2
Mn, theo.
d
(g mol21)
DPc
M1 M2
Mn
c
(g mol21)
Mn
e
(g mol21) -DM
e
Mn
f
(g mol21) -DM
f
P1 DMAEMA 9 7.4 39g 45g 4,500 41 5.5 5,200 6,100 1.16 6,300 1.13
P2 DMAEMA 4 4 42g 50g 5,200 40 10 5,900 7,600 1.17 7,800 1.15
P3 tBAEMA 19 9.5 29g 70g 3,700 35 3.7 4,500 5,200 1.19 7,100 1.17
P4 tBAEMA 5.7 3.8 36g 72g 5,300 35 9.2 5,500 7,900 1.15 11,900 1.16
P5 AEMAHCI 9 9.1 45c 44c 5,000 42 4.6 5,200 5,100 1.13 9,200 1.15
P6 AEMAHCI 4 3.7 48c 52c 5,900 30 8.2 4,600 4,500 1.19 11,000 1.15
P7h AEMA 9 45 5 5,200 5,300 1.18 9,000 1.10
P8i AEMA 3.6 35 9.8 5,000 4,800 1.18 10,000 1.15
a Initial monomer feed ratio.
b Monomer ratio in the isolated copolymer.
c Determined by 1H NMR spectroscopy.
d Determined by the formula Mn,theo.5 [([M]M1/[CTA] 3 Conv. 3
MM1)1 ([M]M2/[CTA] 3 Conv. 3 MM2)1 (MCTA)].
e Determined by SEC in CHCl3 analysis (RI detection, PMMA
calibration).
f Determined by SEC in DMAc analysis (RI detection, PMMA
calibration).
g Determined by GC.
h Deprotonated form of P5.
i Deprotonated form of P6.
FIGURE 2 1H NMR spectra (300 MHz, CDCl3) of P1, P3, and P5
and the assignment of the peaks used to calculate the DP.
[Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
FIGURE 3 Normalized SEC traces in CHCl3 (RI detection, elu-
ent: CHCl3) of isolated copolymers of P1-P6. [Color figure can
be viewed in the online issue, which is available at wileyonline-
library.com.]
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are used in these SEC systems compared to PMMA homopo-
lymers. In particular the polar eluent of the SEC in DMAc
apparently results in an increased hydrodynamic volume of
the amine-containing polymers, which directly leads to an
increased apparent molar mass.
Finally the charged copolymers that contain AEMAHCI (P5-
P6) were treated with AmberlystV
R
A21 to obtain the desired
primary amino-functionalized copolymers (P7-P8). Elemental
analysis results demonstrated a significant decrease in the
chlorine content after the deprotonation reactions (Support-
ing Information Table S1). Both SEC systems revealed no
change after the deprotonation reactions (Supporting Infor-
mation Figs. S4–S7), which ensures the absence of disulfide
bond formation, which could possibly occur subsequent to
an end group cleavage of the polymers with AmberlystV
R
A21.
It should also be noted that the 1H NMR spectrum of P8
(Supporting Information Fig. S15) was measured in CDCl3
instead of MeOD since the polymer solubility after deproto-
nation changed dramatically, indicating the decreased polar-
ity of the deprotonated polymer.
Preparation of Nanoparticle Suspensions
Polymeric nanoparticles were prepared from the synthesized
tertiary (P1, P2), secondary (P3, P4) and primary (P7, P8)
amino-functional MMA based copolymers by means of nano-
precipitation with subsequent solvent evaporation without
any need of stabilizers/surfactants. The acetone/water ratio
was kept at 0.5 for all suspensions. In order to obtain differ-
ently sized nanoparticles, two different initial acetone-
polymer solution concentrations (1 mg mL21, 10 mg mL21)
and two different dropping methods (dropping acetone poly-
mer solution to water (AW) and dropping water to acetone
polymer solution (WA)) were applied for each polymer. In
general, smaller nanoparticles were obtained with dropping
acetone polymer solution to water (AW) than dropping
water to acetone polymer solution (WA) (Fig. 4), which is
commonly observed for the nanoprecipitation method.42 For
the initial acetone-polymer solution concentration of 1 mg
mL21, nanoparticles with monomodal size distributions (Fig.
4) and low polydispersity (PDI) values (Table 3) were
obtained from all polymers.
However, with the initial acetone-polymer concentration of
10 mg mL21, nanoparticles with monomodal size distribu-
tions could only be obtained from the copolymers that con-
tained DMAEMA and AEMA (P1, P2, P7, and P8), which
both have a random comonomer distribution. In contrast,
the gradient copolymers of tBAEMA (P3-P4) yielded nano-
particles and undefined aggregates which result in multimo-
dal size distributions and high PDI values. This might be due
to the tightly spaced amino groups along the polymer chain,
FIGURE 4 Intensity size distributions of nanoparticles in water
(P1, P3, and P7) with the initial acetone-polymer concentration
of 1 mg mL21, prepared by dropping acetone-polymer solution
to water (AW) or dropping water to acetone-polymer solution
(WA). [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
TABLE 3 Characterization Results of the Prepared Nanoparticles
Z-averageb [d, nm] PDIb Zeta potentialc [mV]
Polymer Methoda c5 1 g L21 c5 10 g L21 c51 g L21 c5 10 g L21 c5 1 g L21 c510 g L21
P1 AW 15262 1236 1 0.1660.02 0.126 0.01 1356 4.4 1376 0.3
WA 34063 7206 18 0.1160.03 0.076 0.05 1256 4.3 1486 1.1
P2 AW 18462 1316 2 0.1660.01 0.116 0.04 1526 0.4 1316 0.7
WA 47363 6366 4 0.1860.04 0.076 0.05 1476 0.4 1516 0.7
P3 AW 12661 2006 1d 0.1260.02 0.196 0.03d 1446 3.3 1 566 9d
WA 31463 1079628d 0.1460.04 0.266 0.12d 1296 0.4 1 406 3d
P4 AW 16962 1586 1d 0.1560.01 0.156 0.03d 1366 6.4 1 416 3d
WA 33163 6106 12d 0.0960.05 0.146 0.01d 1206 2.1 1 266 2d
P7 AW 12161 1106 1 0.1760.01 0.146 0.02 1566 3.2 1596 0.6
WA 30662 3396 2 0.1160.02 0.106 0.03 1616 0.5 1646 1.0
P8 AW 13361 1826 1 0.1460.02 0.086 0.04 1546 2.1 1596 0.8
WA 25463 5826 13 0.0760.05 0.176 0.02 1536 3.7 1616 0.6
a AW, dropping acetone to water; WA, dropping water to acetone.
b Average values of three DLS measurements.
c Average values of three zeta potential measurements.
d Nanoprecipitation with acetate buffer (pH55) as nonsolvent.
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which result in strong intrachain electrostatic repulsion caus-
ing retardation of the protonation of the amino groups.43
This would result in lower pKa values of gradient tBAEMA
copolymers, although all used amino methacrylate monomers
have similar pKa values22–24 and prevent the nanoparticles
from acquiring an appreciable cationic character at neutral
pH values. Thus, favored van der Waals attraction results in
particle aggregation. To support this assumption, instead of
pure water an acetate buffer system with a pH value of 5
was used as nonsolvent for the nanoprecipitaion of P3 and
P4 with an initial acetone-polymer concentration of 10 mg
mL21. In this case, nanoparticles with monomodal size dis-
tributions and low PDI values could be obtained, presumably
due to the electrostatic stabilization of the nanoparticles as a
consequence of protonation of the closely spaced amino
chains at acidic pH values. By dropping acetone-polymer
solution to water (AW), small nanoparticles with comparable
sizes (Z-average diameter between 110 and 184 nm) were
obtained for both initial acetone-polymer concentrations
(c5 1 mg mL21, c5 10 mg mL21, for P3 and P4 at pH 5).
The acetone-polymer concentration did not affect the nano-
particle size significantly. However, by dropping water into
acetone-polymer solution, relatively smaller nanoparticles (Z-
average diameter between 254 and 473 nm) were formed at
an initial acetone-polymer concentration of 1 mg mL21 com-
pared to 10 mg mL21 (Z-average diameter between 339 and
720 nm) (Fig. 4). As intended, the zeta potential of all sus-
pensions shows positive values in between 120 to 164 mV
indicating a high colloidal stability. The long term stability of
the nanoparticle suspensions was tested at room tempera-
ture for three weeks, showing no change in size and size dis-
tributions. SEM investigations revealed that all nanoparticles
have spherical shapes (Fig. 5, Supporting Information Figs.
S16–S18).
pH-Response Test of the Nanoparticles
The pH-responsive behavior behavior was tested by storing
nanoparticle suspensions at various pH values. Dilute buffer
systems were used to prevent salting out effects. The DLS
measurements (A, Fig. 6) revealed that nanoparticles from
P1 at pH 7 to 8 were not stable and are significantly larger
with higher PDI values compared to water suspensions.
Undefined aggregates were also observed at pH 7 to 8. This
can be explained by the low zeta potential of the nanopar-
ticle suspensions (B, Fig. 6) at these pH values. At low zeta
potential values, van der Waals attractions become stronger
than electrostatic repulsions, which result in aggregation. In
general, stable colloidal dispersions have zeta potentials
beyond 620 mV.44 In agreement with this, P1 nanoparticles
are stable at pH values of 3.4, 4, 5, 6 and 9 with relatively
high absolute zeta potentials. It should be noted that P1
nanoparticles have negative zeta potentials at pH 9 as
already reported for the p(DMAEMA) microgels above their
isoelectric point.45 Unlike P1, P2 nanoparticles did not show
any sign of instability at pH 7, only at pH values of 8 and 9
due to the higher DMAEMA content in P2, meaning a stron-
ger cationic character. At pH values of 3.4 to 5, P2 nanopar-
ticles are protonated and dissolve as already reported for
DMAEMA functional micelles at acidic conditions. The disso-
lution is also monitored by the significant decrease in the
derived count rate obtained from DLS measurements that is
directly proportional to the size and the number of the nano-
particles.46 A subsequent increase of the pH value back to
the initial pH value of 7.5 resulted in a significant increase
in the derived count rate and a Z-average diameter slightly
larger than the original nanoparticles (Z-average
diameter5 180 nm, PDI5 0.38), which hints toward the
reversible dissolution ability of the nanoparticles. Further-
more, the copolymer P2 itself also revealed complete
FIGURE 5 SEM images of nanoparticles that were prepared from P1, P3, and P7 (1 mg mL21) by dropping acetone-polymer solu-
tion to water (AW) or dropping water to acetone-polymer solution (WA).
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dissolution in aqueous media (0.3 mg/mL) at a pH value of
3.4. A dynamic increase of the pH value to the pH value of
7.5 resulted in spontaneous nanoparticle formation; DLS
measurements ensured the nanoparticle formation (Z-aver-
age diameter5 124 nm, PDI5 0.34). In contrast, copolymer
P1 did not show any solubility in acidic aqueous media. Sim-
ilar results were also obtained with nanoparticles prepared
from Eudragit E100 as a reference pH-responsive material
(Supporting Information Fig. S19).27
Due to the tightly spaced tBAEMA moieties that prevent pro-
tonation at neutral pH values, nanoparticles of P3 and P4
demonstrated less stability around neutral pH values com-
pared to the DMAEMA functional nanoparticles. As shown in
Figure 6, P3 nanoparticles aggregate between pH 6 to 8 and
P4 nanoparticles aggregate between pH 7 to 9 as a conse-
quence of the low zeta potential values. At acidic pH values,
P3 and P4 nanoparticles were both stable due to the proto-
nation of the tBAEMA. It should be noted that there was no
nanoparticle dissociation observed even for P4 that contains
21% tBAEMA.
Nanoparticles derived from the AEMA copolymers (P7 and
P8) revealed a higher stability compared to the DMAEMA
and tBAEMA based nanoparticles around neutral pH values.
Compared to the DMAEMA and tBAEMA nanoparticles,
higher isoelectric points of the AEMA nanoparticles at a pH
value around 9, as estimated from Figure 6(B), also support
the higher stability of the AEMA based nanoparticles around
neutral pH values. This can be explained by the primary
amino structure of the AEMA that renders nanoparticles to
protonate easily under neutral conditions. As shown in Fig-
ure 6, P7 and P8 nanoparticles are stable at pH values of 6
and 7 with relatively high zeta potential values. However,
they tend to aggregate at pH values of 8 and 9 as a conse-
quence of the low zeta potential values. Although P7 nano-
particles are stable at pH values of 3.4, 4, and 5, P8
nanoparticles with larger amino content were protonated
and dissolved at these pH values.
Fluorescence Spectroscopic Study of the Nanoparticles
Pyrene as hydrophobic fluorescent probe was encapsulated
as a model drug in P2 and P8 nanoparticles due to their dis-
solution ability at acidic pH values. The fluorescence emis-
sion spectra of pyrene against P2 nanoparticles at various
pH values are shown in Figure 7. Pyrene in pure water is
FIGURE 6 (A) Z-Average diameter (represented up to 1000 nm) and PDI values of nanoparticles as a function of the pH value. (B)
Zeta potentials of the nanoparticles as a function of the pH value. [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
FIGURE 7 Fluorescence emission spectra of pyrene (6 3 1025
mol L21) against P2 nanoparticles (0.15 mg mL21) at various
pH values. Pyrene in pure water was used as control. [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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used as control. The total intensities of the emission spectra
of the nanoparticle suspensions at pH values from 7 to 9 are
significantly higher compared to the emission intensity of
the control. This indicates that pyrene is transferred into the
hydrophobic domains of the nanoparticles and/or aggre-
gates. However, at pH values of 3.4 to 5, the emission inten-
sity of the pyrene is similar to the intensity of the control,
which clearly reveals the dissolution of P2 nanoparticles at
these pH values. P8 nanoparticles showed similar results
(Supporting Information Fig. S20). However, compared to the
same concentration of P2 nanoparticles they have lower
pyrene fluorescence intensities at pH values 7 to 9. This can
be due to the lower hydrophobicity of the P8 nanoparticles
compared to the P2 nanoparticles, meaning that P2 might
show in general higher encapsulation efficiencies for hydro-
phobic drugs.
Cytotoxicity of the Nanoparticles in L929 Cells
To evaluate the cytotoxicity of the nanoparticles, one nano-
particle sample of each copolymer prepared from 1 mg
mL21 AW technique and water soluble polymer P6 was
investigated at the indicated concentrations (Fig. 8). The
cytotoxicity assay results showed that the nanoparticles did
not have any significant cytotoxic effect on L929 cells after
24 h incubation at up to 1 mg mL21. These results are
promising in comparison to the previous reports because
cationic nanoparticles have frequently been associated with
toxic effects in cell studies.47,48 It should be noted that nano-
particles based on PMMA are known as nontoxic, whereas
homopolymers based on PDMAEMA and PAEMA are known
to be toxic.49 P6 showed a severe toxic effect on the cells,
which is due to the primary amino functional AEMA moieties
in the copolymer. However, nanoparticles, which are derived
from P8 (the deprotonated form of P6), are nontoxic. This
might be due to the change of the cationic charge of the
polymer. P8 contains pH-responsive primary amines that are
not fully protonated at the pH values applied. This leads to a
decreased water solubility enabling nanoparticle formation.
Due to the fact that the cationic charges are mainly responsi-
ble for cytotoxicity, the reduced charge content possibly also
results in less destructive effects on the cell membrane.50
Moreover, it was already demonstrated that cationic poly-
plexes with a comparable size to the nanoparticles show less
cytotoxic effects in contrast to the free cationic polymer
chains.51 The cytotoxicity of single cationic polymer chains is
based on the disruption of the lipid double layer by the for-
mation of nanoscale pores or membrane thinning (2 to
5 nm).52 Thus, the reduced cytotoxicity of the nanoparticle
can be attributed to the combination of reduced cationic
charge and less disruptive cell membrane interaction.
CONCLUSIONS
A library of well-defined copolymers of MMA with DMAEMA,
tBAEMA and AEMAHCI was synthesized via RAFT polymer-
ization by varying the initial monomer feed ratios to alter
the amino content in the copolymers and in the correspond-
ing nanoparticle. The controlled nature of the polymeriza-
tions was certified by kinetic studies. By variation of the
initial formulation conditions during the nanoprecipitation
method, such as polymer concentration and dropping
method, well-defined nanoparticles from the synthesized
copolymers with varying sizes were successfully prepared.
Moreover, pH-stability tests demonstrated that, depending on
the structure and amount of the amino functionality in the
copolymers, the corresponding nanoparticles reveal a pH
response. Fluorescence spectroscopic studies of pyrene as
model drug revealed the dissolution of two nanoparticle
batches at acidic pH values. Moreover, none of these nano-
particles exhibited any cytotoxic effect on L929 cells.
The results encourage the use of these polymeric nanopar-
ticles as novel carriers for the controlled release of loaded
pharmaceutical agents in acidic environment, for example,
cancer cells or endosomal cellular compartments. To opti-
mize the release profile, the polymeric composition can be
varied. Future investigations will deal with the controlled
release of active payloads such as anticancer drugs but also
with the delivery and release of genetic material, where the
cationic moieties might favor the encapsulation efficiency
and the burst release from endosome.
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FIGURE 8 Cytotoxicity test of nanoparticles (NPs) that were pre-
pared from P1, P2, P3, P4, P7, P8 and water soluble polymer P6
in L929 cells. The relative viability is expressed as percentage to
control cells not treated with nanoparticles. Untreated cells on
the same well plate were used as positive controls. Data repre-
sent means6SD, n6. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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Figure SI-1 Overlay of the SEC traces (CHCl3) from kinetic studies of the RAFT copolymerization of MMA with 
10% comonomer: DMAEMA (P1), tBAEMA (P3) and AEMA·HCI (P5). [M]/[CPADB]/[AIBN] = 100/1/0.25; [M]0 
= 2 mol L-1. Polymerization conditions for (P1 and P3): Solvent ethanol, T = 70 °C. Polymerization conditions for 
P5: Solvent methanol under reflux. 
 
 
 
Figure SI-2 Kinetic studies of the RAFT copolymerization of MMA with 20 mol% comonomer DMAEMA (P2), 
tBAEMA (P4) and AEMA·HCI (P6). [M]/[CPADB]/[AIBN] = 100/1/0.25; [M]0 = 2 mol L
-1. Polymerization 
conditions for (P2 and P4): Solvent ethanol, T = 70 °C. Polymerization conditions for P6: Solvent methanol under 
reflux. (A) Semilogarithmic kinetic plots. (B) Mn and Mw/Mn evolution with total monomer conversion. (C) SEC 
overlay traces (CHCl3). 
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Figure SI-3 Normalized SEC traces (DMAc, RI detection) of the isolated copolymers of P1-P6. 
 
 
Figure SI-4 Normalized SEC traces (CHCl3, RI detection) of the isolated copolymers P5 and P7. 
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Figure SI-5 Normalized SEC traces (DMAc, RI detection) of isolated copolymers P5 and P7. 
 
 
Figure SI-6 Normalized SEC traces (CHCl3, RI detection) of isolated copolymers P6 and P8. 
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Figure SI-7 Normalized SEC traces (DMAc, RI detection) of isolated copolymers P6 and P8. 
 
 
 
Figure SI-8 1H NMR spectrum (300 MHz, CDCl3) of P1. 
 
S6 
 
 
Figure SI-9 1H NMR spectrum (300 MHz, CDCl3) of P2. 
 
Figure SI-10 1H NMR spectrum (300 MHz, CDCl3) of P3. 
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Figure SI-11 1H NMR spectrum (300 MHz, CDCl3) of P4. 
 
Figure SI-12 1H NMR spectrum (300 MHz, CDCl3) of P5. 
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Figure SI-13 1H NMR spectrum (300 MHz, MeOD) of P6. 
  
 
Figure SI-14 1H NMR spectrum (300 MHz, CDCl3) of P7. 
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Figure SI-15 1H NMR spectrum (300 MHz, CDCl3) of P8. 
 
 
Figure SI-16 SEM images of nanoparticles that were prepared from P2, P4 and P8 (1 mg mL-1) by dropping 
acetone-polymer solution to water (AW) or dropping water to acetone-polymer solution (WA). 
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Figure SI-17 SEM images of nanoparticles that were prepared from P1 and P2 (10 mg mL-1) by dropping acetone-
polymer solution to water (AW) or dropping water to acetone-polymer solution (WA). 
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Figure SI-18 SEM images of nanoparticles that were prepared from P7 and P8 (10 mg mL-1) by dropping acetone-
polymer solution to water (AW) or dropping water to acetone-polymer solution (WA). 
 
 
Figure SI-19 (A) Z-Average diameter (represented up to 1000 nm) and PDI values of Eudragit E100 nanoparticles 
as a function of the pH value. (B) Zeta potential of the Eudragit E100 nanoparticles as a function of the pH value. 
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Figure SI-20 Fluorescence emission spectra of pyrene (6 × 10-5 mol L-1) with P8 nanoparticles (0.15 mg mL-1) at 
various pH values. Pyrene in pure water was used as control.  
 
  
Table SI-1 C, H, N, S and Cl contents (mass % in dry sample) in the copolymers of P5, P6, P7 and P8 that were 
determined by elemental analysis. 
Polymer C H N S Cl 
P5 56.30 7.86 1.73 0.81 3.03 
P7 58.31 8.00 1.73 0.85 1.01 
P6 52.97 7.85 2.95 0.94 4.92 
P8 55.80 7.75 3.02 0.89 0.92 
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Abstract  
A primary amino functionalized methyl methacrylate (MMA) based statistical copolymer is 
covalently coupled with retinoic acid (RA) and a fluorescent dye (DY590) in order to 
investigate the feasibility of the RA containing polymeric nanoparticles for Raman imaging 
studies, and to study the possible selectivity of RA for hepatic stellate cells (HSC) via 
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intravital microscopy. Cationic nanoparticles are prepared by utilizing the nanoprecipitation 
method using modified polymers. Raman studies show that RA functional nanoparticles can 
be detectable in all tested cells without any need of additional label. Moreover, intravital 
microscopy indicates that DY590 is eliminated through the hepatobiliary route but not if used 
as covalently attached tracing molecule for nanoparticles. However, it is a suitable probe for 
sensitive detection of polymeric nanoparticles.   
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1. Introduction  
Polymeric nanoparticles have gained a great interest for potential applications such as 
imaging, diagnostics and targeted drug delivery. Most of these systems rely on the physical 
encapsulation of active molecules into nanoparticles during the self-assembly of the 
corresponding polymers in aqueous solution. However, these systems usually exhibit some 
drawbacks such as insufficient loading and premature release of the cargo. Conjugation of 
polymers with bioactive molecules can overcome these limitations.[1] In this study, retinoic 
acid (RA) was covalently attached to a primary amino functionalized methyl methacrylate 
(MMA) based statistical copolymer via an amide bond to investigate the feasibility of the 
retinoic acid containing polymeric nanoparticles for receptor mediated uptake by hepatic 
stellate cell (HSC) a resident perisinusoidal cell that is mainly responsible for liver cirrhosis.[2-
4] These cells regulate sinusoidal blood flow in health and disease and are known to take up 
and store vit. A through receptors for a retinol binding protein.[5] Because of a relatively long 
conjugated π-bond system, retinol derivatives have very unique Raman properties, which 
make them ideal for Raman microscopic imaging studies in cell cultures. In order to further 
test the receptor mediated targeting concept and the possible selectivity of the retinoic acid for 
hepatic stellate cells in vivo, the copolymer was functionalized with a fluorescent dye with an 
activated ester. Retinoic acid and dye functionalized polymers were then subsequently self-
assembled into nanoparticles via the nanoprecipitation method, and their cellular uptake 
mechanisms were investigated by Raman and intravital microscopy. 
Over the past 10 years, Raman microscopic spectroscopy and imaging has become an 
attractive tool to spectroscopically characterize individual cells. The spatial resolution is 
analogous to conventional as well as fluorescence microscopy and only diffraction limited. By 
introducing a pinhole into the pathway of the collected light, Raman microscopy can also be 
applied confocally. Based on the collected spectral information, it is possible to image 
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individual cellular components or organelles, such as nucleus, endoplasmic reticulum, Golgi 
apparatus, vesicles or mitochondria.[6-8] Apart from subcellular structures it is possible to 
monitor the intracellular uptake of individual species (e.g. molecules and particles) based on 
their spectral properties. If the spectral contrast with respect to the cellular environment is 
sufficient, individual species can be monitored directly. It is also possible to introduce 
molecular functionalities possessing a unique Raman signature. Very popular in that respect is 
the introduction of deuterium by exchanging the hydrogens of a molecule. Consequently, the 
chemical properties remain unaltered, however, the spectroscopic features change 
significantly by shifting the observed scattering intensities of the CH/CD bonds by about 
1000 wavenumbers. The concept of stable isotopic labeling has for instance been applied to 
study uptake dynamics of individual amino acids, deuterated lipids and liposomal 
nanoparticles.[9-13]  
Very high Raman sensitivity, because of high Raman scattering cross sections, offer 
molecules with -conjugation. Examples of molecular families with high -conjugation are 
carotenoids or porphyrins. Recently, Raman microscopy has been applied to study the uptake 
efficiency of beta-carotene loaded PLGA nanoparticles.[14] The penetration of beta-carotene 
into skin has also been studied. Retinol or vitamin A as another member of the carotenoid 
family has also ideal properties for direct observation by Raman spectroscopy. Only recently, 
Raman spectroscopy has been used to quantify vitamin A in hepatic stellate cells (HSCs) of 
the liver.[15] HSCs are known to take up vitamin A independent of their needs though cell-type 
specific receptors[5] and store it in large vesicles located near their nuclei.[16] They serve as 
vitamin A storage and control its availability and, thereby, also protect from vitamin A 
intoxication. Besides controlling vitamin A availability,[17] HSC control the production and 
deposition of extracellular matrix proteins, mostly collagen, and intrahepatic blood pressure. 
Upon activation, HSCs contract and troch the sinusoids thereby limiting their diameter, 
increasing intrahepatic resistance and decreasing blood flow through the liver. HSC activation 
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occurs after a vast of stimuli. Chronic activation leads not only to an increased local and 
systemic blood pressure and transformation of HSCs to fibroblasts.[18] Activated HSCs are in 
a permanent contracted state, lose their vitamin A storage ability, exhibit a high proliferative 
capacity and deposit great amounts of extracellular matrix increasing liver stiffness and 
impairing many of its functions. While this state, referred to as liver fibrosis, is reversible in 
the beginning when the activating stimulus is removed, further activation of the liver 
ultimately processes to liver cirrhosis where the only remaining causative treatment is a liver 
transplantation. Novel targeted therapeutic strategies aim towards preventing the activation of 
HSCs and limiting their proliferative capacity[19] as well the deposition of collagen[4, 20] in an 
activating state. Different strategies including targeted nitric oxide release[21] in hepatic 
stellate cells or different antisense-based methods to suppress genes involved in the 
transcription, translation, protein-folding, activation or excretion of collagen are used 
successfully in experimental studies.[22] Due to the location of HSCs around the capillaries in 
the liver, sufficient concentrations of a drug remains challenging and different methods are 
applied to deliver molecules to HSCs based on their feature to take up and store vitamin A in 
the previously mentioned “need-independent” manner. 
 
2. Results and discussion 
For the presented in vitro and in vivo studies three different polymeric particles were 
synthesized. As the major aspect of the study is to investigate the possible selectivity of the 
retinoic acid for hepatic stellate cells three different PMMA based particle were synthesized. 
Retinoic acid functionalized particles can be directly monitored by Raman microscopy, which 
is ideal to monitor intracellular uptake behavior on the single cellular level. Because Raman 
imaging is usually very time consuming and therefore limited in the field of view (FOV), 
retinoic acid-modified PMMA particles were also functionalized with DY590 as a 
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fluorescence label. As a blind test for the in vivo studies pure PMMA particles were also 
labeled with DY590. 
2.1. Polymer synthesis 
A statistical copolymer (p(MMA-stat-AEMA·HCl) (PRAFT)) of methyl methacrylate (MMA) 
and 2-aminoethyl methacrylate hydrochloride (AEMA·HCl) was synthesized via the 
reversible addition-fragmentation chain transfer (RAFT) polymerization as described 
earlier.[23] It was characterized by size-exclusion chromatography (SEC) showing a number-
average molar mass (Mn) of 5,100 g mol
-1 with a dispersity (Đ) of 1.13. The degree of 
polymerization for MMA and AEMA·HCl was estimated by 1H NMR spectroscopy as 42 and 
6, respectively. For functionalization with retinoic acid (RA), the amino functionalities of 
PRAFT were modified with RA (Scheme 1). However, the ω RAFT end-group of PRAFT 
exhibits a strong UV absorption, which is in a similar region with RA. As a consequence, in 
order to prove the covalent coupling of RA to the polymer by the SEC (UV detector) and UV-
vis spectrophotometry, the ω RAFT end-group of the polymer was cleaved by following a 
procedure reported in literature before, yielding hydroxyl-terminated polymer (P
OH
) (Scheme 
1).
[24]
 The cleavage of the RAFT end-group is indicated by a color change from pink to white. 
UV-vis spectroscopy further verified the cleavage of the ω RAFT end-group by the 
disappearance of UV absorbance at 305 nm in chloroform (Figure S1). In agreement with this, 
SEC analysis using UV detection at 300 nm of the polymer before and after end-group 
removal confirmed the complete elimination of the RAFT end-group by the disappearance of 
the UV absorption (Figure S3). In contrast, SEC analysis with RI detection revealed no 
significant changes in the Mn and Đ values (Figure S2). The 
1
H NMR spectrum also 
confirmed the disappearance of the ω RAFT end-group signals (δ = 7.84, 7.48, and 7.35 ppm) 
(Figure S4).  
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Scheme 1. Schematic representation of the (i) RAFT end group cleavage; (ii) deprotonation 
of POH; (iii) coupling of the retinoic acid (RA) to deprotonated form of POH; (iv and v) 
coupling of DY590 to PRA and deprotonated form of POH. 
 
2.2. Coupling of retinoic acid and DY590 to POH and nanoparticle formulation 
The charged polymer that contains HCl salt was treated with Amberlyst® A21 before 
coupling reactions to obtain the desired primary amino-functionalized polymer (Scheme 1). 
Subsequently, RA was covalently conjugated to the pendant primary amino groups of the POH 
by DCC coupling, yielding RA conjugated polymer (PRA) (Scheme 1). Covalent conjugation 
of the RA to the polymer was confirmed by 1H NMR, SEC and UV-vis spectrophotometry. 
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After the coupling reaction, various characteristic signals of RA appeared without any shift in 
the 1H NMR spectrum of PRA compared to the spectrum of the POH, indicating the covalent 
attachment of RA to the polymer without any isomerization (Figure S5). By comparing the 
relative signal intensity ratio of methyl protons of MMA (δ = 3.60 ppm, peak “a” in Figure 
S5) (calibrated to DP = 42) to methine protons of RA (δ = 5.82 ppm, peak “c” in Figure S5), 
the RA content in one PRA chain was estimated as 1. SEC reveals a slight increase in the 
molar mass value after RA coupling caused by the increased hydrodynamic volume of the 
copolymer in chloroform after RA conjugation (Figure S6). Due to the conjugated polyene 
chain, RA has a strong UV absorbance at λmax = 365 nm in chloroform. The λmax of the RA in 
chloroform was blue shifted by 8 nm after coupling to the POH (Figure S7), which could be 
attributed due to the stacked polyene chains.[25] Moreover, SEC analysis of the PRA with 
overlapping RI and UV signals (at 340 nm) confirms the covalent attachment of the RA to the 
polymer (Figure S8). In a next step, NHS ester functional fluorescent dye DY590 was 
covalently coupled to the primary amino groups of the PRA and POH by using an amine NHS 
ester amidification reaction, resulting in PRA-DY590 and PDY590, respectively (Scheme 1). SEC 
(RI detector) showed no significant molar mass or dispersity changes after the coupling 
reaction (Figure S9-10), indicating DY590 has no impact on the hydrodynamic size of the 
polymers. DY590 has a strong UV absorption at λmax = 578 nm in chloroform (Figure S11). 
After the coupling reactions, λmax of the DY590 in chloroform was red shifted by 4 nm for 
both polymers (PRA-DY590 and PDY590) (Figure S11-12). SEC analysis of PRA and POH 
with UV detection at 600 nm revealed no signal, but DY590 coupled polymers (PRA-DY590 and 
PDY590) exhibited intense signals, which overlap with their respective RI signals (Figure S13-
14). This confirms the covalent coupling of DY590 to the polymers. The disappearance of the 
UV signals (at 600 nm) at high elution volumes in SEC analysis proved that there was no free 
DY590 left after each reaction. Therefore, by comparing the initial feed ratios of the polymer 
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and the DY590, it was assumed that one of every 39 polymer chain contains one DY590 
molecule.   
Polymeric nanoparticles were prepared from the synthesized RA and DY590 coupled 
polymers (PRA, PRA-DY590 and PDY590) by nanoprecipitation with subsequent solvent 
evaporation method.[26-27] Nanoparticles with monomodal size distributions (Z-average 
diameters between 73 and 85 nm) with relatively narrow polydispersity index (PDI) values 
were obtained for all polymers (Table S1, Figure S15). All suspensions exhibit positive ζ-
potential values as a consequence of the primary amino functionality of the copolymers 
(Table S1).[28] 
 
2.3. Raman imaging of particle uptake 
LX-2 human liver cells where incubated with PRA nanoparticles at a concentration of 
50 µg/mL for two time intervals of 1 and 3 hours. The time intervals were chosen according 
to previous incubation experiments with particle systems of similar size. Figure 1 displays the 
Raman spectra of pure RA and the PRA nanoparticles. The spectrum of RA is clearly 
dominated by the Raman intensity of the C=C symmetric stretching vibrations of the 
conjugated π-bonds at 1594 cm-1. The Raman spectrum of the RA modified nanoparticles still 
exhibits this intensity as the most prominent Raman band. All other spectral features originate 
from vibrations of the polymeric matrix for instance the CH stretching vibrations at 2954 cm-
1, the C=O stretching of the ester bonds of the methacrylate or CH scissoring vibrations at 
1452 cm-1. 
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Figure 1. Raman spectra of RA (retinoic acid) (a) and RA modified methacrylate (PRA) 
polymeric nanoparticles (b). 
 
Figures 2A and 2C show the Raman images of two LX-2 cells incubated with PRA NPs for 1 
and 3 hours at a concentration of 50 mg/mL. The distribution of the nanoparticles is plotted in 
red, the cytosol in cyan. The associated spectral information is plotted in corresponding colors 
in Figures 2B and 2D. The Raman images were reconstructed using a typical spectral 
unmixing algorithm, which searches a given dataset for the most dissimilar spectral 
components, usually refered to as endmembers. Usually the number of endmembers can be set 
to the number of molecular species that can be observed, as for instance proteins, lipids and in 
the reported examples retinoic acid. For Raman imaging of individual cells usually 3 to 4 
endmembers are sufficient to reconstruct the image. Because a water immersion objective was 
used one spectral endmember always corresponds to the plain surrounding water.[7] After 1 
hour, the endocytotic uptake of the particles is clearly visible. Small vesicle-like inclusions on 
the order of 0.5 to 1 µm are distributed throughout the cytosol. The corresponding endmember 
spectrum (also in red) distinctly shows the typical RA Raman band at 1596 cm-1. The other 
Raman bands of the red spectrum are typical Raman bands of proteins and can be assigned to 
vibrations of the protein backbones and their residues. Characteristic protein bands are for 
instance the C=O stretching vibrations of carbonyl groups at 1650 cm-1, usually refered to as 
amide I band, CH2 scissoring deformations of methylene groups at 145 cm
-1, or the all 
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symmetric phenylalanine ring breathing at 1002 cm-1. Interestingly, only the very strong RA 
associated 1596 cm-1 band is represented in the observed endmember spectra, none of the 
other methacrylic polymer bands is distinctly visible. However, all of these bands overlay 
with the spectral features of the proteins and are, therefore, more likely masked by these, as 
early degradation of the nanoparticles is not very likely. The cyan endmember spectrum 
associated with the cytosol exhibits all of the typical protein bands and has the appearance of 
typical Raman spectra of cells.  
The Raman image in Figure 2C shows the particle distribution after 3 hours. The uptake is 
apparently continuously increased and has reached a level where in some regions of the 
cytosol individual endocytotic vesicles cannot be resolved or have aggregated in sizes of 
several micrometers. Large inclusions of the particles can be observed throughout the whole 
cell. The corresponding endmember spectrum is now dominated by the RA marker band at 
1596 cm-1. The band is three times as intense compared to the 1 hour incubation time. In 
addition, also the region below the marker band is now altered and bears additional features of 
the RA spectrum. The endmember associated with the cytosol again exhibits all typical 
protein bands. 
 
Figure 2. Raman images of LX-2 cells incubated with PRA nanoparticles for 1 hour (A) and 
3 hours (C) along with the corresponding spectral information plotted in (B) and (D) 
respectively. The distribution of the nanoparticles is shown in red. Distinctly pronounced in 
the Raman spectra is the RA marker band at 1596 cm-1. 
 
Several cells have been imaged by Raman microscopy for the two incubation intervals to 
assure an observation of representative uptake patterns. In Figure 3, the Raman images of five 
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cells for both incubation times are presented. The top row shows the results for the incubation 
of 1 hour. Similar to the image already discussed for Figure 2A, all cells exhibit small vesicle-
like inclusions due to endocytosis. No enhanced aggregation in the vicinity of the cellular 
membranes was observed and the distribution is random. Vesicle size and number are on the 
same order. The size of the endocytes does not reflect the size of the nanoparticles, which 
might be a hint for more than one particle per endocyte. For 3 hours of incubation, the uptake 
is significantly increased. All cells show amounts of particles that fill entire fractions of the 
cytosol and a level of saturation is apparent. For longer incubation times, the cell survival rate 
critically decreased. The spectral information associated with the Raman images shows 
similar increases in intensity as discussed for Figure 2 (data not shown). 
 
Figure 3. LX-2 cells incubated with PRA nanoparticles for 1 hour (top row) and 3 hours 
(bottom). 
 
It is important to note at this point that no native intracellular retinol or retinol derivatives was 
observed in untreated cells, which is in contrast to previous Raman experiments on hepatic 
stellate cells freshly extracted from rat or mouse liver.[29-30]  It is not entirely clear why for the 
LX-2 cells we did not observe the presence of any retinol derivatives by Raman spectroscopy. 
A very crucial aspect for Raman measurements in general, is that the sensitivity is 
intrinsically low compared to for instance fluorescence. It is generally very rare to detect 
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chemical species below the milli-molar range. In cells it is difficult to address concentrations 
in a similar way as in solution. Although 60% of the cytosol is made up of water, various 
compounds can aggregate in cellular organelles. It is well known that retinol aggregates in 
hepatic stellate cells. Testerink et al. report concentrations of 10% (estimated mass 
percentages) localized in lipid droplets, which corresponds to concentrations well measurable 
by Raman spectroscopy. Interestingly, Galler et al. observe a retinol decrease with ongoing 
proliferation and no detection of retinol in HSCs already 5 days after isolation. It is therefore 
reasonable to assume that unlike freshly isolated HSCs, LX-2 cultured cells do not exhibit 
retinol derivatives at concentrations measurable by Raman spectroscopy. 
 
 
2.4. Intravital microscopy 
 
Intravital microscopy is a powerful technique to monitor physiologic effects in real-time in 
vivo. FVB/N mice were injected with DY590 during imaging and its distribution pattern is 
analyzed at different time points (Figure 4A). Hepatocytes are identified by their high 
intracellular NAD(P)H concentration which is visualized by excitation at 375 to 405 nm. 
DY590 quickly occurs in portal vein distributing though sinusoids. Already after 30 s a 
hepatic lining of the dye occurs. After 5 min the dye is internalized into hepatocytes and after 
20 min line structure on the hepatocytes get visible while the dye disappeared from the blood 
vessels. DY590 accumulates further in periportal area (Figure 4B) suggesting a transporter 
mediated transport into hepatocytes. After approximately 40 min most of the dye is eliminated 
into the canalicular system which drains into bile ducts and subsequently process in the 
duodenum. DY590 thereby allows the reconstruction of the canalicular network in the liver 
under most physiologic conditions (Figure 4C).  
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Figure 4. Intravital microscopy of DY590 in the murin liver. A) Uptake and elimination of 
DY590 in the murine liver. B) Zonal uptake of DY590. C) Reconstruction of a in vivo z-stack 
depicting the DY590 filled canalicular network indicating the hepatic elimination of the dye.    
 
When DY590 is conjugated to the cationic polymers POH and PRA and formed to 
nanoparticles, it loses its hepatobiliary clearance (Fig. 5). Both nanoparticles PDY590 and PRA-
DY590 did not enter hepatocytes but are instead uptaken by cells located in the sinusoids. 
Greater occurring accumulations, especially in the curves of the sinusoids, can be contributed 
to Kupffer cells and HSC. Smaller accumulations scattered along the sinusoids can be 
assigned to liver sinusoidal endothelia cells (LSECs). Kupffer cells represent the largest 
population of local macrophages in the liver and are together with LSECs the immunological 
line of defense in the liver. It is known for nanoparticles exhibiting cationic charge to be 
recognized and eliminated quickly by immune cells in particular in the liver. Interestingly, the 
conjugation of retinoic acid did not alter pharmacokinetics of the nanoparticles. This indicates 
the importance of a carefully engineered surface to employ targeting moieties.   
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Figure 5. Hepatic uptake of DY590 conjugated polymeric nanoparticles without (PDY590) and 
with (PRA-DY590) retinoic acid after 40 min. 
 
 
3. Conclusions 
In conclusion, polymeric nanoparticles were prepared by using a cationic methacrylate based 
polymer, which is functionalized with RA and/or a fluorescent dye (DY590). Raman imaging 
of RA functionalized nanoparticle (PRA) uptake was studied on human liver cells. The in vitro 
studies of the retinoic acid modified PMMA particles on LX-2 cells show a very high 
intracellular uptake efficacy. Initial endocytosis is on the order of less than an hour. After one 
hour, the presence of the particles was evident randomly distributed throughout the cytosol. 
Longer incubation times lead to continuous uptake, whereby large areas of the cytosol are 
apparently filled with endocytotic vesicles until a maximum capacity is reached within several 
hours. It was possible to monitor the uptake of the RA-PMMA particles in a completely label 
free manner using Raman microscopy. The advantage of the technique is that the addition of 
fluorescence labels can be avoided. Fluorescence labels are of significant molecular size and 
often change the chemical or biochemical properties of the molecules or in this case 
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nanoparticles. For further development and optimization of such particle systems, Raman 
spectroscopy has great potential, as it is an analytical tool, which also offers the possibility of 
quantification of the intracellular uptake and therefore the possibility to compare the efficacy 
of different polymeric systems. Potentially Raman microscopy can also be applied on 
dissected liver tissue. In the quiescent state, HSC store 90% of body vitamin A and regulate 
nutritive perfusion at the level of individual sinusoids. It is therefore expected (and has been 
shown) that untreated liver tissue contains to a great extent vitamin A, which has to be 
accounted for in carful comparative studies, which will be subject to further investigations in 
the near future. 
Intravital microscopy is utilized to monitor the distribution of free DY590 and nanoparticles 
PDY590 and PRA-DY590 in vivo. In case of only injection of free DY590, it is internalized in 
hepatocytes and eliminated into the canalicular system. Whereas in the case of DY590, 
conjugated nanoparticles (PDY590 and PRA-DY590), hepatobiliary clearance was not evident as 
the nanoparticles did not enter hepatocytes but are instead uptaken by cells located in the 
sinusoids. The results clearly show that modification of polymers with RA for the formulation 
of nanoparticles for targeted delivery to HSC can be monitored by Raman microscopy. 
Consequently, further uptake and selectivity studies are planned to investigate the potential of 
RA modified polymeric nanoparticles for treating liver diseases.   
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EXPERIMENTAL SECTION 
Materials 
All-trans-retinoic acid (RA), dicyclohexylcarbodiimide (DCC), azobisisobutyronitrile (AIBN), 
triphenylphosphine (PPh3), and Amberlyst
®
 A21 were purchased from Sigma Aldrich and used as 
received. DY590 was obtained from Dyomics GmbH (Germany). 
Instruments and methods 
Proton nuclear magnetic resonance (
1
H NMR) spectra were recorded at room temperature in 
CDCl3 or CD3OD on a Brucker Avance 300 MHz. The chemical shifts are given in ppm. 
Size-exclusion chromatography (SEC) measurements were performed on a Shimadzu system 
equipped with a SCL-10A system controller, a LC-10AD pump, a RID-10A refractive index 
detector, and a PSSSDV-linear S column (5 µm particle size; Polymer Standards Service GmbH, 
Mainz, Germany) at 40 °C using a chloroform (CHCl3), triethylamine and 2-propanol (94:4:2) 
mixture as eluent at a flow rate of 1 mL min
-1
. The system was calibrated with a linear calibration 
curve built from poly(methyl methacrylate) (PMMA) standards of narrow dispersity (Mp = 410 to 
88,000 g mol
-1
). 
Dynamic light scattering was performed on a Zetasizer Nano ZS (Malvern Instruments, 
Herrenberg, Germany). After an equilibration time of 180 s, 3 × 30 runs were carried out at 25 °C 
(λ = 633 nm). The counts were detected at an angle of 173°. Each measurement was performed in 
triplicate. The mean particle size was approximated as the effective (Z-average) diameter and the 
width of the distribution as the polydispersity index of the particles (PDI) obtained by the 
cumulants method assuming a spherical shape of the nanoparticles. 
Electrophoretic light scattering was used to measure the electrokinetic potential, also known as ζ-
potential. The measurements were performed on a Zetasizer Nano ZS (Malvern Instruments, 
Herrenberg, Germany) by applying laser Doppler velocimetry. For each measurement, 10 runs 
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were carried out using the slow-field and fast-field reversal mode at 150 V. Each experiment was 
performed in triplicate at 25 °C.  
Raman measurements 
Raman images were acquired using a confocal Raman Microscope Model alpha300 R (WITec, 
Ulm, Germany) and a Nikon water immersion objective with a magnification of 60x and a 
numerical aperture of 1.00. An excitation wavelength of 785 nm was provided by a cw diode 
laser (Toptica Photonics, Gräfelingen, Germany). Raman images were taken at a step size of 
0.5 µm with an integration time of 0.5 s. Each pixel in an image represents one spectrum. If not 
declared otherwise, a grating of 300 grooves/mm was used, leading to a spectral resolution of 
around 6 cm
-1
. 
Data analysis of Raman measurements 
All spectra were cleared from cosmic rays before analysis using the software CytoSpec 
(Cytospec, Berlin, Germany). Image analysis and spectral quantification was then performed in 
MatLab (MathWorks, Natick, MA). Baseline correction with a second order polynomial and 
vector normalization was implemented. Images acquired with Raman microspectroscopy were 
analyzed by the N-FINDR spectral unmixing algorithm described by Winter et al.
1,2
 A 
wavenumber region from 500 to 3100 cm
-1
 was used. 
Cell culture: 
Human LX2 (cell line CCL-2, ATCC, Manassas, VA) were grown in 75-cm3 culture flasks with 7 mL of 
Dulbecco's modified Eagle's medium/Nutrient mixture F-12 DMEM/F12 and 2% fetal kalf serum at 37°C 
and 5% CO2. 100 µL of 1% Pen/Strep was added. Cells were seeded onto and allowed to attach to 
polished CaF2 substrates (Wilmad LabGlass, Buena, NJ), which were chosen to avoid background 
scattering that is observed from regular glass windows. The CaF2 substrates were removed from the 
culture medium after incubation with , and the cells were fixed in a 10% phosphate buffered formalin 
solution and washed in phosphate buffered saline.  
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Animals 
Animal studies were conducted in accordance with animal welfare legislation under pathogen-
free conditions in the animal facility of the Jena University Hospital. During all procedures and 
imaging methods, animals remained under deep general anesthesia using Isoflurane and pain-
reflexes were assessed to gauge the depth of anesthesia. The body temperature further was 
permanently kept on 37 °C using feed-back controlled heating plate. 
Intravital microscopy 
Intravital microscopy was performed as described before.
3
 Briefly, a sterile tail-vein catheter was 
placed in the tail-vein of male FVB/NRj mice. Afterwards the left lateral abdomen was shaved 
and opened and the left lateral liver lobe was exposed on a cover slip and subsequently fixed on it 
by a drop of n-butyl-2-cyanoacrylat (Histoacryl, B. Braun Melsungen AG, Germany). For the 
analysis an inverted confocal laser scanning microscope (LSM-780, Zeiss AG, Jena, Germany) 
was used. The liver architecture was visualized using the NAD(P)H/H+ autofluorescence 
(excitation 375 to 405 nm, emission 410 to 556 nm band-pass on photomultiplier tube). DY590 
was excited at 561 nm and emitted light detected on a GaAsP Detector through a 566 to 704 nm 
band-pass filter.  
Synthesis 
RAFT end group transformation 
A solution of 900 mg p(MMA-stat-AEMA·HCl) (P
RAFT
) and 300 mg of AIBN in 200 mL of 
THF and 2 mL of triethylamine was stirred vigorously at 60 °C under ambient atmosphere.  After 
the discoloration of the solution (~ 3 h), the temperature was reduced to 40 °C and 150 mg of 
triphenylphosphine was added. After 30 min, the polymer was purified by precipitating in hexane 
(3 times). The reader is referred to the note of caution in the followed literature due to the 
possible formation of small amounts of potentially explosive THF-peroxides during the reaction.
4
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In situ deprotonation of P
OH
 
Ion exchange resin Amberlyst
®
 A21 was used to deprotonate P
OH
. P
OH
 was dissolved in 
dichloromethane, mixed with Amberlyst
®
 A21 and stirred for 10 min at room temperature. 
Subsequently, Amberlyst
®
 A21 beads filtered and the resulting solution was used for the coupling 
reactions. 
Coupling of the retinoic acid to P
OH
 
28.4 mg DCC (0.138 mmol) and 46 mg of RA (0.153 mmol) were dissolved in 4 mL of CH2Cl2 
and gently stirred for 30 min at room temperature in the dark. 270 mg of P
OH
 (0.054 mmol) 
dissolved in 10 mL of CH2Cl2 was then added to the solution. The resulting reaction mixture was 
stirred in the dark for 90 min at room temperature. Thereafter, the reaction mixture was filtered to 
get rid of the N,N'-dicyclohexylurea. Subsequently, the corresponding polymer P
RA
 was obtained 
precipitation into hexane (5 times) and by removal of the volatiles under reduced pressure at 
room temperature. 
Coupling of DY590 to P
OH
 or P
RA
 
240 mg P
OH
 or P
RA
 and 1 mg of DY590 were dissolved in 8 mL of CH2Cl2 and stirred for 
overnight at room temperature in the dark. The resulting products were obtained by precipitating 
in hexane and drying under reduced pressure.  
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Figure S1. UV/vis spectra of PRAFT and POH in CHCl3. 
 
 
Figure S2. Normalized SEC (RI detection) traces in CHCl3 of P
RAFT and POH. 
 
 7 
 
Figure S3. Calibrated SEC (UV detection) traces in CHCl3 of P
RAFT and POH. 
 
 
Figure S4. 1H NMR overlay spectra (300 MHz, CDCl3) of P
RAFT and POH. 
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Figure S5. 1H NMR spectra (300 MHz, CDCl3) of retinoic acid (RA) and RA coupled polymer 
(PRA). 
 
 
Figure S6. Normalized SEC (RI detection) traces in CHCl3 of P
RAFT and POH. 
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Figure S7. Normalized UV/vis spectra of retinoic acid (RA) and retinoic acid coupled polymer 
PRA in CHCl3. 
 
 
Figure S8. Normalized SEC traces in CHCl3 of P
RA (RI and UV at 340 nm). 
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Figure S9. Normalized SEC (RI detection) traces in CHCl3 of P
RA and PRA-DY590. 
 
 
Figure S10. Normalized SEC (RI detection) traces in CHCl3 of P
OH and PDY590. 
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Figure S11. (A) Normalized UV/vis spectra of DY590 and retinoic acid (RA) as well as DY590 
coupled polymer PRA-DY590 in CHCl3. (B) Normalized UV/vis spectra (between 475-650 nm) of 
DY590 and retinoic acid (RA) as well as DY590 coupled polymer PRA. 
 
 
Figure S12. Normalized UV/vis spectra of DY590 and DY590 coupled polymer PDY590 in 
CHCl3. 
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Figure S13. Normalized SEC traces in CHCl3 of P
RA-DY590 (RI and UV at 600 nm). 
 
 
Figure S14. Normalized SEC traces in CHCl3 of P
DY590 (RI and UV at 600 nm). 
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Figure S15. Intensity size distributions of the nanoparticles in water with an initial acetone-
polymer concentration of 4 mg mL-1, prepared by dropping acetone-polymer solution to water. 
 
Table S1. Selected characterization results of the prepared nanoparticles. 
Entry Z-average [d, nm]a PDIa ζ-potentialb 
PRA 78 ± 1 0.17 ± 0.01 + 28 ± 7 
PRA-DY590 85 ± 1 0.18 ± 0.01 + 49 ± 3 
PDY590 72 ± 1 0.12 ± 0.02 + 30 ± 5 
a Average values of three DLS measurements. b Average values of three ζ-potential measurements 
in pure water.  
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ABSTRACT: In this study, we designed, synthesized, and
characterized a novel pH- and redox responsive nanoparticle
system for the enhanced spatial delivery of hydrophobic drugs.
A statistical copolymer library of pyridyldisulﬁde ethyl
methacrylate (PDSM) with diﬀerent compositions of 2-((tert-
butoxycarbonyl)(2-((tert-butoxycarbonyl)amino)ethyl)amino)-
ethyl methacrylate (BocAEAEMA) was synthesized using the
reversible addition−fragmentation chain transfer (RAFT)
polymerization process. The controlled nature of the radical
polymerization was demonstrated by a kinetic study. The Boc-
groups were cleaved to obtain the desired amino functional copolymers. Nanoparticles were prepared by nanoprecipitation and
characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM), and transmission electron microscopy
(TEM). Diﬀerently sized nanoparticles that have monomodal size distributions ranging from 50 to 460 nm with positive ζ-
potential values were obtained by varying initial conditions of the formulations. The pH- and redox responsiveness of the
nanoparticle systems was investigated by the DLS and ζ-potential measurements. The pH-responsiveness test results
demonstrated that the obtained nanoparticles reveal a pH response, such as changes in the size and ζ-potential values upon pH
value change. Moreover, redox responsiveness tests revealed the stability of the nanoparticles at a glutathione (GSH)
concentration found in the plasma of the human body (10 μM) and the disassembly ability of the nanoparticles in a mimicking
intracellular reductive environment (10 mM GSH). The antitumor drug doxorubicin (DOX) was used to investigate the
encapsulation and release capability of the nanoparticles. Release studies showed that the DOX release was signiﬁcantly
accelerated in the presence of 10 mM GSH compared to the physiological conditions. Confocal laser scanning microscopy
(CLSM) studies indicated that DOX-loaded nanoparticles were taken up eﬃciently by HEK cells, and DOX was released from
the nanoparticles and interacted with the chromosomes in the cell nuclei after 6 h. Cytotoxicity tests revealed that DOX-loaded
nanoparticles decreased the cell viability in a concentration and time dependent manner comparable or even better as the free
DOX, whereas pure particles are biocompatible.
■ INTRODUCTION
In the past few decades, increasing attention has been drawn on
stimuli responsive polymeric nanoparticles, also called “smart
nanoparticles”, based on their potential applications in life
sciences.1 Smart polymeric nanoparticles respond to various
physical (light,2 temperature,3 ultrasound,4 magnetic,5 and
mechanical6), chemical (ionic strength,7 pH value,8 and
redox9), or biological (enzyme10 and receptor11) stimuli.
Among these, pH- and redox-responsive nanoparticles are
regarded as highly promising vehicles for the selective delivery
of pharmaceutical agents to the desired sites, in response to
speciﬁc microenvironmental conditions. Because of the pH
value gradients in intracellular pathways (5.0 to 6.0 for
endosomes and 4.0 to 5.0 for lysosomes), pH-sensitive
polymeric nanoparticles can enhance the therapeutic activity
of loaded drugs by spatially controlled release.12 One of the
main strategies to obtain pH-responsive polymeric nano-
particles is incorporating ionizable segments in the backbone
of the polymers, such as amino and/or carboxyl groups,13−15
which can render tunable pH sensitivity to the corresponding
nanoparticles. On the other hand, endo-/lysosomes and the
cytosol have reductive environments compared to the
extracellular compartments due to the active accumulation of
proteinogenic cysteine and the presence of reductive enzymes,
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such as gamma-interferon inducible lysosomal thiol reductase
(GILT), in lysosomes and the higher glutathione (GSH)
concentrations in the cytosol (100−1000 times higher than the
extracellular GSH).16,17 Therefore, redox-sensitive polymeric
nanoparticles that respond to reductive environments of endo-/
lysosomes or cytosol provide a rationale for the intracellular
delivery of pharmaceutical payloads. Accordingly, polymers
containing disulﬁde groups have been intensively investigated
for the design of redox responsive nanocarriers for drug
delivery applications due to their ability to undergo reduction in
the endocytotic pathway and/or in the cytosol.18−21
In this study, a library of well-deﬁned statistical copolymers
of pyridyldisulﬁde ethyl methacrylate (PDSM) with diﬀerent
composit ions of 2-(( tert -butoxycarbonyl)(2-(( tert -
butoxycarbonyl)amino)ethyl)amino)ethyl methacrylate (Bo-
cAEAEMA) were synthesized using the RAFT polymerization
process (Scheme 1) to obtain a novel pH- and redox responsive
drug delivery vehicle for the controlled release of doxorubicin
(DOX) in the intracellular environment.22 DOX is a potent
anticancer drug used for the treatment of various cancers, such
as lung, ovarian, and breast cancer. However, in clinical therapy
it suﬀers from poor aqueous solubility, rapid elimination, severe
side eﬀects, low selectivity, and multidrug resistance.23,24 To
overcome these limitations, various drug delivery systems such
as dendrimers, micelles, liposomes, and polymeric nanoparticles
have been developed. Among these, stimuli-responsive
polymeric nanoparticles have emerged as promising candidates
for the controlled delivery of DOX owing to their reduced side
eﬀects, prolonged circulation time, and increased drug
concentration in tumor tissues by the enhanced permeability
and retention eﬀect (EPR).25,26 Dual responsive nanoparticles
are designed in such a way that (i) PDSM is used as GSH
responsive moiety,27−30 which is well-known for exhibiting a
GSH response due to the pyridyldisulﬁde groups that undergo
direct coupling with free thiols under ambient conditions; (ii)
additionally AEAEMA is used as pH-responsive functionality
since it contains primary and secondary amino groups in the
side chain. The relatively new amino methacrylate (BocAEAE-
MA) was chosen, which has been recently polymerized for the
ﬁrst time via the RAFT polymerization technique by the groups
of Bulmus and Becer.31 To investigate the eﬀect of the amino
content on the size and stimuli response of the corresponding
nanoparticles, the copolymer composition was varied by using
diﬀerent monomer feed ratios. The AEAEMA content in the
copolymers was kept low (up to 50%) because of the required
hydrophobicity of the copolymers to form nanoparticles.32,33
The reported polymer design has the following advantages over
previously reported drug delivery systems based on amphiphilic
block copolymers. First, a statistical monomer distribution
within the polymers was chosen because block copolymers with
an amphiphilic character may self-assemble into micelles.
However, beyond their critical micelle concentration (CMC),
polymeric micelles can disintegrate into unimers in vivo,
resulting in premature release of their payloads in undesired
locations.34 Moreover, statistical copolymer assemblies may
provide a certain fraction of surface exposed functional
hydrophobic moieties, which can enable decoration of
corresponding assemblies with ligands and/or functional
molecules, unlike the block copolymer assemblies, where the
hydrophobic units are hidden in the core of the micelles or
bilayer of the vesicles.35,36 Additionally, our synthetic approach
involves only a facile one-step reaction. This is an advantage
over the block copolymer synthesis, which involves sequential
controlled polymerizations or postpolymerization treat-
ments.37,38 Second, AEAEMA moieties in the copolymers
render cationic surface charge to the corresponding nano-
particles. This can enhance the cell internalization of the
nanoparticles. It is known that cationic nanoparticles are more
rapidly internalized by the cells compared to negatively charged
and neutral ones due to their high aﬃnity for the negatively
charged phospholipid bilayer of cell membranes.39 Moreover,
primary amino functionality of the AEAEMA can allow
conjugation to other molecules such as proteins and
polypeptides.40 Third, a serious challenge for successful drug
delivery into the cytosol of cells is the endosomal escape.41
Disruption of endosomal membranes via the proton-sponge
eﬀect is one approach to overcome this challenge. AEAEMA’s
half spermine/spermidine like structure, which possibly causes
the proton-sponge eﬀect in the acidic environment of
endosomes,42 can provoke endosomal rupturing. Finally, the
ability of the PDSM-based nanoparticles to encapsulate and
release guest molecules using the redox trigger can sustain the
targeted spatial drug delivery in the endo-/lysosomes or in the
cytosol.
■ EXPERIMENTAL SECTION
Materials. The monomers pyridyldisulﬁde ethyl methacrylate
(PDSM) and 2-((tert-butoxycarbonyl)(2-((tert-butoxycarbonyl)-
amino)ethyl)amino)ethyl methacrylate (BocAEAEMA) were synthe-
sized according to the procedures reported elsewhere (see Supporting
Information for detailed NMR studies).31,43 N-Hydroxyethylethylene-
diamine, di-tert-butyldicarbonate, methacryloyl chloride, aldrithiol-2, 2-
mercaptoethanol, glacial acetic acid, 4,4′-azobis(4-cyanopentanoic
acid) (ACVA), 4-cyano-4-(phenylcarbonothioylthio) pentanoic acid
(CPADB), 1,3,5-trioxane, N,N-dimethylacetamide (DMAc), reduced
L-glutathione and pyrene were purchased from Sigma-Aldrich.
Doxorubicin hydrochloride (DOX) was purchased from Cayman
Chemical. AlamarBlue and Hoechst 33342 were obtained from
Thermo Fischer. If not stated otherwise, cell culture materials, cell
culture media, and solutions were obtained from Biochrom. All other
Scheme 1. Schematic Representation of the RAFT Copolymerization of PDSM with BocAEAEMA
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chemicals were obtained from standard suppliers and used without
puriﬁcation unless speciﬁed.
Instruments and Methods. Proton nuclear magnetic resonance
(1H NMR) spectra were recorded at room temperature in CDCl3 or
CD3OD on a Bruker Avance 300 or 400 MHz using the residual
solvent resonance as an internal standard. The chemical shifts are
given in ppm.
Size-exclusion chromatography (SEC) measurements were per-
formed on two diﬀerent set-ups. SEC in CHCl3: Shimadzu system
equipped with a SCL-10A system controller, a LC-10AD pump, a
RID-10A refractive index detector, SPD-10AD VP (UV detector), and
a PSSSDV-linear S column (5 μm particle size; Polymer Standards
Service GmbH, Mainz, Germany) at 40 °C using a chloroform,
triethylamine, and 2-propanol (94:4:2) mixture as eluent at a ﬂow rate
of 1 mL min−1. The system was calibrated with polystyrene (PS)
standards (Mp = 370 to 128 000 g mol
−1). SEC in DMAc: Agilent
1200 series equipped with a G1310A pump, a G1315D DA detector, a
G1362A RI detector, and PSS GRAM 30 Å/1000 Å (10 μm particle
size) columns in series at 40 °C using N,N-dimethylacetamide
(DMAc) with 2.1 g L−1 LiCl as eluent at a ﬂow rate of 1 mL min−1.
The system was calibrated with polystyrene (PS) standards (Mp = 100
to 1 000 000 g mol−1).
Dynamic light scattering was performed on a Zetasizer Nano ZS
(Malvern Instruments, Herrenberg, Germany). After an equilibration
time of 180 s, 3 × 30 runs were carried out at 25 °C (λ = 633 nm).
The counts were detected at an angle of 173°. Each measurement was
performed in triplicate. The mean particle size was approximated as
the eﬀective (Z-average) diameter and the width of the distribution as
the polydispersity index of the particles (PDI) obtained by the
cumulants method assuming a spherical shape of the nanoparticles.
Electrophoretic light scattering was used to measure the electro-
kinetic potential, also known as ζ-potential. The measurements were
performed on a Zetasizer Nano ZS (Malvern Instruments, Herrenberg,
Germany) by applying laser Doppler velocimetry. For each measure-
ment, 10 runs were carried out using the slow-ﬁeld and fast-ﬁeld
reversal mode at 150 V. Each experiment was performed in triplicate at
25 °C.
For scanning electron microscopy (SEM), 5 μL of the suspensions
were placed on a mica surface and dried overnight at room
temperature under atmospheric pressure. Afterward, samples were
investigated using a Sigma VP ﬁeld emission scanning electron
microscope (Carl-Zeiss AG, Germany). The samples were coated with
a thin layer (4 nm) of platinum via sputter coating using a Bal-TEC
020 HR Sputtering Coater.
Transmission electron microscopy (TEM) was carried out on a FEI
Technai G2 20 transmission electron microscope.
The ﬂuorescence spectra of pyrene solutions were recorded on a
Jasco FP-6500 ﬂuorometer applying an excitation wavelength of
335 nm. The emission spectra were recorded from 350 to 600 nm.
The excitation and emission bandwidths were 5.0 and 5.0 nm,
respectively.
Synthesis. RAFT Polymerization. PDSM was copolymerized with
BocAEAEMA using CPADB as chain transfer agent (CTA) and ACVA
as initiator. The initial monomer feed ratios of the monomers and
overall monomer to CTA ratio was varied. All polymerizations were
carried out at 70 °C for 8 h in an oil bath. The polymerizations were
performed in a 0.5 M DMAc solution. The used initial feed ratios are
summarized in Table 1. An exemplary RAFT copolymerization
procedure (Table 1, P5) is as follows: 400 mg PDSM
(1.567 mmol), 146 mg BocAEAEMA (0.392 mmol), 15.7 mg CPADB
(0.056 mmol) and 3.94 mg ACVA (0.014 mmol) were dissolved in
DMAc in a Biotage microwave reaction vial (5 mL) equipped with a
magnetic stir bar. The total volume of the reaction mixture was 3.92
mL. After the reaction was degassed for 40 min by argon purging, the
t0 sample for
1H NMR was taken, and the ﬂask was immersed in a pre-
heated oil bath under stirring at 70 °C. After 8 h, the polymerization
was stopped by cooling to room temperature and exposing to air.
Monomer conversions were determined via 1H NMR by using 1,3,5-
trioxane as internal standard. The polymer was puriﬁed by
precipitating in cold diethyl ether (2 times). The resulting pink
colored polymer was dried under high vacuum at room temperature
until constant weight to produce an overall yield of 70%. The number-
average molar mass (Mn) and molar mass dispersity (ĐM) were
determined by two diﬀerent SEC systems by using PS standards. SEC
in CHCl3: Mn = 7,500 g mol
−1 and ĐM = 1.17. SEC in DMAc: Mn =
8,000 g mol−1 and ĐM = 1.14.
1H NMR (CDCl3, 300 MHz): δ = 8.45,
7.65, and 7.08 (Ar−H, PDSM), 7.87, 7.52, and 7.36 (Ar−H, CPADB),
4.22 (−OCH2CH2−S−S−), 4.02 (−OCH2CH2−N−), 3.30 (−CH2−
N(COO(CH3) 3−CH 2−CH 2−NH(COO(CH3 ) 3 ) ) , 3 . 0 1
(−OCH2CH2−S−S−), 2.50 (−CH2CH2CO2OH, CPDB), 2.4−0.7
(backbone), 1.41 (−CO2OC(CH3)3) ppm.
The degree of polymerization (DP) for each polymer was calculated
from the signal integrals in the 1H NMR spectrum (Figure S5) of the
puriﬁed copolymer using the following equations:
=DP I peak b
I peak f
( )/2
( )/2PDSM (1)
= ′DP I peak b
I peak f
( )/6
( )/2BocAEAEMA (2)
with I(peak b) corresponding to the integral of the methylene proton
peaks of the PDSM at 3.02 ppm, I(peak b′) corresponding to the
integral of methylene proton peaks of the BocAEAEMA at 3.31 ppm,
and I(peak f) corresponding to the integral of two methylene protons
of the dithiobenzoate end group at 2.52 ppm. Molar mass values were
calculated by using the following equation:
= × + ×
+
M M M
M
(DP ) (DP )n,NMR PDSM PDSM BocAEAEMA BocAEAEMA
CTA (3)
Table 1. Selected Characterization Data of the PDSM (M1) Copolymers with BocAEAEMA (M2)
entry
total
monomer/CTA/ACPA f(M1/M2)a F(M1/M2)b
convn [%]c
M1/M2
Mn,theo.
d
[g mol−1]
DPc
M1/M2
Mn
c
[g mol−1]
Mn,SEC
e
[g mol−1] ĐM
e
Mn,SEC
f
[g mol−1] ĐM
f
P1g 38.07/1/0.25 76/0 7700 24/0 6400 7200 1.22 7300 1.18
P2 37.19/1/0.25 19.0 19.1 78/60 7700 23/1.2 6600 6600 1.15 7000 1.13
P3 36.40/1/0.25 9.0 11.1 73/62 7200 21/1.9 6300 7200 1.20 7400 1.15
P4 35.62/1/0.25 5.7 7.5 87/67 8300 24/3.2 7600 8300 1.14 8300 1.14
P5 34.86/1/0.25 4.0 5.5 75/60 7200 21/3.8 7000 7500 1.17 8000 1.14
P6 33.42/1/0.25 2.3 3.5 78/70 7600 19/5.5 7200 8600 1.16 9200 1.13
P7 32.17/1/0.25 1.5 2.5 78/68 7400 17/6.8 7200 9100 1.10 10 000 1.09
P8 29.86/1/0.25 0.7 1.0 83/74 7700 11/11 7200 8600 1.13 9700 1.12
P9h 25.92/1/0.25 0/69 6900 0/18.3 7100 6100 1.07 7600 1.08
aInitial monomer feed ratio. bMonomer ratio in the isolated copolymer. cDetermined by 1H NMR spectroscopy. dDetermined by the formula
Mn,theo. = [([M]M1/[CTA] × convn × MM1) + ([M]M2/[CTA] × convn × MM2) + (MCTA)].
eDetermined by SEC in CHCl3 analysis (RI detection,
PS calibration). fDetermined by SEC in DMAc analysis (RI detection, PS calibration). gHomopolymer of the PDSM. hHomopolymer of the
BocAEAEMA.
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in which the molar masses of the PDSM, BocAEAEMA, and RAFT
agent are 255.35 g mol−1, 372.46 g mol−1, and 279.38 g mol−1,
respectively.
Kinetic Study of the Polymerization. During polymerization of P7,
aliquots of 0.2 mL were taken periodically from the reaction mixture
by a syringe purged with argon. From each sample, conversions were
calculated via 1H NMR by using 1,3,5-trioxane as internal standard.
Molar masses and dispersities were determined via SEC analysis
(DMAc, RI detection).
Deprotection of the Polymers. Triﬂuoroacetic acid was used for
the removal of Boc-groups from BocAEAEMA containing polymers
(P2−P9). An exemplary deprotection reaction procedure (Table 1,
P5) is as follows: P5 was dissolved in CH2Cl2 (2 mL). Triﬂuoroacetic
acid (1 mL) was added dropwise into the solution at 0 °C. The ﬁnal
solution was stirred at room temperature for 40 min. The volatiles
were removed by purging N2 at room temperature. The residue was
redissolved in a minimum amount of methanol and precipitated in
diethyl ether. The resulting polymer was dried under high vacuum at
room temperature. Mn and ĐM values were determined by SEC in
DMAc by using PS standards. SEC in DMAc: Mn = 8,000 g mol
−1 and
ĐM = 1.14.
1H NMR (CDCl3, 300 MHz): δ = 8.45, 7.65, and 7.08
(Ar−H, PDSM), 7.87, 7.52, and 7.36 (Ar−H, CPADB), 4.22
(−OCH2CH2−S−S−), 4.02 (−OCH2CH2−N−), 3.30 (−CH2−N-
(COO(CH3)3−CH2−CH2−NH(COO(CH3)3)), 3.01 (−OCH2CH2−
S−S−), 2.50 (−CH2CH2CO2OH, CPDB), 2.4−0.7 (backbone) ppm.
Preparation of the Nanoparticle Suspensions. For nanoprecipi-
tation, the corresponding polymers (deprotected form of P2, P3, and
P4) were dissolved in acetone at a ﬁnal concentration of 5 or 3 mg
mL−1, respectively, and subsequently added dropwise to deionized
water under continuous stirring at 500 rpm (acetone to water, AW
method). For the water to acetone (WA) method, deionized water was
added dropwise to the acetone polymer solution under stirring at
500 rpm. The acetone/water (solvent/nonsolvent) ratio was kept
constant at 0.5 for all suspensions. After removal of the acetone by
stirring overnight at room temperature (GC analysis ensured complete
removal of the acetone), the nanoparticles were characterized by DLS
(performed in pure water) and SEM without ﬁltration.
pH-Response Test of the Nanoparticles. For the pH-response test
of the nanoparticles, nanoparticle suspensions that were derived from
the deprotected form of P2, P3, and P4 by the WA method with an
initial acetone polymer concentration of 5 mg mL−1 were used. In a
typical experiment, the P2 nanoparticle suspension (2 mL, c = 2.5 mg
mL−1) was diluted to a ﬁnal volume of 50 mL (c = 0.1 mg mL−1), and
the pH value was recorded. The ﬁnal suspension was divided into two
equal volumes. The resulting suspensions were titrated with 0.01 M
HCl or 0.01 M NaOH. During titrations, 650 μL suspensions were
taken periodically. For each sample, DLS and ζ-potential measure-
ments were performed.
Redox-Response Test of the Nanoparticles. For the redox
response test of the nanoparticles, nanoparticle suspensions that
were derived from the deprotected form of P2, P3, and P4 by utilizing
the WA method with an initial acetone polymer concentration of 5 mg
mL−1 or 3 mg mL−1 were used. In a typical experiment, the P2
nanoparticle suspension (50 μL, c = 2.5 mg mL−1) was diluted to a
ﬁnal volume of 325 μL (c = 0.385 mg mL−1). The ﬁnal suspension was
mixed with 325 μL of 20 mM or 20 μM glutathione in a DLS cuvette.
The temperature of the DLS was set to 37 °C and the attenuation level
was set to 7. DLS measurements were performed periodically to follow
the change in size distribution and signal strength.
Fluorescence Spectroscopic Study of the Nanoparticles. A 100 μL
aliquot of stock solution of pyrene (120 × 10−5 mol L−1) in acetone
was added to 1 mL of the nanoparticle suspensions (1.5 mg mL−1).
The samples were incubated at 37 °C for 24 h to remove acetone and
to give a ﬁnal pyrene concentration of 12 × 10−5 mol L−1. 50 μL of the
ﬁnal suspensions were mixed with 950 μL of pure water and 1 mL of
20 mM glutathione in Eppendorf vials to give a ﬁnal pyrene
concentration of 6 × 10−6 mol L−1. The temperature of the vials
was set to 37 °C. Fluorescence measurements were performed
periodically to follow the change in ﬂuorescence emission intensity.
For the pH dependent pyrene ﬂuorescence intensity study, 40 μL of
a P2 nanoparticle suspension with a pyrene concentration of 12 ×
10−5 mol L−1 was mixed with 1950 mL 0.1 M buﬀer solutions at
various pH values to give a ﬁnal pyrene concentration of 4.8 × 10−6
mol L−1 and to give a nanoparticle concentration of 0.060 mg mL−1.
Fluorescence measurements were performed to follow the change in
ﬂuorescence emission intensity.
Encapsulation of DOX. For DOX encapsulation, P3-d (30 mg)
and DOX (3 mg) were dissolved in 3 mL DMF. Subsequently, 6 mL
of deionized water was added dropwise to the DMF solution under
continuous stirring at 500 rpm. Excess drug and DMF were removed
by dialysis (1 L, 24 h; MWCO: 3500 g/mol) against deionized water.
External medium was renewed four times in the course of dialysis.
Total concentration of the DOX-loaded nanoparticle suspension
concentration after dialysis was found as 1.39 mg/mL. The amount of
DOX in the nanoparticles was calculated by two diﬀerent methods
allowing a cross-check. First, DOX-loaded nanoparticle suspensions
were freeze-dried, dissolved in DMF, and analyzed by UV−vis
spectroscopy. Second, ﬂuorescence emission intensity of the DOX-
loaded nanoparticle suspension at λex/λem 478/598 nm was measured
in deionized water. Quantiﬁcation was performed using UV-vis
absorbance calibration function of DOX in DMF (Figure S6) and
ﬂuorescence intensity calibration function of DOX in deionized water
(Figure S7).
Drug loading eﬃciency (DLE) and drug loading content (DLC)
were calculated according to the following equations:
= ×DLE mass of the loaded drug
mass of the drug in feed
100%
(4)
= ×DLC mass of the loaded drug
total mass of polymer and loaded drug
100%
(5)
Release Studies of DOX. The release of the DOX from the
nanoparticle suspensions were investigated at 37 °C under three
diﬀerent conditions: (i) Acetate buﬀer (100 mM, pH 5.0) containing
10 mM GSH, (ii) PBS buﬀer (100 mM, pH 7.4) containing 10 mM
GSH. A 3 mL aliquot of DOX-loaded nanoparticle suspensions in
deionized water was added into a dialysis bag (MWCO: 3500 g/mol)
and soaked in a glass bottle containing 55 mL of appropriate buﬀer
and gently stirred. At various time intervals, 1 mL of the release media
was taken out and replenished with an equal volume of fresh media.
The amount of released DOX was calculated by ﬂuorescence
measurements as mentioned above.
Cell Lines and Culture Conditions. The cell lines L929 (CCL-1,
ATCC) and HEK-293 (CRL-1573, ATCC) were cultured in DMEM
culture media and RPMI 1640 medium supplemented with 10% fetal
calf serum (FCS), 100 μg mL−1 streptomycin and 100 IU mL−1
penicillin, respectively. The cells were cultured at 37 °C in humidiﬁed
5% CO2 atmosphere.
Cytotoxicity Test of Pure and DOX-Loaded Nanoparticles.
The cytotoxicity was tested with L929 cells, as this sensitive cell line is
recommended by ISO10993−5 (n = 3 × 6). In detail, cells were
seeded at 104 cells per well in a 96-well plate and were incubated for
24 h. No cells were seeded in the outer wells. Afterward, the media
were replaced by fresh media and incubated for 30 min. The
nanoparticle suspensions were added in the indicated end concen-
tration range, and the cells were incubated at 37 °C for 24 and 48 h.
Subsequently, the medium was replaced by fresh medium and
AlamarBlue as recommended by the supplier. After incubation for
4 h, the ﬂuorescence intensity was measured at Ex 570/Em 610 nm,
with untreated cells on the same well plate serving as controls.
Live Cell Imaging of Pure and DOX-Loaded Nanoparticles.
As recommended, HEK-293 cells were used for uptake studies.
Therefore, cells (105 cells mL−1) were seeded on glass-bottomed
dishes and cultured for 24 h in a humidiﬁed atmosphere. One hour
prior to the addition of nanoparticles, the medium was replaced with
fresh one. Nanoparticles were added to the cells and incubated for 6
and 24 h. Afterward, Hoechst 33342 for nucleus staining was added to
the media. Imaging was performed with a LSM880, Elyra PS.1 system
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(Zeiss, Oberkochen, Germany) applying a 63 × 1.4 NA plan
apochromat oil objective. Excitation wavelengths of 405 nm
(excitation grating 23.0 μm) and 488 nm (excitation grating 28.0
μm) were used.
■ RESULTS AND DISCUSSION
A library of statistical copolymers of PDSM and BocAEAEMA
was synthesized via the RAFT polymerization process. In order
to investigate the possible eﬀect of the monomer composition
on the physical properties and stimuli response of the
corresponding nanoparticles, a number of copolymers with
similar molar mass values but varying monomer compositions
were synthesized. To the best of our knowledge, the RAFT
copolymerization of PDSM and BocAEAEMA has never been
reported in the open literature so far. Yet, the CTA used in
these experiments has previously shown a good behavior in
RAFT polymerizations of both monomers.31,43 In accordance
to previous research, the [CTA]/[ACVA] ratio was kept at 1/
0.25 regarding the polymerization rate to gain control over the
molar mass.44 Diﬀerent initial monomer feed ratios were
applied for each copolymerization to vary the amino content in
the copolymers. The targeted molar mass value was Mn,tg =
10 000 g mol−1 at 100% conversion. All polymerizations were
carried out in DMAc at 70 °C with a monomer concentration
of 0.5 mol L−1.
Kinetic Study. The distribution of the monomers among
the polymer chains could potentially aﬀect the particle
morphology. To obtain information about the sequence of
the monomers in the copolymer chains, a kinetic study was
performed for the copolymerization of P7. The kinetic study
plots of the RAFT copolymerization of P7 are displayed in
Figure 1. Analysis of the kinetic samples by means of SEC in
DMAc revealed monomodal molar mass distributions that shift
to lower elution volumes in the course of the polymerization
(Figure 1c). The evolution of Mn and ĐM versus conversion is
shown in Figure 1a. At zero conversion, Mn could not be
extrapolated to a zero molar mass value. This phenomenon has
been observed by a number of researchers and is attributed to a
low chain-transfer constant of the utilized CTA in the
polymerizations.45−47 However, the molar mass Mn was
found to increase linearly with respect to the total monomer
conversion with ĐM lower than 1.2 suggesting a RAFT-
controlled mechanism. The semilogarithmic kinetic plots are
linear (Figure 1b) for both monomers, indicating a pseudo ﬁrst
order polymerization rate with respect to the monomer
concentration and a constant concentration of the propagating
radicals during the RAFT polymerization. No induction period
was observed for both monomers. The slope of PDSM was
steeper than for BocAEAEMA in the semilogarithmic plot,
which indicates that PDSM was consumed faster than
BocAEAEMA. Indeed, the compositions in the isolated
polymer deviated from the initial monomer feed ratio.
Figure 1. Kinetic studies of the RAFT copolymerization of PDSM with BocAEAEMA. [PDSM]/[BocAEAEMA]/[CPADB]/[AIBN] = 23.42/
10.05/1/0.25; [M]0 = 0.5 mol L
−1. Polymerization conditions: Solvent DMAc, T = 70 °C. (a) Mn and ĐM evolution with total monomer conversion.
(b) Semilogarithmic kinetic plot. (c) SEC in DMAc overlay curves.
Figure 2. 1H NMR spectra (300 MHz, CDCl3) of P1, P6, and P9 and
the assignment of the peaks used to calculate the degree of
polymerization (DP).
Figure 3. Normalized SEC traces in DMAc of isolated copolymers of
P1 to P9.
Figure 4. 1H NMR spectra (300 MHz, CDCl3) of P3 and deprotected
form of P3 (P3-d).
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Table 2. Selected Characterization Results of the Prepared Nanoparticles
Z-average [d, nm]a PDIa ζ-potentialb
entry c = 3 g L−1 c = 5 g L−1 c = 5 g L−1 c = 3 g L−1 c = 5 g L−1 c = 5 g L−1 c = 3 g L−1 c = 5 g L−1 c = 5 g L−1
P2 264 ± 1c 466 ± 4c 74 ± 1d 0.07 ± 0.02c 0.07 ± 0.02c 0.20 ± 0.01d 74 ± 2c 72 ± 5c 69 ± 3d
P3 240 ± 1c 274 ± 1c 51 ± 1d 0.06 ± 0.02c 0.11 ± 0.02c 0.26 ± 0.01d 54 ± 2c 62 ± 2c 72 ± 5d
P4 117 ± 1c 180 ± 1c e 0.15 ± 0.01c 0.05 ± 0.01c e 52 ± 2c 59 ± 3c e
aAverage values of three DLS measurements. bAverage values of three ζ-potential measurements. cWA, dropping water to acetone. dAW, dropping
acetone to water. eNo well-deﬁned nanoparticles.
Figure 5. (a) Intensity size distributions of nanoparticles in water (P2, P3, and P4) with an initial acetone-polymer concentration of 5 mg mL−1,
prepared by dropping acetone-polymer solution to water (WA). (b) Intensity size distributions of nanoparticles in water (P2 and P3) with an initial
acetone-polymer concentration of 5 mg mL−1, prepared by dropping acetone-polymer solution to water (AW).
Figure 6. SEM images of nanoparticles that were prepared from P2, P3, and P4 (5 mg mL−1) by dropping water to acetone-polymer solution (WA).
Upper scale bars represent 200 nm; lower scale bars represent 1000 nm.
Figure 7. (a) Z-Average diameter and PDI values of nanoparticles as a function of the pH value. (b) ζ-Potentials of the nanoparticles as a function of
the pH value.
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Copolymer Synthesis and Characterization. The
resulting copolymer library was characterized by 1H NMR
spectroscopy (Figure 2) and SEC measurements on two
systems (Table 1). 1H NMR spectra of the isolated copolymers
revealed the presence of the α (δ = 2.50 ppm) and ω (δ = 7.84,
7.48, and 7.35 ppm) RAFT end groups (Figure S5). The ω
RAFT end group proton signals overlap with the pyridyldi-
sulﬁde proton signals (δ = 8.45, 7.65, and 7.08 ppm), whereas
the α RAFT end group protons enable the estimation of the
degree of polymerization (DP) for each monomer (see
Experimental Section for details). The according number-
average molar mass (Mn) values calculated by
1H NMR are in
good agreement with the theoretical values that were calculated
from the [monomer] to [CTA] ratio and the monomer
conversions. The compositions of the isolated copolymers
(F(M1/M2)) were calculated by comparing the DP values for
each monomer (Table 1). The integrals of the pyridyldisulﬁde
protons and the methylene protons of the polymer side groups
of the PDSM (δ = 8.45 and 3.02) are in good agreement with
each other indicating the absence of side transfer reactions
during the polymerization.
The isolated copolymers were analyzed using two diﬀerent
SEC systems (Figure 3, Figure S8). Both systems revealed
monomodal traces and low dispersities (ĐM < 1.3) for all
polymers. In general, SEC in DMAc revealed higher molar mass
values compared to the SEC investigations in CHCl3. This is
caused by the increased hydrodynamic volume of the
BocAEAEMA containing polymers in polar solvents, which
results in higher apparent molar mass values. Both SEC systems
revealed slightly higher molar mass values than the molar mass
values determined by 1H NMR spectra due to the PS
calibration in the SEC systems, resulting in a relative molar
mass value.
Deprotection of the Polymers and Long-Term
Stability Test. Prior to the nanoparticle formulation, the
polymers were treated with triﬂuoroacetic acid to obtain the
desired primary and secondary amino containing copolymers.
The 1H NMR spectrum indicates the complete removal of the
Boc-groups by the disappearance of the peak at 1.41 ppm,
Figure 8. (a) Z-Average diameter and PDI values of nanoparticles as a function of 10 μM and 10 mM GSH. (b) Derived count rate of the
nanoparticles as a function of 10 μM and 10 mM GSH.
Figure 9. Fluorescence emission spectra of pyrene (6 × 10−6 mol L−1) against P2, P3, and P4 nanoparticles (0.075 mg mL−1) as a function of time.
Pyrene in pure water was used as control.
Figure 10. Drug release of DOX-loaded nanoparticles at pH 7.4
(blue), pH 7.4 with 10 mM GSH (red), and pH 5.0 with 10 mM GSH
(black).
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which corresponds to the tert-butoxy carbonyl protons (Figure
4). SEC in DMAc reveals a slight increase in the molar mass
values after deprotection of the Boc-groups (Figure S16−22)
caused by the increased hydrodynamic volume of the
copolymers in DMAc after deprotection. To investigate the
long-term stability of the polymers, P6 and its deprotected form
P6-d were stored at room temperature for six months. Then,
1H NMR and SEC measurements were performed. A change
cannot be observed for P6 in the SEC trace or in the 1H NMR
spectrum. However, SEC in CHCl3 reveals an appearance of a
small shoulder at around double molar mass region for P6-d
(Figure S23a). This is attributed the nucleophilic attack of
primary amino groups of AEAEMA to the thiocarbonylthio
RAFT end groups, which is a well-known reaction between the
RAFT-generated polymers and the primary amino groups
leading to thiol terminated polymers.48 A signiﬁcant reduction
of the characteristic UV absorbance in the SEC at 340 nm
(calibrated relating to the maximum of the corresponding RI
curves) of the thiocarbonylthio end group proves this
assumption (Figure S23b). Such a reaction would be expected
to cause a polymer−polymer coupling via disulﬁde formation
and/or coupling with the pyridyldisulﬁde groups of the
polymer side chains via thiol disulﬁde exchange reactions.
However, the 1H NMR spectrum shows no change in the ratio
of the integral values between the pyridyldisulﬁde protons and
the methylene protons of the polymer side groups of the
PDSM (δ = 8.45 and 3.02) (Figure S24), suggesting that the
appearance of the shoulder in the SEC trace is due to the
polymer−polymer coupling via disulﬁde formation. These
results also suggest the stability of the pyridyldisulﬁde units
in the presence of amino groups.
Nanoparticle Formulation and Characterization. Poly-
meric nanoparticles were prepared from the deprotected
copolymers of P2, P3, and P4, which contain 5, 8, and 12
mol% AEAEMA functionality, respectively, by means of
nanoprecipitation with subsequent solvent evaporation without
any need of stabilizers/surfactants. No nanoparticles could be
obtained using higher mol% AEAEMA containing polymers
(P5−P9) due to their insuﬃcient hydrophobicity. In order to
obtain diﬀerently sized nanoparticles, two diﬀerent initial
acetone-polymer solution concentrations (3 and 5 mg mL−1)
and two diﬀerent dropping methods (dropping acetone
polymer solution to water (AW) as well as dropping water to
acetone polymer solution (WA)) were applied for each
polymer. By dropping water to acetone polymer solution
(WA), nanoparticles with monomodal size distributions and
low polydispersity (PDI) values were obtained with both initial
acetone-polymer solution concentrations (Table 2, Figure 5).
Smaller nanoparticles (Z-average diameter between 117 and
264 nm) were formed at a lower initial acetone-polymer
concentration of 3 mg mL−1 compared to 5 mg mL−1 (Z-
average diameter between 180 and 466 nm) for all polymers,
which is a common phenomenon in nanoprecipitation.49
Moreover, it could be observed that there is a correlation
between the mol% of AEAEMA content of the polymers and
the size of the corresponding nanoparticles: An increase of the
AEAEMA content results in a decrease of the nanoparticles size
of both initial polymer concentrations. It is well-known that
preparation variables, such as the choice of organic solvent and
initial polymer concentration in the organic phase, inﬂuence the
properties of the ﬁnal nanoparticles.50 However, to the best of
our knowledge, there has been no literature example which
describes the inﬂuence of the polymer composition on the size
of the nanoparticles. Nevertheless, very recently Reisch et al.
reported that the presence of charged groups in polymer chains
can reduce the size of polymer nanoparticles fabricated by
nanoprecipitation.51 By dropping acetone-polymer solution
(AW) to water, nanoparticles with monomodal intensity size
distributions and acceptable polydispersity (PDI) values were
obtained from P2 and P3 with an initial acetone-polymer
solution concentration of 5 mg mL−1 (Table 2, Figure 5). In
contrast, P4 yielded multiple intensity distributions and
relatively high PDI values by utilizing the AW method and an
initial polymer concentration of 5 mg mL−1. This is attributed
to the higher hydrophilicity of the P4 compared to the P3 and
P2 which pushes P4 out of the Ouzo region under the applied
conditions. It is known that production of metastable
dispersions or emulsions is limited to a small region of the
composition map, called the Ouzo region.33,52 In accordance,
the lower initial acetone-polymer concentration (3 mg mL−1)
used in AW method, did not result in the formulation of well-
deﬁned nanoparticles with any of the polymers. The dropping
method aﬀected particle size signiﬁcantly. By AW method,
relatively smaller nanoparticles were obtained compared to WA
method at an initial acetone-polymer concentration of 5 mg
mL−1 for P2 and P3, which is commonly observed for the
nanoprecipitation method.53 The ζ-potential of all suspensions
shows positive values higher than +50 mV as a consequence of
the amino functionality of the copolymers, indicating a high
colloidal stability. The long-term stability of the nanoparticle
suspensions was tested at room temperature for 6 weeks,
showing no change in size and size distributions. SEM (Figure
Figure 11. (a) Cytotoxicity test of nanoparticles (NPs) that were prepared from P2, P3, P4, and AEAEMA homopolymer P9 in L929 cells. (b)
Cytotoxicity test of DOX-loaded nanoparticles and free DOX in L929 cells. The relative viability is expressed as percentage to control cells not
treated with NPs. Untreated cells on the same well plate were used as positive controls.
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6 and Figure S26) and TEM (Figure S25) investigations
revealed that all nanoparticles have uniform spherical shapes.
pH-Response Test of the Nanoparticles. For the
understanding of the pH-responsive behavior of the nano-
particles, nanoparticle suspensions were titrated in the pH value
range from 3.5 to 9. Simultaneous size and ζ-potential
measurements were applied (Figure 7). P2 nanoparticle
suspensions possess stable size values at low pH values (pH
≤ 5.0). At higher pH values, the size of the nanoparticles
gradually increases and they start to precipitate above a pH
value of 7.5. This is due to the deprotonation of the amino
groups at high pH values. In agreement with this, the ζ-
potential is inversely proportional to the pH with the ζ-
potential reaching 0 mV at the isoelectric point (IEP) at a pH
value of around 7.5. The nanoparticles derived from P3 and P4
show higher IEP values, at a pH value of above 8.5, compared
to the P2 nanoparticles. This is due to the higher AEAEMA
content of the corresponding polymers compared to P2. In
contrast to P2 and P3 nanoparticles, the ζ-potential proﬁle of
P4 nanoparticles displays a maximum at around pH 5. At lower
pH values, a reduction in the ζ-potential can be observed. This
is attributed to the amount of HCl that is used for the titration
of P4 nanoparticles, which is higher than for the titration of P2
and P3 nanoparticles due to the high AEAEMA content. It is
known that excess HCl could act as a salt and screen the
positive charge arising from the amino groups, which could
Figure 12. Live cell CLSM images of HEK cells incubated with DOX-loaded nanoparticles and free DOX at 1 μg/mL pure and encapsulated DOX.
For each panel, the images from left to right show DOX ﬂuorescence in cells (red), cell nuclei stained by Hoechst (blue), and overlays of the two
images and a brightﬁeld image. The scale bars correspond to 20 μm in all the images. Key: (A) DOX-loaded nanoparticles, 6 h incubation; (B) free
DOX, 6 h incubation; (C) DOX-loaded nanoparticles, 24 h incubation; (D) free DOX, 24 h incubation.
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result in a decrease in the ζ-potential.40 It should also be noted
that P4 nanoparticles that contain the highest AEAEMA
content have stable size values up to a pH value of 6.5.
Redox Response Test of the Nanoparticles. The redox
responsive behavior of the nanoparticles was tested via the
addition of the reducing agent glutathione (GSH) at a
concentration of 10 μM and 10 mM to the nanoparticle
suspensions at 37 °C. The changes in particle size were
recorded by DLS at various time intervals (Figure 8). At a GSH
concentration similar like in the plasma of the human body (10
μM), no change was observed neither in the nanoparticle size
distribution nor in the derived count rate for all nanoparticle
suspensions implying the stability of the nanoparticle
suspensions in the plasma. However, in a mimicking intra-
cellular reductive environment (10 mM GSH), P2 nano-
particles underwent rapid aggregation, meaning the average
particles size was increased from 460 to 660 nm just after 1 h
and up to 1330 nm after 3.5 h as well as broader distributions,
indicating the disassembly of the nanoparticles. This is due to
the reaction of GSH with the disulﬁde functionality of the
PDSM that converts the amphiphilic copolymer into a more
hydrophilic polymer. This conversion causes nanoparticles to
disassemble. In accordance, a rapid decrease in the derived
count rate was observed in the presence of 10 mM GSH.
Moreover, the P2 nanoparticle suspension turned from an
opalescent into a colorless solution over time in the presence of
10 mM GSH, conﬁrming the disassembly of the nanoparticles.
Unlike P2, P3 nanoparticles revealed an induction period of
around 1 h to respond to 10 mM GSH. However, after this
induction period again a fast increase in the particle size with
broader distributions and a rapid decrease in the derived count
rate were observed. P3 nanoparticles also became colorless after
being treated with 10 mM GSH. Like P3, P4 nanoparticles
revealed an induction period of around 1 h before showing any
response to the 10 mM GSH. After approximately 1 h, a rapid
increase in the particle size without aggregation was observed.
In accordance, an increase in the derived count rate for the P4
nanoparticles was observed between 2 and 6 h. This is due to
the rapid increase in size of the P4 nanoparticles. However,
after about 6 h a slower decrease in the derived count rate
compared to P2 and P3 nanoparticles was observed, indicating
partial disassembly of the nanoparticles. This phenomenon,
slower disassembly of P4 nanoparticles compared to P2 and P3
nanoparticles, is attributed to the slower diﬀusion of the polar
GSH within the most hydrophilic P4 nanoparticles, having the
highest AEAEMA content.
Fluorescence Spectroscopic Study of the Nano-
particles. In order to conﬁrm the ability of the nanoparticles
to encapsulate hydrophobic guest molecules and to release
them under elevated GSH concentration, pyrene as hydro-
phobic ﬂuorescent probe was encapsulated as a model drug in
P2, P3, and P4 nanoparticles by utilizing the WA technique
using polymer concentrations of 3 mg mL−1. The ﬂuorescence
emission spectra of pyrene encapsulated P2, P3, and P4
nanoparticles at 10 mM GSH concentration as a function of
time are shown in Figure 9 with a ﬁxed excitation wavelength of
335 nm. Pyrene in pure water at 10 mM GSH concentration is
used as control. The total intensities of the emission spectra of
the nanoparticle suspensions at time zero are signiﬁcantly
higher compared to the emission intensity of the control. This
indicates that pyrene is transferred into the hydrophobic
domains of the nanoparticles. Moreover, it could be observed
that an increase of the AEAEMA content results in a decrease
in the ﬂuorescence intensity of the nanoparticles at time zero.
This can be explained by the increased hydrophilicity of the
nanoparticles with increasing AEAEMA content, which might
cause a decrease in the encapsulation eﬃciency of hydrophobic
pyrene. Moreover, the total intensities of the emission spectra
of the nanoparticle suspensions showed a gradual decrease over
time. Indeed, after 120 min the emission intensity of the pyrene
decreased to the intensity of the control for each system, which
indicates the capability of the nanoparticles to release their
hydrophobic cargos in response to the GSH stimulus.
Moreover, the ﬂuorescence emission spectra of pyrene against
P2 nanoparticles at various pH values was investigated (Figure
S27). A gradual decrease in the emission intensity of the pyrene
can be observed as the pH value of the medium decreases from
7.4 to 5. This can be explained by the protonation of the amino
groups, which makes the corresponding polymers more
hydrophilic and thus results in a lower pyrene encapsulation.
Notably, a change in the pH value from 5 to 4 did not result in
a decrease in the emission intensity of the pyrene. This is
attributed to the complete protonation of amino groups above
a pH value of 5, which did not cause any physical change to the
P2 nanoparticles. This conclusion is in accordance with the pH-
response test of the P2 nanoparticles, which revealed no change
of the size of a pH value of 4 and 5 (see above).
Loading and Release Studies of DOX. DOX was
encapsulated in P3 nanoparticles using the nanoprecipitation
method. The resulting DOX-loaded nanoparticles have a Z-
average diameter of 130 nm, a PDI value of 0.1 and a ζ-
potential of +30 mV (Figure S28). The target drug loading
content was 10%. The drug loading eﬃciency and drug loading
content were calculated as 19.2% and 1.9%, respectively. The
release of the DOX was investigated at 37 °C using three
diﬀerent conditions as reported in Figure 10. The results reveal
that 91% DOX is released in 7 h under a reducing environment
containing 10 mM GSH at pH 7.4, which is due to the
disassembly of the nanoparticles caused by the reaction of GSH
with the disulﬁde functionality of the PDSM. The release of
DOX is slightly accelerated at pH 5.0 in the presence of 10 mM
GSH, in which 98% DOX was released in 7 h. This is due to the
protonation of the amino groups of AEAEMA. These results
indicate that an acidic pH value and a high GSH concentration
have a synergetic eﬀect on the DOX release of the
nanoparticles. Under physiological conditions (pH 7.4), the
release of DOX is slower with 57% DOX in 7 h. It should be
noted, that although the release of DOX under physiological
conditions is slightly higher than previously reported DOX
delivery systems based on amphiphilic block copolymers, it is
still in an acceptable range.54
Cytotoxicity of the Nanoparticles, AEAEMA Homo-
polymer, DOX-Loaded Nanoparticles, and Free DOX. In
order to evaluate the cytotoxicity of the systems, nanoparticle
samples of P2, P3, and P4 prepared from 5 mg mL−1 by the
WA technique and the water-soluble AEAEMA homopolymer
P9 were investigated at the indicated concentrations (Figure
11a). The cytotoxicity assay results showed that the nano-
particles did not have any signiﬁcant cytotoxic eﬀect on L929
cells after 48 h of incubation at concentrations up to 0.75 mg
mL−1. However, a slight cytotoxic eﬀect at 1 mg mL−1 with a
cell viability of about 70% was observed (general threshold for
cytotoxicity is 70% cell viability). The AEAEMA homopolymer
P9 revealed no toxic eﬀect on the cells up to 0.5 mg mL−1, but
a signiﬁcant loss in cell viability of about 50% at 0.75 mg mL−1
and a severe loss in cell viability of about 90% at 1 mg mL−1
Macromolecules Article
DOI: 10.1021/acs.macromol.5b02603
Macromolecules 2016, 49, 3856−3868
3865
could be observed. This is due to the primary and secondary
amino functionalities of AEAEMA, which can be associated
with toxic eﬀects in cell studies.15,55,56 The higher cell viability
of the nanoparticles compared to the AEAEMA homopolymer
at increased concentrations can be explained by the lower
amino content (up to 12 mol% AEAEMA) in the
corresponding copolymers compared to the AEAEMA
homopolymer. Moreover, the cytotoxicity of the DOX-loaded
nanoparticles was evaluated to compare with the DOX-free
nanoparticles by using free DOX as a control. Though DOX-
free nanoparticles show no cytotoxic eﬀects at similar particle
concentrations, the cell viability decreased with an increasing
concentration of the DOX-loaded nanoparticles even after 24 h
incubation (Figure 11b). Similar results were observed for free
DOX. Prolonged incubation of 48 h resulted in a slightly lower
cell viability of free DOX. These results indicate the eﬃcient
release of DOX from the nanoparticles in the intracellular
environment, which inhibits the proliferation of the cells.
Cellular Uptake and Intracellular Drug Release. The
cellular uptake and intracellular drug release proﬁles of the
DOX-loaded nanoparticles in comparison with free DOX were
studied in HEK cells using confocal laser scanning microscopy
(CLSM). After 6 h of incubation, DOX ﬂuorescence can mainly
be observed in the cytosol and in the nuclei for cells treated
with DOX-loaded nanoparticles (Figure 12A) indicating that
DOX-loaded nanoparticles have been taken up eﬃciently by
the cells (no aggregation of nanoparticles at the cell surface)
and some of the DOX released from the nanoparticles by the
intracellular triggers meaning an acidic and reductive environ-
ment of the endosomes and/or a high GSH concentration of
the cytosol. Within the same incubation time, free DOX mainly
accumulated in the nuclei with higher ﬂuorescence intensity
than DOX-loaded nanoparticles (Figure 12B). This can be
attributed to a time dependent cell internalization of the
nanoparticles by energy-dependent endocytosis in contrast to
the free DOX, which is rapidly internalized through diﬀusion.57
Furthermore, although the DOX release of the nanoparticles
was not complete, the intensity of the DOX ﬂuorescence inside
the cell nuclei increased by prolonging the incubation time to
24 h (Figure 12C), which is similar to the free DOX (Figure
12D). Taking the CLSM results into account, a triggered
release caused by a change in the pH value or the reductive
environment can be assumed. Furthermore, the images show
that to some extend the DOX is not fully released from the
nanoparticles but the toxic eﬀect is comparable to free DOX.
These results are promising for the targeted cancer therapy
since it is known that the accumulation of DOX in the cell
nuclei is crucial to induce cell death.58
■ CONCLUSIONS
In this study, a well-deﬁned statistical copolymer library of
PDSM and BocAEAEMA was prepared via RAFT polymer-
ization. Copolymerization was shown to proceed with a ﬁrst
order kinetics and a linear evolution of the molar mass versus
conversion. In order to alter the amino content in the
copolymers and in the corresponding nanoparticles, the initial
monomer feed ratios were varied. Boc-groups were cleaved
prior to the nanoparticle formulation to obtain desired primary
and secondary amino functional polymers. Copolymers that
contain up to 12 mol% AEAEMA functionality were shown to
self-assemble into nanoparticles in aqueous solution via
nanoprecipitation with application of the subsequent solvent
evaporation method. The corresponding nanoparticles have
been demonstrated to be dual responsive to both pH value and
glutathione content. The ability of the nanoparticles to
encapsulate DOX and release it under various triggered
conditions was conﬁrmed. CLSM studies showed that DOX-
loaded nanoparticles were eﬃciently taken up by HEK cells.
The acidic pH value in the endosomes and the high glutathione
concentration inside the cytosol caused intracellular DOX
release, showing a comparable cytotoxicity of free and
encapsulated DOX. In comparison, none of the DOX-free
nanoparticles exhibited any signiﬁcant cytotoxic eﬀect on L929
cells at concentrations up to 0.75 mg mL−1. Consequently,
these nanoparticles may serve as promising smart drug delivery
vehicles for the controlled delivery of DOX.
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ium für Wirtschaft, Wissenschaft, und Digitale Gesellschaft
(TMWWDG, ProExzellenz I, NanoConSens), and the German
Federal Ministry of Education & Research (BMBF,
#031A518B). The SEM facilities of the Jena Center for Soft
Matter (JCSM) were provided by grants from the German
Research Council (DFG) and the European Fonds for Regional
Development (EFRE). We also express our gratitude to Dr.
Wolfgang Günther for helpful discussion.
■ REFERENCES
(1) Cheng, R.; Meng, F.; Deng, C.; Klok, H.-A.; Zhong, Z. Dual and
multi-stimuli responsive polymeric nanoparticles for programmed site-
specific drug delivery. Biomaterials 2013, 34, 3647−3657.
(2) Yan, B.; Boyer, J.-C.; Habault, D.; Branda, N. R.; Zhao, Y. Near
Infrared Light Triggered Release of Biomacromolecules from Hydro-
gels Loaded with Upconversion Nanoparticles. J. Am. Chem. Soc. 2012,
134, 16558−16561.
(3) Jeong, B.; Bae, Y. H.; Kim, S. W. Drug release from biodegradable
injectable thermosensitive hydrogel of PEG−PLGA−PEG triblock
copolymers. J. Controlled Release 2000, 63, 155−163.
(4) Chen, Y.; Yin, Q.; Ji, X.; Zhang, S.; Chen, H.; Zheng, Y.; Sun, Y.;
Qu, H.; Wang, Z.; Li, Y.; Wang, X.; Zhang, K.; Zhang, L.; Shi, J.
Macromolecules Article
DOI: 10.1021/acs.macromol.5b02603
Macromolecules 2016, 49, 3856−3868
3866
Manganese oxide-based multifunctionalized mesoporous silica nano-
particles for pH-responsive MRI, ultrasonography and circumvention
of MDR in cancer cells. Biomaterials 2012, 33, 7126−7137.
(5) Wang, Y.; Wang, G.; Xiao, Y.; Yang, Y.; Tang, R. Yolk−Shell
Nanostructured Fe3O4@NiSiO3 for Selective Affinity and Magnetic
Separation of His-Tagged Proteins. ACS Appl. Mater. Interfaces 2014,
6, 19092−19099.
(6) Hsu, L.; Weder, C.; Rowan, S. J. Stimuli-responsive,
mechanically-adaptive polymer nanocomposites. J. Mater. Chem.
2011, 21, 2812−2822.
(7) Gambinossi, F.; Chanana, M.; Mylon, S. E.; Ferri, J. K. Stimulus-
Responsive Au@(MeO2MAx-co-OEGMAy) Nanoparticles Stabilized
by Non-DLVO Interactions: Implications of Ionic Strength and
Copolymer (x:y) Fraction on Aggregation Kinetics. Langmuir 2014,
30, 1748−1757.
(8) Du, J.-Z.; Mao, C.-Q.; Yuan, Y.-Y.; Yang, X.-Z.; Wang, J. Tumor
extracellular acidity-activated nanoparticles as drug delivery systems for
enhanced cancer therapy. Biotechnol. Adv. 2014, 32, 789−803.
(9) Wang, Y.-C.; Wang, F.; Sun, T.-M.; Wang, J. Redox-Responsive
Nanoparticles from the Single Disulfide Bond-Bridged Block
Copolymer as Drug Carriers for Overcoming Multidrug Resistance
in Cancer Cells. Bioconjugate Chem. 2011, 22, 1939−1945.
(10) Nguyen, M. M.; Carlini, A. S.; Chien, M.-P.; Sonnenberg, S.;
Luo, C.; Braden, R. L.; Osborn, K. G.; Li, Y.; Gianneschi, N. C.;
Christman, K. L. Enzyme-Responsive Nanoparticles for Targeted
Accumulation and Prolonged Retention in Heart Tissue after
Myocardial Infarction. Adv. Mater. 2015, 27, 5547−5552.
(11) Zhang, P.; Chiu, Y.-C.; Tostanoski, L. H.; Jewell, C. M.
Polyelectrolyte Multilayers Assembled Entirely from Immune Signals
on Gold Nanoparticle Templates Promote Antigen-Specific T Cell
Response. ACS Nano 2015, 9, 6465−6477.
(12) Oishi, M.; Kataoka, K.; Nagasaki, Y. pH-Responsive Three-
Layered PEGylated Polyplex Micelle Based on a Lactosylated ABC
Triblock Copolymer as a Targetable and Endosome-Disruptive
Nonviral Gene Vector. Bioconjugate Chem. 2006, 17, 677−688.
(13) Ko, J.; Park, K.; Kim, Y.-S.; Kim, M. S.; Han, J. K.; Kim, K.; Park,
R.-W.; Kim, I.-S.; Song, H. K.; Lee, D. S.; Kwon, I. C. Tumoral acidic
extracellular pH targeting of pH-responsive MPEG-poly(β-amino
ester) block copolymer micelles for cancer therapy. J. Controlled
Release 2007, 123, 109−115.
(14) Lackey, C. A.; Press, O. W.; Hoffman, A. S.; Stayton, P. S. A
Biomimetic pH-Responsive Polymer Directs Endosomal Release and
Intracellular Delivery of an Endocytosed Antibody Complex.
Bioconjugate Chem. 2002, 13, 996−1001.
(15) Yildirim, T.; Rinkenauer, A. C.; Weber, C.; Traeger, A.;
Schubert, S.; Schubert, U. S. RAFT made methacrylate copolymers for
reversible pH-responsive nanoparticles. J. Polym. Sci., Part A: Polym.
Chem. 2015, 53, 2711−2721.
(16) Arunachalam, B.; Phan, U. T.; Geuze, H. J.; Cresswell, P.
Enzymatic reduction of disulfide bonds in lysosomes: characterization
of a gamma-interferon-inducible lysosomal thiol reductase (GILT).
Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 745−50.
(17) Gainey, D.; Short, S.; McCoy, K. L. Intracellular location of
cysteine transport activity correlates with productive processing of
antigen disulfide. J. Cell. Physiol. 1996, 168, 248−254.
(18) Bulmus, V.; Woodward, M.; Lin, L.; Murthy, N.; Stayton, P.;
Hoffman, A. A new pH-responsive and glutathione-reactive, endo-
somal membrane-disruptive polymeric carrier for intracellular delivery
of biomolecular drugs. J. Controlled Release 2003, 93, 105−120.
(19) Wu, L.; Zou, Y.; Deng, C.; Cheng, R.; Meng, F.; Zhong, Z.
Intracellular release of doxorubicin from core-crosslinked polypeptide
micelles triggered by both pH and reduction conditions. Biomaterials
2013, 34, 5262−5272.
(20) Klaikherd, A.; Nagamani, C.; Thayumanavan, S. Multi-Stimuli
Sensitive Amphiphilic Block Copolymer Assemblies. J. Am. Chem. Soc.
2009, 131, 4830−4838.
(21) Zhang, J.; Wu, L.; Meng, F.; Wang, Z.; Deng, C.; Liu, H.;
Zhong, Z. pH and Reduction Dual-Bioresponsive Polymersomes for
Efficient Intracellular Protein Delivery. Langmuir 2012, 28, 2056−
2065.
(22) Moad, G.; Rizzardo, E.; Thang, S. H. Radical addition−
fragmentation chemistry in polymer synthesis. Polymer 2008, 49,
1079−1131.
(23) Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in
cancer: role of ATP-dependent transporters. Nat. Rev. Cancer. 2002, 2,
48−58.
(24) Yeh, E. T. H.; Tong, A. T.; Lenihan, D. J.; Yusuf, S. W.;
Swafford, J.; Champion, C.; Durand, J.-B.; Gibbs, H.; Zafarmand, A. A.;
Ewer, M. S. Cardiovascular Complications of Cancer Therapy:
Diagnosis, Pathogenesis, and Management. Circulation 2004, 109,
3122−3131.
(25) Taurin, S.; Nehoff, H.; Greish, K. Anticancer nanomedicine and
tumor vascular permeability; Where is the missing link? J. Controlled
Release 2012, 164, 265−275.
(26) Bae, Y. H.; Park, K. Targeted drug delivery to tumors: Myths,
reality and possibility. J. Controlled Release 2011, 153, 198−205.
(27) Car, A.; Baumann, P.; Duskey, J. T.; Chami, M.; Bruns, N.;
Meier, W. pH-Responsive PDMS-b-PDMAEMA Micelles for Intra-
cellular Anticancer Drug Delivery. Biomacromolecules 2014, 15, 3235−
3245.
(28) K. C., R. B.; Thapa, B.; Xu, P. pH and Redox Dual Responsive
Nanoparticle for Nuclear Targeted Drug Delivery. Mol. Pharmaceutics
2012, 9, 2719−2729.
(29) Jia, L.; Cui, D.; Bignon, J.; Di Cicco, A.; Wdzieczak-Bakala, J.;
Liu, J.; Li, M.-H. Reduction-Responsive Cholesterol-Based Block
Copolymer Vesicles for Drug Delivery. Biomacromolecules 2014, 15,
2206−2217.
(30) Jia, Z.; Wong, L.; Davis, T. P.; Bulmus, V. One-Pot Conversion
of RAFT-Generated Multifunctional Block Copolymers of HPMA to
Doxorubicin Conjugated Acid- and Reductant-Sensitive Crosslinked
Micelles. Biomacromolecules 2008, 9, 3106−3113.
(31) Kurtulus, I.; Yilmaz, G.; Ucuncu, M.; Emrullahoglu, M.; Becer,
C. R.; Bulmus, V. A new proton sponge polymer synthesized by RAFT
polymerization for intracellular delivery of biotherapeutics. Polym.
Chem. 2014, 5, 1593−1604.
(32) Fessi, H.; Puisieux, F.; Devissaguet, J. P.; Ammoury, N.; Benita,
S. Nanocapsule formation by interfacial polymer deposition following
solvent displacement. Int. J. Pharm. 1989, 55, R1−R4.
(33) Schubert, S.; Delaney, J. J. T., Jr.; Schubert, U. S. Nano-
precipitation and nanoformulation of polymers: from history to
powerful possibilities beyond poly(lactic acid). Soft Matter 2011, 7,
1581−1588.
(34) Jiang, J.; Qi, B.; Lepage, M.; Zhao, Y. Polymer Micelles
Stabilization on Demand through Reversible Photo-Cross-Linking.
Macromolecules 2007, 40, 790−792.
(35) Ryu, J.-H.; Bickerton, S.; Zhuang, J.; Thayumanavan, S. Ligand-
Decorated Nanogels: Fast One-Pot Synthesis and Cellular Targeting.
Biomacromolecules 2012, 13, 1515−1522.
(36) Li, L.; Raghupathi, K.; Song, C.; Prasad, P.; Thayumanavan, S.
Self-assembly of random copolymers. Chem. Commun. 2014, 50,
13417−13432.
(37) Wong, C.-H.; Zimmerman, S. C. Orthogonality in organic,
polymer, and supramolecular chemistry: from Merrifield to click
chemistry. Chem. Commun. 2013, 49, 1679−1695.
(38) Quemener, D.; Davis, T. P.; Barner-Kowollik, C.; Stenzel, M. H.
RAFT and click chemistry: A versatile approach to well-defined block
copolymers. Chem. Commun. 2006, 5051−5053.
(39) Arvizo, R. R.; Miranda, O. R.; Thompson, M. A.; Pabelick, C.
M.; Bhattacharya, R.; Robertson, J. D.; Rotello, V. M.; Prakash, Y. S.;
Mukherjee, P. Effect of Nanoparticle Surface Charge at the Plasma
Membrane and Beyond. Nano Lett. 2010, 10, 2543−2548.
(40) Penfold, N. J. W.; Lovett, J. R.; Warren, N. J.; Verstraete, P.;
Smets, J.; Armes, S. P. pH-Responsive non-ionic diblock copolymers:
protonation of a morpholine end-group induces an order-order
transition. Polym. Chem. 2016, 7, 79−88.
Macromolecules Article
DOI: 10.1021/acs.macromol.5b02603
Macromolecules 2016, 49, 3856−3868
3867
(41) de Bruin, K. G.; Fella, C.; Ogris, M.; Wagner, E.; Ruthardt, N.;
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 Figure S1. 
1
H NMR spectrum (300 MHz, CDCl3) of pyridyldisulfide ethylmethacrylate (PDSM) 
and the assignment of the peaks. 
 
 
Figure S2. 
1
H NMR spectrum (400 MHz, CDCl3) of 2-((tert-butoxycarbonyl)(2-((tert-
butoxycarbonyl)amino)ethyl)amino)ethylmethacrylate (BocAEAEMA) and the assignment of the 
peaks. 
 
 Figure S3. 
13
C NMR spectrum (400 MHz, CDCl3) of 2-((tert-butoxycarbonyl)(2-((tert-
butoxycarbonyl)amino)ethyl)amino)ethylmethacrylate (BocAEAEMA) at 25 °C and the 
assignment of the peaks. 
 
Figure S4. 
13
C NMR spectrum (400 MHz, CDCl3) of 2-((tert-butoxycarbonyl)(2-((tert-
butoxycarbonyl)amino)ethyl)amino)ethylmethacrylate (BocAEAEMA) at 0 °C. 
 
Additional comments on 
1
H and 
13
C NMR spectrum of 2-((tert-butoxycarbonyl)(2-((tert-
butoxycarbonyl)amino)ethyl)amino)ethylmethacrylate (BocAEAEMA): The characteristic 
signal of amide proton ,-NH, is observed as duplicate (at 4.79 and 4.99 ppm) instead of a singlet 
(Figure S2). This is attributed to the presence of two possible isomers (E/Z) of the Boc protection 
groups. To prove this assumption, we applied 
13
C NMR experiments at 25 and 0 °C. Figure S3 
demonstrate a 
13
C NMR spectrum of BocAEAEMA at 25 °C. All characteristics carbon peaks of 
the BocAEAEMA at 25 °C can be assigned. However, at 156 ppm carbonyl carbon peaks of the 
Boc protecting groups (b and b’, Figure S3) overlap and were not separated well. Therefore, 13C 
NMR at 25 °C is found to be not informative to prove the isomerization. However, at 0 °C 
carbonyl carbon peaks of the Boc groups at around 156 ppm were separated well (Figure S4). 
Indeed, four separated peaks can be observed, which proves the (E/Z) isomerization of both Boc 
groups. 
 
Figure S5. 
1
H NMR spectrum (300 MHz, CDCl3) of P5 and the assignment of the peaks used to 
calculate the degree of polymerization (DP). 
 Figure S6. The UV-vis absorbance intensity of DOX in DMF at a wavelength of 480 nm as a 
function of DOX concentration.  
 
 
Figure S7. The fluorescence intensity of DOX in deionized water at emission wavelength of 598 
nm, excitation wavelength of 488 nm, as a function of DOX concentration. 
 Figure S8. Normalized SEC traces in CHCl3 of isolated copolymers of P1 to P9. 
 
Figure S9. 
1
H NMR spectra (300 MHz, CDCl3) of P2 and deprotected form of P2 (P2-d). 
 
 
 Figure S10. 
1
H NMR spectra (300 MHz, CDCl3) of P4 and deprotected form of P4 (P4-d).  
 
Figure S11. 
1
H NMR spectrum (300 MHz, CDCl3) of deprotected form of P5 (P5-d). 
 
 Figure S12. 
1
H NMR spectrum (300 MHz, CDCl3) of deprotected form of P6 (P6-d). 
 
 
 
Figure S13. 
1
H NMR spectrum of P7 (300 MHz, CDCl3) and 
1
H NMR spectrum (300 MHz, 
MeOD) of deprotected form of P7 (P7-d).  
 
  
Figure S14. 
1
H NMR spectrum of P8 (300 MHz, CDCl3) and 
1
H NMR spectrum (300 MHz, 
MeOD) of deprotected form of P8 (P8-d). 
 
 
Figure S15. 
1
H NMR spectrum (300 MHz, D2O) of deprotected form of P9 (P9-d). 
 
 Figure S16. Normalized SEC traces in DMAc of P2 and deprotected form of P2 (P2-d). 
 
 
 
Figure S17. Normalized SEC traces in DMAc of P3 and deprotected form of P3 (P3-d). 
 
  
Figure S18. Normalized SEC traces in DMAc of P4 and deprotected form of P4 (P4-d). 
 
 
 
Figure S19. Normalized SEC traces in DMAc of P5 and deprotected form of P5 (P5-d). 
 Figure S20. Normalized SEC traces in DMAc of P6 and deprotected form of P6 (P6-d). 
 
 
 
Figure S21. Normalized SEC traces in DMAc of P7 and deprotected form of P7 (P7-d). 
 
  
Figure S22. Normalized SEC traces in DMAc of P8 and deprotected form of P8 (P8-d). 
 
 
Figure S23. (a) Normalized SEC (RI) traces in CHCl3 of P6-d before and after six months 
storage at room temperature. (b) Calibrated SEC (UV) traces in CHCl3 of P6-d before and after 
six months storage at room temperature. 
 
 
 Figure S24. 
1
H NMR spectrum of P6-d (300 MHz, CDCl3) before and after six months storage at 
room temperature. 
 
Figure S25. TEM images of nanoparticles that were prepared from P2 and P3 (5 mg mL
-1
) by 
dropping acetone-polymer solution to water (AW). 
 
 Figure S26. SEM images of nanoparticles that were prepared from P2, P3 and P4 (3 mg mL
-1
) 
by dropping water to acetone-polymer solution (WA). Scale bars represent 1000 nm. 
 
 
Figure S27. Fluorescence emission spectra of pyrene (4.8 × 10
-6
 mol L
-1
) in P2 nanoparticles 
(0.060 mg mL
-1
) as a function of the pH value. Pyrene in pure water was used as control. 
 Figure S28. Intensity size distribution of DOX-loaded nanoparticles in water. 
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Dual pH and ultrasound responsive nanoparticles
with pH triggered surface charge-conversional
properties†
Turgay Yildirim,a,b Ilknur Yildirim,a,b Roberto Yañez-Macias,b,c Steﬃ Stumpf,a,b
Carolin Fritzsche,a,b Stephanie Hoeppener,a,b Carlos Guerrero-Sanchez,a,b
Stephanie Schubert*b,d and Ulrich S. Schubert*a,b
A series of dual pH- and ultrasound responsive statistical copolymers were synthesized via the reversible
addition–fragmentation chain transfer (RAFT) polymerization of 3,4-dihydro-2H-pyran (DHP) protected
HEMA 2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl methacrylate (THP-HEMA) and 2-(dimethylamino)ethyl
methacrylate (DMAEMA). The RAFT-controlled nature of the (co)polymerizations was veriﬁed by detailed
kinetic studies. The chemical structure and the co-monomer composition of the copolymers were
conﬁrmed by 1H NMR spectroscopy. The number-average molar mass values (Mn) and dispersities (ĐM =
Mw/Mn) of the copolymers were estimated by size exclusion chromatography (SEC). The thermal pro-
perties of the (co)polymers were analyzed by means of thermogravimetric analysis (TGA) and diﬀerential
scanning calorimetry (DSC). Additionally, the DMAEMA moieties of the copolymers were quaternized with
an excess of methyl iodide. The synthesized polymers self-assemble into nanoparticles in aqueous media
via the nanoprecipitation method and were characterized by dynamic light scattering (DLS) and trans-
mission electron microscopy (TEM). Zeta potential measurements revealed that all DMAEMA containing
nanoparticles undergo a surface charge conversion from positive to negative at slightly acidic pH values.
However, quaternized DMAEMA nanoparticles possess pH independent positive surface charges. At acidic
pH values, the nanoparticles disassemble and dissolve in water due to the protonation of the DMAEMA
moieties and/or due to the acidic hydrolysis of the THP-HEMA groups. It was found that the surface
charge and the stability of the nanoparticles were greatly aﬀected by the DMAEMA content of the poly-
mers, meaning that the isoelectric point (IEP), at which the charge is reversed and the pH value at which
the disassembly occurs, increased with the higher DMAEMA content in the copolymer. Moreover, it was
proven that the ionization of the carboxyl RAFT end-group of the polymers enhanced the anionic charac-
ter and the stability of the nanoparticles at neutral pH values. DLS and scanning electron microscopy
(SEM) measurements revealed that these nanoparticles can be further disrupted by ultrasound exposure.
Nile Red was encapsulated into nanoparticles as a model hydrophobic drug. The release proﬁle of the
Nile Red was signiﬁcantly accelerated in acidic media or under ultrasound exposure. The cytotoxicity
assay results showed that negatively charged nanoparticles are non-toxic and biocompatible, whereas
positively charged nanoparticles are extremely toxic to L929 cells.
Introduction
Over the past few decades, a large number of nanoparticle
based drug delivery systems have been used in various stages
of clinical applications.1 These carriers improve drug treat-
ments by altering their pharmacokinetics and biodistribution
profiles. Nevertheless, uncontrolled drug release and poor
cellular internalization are still issues limiting the therapeutic
eﬃcacy. To overcome these limitations, increasing attention
has been drawn to stimuli responsive polymeric nanoparticles,
also called “smart nanoparticles”. The surface charge of the
†Electronic supplementary information (ESI) available: Additional 1H NMR, SEC
and DLS data. See DOI: 10.1039/c6py01927g
aLaboratory of Organic and Macromolecular Chemistry (IOMC),
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nanoparticles has a significant influence on the blood circula-
tion, cellular uptake and the safety of the nanocarriers. For
instance, it is known that positively charged nanoparticles are
more rapidly internalized by the cells than neutral and nega-
tively charged ones as a result of their high aﬃnity for the
negatively charged phospholipid bilayer of cell membranes.2
However, the positive charge of the nanoparticles can cause
nonspecific cellular uptake and strong interaction with pro-
teins in the bloodstream, which causes severe aggregation and
rapid clearance from circulation. Moreover, positively charged
nanoparticles can perturb the structure of the plasma mem-
brane, which induces high cytotoxicity and excessive immune
response.3 In contrast, neutral and negatively charged nano-
particles have shown prolonged circulation times and less
interactions with serum proteins in in vivo experiments.4 As a
consequence, considering the slightly acidic pH value of the
tumor extracellular environment (6.5 to 7.2) and the above
mentioned facts, the development of stimuli responsive,
charge-conversional nanoparticle systems, which have negative
or neutral surface charge values under physiological con-
ditions but become positively charged under a slightly acidic
environment, would yield interesting candidates for intrave-
nous antitumor drug delivery systems. Such systems are
expected to improve the targeting eﬃciency by combining the
advantages of positively and negatively charged nano-
particles.5,6 There are two main strategies for the fabrication of
polymeric surface charge-conversional nanoparticle systems.
The first and most intensively investigated strategy relies on
the tumor pH-triggered cleavage of the amide bond between
an amino and 2,3-dimethylmaleic anhydride at the tumor site,
which results in a charge conversion from negative to
positive.7–10 The second strategy involves polymers that have
ionizable segments such as amino and/or carboxyl groups in
the backbone. In this case, the charge conversion ability of the
nanoparticles is sustained by the protonation and deprotona-
tion of the ionizable groups of the polymer upon change of pH
value.11–13 These studies demonstrated the enhanced cellular
uptake of the surface charge-conversional nanoparticles.
However, to improve the therapeutic eﬃciency the loaded
cargo should additionally be released rapidly when the desired
destination is reached. Therefore, several surface charge-
conversional nanoparticles combined with stimuli responsive
drug release profiles have been investigated. Stimuli respon-
sive nanoparticles can enhance the therapeutic activity of
loaded drugs by spatially controlled release via responding to
various exogenous (light,14 temperature,15 ultrasound,16 and
magnetic field17) or endogenous (pH value,18 redox,19
enzyme,20 and receptor21) stimuli. Among these stimuli, pH
value and redox responsiveness are the most frequently used
ones due to the pH gradients in tissues (e.g. normal vs. tumor
tissue) and intracellular pathways (during endocytosis pH
value decreases from 7.4 to 5.0–6.0 in endosomes and to
4.0–5.0 in lysosomes) and the reductive environment of the
cytosol compared to extracellular environments (100 to 1000
times higher glutathione (GSH) concentration than the extra-
cellular GSH).22 Though most of the reported drug release
mechanisms depend on the endogenous stimuli triggered
release mechanisms like endosomal pH value or redox poten-
tial, they are complicated and limit the control over drug
release.23 In contrast, exogenous stimuli are independent of
the complex conditions of the biological environment that can
enable a precise control over the release of encapsulated cargo.
Among the exogenous stimuli ultrasound has recently
attracted much attention since ultrasound is noninvasive and
can penetrate deep into the interior of the body.16,24–26
Moreover, ultrasound can be localized in space and time,
which prevents damage to healthy tissue.
In this contribution, a library of well-defined statistical
copolymers of 2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl methacry-
late (THP-HEMA) with diﬀerent compositions of 2-(dimethyl-
amino)ethyl methacrylate (DMAEMA) were synthesized using
the RAFT polymerization process (Scheme 1) to develop a
novel pH value and an ultrasound responsive drug delivery
system, which possesses the following features: (i) a charge
conversion from negative to positive under slightly acidic con-
ditions and (ii) nanoparticle disassembly at endosomal pH
values or by ultrasound exposure. We used THP-HEMA as a
hydrophobic moiety of the polymers because its cyclic acetal
functionality can be cleaved under acidic conditions.27 This
converts the hydrophobic part of the polymer into hydrophilic
HEMA leading to an imbalance of the hydrophilic/lipophilic
ratio resulting in the disassembly of the corresponding nano-
particles. Additionally, it is known that THP functional nano-
particles can be disrupted by ultrasound treatment.28,29
Scheme 1 Schematic representation of the RAFT copolymerization of THP-HEMA with DMAEMA.
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DMAEMA was used as a hydrophilic moiety since it is a weak
polyelectrolyte in water with a pKa value of ∼7.4. Therefore, it
is expected that partial protonation of DMAEMA groups can
render the surface charge conversion at slightly acidic pH
values and complete protonation of the DMAEMA groups at
endosomal pH values may cause nanoparticle disassembly.
Findings on the synthesis and self-assembly behavior of these
polymers in aqueous media, pH value and ultrasound respon-
siveness of the corresponding nanoparticles, the release kine-
tics of the encapsulated Nile Red in response to pH value and
ultrasound, and the eﬀect of surface charge on the cytotoxicity
of nanoparticles are discussed below.
Experimental section
Materials
The THP-HEMA was synthesized according to the procedure
reported elsewhere (see Fig. S1† for the 1H NMR spectrum).27
4,4′-Azobis(4-cyanovaleric acid) (ACVA), 4-cyano-4-(phenyl-
carbonothioylthio)pentanoic acid (CPADB), 4-cyano-4-[(dodecyl-
sulfanylthiocarbonyl)sulfanyl]pentanol (CDP), 1,3,5-trioxane,
N,N-dimethylaminoethyl methacrylate (DMAEMA), methyl
iodide (MeI), and Nile Red were purchased from Sigma
Aldrich. AlamarBlue was obtained from Life Technologies.
Consumables for cell culture, like pipettes and cell culture
plates (96 well) were obtained from Corning (USA) and Greiner
Bio-one (Austria/Germany). If not stated otherwise, cell culture
media and supplements (L-glutamine, antibiotics) were
obtained from Biochrom (Merck Millipore, Germany). Poly
(methyl methacrylate) (PMMA) (Mn = 13 500 g mol
−1, ĐM =
1.13) was obtained from Polymer Libraries GmbH (Germany).
All other chemicals were purchased from standard suppliers
and used without further purification.
Instruments and methods
Proton nuclear magnetic resonance (1H NMR) spectra were
recorded at room temperature in CDCl3 or DMSO-d6 on a
Bruker Avance 300 MHz. The chemical shifts are given in ppm.
Size-exclusion chromatography (SEC) measurements were
performed on a Shimadzu system equipped with a SCL-10A
system controller, a LC-10AD pump, a RID-10A refractive index
detector, and a PSSSDV-linear S column (5 µm particle size;
Polymer Standards Service GmbH, Mainz, Germany) at 40 °C
using a CHCl3, triethylamine and 2-propanol (94 : 4 : 2)
mixture as the eluent at a flow rate of 1 mL min−1. The system
was calibrated with a linear calibration curve built from poly
(methyl methacrylate) (PMMA) standards of narrow dispersity
(Mp = 410 to 88 000 g mol
−1).
Diﬀerential Scanning Calorimetry (DSC) measurements
were performed on a Netzsch DSC F1 Phoenix under a nitro-
gen atmosphere using a heating rate of 20 K min−1 from −50
to +150 °C. 2 cycles were recorded for each sample. The glass
transition temperature (Tg) values are reported for the second
heating run.
Thermogravimetric analysis (TGA) was performed under a
nitrogen atmosphere on a Netzsch TG 209 F1 Iris in the
range of room temperature to 800 °C with a heating rate of
20 K min−1. The corresponding decomposition temperatures
were determined at the decay point of the curves.
Solubility of the polymers was tested on a Crystal 16™ from
Avantium Technologies being connected to a chiller (Julabo FP
40) using a wavelength of 500 nm.
Dynamic light scattering was performed using a Zetasizer
Nano ZS (Malvern Instruments, Herrenberg, Germany). After
an equilibration time of 180 s, 3 × 30 runs were carried out at
25 °C (λ = 633 nm). The counts were detected at an angle of
173°. Each measurement was performed in triplicate. The
mean particle size was calculated applying the nonlinear least-
squares fitting mode. The Z-average diameter and the width of
the distribution as the polydispersity index of the particles
(PDI) were obtained by the cumulants method assuming a
spherical shape of the particles.
Electrophoretic light scattering was used to measure the
electrokinetic potential, also known as ζ-potential. The
measurements were performed on a Zetasizer Nano ZS
(Malvern Instruments, Herrenberg, Germany) by applying laser
Doppler velocimetry. For each measurement, 10 runs were
carried out using the slow-field and fast-field reversal mode at
150 V. Each experiment was performed in triplicate at 25 °C.
For scanning electron microscopy (SEM), 5 μL of the sus-
pensions were placed on a mica surface and dried overnight at
room temperature under atmospheric pressure. Afterwards,
samples were investigated using a Sigma VP field emission
scanning electron microscope (Carl-Zeiss AG, Germany). The
samples were coated with a thin layer (4 nm) of platinum via
sputter coating using a Bal-TEC 020 HR Sputtering Coater.
Transmission electron microscopy (TEM) was carried
out utilizing a FEI Technai G2 20 transmission electron
microscope.
The fluorescence spectra of Nile Red were recorded on a
Jasco FP-6500 fluorometer applying an excitation wavelength
of 549 nm. The emission spectra were recorded from 560 to
800 nm. The excitation and emission bandwidths were 3.0 and
3.0 nm, respectively. For Nile Red release experiments a Tecan
M200 Pro fluorescence microplate reader was used.
Synthesis
RAFT polymerization. A Chemspeed Swing-SLT automated
parallel synthesizer was utilized for the synthesis of P1–P5. For
more details about the automated parallel synthesizer readers
are referred to the literature.30–32 Neat chemicals (THP-HEMA,
DMAEMA and ethanol (solvent reservoir)), stock solutions of
ACVA (13.3 mg mL−1 in ethanol), and of the RAFT agent
(53.0 mg mL−1 in ethanol) were prepared, degassed by purging
with nitrogen for 15 min, and placed inside the automated
synthesizer. Aliquots of THP-HEMA, DMAEMA, ACVA, RAFT
agent stock solutions, and the solvent from the reservoirs were
transferred into parallel reactors with the automated liquid
handling system of the equipment to provide the desired con-
centrations of reagents. In all cases, a total monomer concen-
Paper Polymer Chemistry
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tration of 1 M was maintained. Diﬀerent initial monomer feed
ratios were applied for each copolymerization to vary the
amino content in the copolymers. The targeted molar mass
value was Mn,tg = 10 000 g mol
−1 at 100% conversion. In all
cases a [RAFT]/[initiator] = 1/0.25 was used. The initial feed
ratios used are summarized in Table 1. After all the liquid
transfers were completed, the reaction solutions were addition-
ally degassed through one automated cooling–evacuate–
heating cycle carried out as follows: the reaction mixtures were
cooled to 0 °C, a vacuum (∼5 millibar) was then applied to the
reactor block while heating the reactors up to 0 °C and main-
tained for 2 minutes. After that, the reactors were sealed under
a nitrogen atmosphere and heated to the reaction temperature
(70 °C); the temperature of the reflux condensers on top of the
reactors was set to 5 °C. The onset of the polymerizations was
considered once the reaction temperature in the reactors was
reached. At the pre-established times, an aliquot of 200 µL was
withdrawn with the automated liquid handling system from
the reaction mixtures and placed into NMR tubes and SEC
vials (75 µL each and 50 µL excess) to follow the monomer con-
version and molar mass of the formed polymers, respectively.
SEC and NMR samples for analysis were prepared with the
automated liquid handling system of the synthesizer at the
end of each sampling sequence by adding the corresponding
SEC and NMR solvents. Once the pre-established reaction time
elapsed, the polymerization mixtures were cooled to 20 °C.
Monomer conversions were determined via 1H NMR by using
1,3,5-trioxane as an internal standard. The polymers were puri-
fied by precipitation in cold hexane : diethyl ether (4 : 1). The
resulting pink colored polymers were dried under high
vacuum at room temperature until constant weight to produce
an overall yield of around ∼80%. The number average molar
mass (Mn) and molar mass dispersity (ĐM) were determined by
SEC using PMMA standards. The degree of polymerization
(DP) for each polymer was calculated from the signal integrals
of the 1H NMR spectrum (Fig. 2) of the purified copolymer
using the following equations:
DPTHP‐HEMA ¼ Iðsignal eÞIðsignal aÞ=2 ð1Þ
DPDMAEMA ¼ Iðsignal hÞ=6Iðsignal aÞ=2 ð2Þ
with I(signal e) corresponding to the integral of the methine
proton peaks of the THP-HEMA at 4.65 ppm, I(signal h) corres-
ponding to the integral of methyl proton peaks of the
DMAEMA at 2.30 ppm, and I(signal a) corresponding to the
integral of two aromatic protons of the dithiobenzoate end
group at 7.84 ppm. Number average molar mass values were
calculated by using the following equation:
Mn;NMR ¼ðDPTHP‐HEMA MTHP‐HEMAÞ
þ ðDPDMAEMA MDMAEMAÞ þMCTA
ð3Þ
in which the molar mass of the THP-HEMA, DMAEMA
and RAFT agent is 214.26 g mol−1, 157.21 g mol−1, and
279.38 g mol−1, respectively.
Quaternization of the polymers. For quaternization, each
50 mg of the polymer (P2 to P5) were dissolved in 5 mL of
acetone. Methyl iodide (MeI) was added at room temperature
at a molar ratio of 3 compared to DMAEMA groups. The
mixture was stirred overnight to ensure quantitative conver-
sion. Excess MeI was removed by precipitation in cold hexane.
The resulting quaternized polymers (P2q to P5q) were dried
under high vacuum at room temperature.
Nanoprecipitation of the polymers. For nanoprecipitation,
two diﬀerent methods were used. For the acetone to water
(AW) method, corresponding polymers (P1 to P5, P2q to P5q,
P1OH, P5OH) were dissolved in acetone at a final concen-
tration of 1 mg mL−1 and subsequently added dropwise to de-
ionized water under continuous stirring at 500 rpm. For the
water to acetone (WA) method, deionized water was added
dropwise to the acetone polymer solution (1 mg mL−1) under
stirring at 500 rpm. The acetone/water (solvent/non-solvent)
ratio was kept constant at 0.5 for all suspensions. After
removal of the acetone by stirring overnight at room tempera-
ture in an open vial, the nanoparticles were characterized by
DLS (performed in pure water) and TEM without filtration.
pH-Response test of the nanoparticles. For the pH-response
test of the nanoparticles, 0.1 M acetic acid for a pH value of
3.1, 0.1 M acetate buﬀer for pH values of 4, 5, 6, 6.25, 6.50 and
Table 1 Selected characterization data of the THP-HEMA (M1) (co)polymers with DMAEMA (M2)
Entry
Monomer/
CTA/ACPA f (M1/M2)a F(M1/M2)b
Conv.c [%]
M1/M2
Mn,theo.
d
[g mol−1] DPc M1/M2
Mn
c
[g mol−1]
Mn,SEC
e
[g mol−1] Mw/Mn
e Tg
f [°C]
P1 45.37/1/0.25 85/0 8500 40/0 8800 6300 1.13 29.4
P1OH 45.37/1/0.25 90/0 9000 6800 1.24 —
P2 45.98/1/0.25 19 15.7 85/84 8500 36/2.3 8300 5700 1.18 30.6
P3 46.61/1/0.25 9 8.2 80/90 8100 33/4 7800 5600 1.18 28.0
P4 47.26/1/0.25 5.7 5.6 76/84 7800 31/5.5 7800 6200 1.17 29.9
P5 47.92/1/0.25 4 4 84/87 8500 29/7.3 7600 6300 1.18 29.1
P5OH 47.92/1/0.25 4 4 82/90 8600 6400 1.27 —
a Initial monomer feed ratio. bMonomer ratio in the isolated copolymer. cDetermined by 1H NMR spectroscopy. dDetermined by the formula
Mn,theo. = [([M]M1/[CTA] × Conv. × MM1) + ([M]M2/[CTA] × Conv. × MM2) + (MCTA)].
eDetermined by SEC in CHCl3 analysis (RI detection, PMMA cali-
bration). fDetermined by DSC analysis.
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0.1 M tris buﬀer for the pH values 7, 7.4, 8, and 9 were used.
In a typical experiment, 100 µL of P1 nanoparticle suspension
(0.5 mg mL−1) were mixed with 900 µL acetic or corresponding
buﬀer solutions in Eppendorf tubes and stored at 37 °C for 1 h
while mixing at 200 rpm. Then, DLS and ζ-potential measure-
ments were performed.
Ultrasound-response test of the nanoparticles. Ultrasound
response tests of the nanoparticles were performed by generat-
ing ultrasound using a Hielscher UP 200St instrument. The
general procedure is as follows: 1 mL of nanoparticle suspen-
sion (0.5 mg mL−1) was diluted to a final volume of 5 mL in a
glass vial. The ultrasonic probe was immersed in the middle of
the nanoparticle suspension. In order to minimize the temp-
erature change during the ultrasound exposure, the glass vial
was cooled in an ice bath. After a certain time of ultrasound
treatment, the temperature of the suspensions was monitored
and 100 µL of samples were taken for characterization.
Nile Red encapsulation and release. Nile Red was encapsu-
lated into the polymers by utilizing the co-precipitation tech-
nique. An exemplary procedure is as follows: P1 (10 mg) was
dissolved in 10 mL acetone. Then, 40 µL Nile Red stock solu-
tion (1 mM in acetone) was added. Subsequently, 20 mL of de-
ionized water was added dropwise to the acetone solution
under continuous stirring at 500 rpm. The mixed solutions
were stirred overnight at room temperature in an open vial to
remove the acetone.
To test the ultrasound mediated release of Nile Red from
the nanoparticles, 1 mL of dye encapsulated nanoparticle sus-
pensions was mixed with 9 mL of deionized water. After every
1 minute of ultrasound exposure (40 W), 300 µL of the sample
were taken for the fluorescence spectroscopy analysis.
To test the pH value mediated release of Nile Red from the
nanoparticles, 100 µL of dye encapsulated nanoparticles were
mixed with 900 µL of three diﬀerent buﬀers: (i) acetate buﬀer
(0.1 M, pH 4.0), (ii) acetate buﬀer (0.1 M, pH 6.0), and (iii) tris
buﬀer (0.1 M, pH 8.0) in an Eppendorf tube and stored at
37 °C. 300 µL of the sample were taken periodically and ana-
lyzed by fluorescence spectroscopy. The % release of Nile Red
was calculated by using the following equation:
Release ð%Þ ¼ I0  It
I0
 100 ð4Þ
where I0 corresponds to the initial fluorescence intensity of
Nile Red at 610 nm and It corresponds to the fluorescence
intensity of Nile Red at each time point.
Determination of cytotoxicity. Cytotoxicity studies were per-
formed with the mouse fibroblast cell line L929 (CCL-1,
ATCC), as recommended by ISO10993-5. The cells were routi-
nely cultured in Dulbecco’s modified eagle’s medium sup-
plemented with 10% fetal calf serum (FCS, Capricorn
Scientific, Germany), 100 U mL−1 penicillin and 100 µg mL−1
streptomycin at 37 °C under a humidified 5% (v/v) CO2 atmo-
sphere. In detail, cells were seeded at 104 cells per well in a
96-well plate and incubated for 24 hours. No cells were seeded
in the outer wells. Afterwards, nanoparticles were added to
the cells at indicated concentrations (from 10 µg mL−1 to
1000 µg mL−1), and the plates were incubated for further
24 hours. Subsequently, the medium was replaced by a mixture
of fresh culture medium and the assay reagent AlamarBlue
(resazurin-based solution, Thermo Fisher, Germany, prepared
according to the manufacturer’s instructions). After a further
incubation of 4 hours at 37 °C under a humidified 5% (v/v) CO2
atmosphere, the fluorescence was measured at Ex 570/Em
610 nm, with untreated cells on the same well plate serving as
negative controls. The negative control was standardized as 0%
of metabolism inhibition and referred to as 100% viability. Cell
viability below 70% was considered to be indicative of cyto-
toxicity. Data are expressed as mean ± standard deviation (SD)
of three independent determinations.
Results and discussion
In order to obtain an ultrasound responsive nanoparticle
system with surface charge-conversional properties, a series of
statistical copolymers of THP-HEMA and DMAEMA were syn-
thesized by utilizing the RAFT polymerization process.33 To
the best of our knowledge, the copolymerization of
THP-HEMA and DMAEMA has never been reported so far.
However, both monomers have been successfully polymerized
with RAFT using CPADB as a chain transfer agent (CTA).18,27
For the comprehensive understanding of the eﬀect of
monomer composition on the stimuli response of the corres-
ponding nanoparticles, one homopolymer of THP-HEMA (P1)
and four copolymers of THP-HEMA and DMAEMA (P2 to P5)
with similar molar mass values but varying compositions were
synthesized using ACVA as an initiator and CPADB as a CTA in
ethanol at 70 °C with a monomer concentration of 1 mol L−1
(Scheme 1 and Table 1). Regarding the polymerization rate
and to gain control over the molar mass, the [CTA]/[ACVA] ratio
was kept at 1/0.25.34 To vary the monomer composition,
diﬀerent monomer feed ratios were applied with a targeted
molar mass value of Mn,tg = 10 000 g mol
−1 at 100% conversion
for each polymerization. Concerning the possible toxicity of
tertiary amino groups, the DMAEMA content in the copoly-
mers was kept below 20 mol%. In addition, since the ionizable
carboxylic acid end-group of the CPADB could potentially
aﬀect the pH-responsive behavior of the corresponding nano-
particles, analogues of P1 and P5 (P1-OH and P5-OH) were syn-
thesized by using a non-ionizable hydroxyl functional chain
transfer agent 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfa-
nyl]pentanol (CDP) (Scheme S1† and Table 1) to investigate
the eﬀect of functional groups in the chain transfer agents on
the pH-responsive behavior of the nanoparticles.
Kinetic studies
To verify the RAFT-controlled nature of the (co)polymeriz-
ations, kinetic investigations were performed for P1 to P5. The
kinetic plots are displayed in Fig. 1 and S2.† SEC analysis
revealed that molar mass distributions of the kinetic samples
remain monomodal while shifting to lower elution volumes in
the course of each polymerization (Fig. S2†). The molar mass
Paper Polymer Chemistry
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Mn increases linearly with respect to the total monomer con-
version with ĐM values below 1.3 suggesting a controlled
polymerization mechanism (Fig. 1A). Fig. 1B depicts the semi-
logarithmic kinetic plots. An induction period of around
30 min was observed for both polymerizations as often
reported for RAFT polymerizations. After this induction time,
semilogarithmic plots increase linearly for about 10 h, indicat-
ing a pseudo first order polymerization rate with respect to the
total monomer concentration and a constant concentration of
the propagating radicals during the RAFT polymerization.
Finally, the slopes of the curves are no longer linear, which is
attributed to a decrease in the rate of radical generation
caused by a decrease in the initiator concentration.
Polymer characterization
The resulting (co)polymers were characterized by 1H NMR
spectroscopy and SEC measurements (Table 1). 1H NMR spectro-
scopy analysis of the isolated (co)polymers (P1 to P5) clearly
revealed the presence of the ω-RAFT end groups (δ = 7.84, 7.48,
and 7.35 ppm), and the characteristic signals that are derived
from THP-HEMA (δ = 4.65 to 3.50 ppm) and DMAEMA (δ =
2.58 and 2.30 ppm) (Fig. 2). This enables the estimation of the
degree of polymerization (DP) for each monomer and the
number average molar mass values for P1 to P5. The signal
corresponding to the aromatic protons of the ω-RAFT end
groups were used to calculate the DP of each monomer in the
corresponding polymer. For this purpose, the integral values
were compared with the integral value of the methine proton
peak of the THP-HEMA side chains (peak “e” in Fig. 2) and
the methylene peak of the DMAEMA side chains (peak “h” in
Fig. 2) (see the Experimental section for details). The resulting
Mn values calculated by
1H NMR are in good agreement with
the theoretical values that were calculated from the [monomer]
to [CTA] ratio and the monomer conversions. The monomer
compositions in the isolated copolymers (F(M1/M2)) were cal-
culated by comparing the integral values of peak “e” and peak
“h”. Since the characteristic 1H NMR peaks of the CDP overlap
with the backbone of the polymers, DP and Mn values cannot
be estimated by 1H NMR for P1OH and P5OH.
The isolated copolymers were analyzed using SEC (Fig. 3
and S5†). SEC analysis revealed monomodal traces and low
dispersities (ĐM < 1.3) for all polymers. Molar mass values
obtained by SEC are lower than the molar mass values deter-
mined by 1H NMR spectra due to the PMMA calibration in the
Fig. 1 Kinetic studies of the RAFT homopolymerization of THP-HEMA
(P1) and RAFT copolymerization of THP-HEMA with DMAEMA (P2 to P5).
Polymerization conditions: solvent = ethanol, T = 70 °C, [M]0 = 1 mol
L−1. (A) Mn and ĐM evolution with total monomer conversion. (B)
Semilogarithmic kinetic plots.
Fig. 2 1H NMR spectra (300 MHz, CDCl3) of P1 (bottom) and P5 (top)
and the assignment of the peaks used to calculate the DP.
Fig. 3 Normalized SEC traces in CHCl3 of isolated copolymers of
P1 to P5.
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SEC systems, resulting in a relative molar mass value.
Moreover, molar mass values determined by SEC are similar
for all polymers, which is expected since the same molar mass
values were targeted, and similar total monomer conversions
were obtained for all polymers.
Thermal properties
Thermogravimetric analysis (TGA) was used to study the
decomposition pattern and the thermal stability of the (co)
polymers under a nitrogen atmosphere (Fig. 4A). It can be
observed that the homopolymer P1 undergoes a two-step
degradation. The first step is between 170 and 265 °C (∼45%
of mass loss), which presumably corresponds to the loss of the
pendant THP groups (∼40% of calculated mass loss). This con-
verts P1 to poly(2-hydroxyethyl methacrylate) (PHEMA). The
second step occurs between 290 and 450 °C and is attributed
to the degradation of the PHEMA. This is consistent with the
reported thermal stability studies of PHEMA (stable up to
∼300 °C, a one-step degradation between ∼300 °C and
∼450 °C).35 Similar results were obtained with the copolymers
P2 to P5. However, an increase of the DMAEMA content
resulted in a decrease of the rate of mass loss, which is
attributed to the better thermal stability of the PDMAEMA
than P(THP-HEMA). Thermal transitions of the (co)polymers
(P1 to P5) were studied by diﬀerential scanning calorimetry
(DSC) under a nitrogen atmosphere (Fig. 4B). The homopoly-
mer P1 exhibits a Tg point at 29.4 °C (Table 1). The copolymers
P2 to P5 exhibit single Tg temperatures between 28.0
and 30.6 °C, which are similar to P1, without apparently
any correlation with the DMAEMA content of the polymer.
This is attributed to the low content of DMAEMA moieties (up
to 20%), which are randomly distributed along the polymer
chains.
Quaternization of the polymers
The pendant amino groups of the copolymers (P2 to P5) were
treated with an excess of methyl iodide in acetone in order to
investigate the eﬀect of the quaternization of the DMAEMA
moieties on stimuli response of the corresponding nano-
particles (P2q to P5q) (Scheme S2†). The quantitative quaterni-
zation was verified by the disappearance of the proton signals
of DMAEMA in the 1H NMR spectrum (δ = 2.58 and 2.30 ppm)
(Fig. 5). The more deshielded protons of the DMAEMA after
quaternization cause a shift of the proton peaks to a lower
field.36 SEC reveals a slight increase in the molar mass values
after quaternization caused by the increased hydrodynamic
volume of the copolymers in CHCl3 (Fig. S7†).
Nanoparticle formulation and characterization
Polymeric nanoparticles were prepared from the synthesized
(co)polymers (P1 to P5, P1OH, P5OH, P2q to P5q) by nano-
precipitation with subsequent solvent evaporation without any
need for stabilizers/surfactants. Two diﬀerent dropping
methods (dropping the acetone–polymer solution into water
(AW) as well as dropping water into the acetone–polymer solu-
tion (WA)) were applied for each polymer in order to obtain
diﬀerently sized nanoparticles. Well-defined nanoparticles
with monomodal size distributions and low polydispersity
index (PDI) values were obtained with both dropping methods
for all polymers except P2 (Table 2 and Fig. S8†). As commonly
seen, larger nanoparticles with lower PDI values for all poly-
mers were obtained with the WA method in comparison with
the AW method.37,38 Moreover, smaller nanoparticles were
obtained with quaternized polymers (P2q to P5q) than with
unquaternized ones (P3 to P5) for both dropping methods.
These results are consistent with the recent report of Reisch
et al., which states that the presence of charged groups in
polymer chains can reduce the size of polymer nanoparticles
fabricated by nanoprecipitation.39 Well-defined nanoparticles
could not be obtained using P2, which contains a 5%
DMAEMA functionality. This is attributed to the insuﬃcient
cationic character of the nanoparticles, which is presumably
Fig. 4 (A) TGA thermograms of P1 to P5. (B) DSC heating runs of P1 to
P5 (heating rate: 20 K min−1).
Fig. 5 1H NMR spectra (300 MHz, CDCl3) of P5 and P5q (quaternized
form of P5).
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not high enough to stabilize the nanoparticles. This assump-
tion is reasonable, since there are about 2.3 DMAEMA units in
average (estimated by 1H NMR) in a P2 chain, which are not
completely protonated in pure water (pH ∼ 7). Moreover, there
is one carboxylic acid unit in every P2 chain due to the α end
group of the utilized RAFT agent that is completely ionized in
pure water due to its low pKa value (∼5) leading to a decrease
in the cationic character of the nanoparticles. In contrast to
this, P2q (quaternized form of P2) yielded well-defined nano-
particles, due to having an appreciable cationic character (pH
independent cationic charge). The ζ-potential measurements
in pure water revealed that P3 to P5, P5OH, and P2q to P5q
nanoparticles exhibit positive ζ-potential values higher than
+29 mV with small diﬀerences for AW and WA methods, which
is commonly seen for the nanoprecipitation method.19 The
positive ζ-potential values are due to the protonated or quater-
nized amino groups of the polymers. P1 nanoparticles show
negative ζ-potential values of around −30 mV due to the pres-
ence of carboxyl groups in the polymer. Although there are no
ionizable groups in P1OH it also has negative ζ-potential
values around −30 mV. To understand the source of the nega-
tive ζ-potential of the P1OH further pH dependent ζ-potential
measurements were conducted (see the next section). TEM
analysis (Fig. 6) revealed homogeneous spherical nanoparticles
with diameters in agreement with the DLS measurements. A
long term stability test at room temperature for three weeks
shows no change in the particle size and size distribution
(determined by DLS).
pH-Response test of the nanoparticles
The nanoparticle suspensions were stored at various pH values
for 1 h, and the changes in particle size and ζ-potential values
were recorded. DLS measurements revealed that P1 nano-
particle suspensions possess stable size and PDI values at
neutral and basic pH values (pH = 7.4, 8, and 9). Below 7.4 the
size and PDI values of the nanoparticles gradually increase
whereas they precipitate below a pH value of 6.25 (Fig. 7) due
to the decrease in the ζ-potential values in the acidic pH
regime from −66 mV at a pH value of 9 to −19 mV at a pH
value of 6.2. In general, stable polymeric nanoparticles have
ζ-potential values beyond ±25 mV.40 Upon decreasing the pH
below its IEP, P1 nanoparticles show a surface charge conver-
sion from negative to positive. Armes and coworkers reported
that RAFT based carboxyl end-groups of the nanoparticles can
be ionized at neutral pH values and protonated in acid media
leading to a nanoparticle ζ-potential conversion.41 Therefore,
we first hypothesized that the conversion of the ζ-potential
values of P1 upon change in the pH value could be due to the
protonation of the carboxyl end-group of the polymer. To
examine this hypothesis, the pH responsive behavior of the
P1OH, which is synthesized by using a hydroxyl functional
CTA instead of a carboxyl functional one, was also investigated
as a control experiment. Unexpectedly, P1OH nanoparticles
showed similar size and ζ-potential value changes like P1
nanoparticles upon pH value change, suggesting that both P1
and P1OH nanoparticles exhibit IEPs due to having
Table 2 Selected characterization results of the prepared nanoparticles
Entry
Z-Averagea [d, nm] PDIa ζ-Potentialb
AWc WAd AWc WAd AWc WAd
P1 108 ± 1 242 ± 3 0.14 ± 0.01 0.01 ± 0.01 −31 ± 1 −26 ± 1
P1OH 119 ± 1 223 ± 3 0.08 ± 0.02 0.08 ± 0.02 −33 ± 1 −25 ± 1
P2q 57 ± 1 182 ± 1 0.23 ± 0.01 0.06 ± 0.01 +29 ± 1 +37 ± 2
P3 98 ± 1 216 ± 3 0.13 ± 0.02 0.03 ± 0.01 +42 ± 1 +46 ± 6
P3q 42 ± 1 172 ± 2 0.26 ± 0.01 0.07 ± 0.02 +54 ± 3 +57 ± 1
P4 130 ± 1 233 ± 1 0.13 ± 0.01 0.01 ± 0.01 +48 ± 1 +30 ± 1
P4q 38 ± 1 120 ± 1 0.28 ± 0.01 0.11 ± 0.01 +65 ± 3 +48 ± 1
P5 120 ± 1 247 ± 2 0.11 ± 0.01 0.02 ± 0.01 +45 ± 1 +47 ± 1
P5OH 89 ± 1 229 ± 3 0.15 ± 0.11 0.05 ± 0.03 +42 ± 1 +51 ± 1
P5q 51 ± 1 138 ± 2 0.28 ± 0.01 0.01 ± 0.01 +48 ± 5 +63 ± 2
PMMA — 187 ± 1 — 0.03 ± 0.03 — −18 ± 1
a Average values of three DLS measurements. b Average values of three ζ-potential measurements in pure water. cDropping acetone into water.
dDropping water into acetone.
Fig. 6 TEM images of nanoparticles that were prepared from P1, P3,
P4, and P5 (1 mg mL−1) by dropping acetone–polymer solution to water
(AW).
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THP-HEMA moieties. However, P1 nanoparticles start aggre-
gating at lower pH values than P1OH nanoparticles. This is
attributed to the ionization of the carboxyl end-group of the P1
leading to a better ionic character of P1 than in the case of
P1OH. Moreover, the pH responsive behavior of control PMMA
nanoparticles (Table 2) was also investigated under the same
conditions as a second control experiment; in this case, PMMA
nanoparticles aggregated at the entire pH range presumably
due to the action of buﬀer solutions that screen the weak
repulsive forces between the PMMA nanoparticles. The low
absolute ζ-potential values of the PMMA nanoparticles at all
pH values support this assumption. In contrast to P1 and
P1OH, P3 nanoparticles that contain 10% DMAEMA function-
ality show stable size and PDI values in the pH range from 4 to
6 with ζ-potential value higher than +58 mV, due to an ade-
quate cationic character of the polymer as a result of proto-
nated DMAEMA groups. However, at a pH value of 3.1, P3
nanoparticles showed a significant decrease in size from 200
to 80 nm. This is presumably due to the protonation of
DMAEMA and THP-HEMA groups. The protonation of the
THP-HEMA groups would be expected to cause the cleavage of
the cyclic acetal functionality of the THP-HEMA side chain. To
confirm this assumption, the P3 nanoparticle solution was
treated with 0.1 M acetic acid (pH = 3.1) and stored at 37 °C
for 24 h. The resulting solution was freeze-dried and a
1H NMR spectrum was recorded (Fig. S9†). After treatment
with acetic acid, a new small signal was observed at 4.9 ppm
corresponding to the hydroxyl (–OH) group of poly(2-hydroxy-
ethyl methacrylate) (PHEMA) and suggesting the slow cleavage
of acetal groups.27 Therefore, the quick decrease in size at
pH value 3.1 is attributed to the protonation of DMAEMA
chains. An increase of the pH value from 5 to 6 resulted in a
significant decrease in the ζ-potential of P3 nanoparticles
from +68 mV to +21 mV. This is due to the partial deprotona-
tion of the DMAEMA groups. At higher pH values, the
ζ-potential value of the P3 nanoparticles further decreases and
reaches its IEP at a pH value of ∼7.1. Above its IEP, ζ-potential
values of the nanoparticles show a surface charge conversion
from positive to negative. Due to the insuﬃcient ζ-potential
values (lower than ±20 mV), P3 nanoparticles form aggregates
between the pH values from 6.25 to 7.4. At a pH value of 8, P3
nanoparticles reveal a ζ-potential value of −37 mV; hence, they
are stable in their size and PDI value. A further increase of the
pH value from 8 to 9 resulted in an increase of the absolute
value of the ζ-potential to −60 mV. In contrast to P3 nano-
particles, P2q nanoparticles revealed stable size and PDI
values, no IEP, and ζ-potential values higher than +20 mV over
the entire pH range. This is due to the quaternization of the
DMAEMA groups (Fig. S11†), which imparts a pH independent
cationic character to the nanoparticles. In agreement with
this, although P3 nanoparticles form aggregates at a pH value
of 7.4, P3q nanoparticles showed no change in size even after
23 h storage at 37 °C (Fig. S12†). Although P3 nanoparticles
are stable at pH values of 4.5 and 4.0, the size of the P4 nano-
particles that contain a higher DMAEMA content than P3
decreased from 200 nm to 47 nm at pH 4.5 and to 33 nm at
pH 4 (Fig. 7). Moreover, an increase of the incubation time to
6 h resulted in no detectable DLS signals. This is attributed to
the dissolution of the P4 nanoparticles at these pH values as a
result of the completely protonated DMAEMA moieties. In
accordance with this, P5 nanoparticles that contain the
highest DMAEMA content revealed dissolution even at pH
5. The dissolution abilities of P4 and P5 at these pH values, at
a concentration of 1 mg mL−1, were further confirmed by tur-
bidity measurements with 100% transmittance (Fig. S10†).
Moreover, it was found that the IEP of the nanoparticles in
relation to the pH value increases with the DMAEMA content
in the copolymer. The IEP of P4 nanoparticles was found to be
Fig. 7 (A) Intensity-weighted size and PDI values of nanoparticles as a function of the pH value. (B) ζ-Potentials of the nanoparticles as a function
of the pH value.
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7.2, whereas P5 nanoparticles reached IEP at 7.4. These results
suggest that the dissolution pH as well as the IEP of the nano-
particles can simply be tuned by varying the DMAEMA content
in the copolymers. Moreover, although P5 nanoparticles are
stable at pH 8 with a ζ-potential of −24 mV, the P5OH nano-
particles are not stable at a lower ζ-potential value (−18 mV).
This may be due to the ionization of the carboxyl end-group of
the P5, resulting in a better anionic character.
Ultrasound response test of the nanoparticles
To investigate the ultrasound responsive behavior of the nano-
particles, ultrasound with a power of 20 W and a frequency of
26 kHz was applied to the nanoparticle suspensions. In order
to prevent the thermal hydrolysis of the THP-HEMA moieties,
the temperature of the suspensions was kept constant in the
range of 32 to 34 °C during the ultrasound treatment. The
changes in particle size and PDI values were recorded by DLS
at intervals of 5 minutes of ultrasound exposure. Fig. 8 shows
the DLS results of P1, P3, and P5 nanoparticles subjected to
ultrasound treatment. The size and PDI values of the nano-
particles increase upon prolonged ultrasound exposure
together with a rapid decrease in the derived count rate of the
nanoparticles due to the formation of larger aggregates.
However, the DLS traces of the nanoparticles also reveal the
appearance of some smaller aggregates (Fig. S13†). Moreover,
SEM images of P1 and P5 nanoparticles showed that, although
nanoparticles have uniform spherical shapes prior to ultra-
sound exposure, smaller nanoparticles and irregular larger
aggregates were formed after ultrasound treatment for
30 minutes (Fig. 9). It was found that an increase in the power
of the ultrasound from 20 to 40 W resulted in a faster aggre-
gate formation and a faster decrease in the derived count rate
(Fig. S14†). As a control experiment, ultrasound was also
applied to the PMMA nanoparticles, where no change in size
and the derived count rate of the PMMA nanoparticles was
observed (Fig. S15 and S16†). This confirms that the ultra-
sound response of the nanoparticles is caused by the
THP-HEMA groups in the polymers. To understand the origin
of the nanoparticle disruption, 1H NMR spectra of the freeze-
dried nanoparticles after ultrasound treatment (5 min, 40 W)
were analyzed. However, no change could be observed in the
Fig. 8 (A) Intensity weighted size and PDI values of nanoparticles as a function of the ultrasound (20 W) exposure time. (B) Normalized count rate
of the nanoparticles as a function of the ultrasound (20 W) exposure time.
Fig. 9 SEM images of P1 nanoparticles before (A) and after (B) ultra-
sound exposure. Scale bars represent 1 µm.
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1H NMR spectrum of the nanoparticles (Fig. S17†), meaning
that a physical process disrupted the nanoparticles instead of a
chemical reaction. Therefore, the ultrasound responsive behav-
ior of the nanoparticles was ascribed to their relatively low
Tg values and lack of any crystallization temperatures (Tc)
(Table 1 and Fig. 4), which enable nanoparticles to have high
motion abilities that result in sensitivity to ultrasound.26 To
verify this assumption, a control experiment was conducted
with a poly(methyl acrylate) (PMA) nanoparticle suspension (see
the ESI† for the synthesis details), which has a Tg value of 16 °C
(Fig. S19†), under the same conditions. In this case, some of
the PMA nanoparticles were aggregated just after 1 min of ultra-
sound exposure (40 W). The aggregation of the nanoparticles
was visualized by a color change of the suspension from turbid
to a more clear solution and deposition of some aggregated
polymers on the wall of the glass vial (Fig. S20†). Moreover, DLS
measurements revealed the formation of smaller aggregates
upon ultrasound treatment (Fig. S21†). These results correlate
well with our findings with THP-HEMA nanoparticles and prove
that ultrasound responsive behavior of the THP-HEMA nano-
particles originated from their elastic nature.
Fluorescence spectroscopic studies of the nanoparticles
To examine the ability of the nanoparticles to encapsulate a
hydrophobic guest molecule, Nile Red was used as a model
drug to be encapsulated into the hydrophobic domains of the
nanoparticles.42 Nile Red exhibits an environmentally sensitive
fluorescence behavior. Fig. 10 depicts the fluorescence emis-
sion spectra of Nile Red encapsulated into the nanoparticles
that are formed by unquaternized (Fig. 10A) and quaternized
(Fig. 10B) polymers. The total intensities of the emission
spectra of the nanoparticle suspensions from unquaternized
polymers show similar emission intensities. Moreover, the
emission wavelength maximum of Nile Red is comparable for
all nanoparticles. This indicates that the cores of the nano-
particles have similar hydrophobicities without any correlation
with the DMAEMA content in the polymers, which is reason-
able as most of the DMAEMA moieties are deprotonated at the
pH value of pure water. However, the emission intensity of
Nile Red gradually decreases upon increasing the ratio of the
quaternized DMAEMA content in the nanoparticles.
Additionally, the emission wavelength maximum of Nile Red is
consistently red-shifted from P1 to P5q indicating that the
hydrophilicity of the core of the nanoparticles can be manipu-
lated by simply varying the quaternized DMAEMA content of
the nanoparticles. Additionally, the influence of the pH
change and ultrasound exposure on the dye release profiles of
the nanoparticles was investigated. Fig. 11(A) shows the
release profiles of the Nile Red from P5 nanoparticles at three
diﬀerent pH values. 45% of the Nile Red was released at a pH
value of 8.0 in 8 h. The release was slightly accelerated at a pH
value of 6.0, in which 49% of the Nile Red was released in 8 h.
This is attributed to the partially protonated DMAEMA moi-
eties. At a pH value of 4.0, 75% of the Nile Red was released
due to the dissolution of nanoparticles as a result of complete
protonation of the DMAEMA groups. Fig. 11(B) reveals the
Fig. 10 Fluorescence emission spectra of Nile Red encapsulated into
nanoparticles (0.5 mg mL−1) formed by P1, P3–P5 (A); P1, P2q to
P5q (B).
Fig. 11 (A) Nile Red release from P5 nanoparticles at pH 8.0, pH 6.0,
and pH 4.0. (B) Nile Red release from P1, P4, and PMMA nanoparticles
with ultrasound treatment (40 W, 26 kHz).
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release of Nile Red from P1, P4 and PMMA nanoparticles with
ultrasound exposure. For all nanoparticles, the release of
Nile Red increases with the cumulative ultrasound exposure
time. PMMA nanoparticles released 29% Nile Red
after 7 minutes, whereas 84% and 92% Nile Red was released
from P1 and P4 nanoparticles, respectively. In a control experi-
ment almost no Nile Red release was observed under the same
conditions but without ultrasound exposure (Fig. S22†).
Therefore, the observed fast release of Nile Red was attributed
to the disruption of the THP-HEMA based nanoparticles with
ultrasound treatment.
Cytotoxicity of the nanoparticles in L929 cells
It is known that cationic polymers and nanoparticles fre-
quently show toxic eﬀects in cells, mainly due to their unde-
sired interactions with negatively charged cell membranes.
Therefore, the cytotoxicity of the nanoparticles was investi-
gated using L929 cells (Fig. 12). No significant reduction of
cell viability was observed when treated with up to 1 mg mL−1
P1, P3, and P4 nanoparticles for 24 h incubation.
Consequently, P1, P3, and P4 nanoparticles are nontoxic to the
cells and possess excellent biocompatibility, which can be
attributed to the negative surface charge of the corresponding
nanoparticles in the pH value of the cell media (∼7.4).
However, cell viability decreased to 44% at 1 mg mL−1 P5
nanoparticles. The more positive surface charge leads to a rela-
tively higher toxicity and poor biocompatibility. In accordance
with this, P3q nanoparticles that show pH value independent
positive surface charge revealed a severe loss in cell viability of
about 96% at a concentration of 0.25 mg mL−1. Moreover, cyto-
toxicity becomes even more pronounced in the case of P5q
nanoparticles compared to P3q nanoparticles with an almost
quantitative cell death at 0.10 mg mL−1. The cytotoxicity of the
nanoparticles correlates well with the trend that the more posi-
tive the surface potential is the more toxic eﬀects of the nano-
particles are observed.
Conclusion
In this study, novel surface charge-conversional nanoparticles
at slightly acidic pH values (7 to 7.4) that also show disassem-
bly at acidic pH values (4 to 5) have been presented. The nano-
particles based on a well-defined statistical copolymer library
of THP-HEMA and DMAEMA with diﬀerent monomer compo-
sitions were prepared by RAFT polymerization by varying
initial feed ratios. Kinetic studies demonstrated the pseudo-
first order kinetics. The synthesized polymers self-assembled
into spherical nanoparticles in aqueous solution via nano-
precipitation. It was demonstrated that the incorporation of
DMAEMA units into THP-HEMA based nanoparticles can
sustain eﬀective pH-dependent surface charge conversion pro-
perties. Moreover, the IEP and the disassembly pH value of the
DMAEMA nanoparticles can be systematically tuned by varying
the DMAEMA content of the nanoparticles. The ability of the
nanoparticles to encapsulate Nile Red and release it under
acidic pH values and by ultrasound treatment was confirmed.
Moreover, it was verified that negatively charged nanoparticles
are non-toxic and biocompatible. However, the increased
DMAEMA content or quaternization of DMAEMA units in the
nanoparticles led to a more positive surface charge and
resulted in toxic eﬀects on L929 cells. The results indicate the
potential of these polymeric nanoparticles as novel tumor
extracellular pH triggered charge-conversional drug delivery
systems for cancer therapy. Therefore, our future investigations
will focus on the encapsulation and controlled release of anti-
cancer drugs.
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Figure S1. 1H NMR spectrum (300 MHz, CDCl3) of monomer THP protected HEMA (THP-
HEMA) and assignment of the signals.
Figure S2. Overlay of the SEC traces (CHCl3) from kinetic studies of the RAFT 
copolymerization of P5.
Figure S3. 1H NMR spectra (300 MHz, CDCl3) of P2, P3 and P4.
Scheme S1. Schematic representation of the RAFT copolymerization of THP-HEMA and 
DMAEMA by using CDB as CTA.
Figure S4. 1H NMR spectra (300 MHz, CDCl3) of P1OH and P5OH.
Figure S5. Normalized SEC traces (CHCl3) of the isolated copolymers P1OH and P5OH.
Scheme S2. Schematic representation of the quaternization of the synthesized copolymers (P2 to 
P5).
Figure S6. 1H NMR spectra (300 MHz, CDCl3) of P2q to P4q.
Figure S7. Normalized SEC traces (CHCl3) of the isolated copolymers P5 and P5q.
Figure S8. Normalized intensity size distributions of nanoparticles in water (P1, P3, P4, and P5) 
with an initial acetone-polymer concentration of 1 mg mL-1, (A) prepared by dropping acetone-
polymer solution to water (AW), (B) dropping water to acetone-polymer solution (WA).
Figure S9. 1H NMR spectrum (300 MHz, DMSO-d6) of P3 nanoparticles before and after 
treatment with 0.1 M acetic acid (pH = 3.1, stored at 37 °C for 24 h).
Figure S10. (Left) Transmittance curve of P4 solution at pH 4.0 during heating from 0 to 60 °C 
(c = 1 mg mL-1, heating rate 1 K min−1). (Right) Transmittance curve of P5 solution at pH 5.0 
during heating from 0 to 60 °C (c = 1 mg mL-1, heating rate 1 K min−1).
Figure S11. (Left) Intensity weighted diameters and PDI values of P2q nanoparticles as a 
function of the pH value. (Right) ζ-Potentials of the P2q nanoparticles as a function of the pH 
value.
Figure S12. Intensity weigted size distributions of P3q nanoparticles in water before and after 
storage at pH value of 7.4 for 23 h at 37 °C.
Figure S13. (Left) Intensity weigted size distributions of P1 nanoparticles in water before and 
after 30 min. ultrasound treatment (20 W). (Right) Number % size distributions of P1 
nanoparticles in water before and after 30 min. ultrasound treatment (20 W).
Figure S14. (Left) Intensity weighted size distributions of P1 nanoparticles in water before and 
after 5 min. ultrasound treatment (40 W). (Right) Intensity weighted size distributions of P5 
nanoparticles in water before and after 5 min. ultrasound treatment (40 W).
Figure S15. (Left) Intensity weighted size and PDI values of PMMA nanoparticles as a function 
of the ultrasound irradiation time (20 W). (Right) Normalized count rate of the PMMA 
nanoparticles as a function of the ultrasound irradiation time (20 W).
Figure S16. Intensity weighted size distribution of PMMA nanoparticles in water before and 
after 5 min. ultrasound treatment (40 W). 
Figure S17. 1H NMR spectrum (300 MHz, DMSO-d6) of P5 nanoparticles before and after 
ultrasound treatment (5 min, 40 W).
Synthesis of poly(methyl acrylate) (PMA) and synthesis of PMA nanoparticles:
400 mg methyl acrylate (4.646 mmol), 11.5 mg CPADB (0.041 mmol) and 2.88 mg ACVA 
(0.010 mmol) were dissolved in DMF in a Biotage microwave reaction vial (5 mL) equipped with 
a magnetic stir bar. The total volume of the reaction mixture was 4.65 mL. After the reaction was 
degassed for 40 min by argon purging, the t0 sample for 1H NMR was taken, and the flask was 
immersed in a preheated oil bath under stirring at 70 °C. After 16 h, the polymerization was 
stopped by cooling to room temperature and exposing to air. Monomer conversion was 
determined via 1H NMR as 38%. The polymer was purified by precipitating in cold diethyl ether 
(2 times). The resulting polymer was dried under high vacuum at room temperature until constant 
weight. The number average molar mass (Mn) and dispersity (ĐM) were determined SEC in 
CHCl3 by using PMMA standards. SEC in CHCl3: Mn = 3,200 g mol−1 and ĐM = 1.26 (Figure 
S17). The number average molar mass (Mn) was calculated as 3,700 g mol−1 via 1H NMR by 
comparing the ω-RAFT end groups signals and the methyl proton signal of PMA (Figure S17). 
PMA nanoparticles were prepared by nanoprecipitation method by dropping water into acetone-
polymer solution.
Figure S18. (Left) 1H NMR spectrum (300 MHz, CDCl3) of PMA. (Right) SEC trace (CHCl3) of 
the isolated PMA.
Figure S19. DSC heating run of PMA (heating rate 20 K min-1).
Figure S20. Photograph of PMA nanoparticle suspension before and after 2 min. ultrasound 
treatment (40 W).
Figure S21. Intensity weighted size distribution of PMA nanoparticles in water before and after 
1 and 2 min. ultrasound treatment (40 W).
Figure S22. Fluorescence emission spectra of Nile Red encapsulated P4 nanoparticles (0.5 mg 
mL−1) before and after storage at 37 °C for 10 min. in pure water.
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ABSTRACT  
A series of pH responsive block copolymers were synthesized via the reversible addition-
fragmentation chain transfer (RAFT) polymerization of 3,4-dihydro-2H-pyran (DHP) protected 
2-hydroxyethyl methacrylate (HEMA) (2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl methacrylate 
(THP-HEMA)) and 2-(dimethylamino) ethyl methacrylate (DMAEMA) using p(THP-HEMA) as 
a macro chain transfer agent (mCTA). The degree of polymerization (DP) of the p(THP-HEMA) 
block was fixed to 35, whereas the DP of the p(DMAEMA) block was systematically varied 
from 21 to 50. In aqueous solution, the block copolymer with the shortest p(DMAEMA) block 
(DP = 21) self-assembled into vesicles, while the polymer with 30 units of p(DMAEMA) formed 
a mixture of micelles and vesicles. The polymer with the longest p(DMAEMA) block (DP = 50) 
formed exclusively micelles. The morphology change as a function of monomer composition 
was verified by dynamic light scattering (DLS) and cryo-transmission electron microscopy 
(cryo-TEM) studies. Moreover, the corresponding polymersomes exhibited a morphology 
transition from vesicles at neutral pH values to micelles upon lowering the pH value down to 
endosomal pH value as evidenced by the decrease in the hydrodynamic diameter of the formed 
structures investigated by DLS and cryo-TEM. The capability of polymersomes to encapsulate 
both hydrophobic (e.g., Nile Red) and hydrophilic (e.g., doxorubicin hydrochloride (DOX·HCl)) 
cargos was verified by in vitro studies. Drug release studies demonstrated that the DOX·HCl 
release is significantly accelerated under acidic pH values compared to physiological conditions. 
Cytotoxicity studies revealed that DOX·HCl loaded polymersomes exhibited an efficient cell 
death in L929 cells comparable to free DOX·HCl. Confocal laser scanning microscopy (CLSM) 
and flow cytometry studies showed that DOX·HCl loaded vesicles were easily taken up by L929 
cells and were mainly located in the cytoplasm and cell nuclei after 2 h of incubation.  
 3 
INTRODUCTION 
Self-assembly of amphiphilic polymers, particularly block copolymers, has become a versatile 
and widely used method for the formation of nanostructures with different morphologies such as 
nanospheres, rods, micelles, and vesicles.
1
 Among other, polymeric vesicles, also known as 
polymersomes, have gained great interest due to their potential applications in a broad range of 
areas including as mimics of biological membranes, as microreactors and drug carriers.
2, 3
 
Regarding the latter application, polymersomes are under intense scrutiny due to their ability, 
like lipid-based vesicles (liposomes), to offer hydrophilic aqueous cavities that are suitable for 
encapsulation of hydrophilic molecules as well as a hydrophobic membrane that can incorporate 
hydrophobic species and protect the payloads from the external media.
4
 Compared to liposomes, 
polymersomes have thicker and more stable membranes as a result of higher molar mass values 
of the polymers than lipids. This can remarkably diminish the premature release of the payloads 
during circulation and accordingly decrease the systemic cytotoxicity. Moreover, to improve the 
therapeutic efficiency and to avoid drug resistance in cells the loaded drugs should be released 
rapidly in a controlled way when the target site is reached. Therefore, several stimuli responsive 
polymersomes, which target to release the encapsulated therapeutics in respond to several 
endogenous (pH value,
5
 redox,
6
 and enzyme
7
) and exogenous (temperature,
8
 light,
9
 magnetic 
field,
10
 and ultrasound
11
) stimuli, have been developed by incorporating different responsive 
building blocks into polymers. Among all the stimuli, pH responsiveness is the most intensively 
investigated one due to the pH value gradients found within the physiological environment. For 
instance, tumor and inflammatory tissues are slightly more acidic (pH = 6.5 to 7.2) than normal 
ones (pH = 7.4).
12, 13
 Even within cell compartments there is a pH value gradient. Cytosol has a 
comparable pH value like blood (7.4), whereas the endosome features a pH value between 6.5 to 
 4 
5.0. The pH value even decreases to 4.5 in the lysosome.
14
 The pH responsiveness of the 
polymersomes usually relies on the change in hydrophilicity of the corresponding polymers by 
protonation/deprotonation of ionizable pendant groups or by the cleavage of the pH sensitive 
moieties. The change in hydrophilicity mediates the cargo release, commonly caused by 
dissolution, precipitation, swelling or collapsing of the polymers.
15
 However, a change in 
hydrophilicity can also induce a morphology transition. For instance, several examples of 
micelle-to-vesicle transitions in response to a stimulus have been reported.
16-20
 However, 
polymersomes that can exhibit vesicle-to-micelle transitions are of particular interest for the 
controlled delivery of hydrophilic drugs due to offering a loss of aqueous cavities within the 
vesicles, which can trigger the hydrophilic cargo release. Nevertheless, polymersomes with 
vesicle-to-micelle transition abilities have been rarely observed.
21-23
 
In this study, three well-defined diblock copolymers of poly((THP-HEMA)-b-DMAEMA) 
with a fixed degree of polymerization (DP) of p(THP-HEMA) and a variable p(DMAEMA) 
block length were synthesized by reversible addition-fragmentation chain transfer (RAFT) 
polymerization using a macro chain transfer approach (Scheme 1). It is believed that 
polymersomes can undergo shape transformations in response to stimuli when the membrane has 
a sufficient chain mobility.
24-27
 Previous work within our group has shown that p(THP-HEMA) 
based nanoparticles are responsive to ultrasound due to their high chain mobilities as a result of 
their elastic nature (Tg ~30 °C).
28
 As a consequence, hydrophobic p(THP-HEMA) is selected as a 
building block for the membrane of the polymersomes, which can possibly feature a morphology 
transition upon a change in the hydrophilicity of the polymer. Additionally, the weak 
polyelectrolyte p(DMAEMA) was used as pH responsive hydrophilic block since it can be 
protonated under its pKa value (~7.4) and, hence, change the hydrophobic/hydrophilic ratio of the 
 5 
corresponding copolymer. The findings on the self-assembly behavior of these polymers in 
aqueous media, the pH responsive behavior of the polymersomes, encapsulation studies of both 
hydrophobic Nile Red and hydrophobic doxorubicin hydrochloride (DOX·HCl), and additional 
biological studies to evaluate the capability of the polymersomes as smart DOX·HCl carriers are 
presented herein.  
 
Scheme 1. (A) Schematic representation of the synthesis of mCTA via RAFT polymerization of 
THP-HEMA and (B) its subsequent chain extension with DMAEMA. 
  
 
 
 
 6 
EXPERIMENTAL SECTION 
Materials 
The monomer THP (3,4-dihydro-2H-pyran) protected HEMA (THP-HEMA) 2-((tetrahydro-
2H-pyran-2-yl)oxy)ethyl methacrylate was synthesized according to the procedure reported 
elsewhere.
29
 4,4'-Azobis(4-cyanovaleric acid) (ACVA), 4-cyano-4-(phenylcarbonothioylthio) 
pentanoic acid (CPADB), 1,3,5-trioxane, N,N-dimethylaminoethyl methacrylate (DMAEMA), 
and Nile Red were purchased from Sigma Aldrich. Doxorubicin hydrochloride (DOX·HCl) was 
purchased from Cayman Chemical. AlamarBlue was obtained from Life Technologies. 
Consumables for cell culture, like pipettes and cell culture plates (96 well), were obtained from 
Corning (USA) and Greiner Bio-one (Austria/Germany). If not stated otherwise, cell culture 
media and supplements (L-glutamin, antibiotics) were obtained from Biochrom (Merck 
Millipore, Germany).  
Instruments and methods 
Proton nuclear magnetic resonance (
1
H NMR) spectra were recorded at room temperature in 
CDCl3 or CD3OD on a Brucker Avance 300 MHz. The chemical shifts are given in ppm. 
Size-exclusion chromatography (SEC) measurements were performed on a Agilent 1200 series 
equipped with a G1310A pump, a G1315D DA detector, a G1362A RI detector, and PSS GRAM 
30 Å/1000 Å (10 μm particle size) columns in series at 40 °C using N,N-dimethylacetamide 
(DMAc) with 2.1 g L
−1
 LiCl as eluent at a flow rate of 1 mL min
−1
. The system was calibrated 
with polystyrene (PS) standards (Mp = 100 to 1 000 000 g mol
−1
). 
Dynamic light scattering (DLS) was performed on a Zetasizer Nano ZS (Malvern Instruments, 
Herrenberg, Germany). After an equilibration time of 180 s, 3 × 30 runs were carried out at 
25 °C (λ = 633 nm). The measurements were performed at an angle of 173°. Each measurement 
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was done in triplicate. The size distribution of suspensions were calculated applying the 
nonlinear least-squares fitting mode. 
Electrophoretic light scattering was used to measure the electrokinetic potential, also known as 
ζ-potential. The measurements were performed on a Zetasizer Nano ZS (Malvern Instruments, 
Herrenberg, Germany) by applying laser Doppler velocimetry. For each measurement, 10 runs 
were carried out using the slow-field and fast-field reversal mode at 150 V. Each experiment was 
performed in triplicate at 25 °C.  
Transmission electron microscopy (TEM) was carried out on a FEI Technai G2 20 cryo-
transmission electron microscope. Samples were prepared with a Vitrobot Mark IV system. 8 µL 
of the sample solution (2.5 mg mL
-1
) were transferred onto Quantifoil (R2/2, Quantifoil) grids, 
which were cleaned by Ar plasma cleaning for 2 min prior to preparation. Samples were plunged 
into liquid ethane, transferred, and kept at temperatures below 170 °C by using a Gatan cryo-
stage. Images were recorded with a Mega View G2 CCD camera (OSIS, 1392 × 1040 pixels) or 
an Eagle CCD camera (Eagle 4k HS 200 kV, 4096 × 4096 pixels). 
A Tecan M200 Pro fluorescence microplate reader was used for fluorescence measurements.  
Synthesis 
Synthesis of the macro chain transfer agent (mCTA)  
6 g THP-HEMA (28 mmol), 172 mg CPADB (0.616 mmol) and 12 mg ACVA (0.041 mmol) 
were dissolved in ethanol in a Biotage microwave reaction vial (30 mL) equipped with a 
magnetic stir bar. The total volume of the reaction mixture was 14 mL. After the reaction 
mixture was degassed for 40 min by argon purging, the t0 sample for 
1
H NMR was taken, and the 
vial was immersed in a preheated oil bath under stirring at 70 °C. After 8 h, the polymerization 
was stopped by cooling to room temperature and exposing to air. Prior to precipitation, tf sample 
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was taken to calculate the monomer conversion. Monomer conversion was determined via 
1
H 
NMR by using 1,3,5-trioxane as internal standard. The polymer was purified by precipitating in 
cold diethyl ether (four times). The resulting polymer was dried under high vacuum at room 
temperature until constant weight. An overall yield of 60% was obtained. The number average 
molar mass (Mn) and dispersity (ĐM) were determined by SEC using PS standards. The degree of 
polymerization (DP) for mCTA was calculated from the signal integrals of 
1
H NMR spectrum 
(Figure 1) of the purified polymer using the following equation: 
𝐷𝑃𝑚𝐶𝑇𝐴 =
𝐼(𝑠𝑖𝑔𝑛𝑎𝑙 𝑒)
𝐼(𝑠𝑖𝑔𝑛𝑎𝑙 𝑎)/ 2
 (1) 
with I(signal e) corresponding to the integral of the methine proton peaks of the THP-HEMA 
at 4.65 ppm and I(signal a) corresponding to the integral of two aromatic protons of the 
dithiobenzoate end group at 7.84 ppm. The number average molar mass value of the mCTA was 
calculated by using the following equation:  
Mn,NMR = (DPTHP-HEMA × MTHP-HEMA) + MCTA (2) 
in which the molar mass of the THP-HEMA, and RAFT agent are 214.26 g mol
-1
 and 279.38 
g mol
-1
, respectively. 
RAFT polymerization of A35B21 to A35B50  
For each polymerization, the [mCTA]/[ACVA] ratio was kept as 15/1, and the initial monomer 
concentration was 1 mol L
−1
 in DMF. All polymerizations were carried out at 70 °C. The 
DMAEMA to mCTA ratio and polymerization times were varied as summarized in Table 1. An 
exemplary RAFT block copolymerization procedure (Table 1, A35B50) is as follows: 830 mg 
DMAEMA (28 mmol), 402 mg mCTA (0.052 mmol), 90 mg 1,3,5-trioxane (0.999 mmol), and 
10 mg ACVA (0.036 mmol) were dissolved in DMF (5.28 mL) in a microwave vial. The reaction 
mixture was subsequently flushed with argon for 40 min. After taking the t0 sample for the 
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determination of the monomer conversion, the vial was immersed in a preheated oil bath at 70 °C 
and stirred for 8 h. The reaction mixture was cooled to room temperature, exposed to air, and a 
sample for determination of monomer conversion (tf) was taken. The polymer was purified by 
precipitation in hexane (four times). The Mn and ĐM values were determined by SEC using PS 
standards. The degree of polymerization (DP) for the DMAEMA block was calculated from the 
signal integrals of the 
1
H NMR spectrum (Figure 2) of the purified copolymer using the 
following equation: 
𝐷𝑃𝐷𝑀𝐴𝐸𝑀𝐴 =
𝐼(𝑠𝑖𝑔𝑛𝑎𝑙 ℎ)/6
𝐼(𝑠𝑖𝑔𝑛𝑎𝑙 𝑒)/ 35
    (3)  
with I(signal h) corresponding to the integral of methyl proton peaks of the DMAEMA at 2.30 
ppm, and I(signal e) corresponding to the integral of the methine proton peaks of the THP-
HEMA at 4.65 ppm. Mn values of the block copolymers were calculated by using the following 
equation:  
Mn,NMR = MmCTA + (DPDMAEMA × MDMAEMA)   (4) 
in which the molar mass of the mCTA and DMAEMA are 7,800 g mol
-1
 and 157.21 g mol
-1
, 
respectively. 
Nanoprecipitation of the block polymers 
The corresponding block polymers were dissolved in acetone at a final concentration of 5 mg 
mL
-1
. Subsequently, pure water was added dropwise to the acetone polymer solution under 
stirring at 500 rpm. The acetone/water (solvent/nonsolvent) ratio was kept constant at 0.5 for all 
suspensions. The acetone was evaporated by stirring the open vial for at least 24 h to yield 
aqueous suspensions with a final polymer concentration of 2.5 mg mL
-1
. 
pH-response test of the vesicles  
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For the pH-response tests of the nanoparticles, 0.1 M acetic acid (for a pH value of 3.1), 0.1 M 
acetate buffers (for pH values of 4, 5, 6, 6.25, 6.50), and 0.1 M tris buffers (for the pH values 7, 
7.4, 8, and 9) were used. 200 µL of suspension (2.5 mg mL
-1
) were mixed with 800 mL acetic 
acid and corresponding buffer solutions in Eppendorf tubes and stored at 37 °C for 3 h while 
mixing at 200 rpm. Then, DLS and ζ-potential measurements were performed. 
Nile Red encapsulation and determination of critical aggregation concentration (CAC) 
To encapsulate Nile Red to vesicles, A35B21 (25 mg) was dissolved in 5 mL acetone. Then, 20 
µL Nile Red stock solution (1 mM in acetone) was added. Subsequently, 10 mL of deionized 
water was added dropwise to the acetone solution under continuous stirring at 500 rpm. The 
mixed solutions were stirred overnight at room temperature in an open vial to remove the 
acetone.  Excess Nile Red was removed using a 0.45 μm syringe filter. To calculate the CAC, the 
Nile Red encapsulated A35B21 suspension was diluted to a series of concentrations. The 
corresponding fluorescence emission spectra were recorded with an excitation wavelength at 549 
nm. The maximum emission intensity at a wavelength of 605 nm was plotted as a function of log 
10 of polymer concentration. The CAC was calculated using the antilog of the intersection point 
value of two linear curves.  
Encapsulation of DOX·HCl  
DOX-loaded vesicles were prepared by the nanoprecipitation method. Briefly, A35B21 (50 mg) 
and DOX·HCl (3 mg) were dissolved in 5 mL DMF. The solution was equilibrated for 20 min 
under stirring. Subsequently, 10 mL of pure water was added dropwise to the DMF solution 
under continuous stirring at 500 rpm. DMF was removed by dialysis (3 L, 48 h; MWCO: 3,500 g 
mol
-1
) against tris buffer (pH = 7.4, 0.1 M). The unloaded doxorubicin was removed using a 
0.45 μm syringe filter and stored at 4 °C until used. 500 µL of suspension was lyophilized to 
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determine the suspension concentration. For drug loading quantification, fluorescence intensity 
calibration functions of DOX·HCl in deionized water were used as reported elsewhere.
30
 
Drug loading efficiency (DLE) and drug loading content (DLC) were calculated according to 
the following equations: 
DLE =
weight of the loaded drug 
weight of the drug in feed 
× 100%   (5) 
 
DLC =
weight of the loaded drug 
total weight of polymer and loaded drug
× 100%   (6) 
 
Release studies of DOX·HCl  
Drug release from DOX·HCl encapsulated vesicles was performed in two different buffers: (i) 
Acetate buffer (100 mM, pH 5.0), (ii) Tris buffer (100 mM, pH 7.4) using a dialysis tube. 
Briefly, 3 mL of DOX-loaded vesicle suspensions in deionized water were added into a dialysis 
tube (MWCO: 3,500 g mol
-1
). Subsequently, the dialysis tube was closed and exposed to 65 mL 
of appropriate buffer solutions at 37 °C in the dark. At predetermined time intervals, 1 mL of the 
buffer was taken out and an equal volume of buffer was added. The amount of released drug was 
calculated using a fluorescence intensity calibration function of DOX·HCl in water. 
Determination of cytotoxicity 
Cytotoxicity studies were performed with the mouse fibroblast cell line L929 (CCL-1, ATCC), 
as recommended by ISO10993-5. The cells were routinely cultured in Dulbecco’s modified 
eagle’s medium supplemented with 10% fetal calf serum (FCS, Capricorn Scientific, Germany), 
100 U mL
-1
 penicillin and 100 µg mL
-1
 streptomycin at 37 °C in a humidified 5% (v/v) CO2 
atmosphere. In detail, cells were seeded at 10
4
 cells per well in a 96-well plate and incubated for 
24 h. No cells were seeded in the outer wells. Afterwards, the testing substances (polymeric 
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suspensions) were added to the cells at indicated concentrations (from 50 to 500 µg mL
-1
), and 
the plates were incubated for additional 48 h. Subsequently, the medium was replaced by a 
mixture of fresh culture medium and the assay reagent AlamarBlue (resazurin based solution, 
Thermo Fisher, Germany, prepared according to the manufacturer’s instructions). After a further 
incubation of 4 h at 37 °C in a humidified 5% (v/v) CO2 atmosphere, the fluorescence was 
measured at Ex 570 / Em 610 nm, with untreated cells on the same well plate serving as negative 
controls. The negative control was standardized as 0% of metabolism inhibition and referred to 
as 100% viability. Cell viability below 70% was considered to be indicative for cytotoxicity. 
Data are expressed as mean ± standard deviation (SD) of three independent determinations. 
Comet assay 
Cells were plated in multi-well plates at a density of 1 × 10
4
 cells/cm
2
 and allowed to attach for 
24 h at 37 °C and 5% CO2. Then medium was replaced by culture medium containing free or 
encapsulated DOX·HCl at concentrations of 1, 2.5 or 5 µg mL-1. Duplicate cultures were 
incubated at 37 °C for 24 h and 5% CO2. Following incubation, cells were harvested by trypsin 
treatment and resuspended in PBS to a final concentration of 5 × 10
5 
cells/mL. A 1% low melting 
point agarose solution was prepared in TBE-buffer (90 mM Tris-HCl, 90 mM boric acid, 2 mM 
EDTA, pH 7.5), tempered to 37 °C, and aliquots were mixed with cell-suspensions in a volume 
ratio of 10:1. For each sample, 100 µL of agarose-cell mixture were subjected to a plastic 
agarose gel support (GelBond film agarose support media, Lonza) and immediately covered with 
a coverslip to ensure an even distribution of the cell containing gel. After cooling for 30 min at 
4 °C, the coverslip was removed from the formed gel. Each cell sample was prepared in 
triplicates. Gel-supports were placed in chambers of a 4 well plate, immersed with ice-cold lysis 
buffer and incubated in the dark for 2 hours at 4 °C. After washing with TBE-buffer to remove 
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salts from the lysis buffer, gel-supports were placed into a horizontal electrophoresis chamber 
filled with chilled alkaline electrophoresis buffer (3 mM NaOH, 1 mM EDTA, pH 13). After 
30 min equilibration to allow DNA unwinding and double strand separation, electrophoresis was 
then performed at 1.5 V cm
-1
 for 30 min. Next, gel supports were removed and rinsed with 
icecold distilled water. SYBR Green dye was added to the gels at a concentration of 1 µg mL
-1
 in 
order to stain the DNA. DNA damage was measured using a epifluorescence microscope (Cell 
observer Z1, Zeiss, Oberkochen, Germany) equipped with a 10 × 0.45 NA plan-apochromat 
objective, the appropriate filter set for excitation and emission wavelengths as well as integrated 
software tools. Results are given as the mean tail length of individual comets captured from 100 
cells of triplicate samples. During the whole assay, direct light was excluded from cell samples 
to avoid uncontrolled DNA damage due to UV light. All steps were performed with chilled 
solutions to exclude thermal induction of DNA alterations. 
Live cell imaging 
L929 cells were used for uptake studies. Therefore, cells (10
5
 cells mL
-1
) were seeded on glass-
bottomed dishes and cultured for 24 h in a humidified 5% (v/v) CO2 atmosphere. One hour prior 
to the addition of polymers and drugs, the medium was replaced with fresh one. Loaded 
polymersomes and free DOX were added to the cells and incubated for 2 and 24 h. Imaging was 
performed with an LSM880, Elyra PS.1 system (Zeiss, Oberkochen, Germany) applying a 63 × 
1.4 NA plan apochromat oil objective. Furthermore, excitation wavelengths of 488 nm (exc. 
grating 28.0 µm) were used to detect DOX.  
Flow cytometry study 
According to the CLSM studies, the uptake of free and encapsulated DOX·HCl was quantified 
by flow cytometry. For this purpose, 2 × 10
5
 L929 cells mL
-1
 were seeded on glass-bottomed 
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dishes and cultured for 24 h in a humidified 5% (v/v) CO2 atmosphere. One hour prior to the 
addition of polymers and drugs, the medium was replaced with fresh one. Loaded polymersomes 
and free DOX·HCl were added to the cells and incubated for 2 and 24 h. To determine the 
relative uptake of DOX·HCl, 10,000 cells were measured by flow cytometry using a Cytomics 
FC 500 (Beckman Coulter). The amount of DOX·HCl taken up by the cells were measured by 
the mean fluorescence intensity (MFI) of all cells. The experiments were performed at least three 
times independently. 
Table 1. Selected characterization data of the mCTA. 
Entry THP-
HEMA/ 
CTAa 
CTA/ACVAb Polym. 
time (h) 
Conv. 
[%]c 
 
DPtheo.
d Mn,theo.
e 
[g mol-
1] 
DPf 
 
Mn
g 
[g 
mol-1] 
Mn,SEC
i 
[g mol-
1] 
Mw/Mn
i Tg
j 
mCTA 47.71/1 15/1 8 65 31 6,900 35 7,800 5,800 1.08 24.6 
a
Monomer to CTA ratio. 
b
CTA to ACVA ratio. 
c
Determined by 
1
H NMR spectroscopy. 
d
Determined by the formula DPtheo. = [([M]/[CTA] × Conv.]. 
e
Determined by the formula Mn,theo. 
= [([M]/[CTA] × Conv. × MTHP-HEMA) + (MCTA)]. 
f
Determined by 
1
H NMR spectroscopy of 
isolated mCTA. 
g
Determined by the formula Mn,theo. = [(DP × MTHP-HEMA) + MCTA]. 
i
Determined 
by SEC in DMAc analysis (RI detection, PS calibration). 
j
Determined by DSC analysis. 
 
Table 2. Selected characterization data of the block copolymers (A35B21 to A35B50). 
Entry DMAEMA/ 
mCTAa 
mCTA/ACVAb Polym. 
time (h) 
Conv. 
[%]c 
 
DPtheo.
d Mn,theo.
e 
[g mol-
1] 
DPf 
 
Mn
g 
[g 
mol-1] 
Mn,SEC
i 
[g 
mol-1] 
Mw/Mn
i Tg
j 
A35B21 49.62/1 15/1 4 36 18 10,600 21 11,100 8,300 1.09 24.9 
A35B30 49.62/1 15/1 8 58 29 12,400 30 12,500 9,300 1.08 23.4 
A35B50 102.54/1 15/1 7 49 50 15,700 50 15,700 11,200 1.10 20.7 
a
Monomer to mCTA ratio. 
b
mCTA to ACVA ratio. 
c
Determined by 
1
H NMR spectroscopy. 
d
Determined by the formula DPtheo. = [([M]/[mCTA] × Conv.]. 
e
Determined by the formula 
Mn,theo. = [([M]/[mCTA] × Conv. × MmCTA) + (MmCTA)]. 
f
Determined by 
1
H NMR spectroscopy 
of isolated polymers. 
g
Determined by the formula Mn,theo. = [(DP × MDMAEMA) + MmCTA]. 
i
Determined by SEC in DMAc analysis (RI detection, PS calibration). 
j
Determined by DSC 
analysis. 
  
RESULTS AND DISCUSSION 
A macro chain transfer agent (mCTA) was prepared by RAFT polymerization of THP-HEMA 
in ethanol using CPADB as CTA at 70 °C with a monomer concentration of 1 mol L
-1
 (see 
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Scheme 1 and Table 1).
31
 ACVA that generates the same radical as the R group of the CPADB 
was used as initiator to avoid defects that are caused by the initiator derived chains.
32
 To 
minimize the formation of dead chains and to obtain an acceptable polymerization rate, the 
[CTA]/[ACVA] ratio was kept at 15/1.
33
 In order to ensure chain end retention, the 
polymerization was stopped at 65% monomer conversion after 8 h. After purification, the 
mCTA was characterized by 
1
H NMR spectroscopy and SEC analysis (Table 1). By comparing 
the integral values of the aromatic protons of the ω-RAFT end group at δ = 7.84 ppm (peak “a” 
in Figure 1) and the integral value of the methine proton peak of the THP-HEMA side chains at δ 
= 4.65 ppm (peak “e” in Figure 1), the mean DP of the mCTA was estimated to be 35 (see 
equation 1). The resulting Mn value calculated by 
1
H NMR (7,800 g mol
-1
) is close to the 
theoretical Mn (6,900 g mol
-1
) calculated by the monomer conversion, and they are higher 
compared to the Mn = 5,800 g mol
-1
 obtained by SEC analysis (Table 1). The underestimated 
molar mass by SEC is probably due to the PS calibration of the SEC system. It is known that 
copolymers with hydrophobic to hydrophilic ratios higher than 2:1 favor a vesicle formation. 
However, this is not a definitive rule and exceptions can be observed.
3
 Therefore, the length of 
the p(THP-HEMA) block was kept constant and the p(DMAEMA) block was systematically 
varied to identify the optimal composition for a vesicle formation. Diblock copolymers were 
synthesized via RAFT polymerization by utilization of the mCTA as CTA and ACVA as 
initiator in DMF at 70 °C with a monomer concentration of 1 mol L
-1
 (Scheme 1). Three 
different diblock copolymers were synthesized by variation of the [mCTA] to [DMAEMA] ratio 
or the polymerization time (Table 2). For the sake of the simplicity, a shorthand notation is used 
throughout this contribution to describe the various block copolymers. The letters A and B are 
used to represent the THP-HEMA and DMAEMA blocks, respectively. Thus, AxBy denotes 
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p(THP-HEMA)-b-p(DMAEMA) where x and y indicates the mean DP values of the respective 
blocks. Table 2 summarizes the polymerization conditions and characterization data of the 
isolated AB diblock copolymers that were obtained by 
1
H NMR spectroscopy as well as by SEC 
measurements. The overlay of 
1
H NMR spectra of the mCTA and A35B50 are depicted in Figure 
1. The mean DPs of the DMAEMA block of the copolymers were estimated via 
1
H NMR 
spectroscopy by comparing integral value of the methylene peak of the DMAEMA side chains 
(peak “g”) with the methine proton peak of the THP-HEMA side chains (peak “e”), which is 
calibrated to be 35 units (see equation 3). The resulting Mn values (calculated according to 
equation 4) are in good agreement with the theoretical Mn values that were estimated from the 
DMAEMA conversion. The SEC traces of the purified mCTA and the block copolymers are 
shown in Figure 2. SEC analysis revealed monomodal traces and narrow dispersities (ĐM < 1.10) 
for all polymers, which indicates the effectiveness of mCTA for the controlled RAFT 
polymerization of DMAEMA. A shift to lower elution volumes and the increase of the molar 
mass values were observed as the DMAEMA block length increases with no tailing in the low 
molar mass region. The molar mass values determined by SEC are slightly lower than the 
calculated ones. However, SEC represents a relative method for molar mass determination, 
which relies on the calibration with standard linear PS polymers. 
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Figure 1. 
1
H NMR spectra (300 MHz, CDCl3) of mCTA (bottom) and A35B50 (top) and the 
assignment of the peaks used to calculate the DP. 
 
 
Figure 2. Normalized SEC traces in DMAc of isolated mCTA and block copolymers (A35B21 to 
A35B50). 
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Thermal transitions of the mCTA and block copolymers (A35B21 to A35B50) were studied by 
differential scanning calorimetry (DSC) under nitrogen atmosphere (Figure S3). The mCTA 
exhibits a Tg at 24.6 °C (Table 1), as expected based on our previous report.
28
 All the block 
copolymers have single Tgs, suggesting that the components of block copolymers are 
thermodynamically miscible. The block copolymer A35B21 with the shortest p(DMAEMA) block 
has a Tg value of 24.9 °C, which is similar to the mCTA, this may be ascribed to the small DP of 
the p(DMAEMA) block. However, the Tg values of the A35B30 and A35B50 decrease with 
increasing p(DMAEMA) block length to 23.4 and 20.7 °C, respectively, which could be ascribed 
to a lower Tg value of the p(DMAEMA) (~14 °C) compared to p(THP-HEMA).
34
  
Self-assembly behavior in aqueous media 
To investigate the self-assembly behavior of the amphiphilic diblock copolymers in 
water, aqueous suspensions were prepared by nanoprecipitation (dropping water into 
acetone polymer solutions).
35
 Subsequently, DLS and cryo-TEM measurements were 
performed. Figure 3 summarizes the resulting number and volume distributions obtained 
from DLS and cryo-TEM images of the copolymer assemblies A35B21, A35B30, and 
A35B50. The corresponding DLS intensity distributions of the suspensions are shown in 
Figure S4 to S6. For the most hydrophobic copolymer A35B21, DLS measurements 
revealed a monomodal number distribution with an average hydrodynamic diameter (Dav) 
of 30 nm. However, the volume and intensity distributions exhibited a bimodal 
distribution of small (Dav ~40 nm) as well as medium sized aggregates (Dav ~300 nm). In 
agreement with DLS measurements, cryo-TEM measurements revealed predominantly 
polydisperse vesicles of 20 to 90 nm diameter exhibiting a clear membrane as well as 
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some larger spherical aggregates (~200 nm) (Figure 3, Figure S7). The thickness of the 
vesicle membrane was found to be around 8 ± 2 nm. 
A monomodal number distribution with a Dav of 15 nm was observed from DLS for the 
suspension of the A35B30 block copolymer. Some larger structures are also visible in the 
DLS volume and intensity distributions with a Dav of 120 nm. Cryo-TEM analysis 
showed that spherical micelles with diameters around 12 nm coexist with some 
polydisperse vesicles which have diameters ranging from 30 to 180 nm which might be 
the larger aggregates found by DLS (Figure 3, Figure S8). These observations are in 
accordance with the hydrodynamic diameters obtained from DLS measurements.  
Monomodal number and volume distributions with an Dav of 11 and 13 nm, 
respectively, were obtained from DLS measurements for the suspension of the A35B50 
with the highest DMAEMA content. However, intensity distribution exhibited a bimodal 
size distribution of small (Dav ~13 nm) as well as medium sized aggregates (Dav ~130 
nm). In accordance with the bimodal intensity size distribution obtained from DLS, cryo-
TEM analysis revealed densely packed homogeneous spherical micelles with diameters 
around 10 nm as well as a small number of larger spherical aggregates (Dav ~100 nm) 
(Figure 3, Figure S9). It is known that copolymers with a hydrophilic-to-hydrophobic 
ratio less than 1:2 usually form vesicular aggregates, whereas copolymers with a ratio 
greater than 1:1 favor micelle formation.
3
 Therefore, the observed morphology change 
from vesicles to spherical micelles as the hydrophilicity increrases from A35B21 to A35B50 
correlates to literature. Since the aim of this contribution is the investigation of the 
vesicles as drug delivery vehicles the next sections mainly focuses on A35B21 self-
assemblies, since it features vesicular structures.  
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Figure 3. DLS plots and cryo-TEM images of the suspensions obtained from A35B21, A35B30, 
and A35B50 in water (c = 2.5 mg mL
-1
). 
 
pH-Response test and determination of critical aggregation concentration of the 
vesicles  
As already demonstrated above, the hydrophilic-to-hydrophobic ratio of the copolymers 
plays a critical role on the morphology and the sizes of the self-assembled structures. 
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PDMAEMA is a weak polyelectrolyte in water with a pKa value of ~ 7.4.
14
 Below its pKa 
value, PDMAEMA is hydrophilic due to the protonation of the tertiary amino moieties. In 
contrast, above its pKa PDMAEMA becomes hydrophobic as a consequence of the 
deprotonation of the amino groups. This pH dependent protonation/deprotonation ability 
of the PDMAEMA can alter the hydrophilic-to-hydrophobic ratio of the corresponding 
copolymers and accordingly can change the morphology as well as the size of the self-
assembled structures at different pH values. For this purpose, the pH responsive behavior 
of the vesicles was explored by storing the A35B21 suspension at various pH values for 3 
h. The changes in size and ζ-potential values were recorded. Number size distributions 
and ζ-potentials of the A35B21 suspension as a function of the pH value are demonstrated 
in Figure 4. The corresponding volume and intensity distributions of the A35B21 
suspension as a function of the pH value are shown in Figure S10 and S11. DLS 
measurements revealed that the A35B21 suspension showed stable size distribution at 
neutral pH values (pH = 7.0 and 7.4) (Figure 4). An increase of the pH value from 7.4 to 
8.0 resulted in an increase of the diameter of the vesicles. This is due to the partial 
deprotonation of the DMAEMA groups.
36
 A decrease in the ζ-potential from +33 mV at pH 
7.4 to +20 mV at pH 8.0 proves this assumption. In accordance with this, an additional increase 
of the pH value from 8.0 to 9.0 resulted in a further decrease of the ζ-potential from +20 mV to 
˗11 mV leading to precipitation of the vesicles. In contrast, upon decreasing the pH value from 
neutral to acidic pH values a continuous decrease in the particle diameter together with an 
increase in the ζ-potential was observed. Moreover, the suspension lost its turbidity and became 
transparent at acidic pH values. To understand the origin of the decrease in the size of the 
aggregates, cryo-TEM investigations of the suspensions were performed at pH 7.4 and 5.0, 
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respectively. At pH 7.4, exclusively vesicular aggregates with clear membranes can be seen 
(Figure 5, Figure S12). On the other hand, only homogeneous spherical micelles were observed 
at pH 5.0 (Figure 5, Figure S13). At both pH values the observed diameters correlate well with 
the DLS measurements. Recently, we showed that cleavage of the THP groups in acidic media is 
relatively slow; after treatment with acetic acid (0.1 M, pH = 3.1) at 37 °C for 24 h a negligible 
amount of THP group cleavage was observed.28 In agreement with this, 1H NMR spectrum of the 
freeze dried suspensions after treatment with acetate buffer (0.1 M, pH = 4) at 37 °C for 3 h 
exhibited no change in the 1H NMR spectrum of the A35B21 polymer (Figure S14). As a 
consequence, the decrease in the size at acidic pH values is attributed to the morphology 
transition from vesicles to micelles at acidic pH values as a result of the protonation of the 
DMAEMA groups, which increases the hydrophilic-to-hydrophobic ratio. A subsequent increase 
of the pH value to 7.4 resulted in an increase in diameter, which is only slightly lower than the 
original polymersomes (Figure S15). This hints toward the reversibility of the morphology 
change. 
 
Figure 4. (A) Number size distributions and (B) ζ-potentials of the A35B21 suspension as a 
function of the pH value.  
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Figure 5. (A) Cryo-TEM image of the A35B21 suspension at pH 7.4. (B) Photograph of vial 
containing the A35B21 suspension at pH 7.4. (C) Cryo-TEM image of the A35B21 suspension at 
pH 5.0. (D) Photograph of vial containing the A35B21 suspension at pH 5.0. (E) Schematic 
illustration of the pH value change induced vesicle-to-micelle morphology transition as a result 
of an increase of the volume of hydrophilic block at acidic pH values. 
 
The critical aggregation concentration of the A35B21 suspension at pH 7.4 was estimated 
using hydrophobic Nile Red as a fluorescent probe. It is well know that Nile Red has negligible 
fluorescence intensity in water but its fluorescence intensity significantly increases when it is 
encapsulated in a hydrophobic environment such as in the membrane of polymersomes or in the 
core of micelles.
37, 38
 To estimate the CAC, the Nile Red encapsulated A35B21 suspension was 
diluted and the corresponding fluorescence emission spectra were recorded. Figure 6 depicts the 
Nile Red fluorescence intensity at the emission maxima (λmax = 605 nm) versus the polymer 
concentration. At low concentrations there is almost no change in emission intensity, but above a 
certain polymer concentration the emission intensity increases substantially. The CAC of the 
A35B21 was calculated as 0.084 mg mL
-1
 by using the antilog of the intersection point value of 
the base line and the steep curve. The calculated CAC is in good agreement with before reported 
values for p(THP-HEMA) copolymer based micelles.
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Figure 6. Nile Red fluorescence intensity at the emission maxima (λmax = 605 nm) versus the log 
of polymer concentration. 
 
DOX·HCl loading and release studies  
The encapsulation ability of hydrophilic molecules in the vesicular hydrophilic cavity 
was tested using the water soluble anticancer drug DOX·HCl. The DOX·HCl was 
encapsulated in A35B21 vesicles using nanoprecipitation. DLS measurements revealed that 
the resulting DOX-loaded vesicles have a number average diameter of 30 nm and a ζ-
potential of +30 mV (Figure S16). Cryo-TEM images showed relatively uniform 
vesicular morphology (Figure S17). A drug loading efficiency of 30.7% was obtained at a 
target drug loading content of 4.8%. The drug loading content was calculated as 1.5%. 
The DOX·HCl release was studied at 37 °C in two different media, i.e., tris buffer (pH 
7.4, 100 mM) and acetate buffer (pH 5.0, 100 mM). Figure 7 shows the cumulative 
DOX·HCl release over time. At pH 7.4, 50% DOX·HCl was released in 24 h. In contrast, 
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78% DOX·HCl was released at pH 5.0 in 24 h. The faster DOX·HCl release at pH 5.0 is 
attributed to the loss of the hydrophilic reservoirs of the vesicles. 
 
Figure 7. Drug release of DOX·HCl loaded vesicles at pH 7.4 and pH 5.0.  
 
Cytotoxicity studies 
Cationic polymers and their self-assembled aggregates may induce toxic effects to the 
cells as a result of their disruptive interaction with the plasma membrane.
39
 Hence, the 
cytotoxicity of A35B21, A35B30, and A35B50 as aqueous suspensions were investigated 
using L929 cells (Figure 8 A). The cytotoxicity assay revealed that the A35B21 suspension 
has no significant cytotoxic effect on L929 cells after 48 h incubation at up to a 
concentration of 250 µg mL-1 with a cell viability above 70%, which is considered as the 
general threshold for cytotoxicity. However, an increase of the A35B21 concentration to 
300 µg mL
-1
 resulted in a decrease of the cell viability to 65%, and it continuously 
decreases with an increasing concentration of the A35B21. Our recent study showed that 
p(THP-HEMA) is biocompatible and not cytotoxic.
28
 Therefore, the cytotoxicity of the 
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A35B21 suspension can be attributed to the cationic p(DMAEMA) block, which usually 
exhibits toxic effects at high polymer concentrations.
40, 41
 The A35B30 suspension that 
contains a slightly longer p(DMAEMA) block than A35B21 exhibited a similar cell 
viability compared to A35B21 at all tested concentrations. The A35B50 suspension exhibited 
the most toxic effect to the cells due to the presence of the longest p(DMAEMA) block. 
Additionally, the cytotoxicity of the DOX·HCl encapsulated A35B21 polymersomes on 
the L929 cells after 24 and 48 h of incubation were investigated and compared with the 
cytotoxicity of the free DOX·HCl (Figure 8 B) to evaluate the anticancer efficacy. To 
avoid the toxic effect of the A35B21 suspension at high polymer concentrations, the 
maximum polymer concentration was kept at 250 µg mL
-1
. The DOX·HCl encapsulated 
polymersomes could decrease the cell viability gradually with increasing concentration of 
encapsulated DOX·HCl and with increasing incubation time, which is comparable to the 
free DOX·HCl. Specifically, 60% of the cells died after 48 h of exposure to DOX·HCl 
encapsulated polymersomes with 5 µg mL-1 DOX·HCl. The significantly increased 
cytotoxicity of the DOX·HCl loaded polmersomes compared to the blank ones can be 
attributed to vesicle-to-micelle morphology transitions triggered by the endosomal pH 
values, which can induce the release of encapsulated DOX·HCl within the cells. It is 
known that molecular mechanisms of cytotoxic action of DOX·HCl rely on a) 
intercalation into DNA, b) direct induction of DNA strand breaks and c) evolution of 
radical species provoking DNA strand breaks. All modes of action result in a disruption 
of DNA and RNA synthesis finally leading to cell death.
42, 43
 The comet assay was 
performed to quantify the amount of DNA damage resulting from single and double 
strand breaks as well as from abasic sites.
44
 For the assay, L929 fibroblast cells were 
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treated with three different concentrations of free DOX·HCl and DOX·HCl encapsulated 
A35B21 polymersomes for 24 h. In comet assay, small and fragmented DNA molecules 
show a higher mobility in an electric field than larger intact DNA molecules. The comet 
assay results show that (Figure S18 and S19) DOX·HCl encapsulated A35B21 vesicles 
induce remarkable DNA damages in a concentration dependent manner, which is 
comparable with free DOX·HCl. These results are in agreement with the cytotoxicity 
studies. 
  
 
Figure 8. (A) Cytotoxicity test of A35B21, A35B30, and A35B50 aqueous suspensions in L929 cells 
after 48 h incubation. (B) Cytotoxicity test of DOX·HCl encapsulated A35B21 suspension and 
free DOX·HCl in L929 cells. The relative viability is expressed as percentage to control cells not 
treated with NPs. Untreated cells on the same well plate were used as positive controls. 
 
Cellular uptake studies 
The cellular uptake of the DOX·HCl loaded polymersomes and the free DOX·HCl were 
qualitatively monitored in L929 cells at different time points (2 to 24 h) by confocal laser 
scanning microscopy (CLSM). The red fluorescence of the DOX·HCl enabled the visualization 
of the cells. Figure 9 shows the representative CLSM images of L929 cells treated with free 
DOX·HCl and DOX·HCl loaded polymersomes. After 2 h of incubation, the DOX·HCl 
 28 
fluorescence is clearly visible in the nucleus of the cells (white arrows). This indicates that 
DOX·HCl loaded polymersomes are efficiently taken up by the cells and subsequently 
DOX·HCl is released from the polymersomes in the endo/lysosomes due to morphology change. 
An increase of incubation time of DOX·HCl loaded polymersomes to 24 h resulted in stronger 
DOX·HCl fluorescence, which is similar to the free DOX·HCl. The cellular uptake of the 
DOX·HCl loaded polymersomes and the free DOX·HCl were further quantitatively investigated 
by flow cytometry. Figure 10 illustrates the mean fluorescence intensity ratio of the DOX·HCl 
loaded polymersomes and the free DOX·HCl. Flow cytometry results indicated that the 
intracellular DOX·HCl content released from the polymersomes is higher than that of the free 
DOX·HCl after 2 h and this even becomes more pronounced for longer incubation times. This is 
explained by the faster internalization of the DOX·HCl loaded polymersomes compared to the 
free DOX·HCl. It is known that nanocarriers featuring diameters between 20 and 500 nm are 
taken up by the cells usually by an endocytosis pathway which is energy and time dependent,
45, 46
 
whereas small drugs enter the cells rapidly through passive diffusion.
47, 48
 Therefore, free 
DOX·HCl is usually uptaken by the cells faster than the DOX·HCl loaded nanoparticles. 
However, positive surface charges can significantly enhance the cellular uptake of the 
nanoparticles due their high affinity for the negatively charged phospholipid bilayer of cell 
membranes.
49
 Indeed, several literature examples have demonstrated that cationic nanoparticles 
can enter the cells even faster than the free DOX·HCl.
50-52
 Therefore, the enhanced cellular 
uptake of the polymersomes is attributed to their cationic character. These preliminary results 
demonstrate that A35B21 polymersomes represent promising candidates as effective drug delivery 
platform for the fast and controlled delivery of hydrophilic DOX·HCl within cancer cells. 
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Figure 9. Live cell CLSM images of L929 cells incubated with DOX·HCl-loaded polymersomes 
and free DOX·HCl at 1 μg mL-1 pure and encapsulated DOX·HCl. (A) free DOX·HCl, 2 h 
incubation; (B) DOX·HCl-loaded polymersomes, 2 h incubation; (C) free DOX·HCl, 24 h 
incubation; (D) DOX·HCl-loaded polymersomes, 24 h incubation. The scale bars correspond to 
10 μm in all the images. 
 
 
Figure 10. Mean fluorescence intensity ratio of DOX·HCl loaded polmersomes (A35B21DOX) to 
free DOX·HCl after incubating for 2, 4, and 24 h as observed by flow cytometry. 
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CONCLUSIONS 
In conclusion, a novel, pH responsive polymersome system with a facile synthetic route has 
been developed. For this purpose, a well-defined diblock copolymer library of p(THP-HEMA) 
and p(DMAEMA) was prepared via RAFT polymerization utilizing p(THP-HEMA) as a macro-
chain transfer agent. The DP of the p(THP-HEMA) block was fixed and the DP of the 
p(DMAEMA) block was systematically varied. It was shown that the copolymer with the 
shortest p(DMAEMA) block self-assembled into polymersomes, whereas an increase of the 
p(DMAEMA) block length led to the formation of micellar structures. In addition, the 
polymersomes exhibited a morphology transition from vesicles to micelles upon lowering the pH 
value. The ability of polymersomes to encapsulate the hydrophobic model drug (Nile Red) into 
the membrane and a hydrophilic anticancer drug (DOX·HCl) in the aqueous cavities were 
verified. Drug release studies demonstrated that DOX·HCl release was accelerated in response to 
a decrease in pH value from 7.4 to 5.0. Cytotoxicity studies revealed that DOX·HCl loaded 
polymersomes exhibited an efficient cell death comparable to free DOX·HCl, while the blank 
polmersomes showed no cytotoxic effect up to a tested concentration of 250 µg mL
-1
. 
Furthermore, cell studies revealed that DOX·HCl loaded polymersomes were efficiently taken up 
by cells faster than free DOX·HCl. This novel pH responsive polymersome system offers dual 
loading ability for both hydrophobic and hydrophilic guest molecules and is, therefore, suitable 
to target multiple drug delivery applications.  
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Figure S1. 1H NMR spectrum (300 MHz, CDCl3) of A35B21. 
 
 
Figure S2. 1H NMR spectrum (300 MHz, CDCl3) of A35B30. 
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Figure S3. DSC heating runs of mCTA and the block copolymers A35B21 to A35B50 (heating rate 
20 K min-1). 
 
 
Figure S4. Intensity size distribution of the A35B21 suspensions. 
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Figure S5. Intensity size distribution of the A35B30 suspensions. 
 
 
Figure S6. Intensity size distribution of the A35B50 suspensions. 
 
 
 
 
 5 
 
Figure S7. Cryo-TEM image of the A35B21 suspension in pure water (c = 2.5 mg mL
-1). 
 
 
 
 
 
 
 6 
 
Figure S8. Cryo-TEM image of the A35B30 suspension in pure water (c = 2.5 mg mL
-1). 
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Figure S9. Cryo-TEM image of the A35B50 suspension in pure water (c = 2.5 mg mL
-1). 
 
Figure S10. Volume size distributions of the A35B21 suspension as a function of the pH value. 
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Figure S11.  (A) Intensity size distributions of the A35B21 suspension (A) between 1-10000 nm 
(B) between 8-100 nm as a function of the pH value.  
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Figure S12. Cryo-TEM image of the A35B21 suspension at pH 7.4. 
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Figure S13. Cryo-TEM image of the A35B21 suspension at pH 5.0. 
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Figure S14. 1H NMR spectrum (300 MHz, CDCl3) of A35B21 suspension before and after 
treatment with 0.1 M acetate buffer (pH = 4, stored at 37 °C for 3 h). 
 
 
 
Figure S15. Number size distributions of A35B21 suspensions in different media. 
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Figure S16. Intensity, volume and number size distributions of DOX·HCl loaded polymersomes 
in water. 
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Figure S17. Representative cryo-TEM images of the DOX·HCl loaded polymersomes. 
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Figure S18. Mean tail length of 100 individual comets as a parameter of DNA damage in cells 
treated for 24 h with free DOX·HCl and DOX·HCl encapsulated A35B21 suspension. 
 
 
Figure S19. Pictures show a representative micrographs of an intact nucleus from a control 
sample (A) and the comet like tail of nucleic DNA in a sample treated with 2.5 µg DOX·HCl 
encapsulated A35B21 suspension (B). 
